Split (1)

train · 2.51M rows

text stringlengths 10 159k	url stringlengths 19 865	crawl_date timestamp[s]date 2022-02-01 01:02:23 2024-12-02 05:16:38	lang stringclasses 1 value	lang_conf float64 0.65 1
NEW YORK, May 31, 2022 /PRNewswire/ -- According to the market research report published by P&S Intelligence, the global interactive kiosk market accounted for $26,312.3 million in 2021, which is set to reach $51,582.0 million by 2030, growing at a compound annual growth rate of 7.8% between 2021 and 2030. The growth of the market is driven by the need for enhanced shopping experience, rising demand for self-service in the banking & financial sector, and innovations in touchscreen display technology. Information Kiosks Are Being Widely Used in Retail Stores The retail category is predicted to record the highest growth rate, of over 8.0%, in the coming years, because of the increasing number of retail chains. E-commerce expansion is also boosting the kiosk industry. Retailers use information kiosks to advertise their products and attract more customers, by delivering numerous pieces of information. For instance, in 2021, Crocs had over 70 stores globally with interactive kiosks providing shoppers with product information and facilitating their purchases. Get the sample pages of this report at: https://www.psmarketresearch.com/market-analysis/interactive-kiosk-market/report-sample Substantial Market Growth Expected in APAC The APAC interactive kiosk market is expected to grow at a CAGR of more than 8.0% in the future, owing to the growth of the BFSI industry and the rise of organized retail. The demand for constant access to cash is also propelling the sector, with consumers increasingly preferring touchscreen and interactive ATMs. The growing demand for improved customer experiences and achieve retail automation are pushing the acceptance of several advanced technological solutions by the APAC retail industry. Moreover, China's interactive kiosk market had a substantial size in 2021 because of the growing population and established financial system. Additionally, the food and beverage industry in the country is seeing an increase in vending machine demand. The acceptance of such technology in the People's Republic is likely to be boosted by technological advancements and low production costs. ATM Kiosks Were Widely Used in 2021 In 2021, ATM kiosks held around 40.0% share in the interactive kiosk market. They're self-service kiosks that allow customers to perform transactions conveniently. More-interactive ATMs are being introduced as a result of technological advancements, allowing customers to make transactions while conversing with bank employees at micro branches around the world through video conferencing. Software Solutions Will Grow at Highest Rate Multimedia content management systems, remote management and monitoring features, operating systems, and application stacks are all part of the software. With technological developments, the introduction of user-friendly and robust software solutions, for the smooth running of kiosks, is underway. Kiosk vendors need software solutions to provide customized solutions to sellers, based on product and geographical requirements. Browse detailed report on Interactive Kiosk Market Size, Opportunities, Growth, Challenges, Business Trends and Forecast 2030 Significant Strategic Developments in Interactive Kiosk Market To achieve a significant position, companies are focusing on investments in research and development, as well as partnerships and alliances. For instance, - Devlyn Optical partnered with Advanced Kiosks in May 2022 to create a digital eyecare self-service kiosk that is more cost-effective than traditional doctor visits. - Through the acquisition of Bud Room Inc. in January 2022, High Tide purchased Fastendr Retail Kiosk and Smart Locker Technology, to provide people a better buying experience all through browsing, ordering, and pickup. Interactive Kiosk Market Segmentation Analysis By Type - ATM Kiosks - Information Kiosks - Ticketing Kiosks - Patient Interactive Kiosks - Vending Kiosks By Offering - Hardware - Software - Services By Location - Indoor - Outdoor By Panel Size - 17−32" - Above 32" By Vertical - Retail - Healthcare - BFSI - Government - Transportation - Hospitality - Entertainment Regional Analysis - North America - U.S. - Canada - Europe - Germany - U.K. - Italy - France - Asia-Pacific - China - India - Japan - South Korea - Latin America - Brazil - Mexico - Argentina - Middle East and Africa - Saudi Arabia - South Africa Browse More Related Reports Global Artificial Intelligence in Retail Market Size, Leading Players and Future Analysis Global Automated Machine Learning Market Size, Leading Players and Future Analysis About P&S Intelligence P&S Intelligence provides market research and consulting services to a vast array of industries across the world. As an enterprising research and consulting company, P&S believes in providing thorough insights on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness. P&S keeps the interest of its clients at heart, which is why the insights we provide are both honest and accurate. Our long list of satisfied clients includes entry-level firms as well as multi-million-dollar businesses and government agencies. Contact: Prajneesh Kumar P&S Intelligence Phone: +1-347-960-6455 Email: [email protected] Web: https://www.psmarketresearch.com Follow Us: LinkedIn Twitter SOURCE P&S Intelligence	https://www.prnewswire.com/news-releases/interactive-kiosk-market-revenue-to-cross-51-582-mn-by-2030--says-ps-intelligence-301557625.html	2022-05-31T12:45:48	en	0.905523
Uvalde grieves at funerals for 19 children, 2 teachers after Texas shooting UVALDE, Texas - It should have been the first day of a joyous week for Robb Elementary School students — the start of summer break. Instead, the first two of 19 children slain inside a classroom were being remembered at funeral visitations. The gathering for 10-year-old Amerie Jo Garza was at Hillcrest Memorial Funeral Home on Monday in Uvalde, Texas, directly across from the grade school where the children, along with two teachers, were shot to death last week before the gunman himself was killed. Visitation for another 10-year-old, Maite Rodriguez, was at the town's other funeral home. Over the next two-and-a-half traumatic weeks, people in the southwestern Texas town will say goodbye to the children and their teachers, one heart-wrenching visitation, funeral and burial after another. As family and friends unleash their grief, investigators will push for answers about how police responded to the May 24 shooting, and lawmakers have said they'll consider what can be done to stem the gun violence permeating the nation. This week alone, funerals are planned for 11 children and teacher Irma Garcia. RELATED: Justice Department to investigate police response to Uvalde school shooting On Monday, some mourners at Amerie’s visitation wore lilac or lavender shades of purple — Amerie’s favorites — at the request of her father, Angel Garza. Many carried in flowers, including purple ones. The little girl who loved to draw had just received a cellphone for her 10th birthday. One of her friends told Angel Garza that Amerie tried to use the phone to call police during the assault on her fourth-grade classroom. People arrive to pay their respects during visitation for Amerie Jo Garza at Hillcrest Memorial Funeral Home on May 30, 2022, in Uvalde, Texas. (Photo by Michael M. Santiago/Getty Images) Among the mourners at Amerie's visitation were some of Maite's relatives. Like many people, they were attending both. Maite's family wore green tie-dye shirts with an illustration showing Maite with angel wings. Before going into the funeral home, they stopped at the ditch to see the metal gate gunman Salvador Ramos crashed a pickup truck into before crossing a field and entering the school. "How did he walk for so long?" asked Juana Magaña, Maite's aunt. Hillcrest Memorial itself and the shooting will be forever linked. After Ramos wrecked the truck, two men at the funeral home heard the crash and ran toward the accident scene. Ramos shot at them. He missed and both men made it to safety. Eliahna "Ellie" Garcia’s funeral will be June 6 — the day after she was supposed to turn 10. Her family had been preparing a big birthday bash at her grandmother’s house this coming weekend. She had been hoping to receive gifts related to the Disney movie "Encanto." "She loved that movie and talked a lot about it," said her aunt, Siria Arizmendi. Ellie was quiet even around family but loved doing videos and had been already practicing with her older sister a choreography for her quinceañera party — the celebration of a girl's 15th birthday — even though it was still five years away, Arizmendi said. Ellie's older sister is doing OK, Arizmendi said, understanding their family and others face a long road to recovery. "It is just sad for all the children," she said. Funeral directors, embalmers and others from across Texas arrived to help. Jimmy Lucas, president of the Texas Funeral Directors Association, brought a hearse and volunteered to work as a driver, pitch in for services, or do whatever he could, he told NBC News. Other arriving morticians were there to help with facial reconstruction services given the damage caused by the shooter's military-style rifle. Gov. Greg Abbott, speaking at a Memorial Day event in Longview, urged Texans to keep Uvalde in their prayers. "What happened in Uvalde was a horrific act of evil," Abbott said. "And as Texans, we must come together and lift up Uvalde and support them in every way that we possibly can. It is going to take time to heal the devastation that the families there have gone through and are going through, But be assured, we will not relent until Uvalde recovers." RELATED: Meet the group teaching America’s mayors how to respond to mass shootings The U.S. Department of Justice announced Sunday a review of the law enforcement response. Police have come under heavy criticism for taking well over an hour to kill Ramos inside the adjoining classrooms where he unleashed carnage. Officials revealed Friday that students and teachers repeatedly begged 911 operators for help as a police commander told more than a dozen officers to wait in a hallway. Officials said the commander believed the suspect was barricaded inside an adjoining classroom and that there was no longer an active attack. The revelation raised new questions about whether lives were lost because officers did not act faster to stop the gunman, who was ultimately killed by Border Patrol tactical officers. Authorities have said Ramos legally purchased two guns not long before the school attack: an AR-style rifle on May 17 and a second rifle on May 20. He had just turned 18, permitting him to buy the weapons under federal law. A day after visiting Uvalde and pledging, "We will," in response to people chanting, "Do something," President Joe Biden on Monday expressed some optimism that there may be some bipartisan support to tighten restrictions on the kind of high-powered weapons used by the gunman. "I think things have gotten so bad that everybody’s getting more rational, at least that’s my hope," Biden told reporters before honoring the nation’s fallen in Memorial Day remarks at Arlington National Cemetery. "The Second Amendment was never absolute," Biden said. "You couldn’t buy a cannon when the Second Amendment was passed. You couldn’t go out and buy a lot of weapons." A bipartisan group of senators talked over the weekend to see if they could reach even a modest compromise on gun safety legislation. Encouraging state "red flag" laws to keep guns away from those with mental health issues, and addressing school security and mental health resources were on the table, said Sen. Chris Murphy, who is leading the effort. The group will meet again this week under a 10-day deadline to strike a deal. RELATED: '2nd Amendment was never absolute,' Biden says in gun reform talk ___ Advertisement Nathan Ellgren in Uvalde and Jim Salter in O’Fallon, Missouri, contributed to this report.	https://www.fox35orlando.com/news/uvalde-texas-school-shooting-funerals-for-children-teachers	2022-05-31T12:45:51	en	0.977757
- Sponsorship honors employee Meaghan Addante, who passed away from Cystic Fibrosis (CF) last year at the age of 28. - Under Meaghan's leadership, TK Elevator raised more than CA$500,000 over five years for Cystic Fibrosis Canada, a nonprofit organization dedicated to a finding a cure for CF. - CF is the most common fatal genetic disease affecting more than 4,300 Canadian children and young adults. TORONTO, May 31, 2022 /PRNewswire/ -- TK Elevator Canada was proud to support the Walk to Make Cystic Fibrosis History as a national sponsor, which took place on May 29 across Canada. The Walk to Make Cystic Fibrosis History is Cystic Fibrosis Canada's largest and most successful national event and fundraiser. Participants across more than 70 locations in Canada as well as virtual participants walked and raised money for CF Canada, supporting its mission to find a cure for CF. Six years ago, Meaghan Addante joined TK Elevator Canada tasked with raising CF awareness within the organization and communities. Through her inspirational advocacy, TK Elevator employees participated in a variety of fundraisers including bake sales, raffles, curling bonspiels, bowling events, golf tournaments and art contests. Since adopting CF Canada as its charity of choice in 2016, TK Elevator Canada has consistently exceeded the company's annual goal of raising CA$100,000 for Cystic Fibrosis Canada. To date, TK Elevator Canada has raised more than CA$500,000 as it continues Meaghan's mission after she passed away from the disease last year. "We are proud to support Cystic Fibrosis Canada and its mission to end CF once and for all. This is very personal to us. Meaghan was an inspiration to everyone who met her and her courageous battle with CF and to raise awareness around this disease is a fight we are proud to continue fighting on her behalf," said Kevin Lavallee, CEO BU North America and Group COO Field. A native of Oshawa, Ontario, Addante was diagnosed with CF when she was seven months old. Although Meaghan ultimately succumbed to the disease in 2021, she never let CF stop her from living her life to the fullest nor in her pursuit to inspire and educate others. "This world was a much better place because of Meaghan, and her efforts around CF inspired so many people throughout Canada and around the world. She was relentless in her fight, and that is a tradition we will continue in her honor as we continue working closely with CF Canada," added Gary Medeiros, President and CEO, TK Elevator Canada. Cystic Fibrosis Canada is one of the world's top three charitable organizations committed to finding a cure for Cystic Fibrosis and is an internationally recognized leader in advancing CF research and clinical care. Cystic Fibrosis Canada invests more funding in life-saving CF research and care than any other non-governmental agency in Canada. Since 1960, Cystic Fibrosis Canada has invested more than $261 million in leading research, care and advocacy, resulting in one of the world's highest estimated median age of survival for Canadians living with CF. In 2019, TK Elevator Canada was selected as the recipient of CF Canada's prestigious National Champion Award. The Award recognizes service groups, corporations, companies and businesses that have a presence in at least three regions and have provided exceptional leadership and/or financial support for CF Canada at the national level. This recognition would not have possible without the support of the entire Canada team and the tireless efforts of Meaghan. As Meaghan previously shared: "Maybe I myself won't be saved, and maybe I won't find the cure, but maybe one day people will look back and say, 'that girl made a difference'." PRESS CONTACT Dennis Van Milligen Manager, Public Relations TK Elevator North America P +1 312 525 3190 dennis.vanmilligen@tkelevator.com www.tkelevator.com/ca-en/ ABOUT US TK Elevator With customers in over 100 countries served by more than 50,000 employees, TK Elevator achieved sales of around €8 billion in the fiscal year 2020/2021. Over 1,000 locations around the world provide an extensive network that guarantees closeness to customers. Over the past decades, TK Elevator has established itself as one of the world's leading elevator companies and became independent since its separation from thyssenkrupp AG in August 2020. The company's most important business line is the service business represented by over 24,000 service technicians. The product portfolio covers commodity elevators for residential and commercial buildings to cutting-edge, highly customized solutions for state-of-the-art skyscrapers. In addition, it also consists of escalators and moving walks, passenger boarding bridges, stair and platform lifts. Integrated cloud-based service solutions, such as the MAX platform, are gaining in importance. With these digital offerings, there are no limits to urban mobility anymore. TKE – move beyond. View original content to download multimedia: SOURCE TK Elevator	https://www.wlbt.com/prnewswire/2022/05/31/tk-elevator-canada-sponsors-walk-make-cystic-fibrosis-history/	2022-05-31T12:45:53	en	0.960082
Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA Studies spanning industry-leading hematologic malignancies portfolio and pipeline with new research in solid tumor therapies to highlight precision medicine and targeted therapy strategies RARITAN, N.J., May 31, 2022 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigational therapies that are being studied for the treatment of multiple blood cancers and solid tumors. "The science and data that we will present at ASCO and EHA highlight the breadth and depth of our oncology portfolio and pipeline, and our team's commitment to advance and deliver innovative treatments for patients," said Peter Lebowitz, M.D., Ph.D., Global Therapeutic Area Head, Oncology, Janssen Research & Development, LLC. "Our research and collaborations underscore a focused scientific strategy to deeply understand disease biology in working towards our ultimate goal of preventing, intercepting and one day curing cancer." Consistent with ASCO's theme of Advancing Equitable Cancer Care Through Innovation, Janssen recognizes the importance of eliminating health inequities – from research and clinical trials to access and quality of care – to address the diverse needs of patients and ensure access to cancer therapies. "We are committed to improving representation of real-world patient populations in our clinical development programs and providing access to clinical trials, especially for those in underserved communities," said Craig Tendler, M.D., Vice President, Late Development and Global Medical Affairs, Janssen Research & Development, LLC. "We also look to support investigators, communities and sites to overcome obstacles in oncology clinical trial participation among racial and ethnic minorities so that everyone can benefit from the advances in oncology drug development, which may have a profound impact on the lives of all patients in the future." With nearly six million patients diagnosed annually across hematologic malignancies and prostate, lung and bladder cancers, there remains significant unmet need in the treatment of these complex cancers.1 The latest research and data at ASCO and EHA will demonstrate Janssen's commitment to exploring new vital science for patients in these areas through precision medicine, targeted therapies and novel platforms. "At Janssen, part of our mission to reimagine cancer care includes working to drive better outcomes for patients," said Tyrone Brewer, U.S. President, Oncology, Janssen Biotech, Inc. "The research presented at ASCO underscores our commitment to advancing science, treatment options and patient care across hematologic malignancies, lung cancer, prostate cancer and bladder cancer, and our continued focus on helping patients navigate their treatment journeys." Key ASCO and EHA data presentations include: Leukemia & lymphoma Janssen continues to study IMBRUVICA® (ibrutinib) with the goal of addressing unmet clinical needs and helping to improve outcomes for patients living with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). Data from the Phase 3 SHINE study evaluating IMBRUVICA® in combination with bendamustine and rituximab (BR) in older patients with previously untreated MCL will be featured as an oral presentation (ASCO Oral Abstract: #7502). Additionally, three-year follow-up data from the Phase 2 CAPTIVATE Fixed Duration cohort evaluating IMBRUVICA® plus venetoclax fixed duration treatment for previously untreated patients with CLL or small lymphocytic lymphoma (SLL) will be highlighted in a poster presentation (ASCO Poster Abstract: #7519). At EHA, additional data from the CAPTIVATE study will focus on synergistic activity and immune restoration with this combination regimen. In acute lymphoblastic leukemia or lymphoblastic lymphoma, data from the Phase 2 DELPHINUS study will be featured in an oral presentation, reporting safety and efficacy results for the investigational use of DARZALEX® (daratumumab) in the treatment of pediatric and young adult patients with relapsed or refractory disease (ASCO Oral Abstract: #10001; EHA Poster Session: #P360). Multiple myeloma With a portfolio of four therapies with distinct target antigens and different mechanisms of action, Janssen continues to focus on developing and delivering tailored immunotherapy regimens to treat patients with multiple myeloma. Data at ASCO and EHA will span frontline and relapsed or refractory settings with the latest updates from two investigational therapies and two approved treatments. Two presentations will highlight treatment with DARZALEX® in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma, including updated results from the Phase 3 MAIA study in transplant-ineligible patients (ASCO Poster Abstract: #8044; EHA Poster Session: #P936), and the Phase 2 GRIFFIN study evaluating the investigational use of DARZALEX® in combination with bortezomib, lenalidomide and dexamethasone in transplant-eligible patients (ASCO Poster Abstract: #8011; EHA Poster Session: #P934). In relapsed or refractory disease, results from the POLLUX and CASTOR studies will report on treatment with DARZALEX® in combination with lenalidomide and dexamethasone and in combination with bortezomib and dexamethasone in patients who experienced early or late relapse following at least one prior therapy (ASCO Poster Abstract: #8052; EHA Poster Session: #P933). The latest data to be presented at ASCO and EHA for CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel), Janssen's first approved cell therapy, will include longer-term efficacy and safety results from the CARTITUDE-1 study and cohorts A and B of the CARTITUDE-2 study. Both studies include patients with relapsed or refractory multiple myeloma (ASCO Poster Abstracts: #8020, #8029, #8028; EHA Oral Abstract: #S185). Data at ASCO and EHA for the investigational bispecific antibody teclistamab (BCMAxCD3 bispecific antibody) will include an updated analysis from the Phase 1/2 MajesTEC-1 study evaluating monotherapy treatment for patients with relapsed or refractory multiple myeloma (ASCO Oral Abstract: #8007; EHA Poster Abstract: #P921) and results from an analysis of patients who were previously treated with a BCMA-targeted agent (ASCO Poster Abstract: #8013; EHA Oral Abstract: #S184). Additionally, updated results from the TRIMM-2 study of teclistamab in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in patients with relapsed or refractory multiple myeloma will be presented in an oral session at ASCO and EHA (ASCO Poster Abstract: #8032; EHA Oral Abstract: #S188). Updated results from the Phase 1 MonumenTAL-1 study of the investigational bispecific antibody talquetamab (GPRC5DxCD3 bispecific antibody) as a monotherapy treatment for highly refractory multiple myeloma will be reported (ASCO Poster Abstract: #8015; EHA Oral Abstract: #S182). In addition, updated Phase 1b results from the TRIMM-2 study evaluating talquetamab in combination with DARZALEX FASPRO® for the treatment of relapsed or refractory patients with multiple myeloma will be highlighted (EHA Oral Abstract: #S183). Biomarker-driven solid tumors Janssen's first presentation of tumor-agnostic data will share interim analysis results from the Phase 2 RAGNAR study evaluating the investigational use of BALVERSA® (erdafitinib) in patients with advanced or metastatic solid tumors with fibroblast growth factor receptor (FGFR) alterations (ASCO Oral Abstract: #3007). The interim analysis comprises a patient population with 32 distinct solid tumor histologies. Lung cancer Updated data will be presented for the bispecific antibody RYBREVANT® (amivantamab-vmjw) that highlights Janssen's commitment to precision medicine strategies, with an oral presentation of updated results for RYBREVANT® as a monotherapy in patients with non-small cell lung cancer (NSCLC) characterized by MET exon 14 skipping mutations (ASCO Oral Abstract: #9008). A second oral presentation of the CHRYSALIS-2 study of the investigational combination of RYBREVANT® and lazertinib in patients with exon 19 deletion or L858R EGFR-mutated NSCLC (ASCO Oral Abstract: #9006) will also be reported. Prostate cancer A gene-by-gene analysis will provide new insights from the prospectively designed Phase 3 MAGNITUDE study, which is evaluating the safety and efficacy of the combination of niraparib and abiraterone acetate plus prednisone in patients with homologous recombination repair (HRR)-gene mutated metastatic castration-resistant prostate cancer (mCRPC). The data evaluated HRR gene alterations beyond BRCA1/2, including PALB 2, CHEK2 and other mutations (ASCO Poster Abstract: #5020). Janssen will present baseline patient characteristics and the application of different radiation therapy regimens from the Phase 3 ATLAS study investigating if the addition of ERLEADA® (apalutamide) to a gonadotropin-releasing hormone agonist (GnRH) in participants with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy results in an improvement of metastasis-free survival (ASCO Poster Abstract: #5084). A complete list of Janssen-sponsored abstracts at ASCO and EHA is available at: Janssen.com/ASCO2022. About IMBRUVICA® IMBRUVICA® (ibrutinib) is a once-daily oral medication that is jointly developed and commercialized by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company. IMBRUVICA® blocks the Bruton's tyrosine kinase (BTK) protein, which is needed by normal and abnormal B cells, including specific cancer cells, to multiply and spread. By blocking BTK, IMBRUVICA® may help move abnormal B cells out of their nourishing environments and inhibits their proliferation.2,3,4 IMBRUVICA® is approved in more than 100 countries for at least one indication and has been used to treat more than 250,000 patients worldwide. There are more than 50 company-sponsored clinical trials, including 18 Phase 3 studies, over 11 years evaluating the efficacy and safety of IMBRUVICA®. IMBRUVICA® was first approved by the U.S. Food and Drug Administration (FDA) in November 2013, and today is indicated for adult patients in six disease areas, including five hematologic cancers. These include indications to treat adults with CLL/SLL with or without 17p deletion (del17p), and adults with Waldenström's macroglobulinemia (WM), and adult patients with previously treated mantle cell lymphoma (MCL), as well as to treat adult patients with previously treated marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy, and adult patients with previously treated chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy.5 Accelerated approval was granted for MCL and MZL based on overall response rate. Continued approval for MCL and MZL may be contingent upon verification and description of clinical benefit in confirmatory trials. The National Comprehensive Cancer Network® (NCCN®), recommends ibrutinib (IMBRUVICA®) as a preferred regimen for the initial treatment of CLL/SLL and has Category 1 treatment status for treatment-naïve patients without deletion 17p/TP53 mutation and as a preferred treatment for treatment-naïve patients with deletion 17p/TP53 mutation. The NCCN Guidelines also recommend IMBRUVICA®, with or without rituximab, as a preferred regimen for the treatment of relapsed/refractory MCL, as a Category 1 preferred regimen for both untreated and previously treated WM patients, and as a preferred regimen for relapsed/refractory MZL.6 For more information, visit www.IMBRUVICA.com. About DARZALEX FASPRO® and DARZALEX® DARZALEX FASPRO® received U.S. FDA approval in May 2020 and is approved for eight indications in multiple myeloma (MM), three of which are for frontline treatment in newly diagnosed patients who are transplant eligible or ineligible.7 DARZALEX FASPRO® is the only subcutaneous CD38-directed antibody globally approved to treat patients with MM. DARZALEX FASPRO® is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme's ENHANZE® drug delivery technology. In January 2021, DARZALEX FASPRO® became the first FDA-approved therapy for light chain amyloidosis. In August 2012, Janssen Biotech, Inc. entered into an exclusive global license and development agreement with Genmab A/S to develop, manufacture, and commercialize DARZALEX®.8 DARZALEX® has been approved in eight indications, three of which are in the frontline setting, including for newly diagnosed patients who are transplant eligible as well as those who are ineligible.9 For more information, visit www.DARZALEX.com. About CARVYKTI™ CARVYKTI™ (cilta-cel) received approval by the U.S. FDA in February 2022 for the treatment of adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.10 CARVYKTI™ is a BCMA-directed, genetically modified autologous T-cell immunotherapy, which involves reprogramming a patient's own T cells with a transgene encoding a chimeric antigen receptor (CAR) that directs the CAR positive T cells to eliminate cells that express BCMA. BCMA is primarily expressed on the surface of malignant multiple myeloma B-lineage cells, as well as late-stage B cells and plasma cells. The CARVYKTI™ CAR protein features two BCMA-targeting single domain designed to confer high avidity against human BCMA. Upon binding to BCMA-expressing cells, the CAR promotes T-cell activation, expansion, and elimination of target cells. In December 2017, Janssen Biotech, Inc. entered into an exclusive worldwide license and collaboration agreement with Legend Biotech USA, Inc. to develop and commercialize CARVYKTI™. Cilta-cel received a PRIority MEdicines (PRIME) designation from the European Commission in April 2019, and the Orphan Drug Designation for cilta-cel from the European Commission in February 2020. In May 2022, Janssen announced that the European Commission (EC) granted conditional marketing authorisation of CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy. In March 2022, Janssen announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization of cilta-cel for the treatment of adults with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an IMiD, a PI and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. There are several ongoing Phase 3 clinical trials investigating CARVYKTI™ in earlier treatment settings, including first-line. For more information, visit www.CARVYKTI.com. About Teclistamab Teclistamab is an off-the-shelf, T-cell redirecting, bispecific antibody targeting both BCMA (B-cell maturation antigen) and CD3, the T-cell receptor. BCMA is expressed at high levels on multiple myeloma cells.11,12,13,14,15 Teclistamab redirects CD3-positive T-cells to BCMA-expressing myeloma cells to induce killing of tumor cells.14 Teclistamab is currently being evaluated in several monotherapy and combination studies. In 2020, the European Commission and the U.S. FDA each granted teclistamab Orphan Drug Designation for the treatment of multiple myeloma. In January 2021 and May 2021, teclistamab received a PRIority MEdicines (PRIME) designation by the European Medicines Agency (EMA) and Breakthrough Therapy Designation (BTD) by the U.S. FDA, respectively. PRIME offers enhanced interaction and early dialogue to optimize drug development plans and speed up evaluation of cutting-edge, scientific advances that target a high unmet medical need.16 The U.S. FDA granted teclistamab Priority Review Designation in December 2021. About Talquetamab Talquetamab is a first-in-class, off-the-shelf, investigational T-cell redirecting bispecific antibody targeting both GPRC5D and CD3, a primary component of the T-cell receptor. GPRC5D is a novel target which is highly expressed on multiple myeloma cells. Talquetamab is currently being evaluated in a Phase 1/2 clinical study for the treatment of relapsed or refractory multiple myeloma (NCT03399799) and is also being explored in combination studies (NCT04586426). In January 2021, talquetamab was granted PRIME designation by the European Commission. In 2021, the European Commission and the U.S. FDA each granted talquetamab Orphan Drug Designation for the treatment of multiple myeloma. About BALVERSA® BALVERSA® (erdafitinib) is a once-daily, oral FGFR kinase inhibitor that is approved by the U.S. FDA for the treatment of adults with locally advanced or metastatic urothelial carcinoma (mUC) that has susceptible FGFR3 or FGFR2 genetic alterations and has progressed during or following at least one line of platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Patients are selected for therapy based on an FDA-approved companion diagnostic for BALVERSA®. Information on FDA-approved tests for the detection of FGFR genetic alterations in urothelial cancer is available at: http://www.fda.gov/CompanionDiagnostics. This indication is approved under accelerated approval based on tumor response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.7,15 In addition to RAGNAR, BALVERSA® is being studied in multiple clinical trials including the Phase 3 THOR (NCT03390504) study evaluating BALVERSA® versus standard of care, consisting of chemotherapy (docetaxel or vinflunine) or anti-PD-1 agent pembrolizumab, in participants with advanced urothelial cancer and selected FGFR aberrations with disease progression following one prior line of therapy; and the Phase 2 THOR-2/BLC2003 study (NCT04172675) study examining BALVERSA® versus investigator choice of intravesical chemotherapy in participants who received Bacillus Calmette-Guérin and recurred with high risk non-muscle-invasive bladder cancer.16,17,18 In 2008, Janssen entered into an exclusive worldwide license and collaboration agreement with Astex Pharmaceuticals to develop and commercialize BALVERSA®. For more information, visit https://www.BALVERSA.com. About RYBREVANT® RYBREVANT® (amivantamab-vmjw) received accelerated approval by the U.S. FDA in May 2021 for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.17 This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer prefer NGS-based strategies over PCR-based approaches for the detection of EGFR exon 20 insertion variants and include amivantamab-vmjw (RYBREVANT®) as a subsequent therapy option with a Category 2A recommendation for patients that have progressed on or after platinum-based chemotherapy with or without immunotherapy and have EGFR exon 20 insertion mutation-positive advanced NSCLC.18†‡ RYBREVANT® has also received approval from health authorities in Europe, as well as other markets around the world. RYBREVANT® is being studied in multiple clinical trials, including the Phase 1/1b CHRYSALIS-2 (NCT04077463) study assessing the combination of RYBREVANT® and lazertinib in patients who have progressed after treatment with osimertinib and chemotherapy; as first-line therapy in untreated advanced EGFR-mutated NSCLC in the Phase 3 MARIPOSA (NCT04487080NCT04487080) study assessing amivantamab in combination with lazertinib; the planned Phase 3 MARIPOSA-2 (NCT04988295) study assessing the efficacy of lazertinib, RYBREVANT® and carboplatin-pemetrexed versus carboplatin-pemetrexed in patients with locally advanced or metastatic EGFR exon 19 deletion or exon 21 L858R substitution NSCLC after osimertinib failure; the Phase 3 PAPILLON (NCT04538664) study assessing RYBREVANT® in combination with carboplatin-pemetrexed versus chemotherapy alone in patients with advanced or metastatic EGFR-mutated NSCLC and exon 20 insertion mutations; and the Phase 1 PALOMA (NCT04606381) study assessing the feasibility of subcutaneous (SC) administration of RYBREVANT® based on safety and pharmacokinetics and to determine a dose, dose regimen and formulation for RYBREVANT® SC delivery.19,20,21,22,23,24 * NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. †See the NCCN Guidelines for detailed recommendations, including other treatment options.20 ‡The NCCN Guidelines for NSCLC provide recommendations for certain individual biomarkers that should be tested and recommend testing techniques but do not endorse any specific commercially available biomarker assays or commercial laboratories. For more information, visit: https://www.RYBREVANT.com. About Lazertinib Lazertinib is an oral, third-generation, brain-penetrant, EGFR tyrosine kinase inhibitor (TKI) that targets both the T790M mutation and activating EGFR mutations while sparing wild type-EGFR.25 Interim safety and efficacy results from the lazertinib Phase 1-2 study were published in The Lancet Oncology in 2019. In 2018, Janssen Biotech, Inc. entered into a license and collaboration agreement with Yuhan Corporation for the development of lazertinib. About Niraparib Niraparib is an orally administered, poly-ADP ribose polymerase (PARP) inhibitor that is currently being studied by Janssen for the treatment of patients with prostate cancer. Ongoing studies include the Phase 3 AMPLITUDE study evaluating niraparib in combination with abiraterone acetate plus prednisone in a biomarker-selected patient population with mCSPC; the Phase 3 MAGNITUDE study evaluating niraparib in combination with abiraterone acetate plus prednisone as a first-line treatment option compared to abiraterone acetate and prednisone plus placebo in adults with mCRPC; and QUEST, a Phase 1b/2 study of niraparib combination therapies for the treatment of mCRPC. In April 2022, Janssen announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of niraparib in combination with abiraterone acetate, in the form of a dual action tablet plus prednisone, based on the results of the Phase 3 MAGNITUDE study for the treatment of patients with prostate cancer who have progressed to metastatic castration-resistant prostate cancer (mCRPC) and are positive for homologous recombination repair (HRR) gene alterations. In April 2016, Janssen Biotech, Inc. entered a worldwide (except Japan) collaboration and license agreement with TESARO, Inc. (acquired by GSK in 2018), for exclusive rights to niraparib in prostate cancer. In the U.S., niraparib is indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy; for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy; for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either: a deleterious or suspected deleterious BRCA mutation, or genomic instability and who have progressed more than six months after response to the last platinum-based chemotherapy. In the EU, niraparib is indicated as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response following platinum-based chemotherapy. Niraparib is currently marketed by GSK as ZEJULA®.26 About ERLEADA® ERLEADA® (apalutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with mCSPC.27 ERLEADA® received U.S. FDA approval for nmCRPC in February 2018, and was approved for mCSPC in September 2019.22 To date, more than 50,000 patients worldwide have been treated with ERLEADA®. For more information, visit www.ERLEADA.com. IMBRUVICA® IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS Hemorrhage: Fatal bleeding events have occurred in patients who received IMBRUVICA®. Major hemorrhage (≥ Grade 3, serious, or any central nervous system events; e.g., intracranial hemorrhage [including subdural hematoma], gastrointestinal bleeding, hematuria, and post procedural hemorrhage) occurred in 4.2% of patients, with fatalities occurring in 0.4% of 2,838 patients who received IMBRUVICA® in 27 clinical trials. Bleeding events of any grade including bruising and petechiae occurred in 39%, and excluding bruising and petechiae occurred in 23% of patients who received IMBRUVICA®, respectively. The mechanism for the bleeding events is not well understood. Use of either anticoagulant or antiplatelet agents concomitantly with IMBRUVICA® increases the risk of major hemorrhage. Across clinical trials, 3.1% of 2,838 patients who received IMBRUVICA® without antiplatelet or anticoagulant therapy experienced major hemorrhage. The addition of antiplatelet therapy with or without anticoagulant therapy increased this percentage to 4.4%, and the addition of anticoagulant therapy with or without antiplatelet therapy increased this percentage to 6.1%. Consider the risks and benefits of anticoagulant or antiplatelet therapy when co-administered with IMBRUVICA®. Monitor for signs and symptoms of bleeding. Consider the benefit-risk of withholding IMBRUVICA® for at least 3 to 7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding. Infections: Fatal and non-fatal infections (including bacterial, viral, or fungal) have occurred with IMBRUVICA® therapy. Grade 3 or greater infections occurred in 21% of 1,476 patients who received IMBRUVICA® in clinical trials. Cases of progressive multifocal leukoencephalopathy (PML) and Pneumocystis jirovecii pneumonia (PJP) have occurred in patients treated with IMBRUVICA®. Consider prophylaxis according to standard of care in patients who are at increased risk for opportunistic infections. Monitor and evaluate patients for fever and infections and treat appropriately. Cardiac Arrhythmias, Cardiac Failure and Sudden Death: Fatal and serious cardiac arrhythmias and cardiac failure have occurred with IMBRUVICA®. Deaths due to cardiac causes or sudden deaths occurred in 1% of 4,896 patients who received IMBRUVICA® in clinical trials, including in patients who received IMBRUVICA® in unapproved monotherapy or combination regimens. These adverse reactions occurred in patients with and without preexisting hypertension or cardiac comorbidities. Patients with cardiac comorbidities may be at greater risk of these events. Grade 3 or greater ventricular tachyarrhythmias were reported in 0.2%, Grade 3 or greater atrial fibrillation and atrial flutter were reported in 3.7%, and Grade 3 or greater cardiac failure was reported in 1.3% of 4,896 patients who received IMBRUVICA® in clinical trials, including in patients who received IMBRUVICA® in unapproved monotherapy or combination regimens. These events have occurred particularly in patients with cardiac risk factors including hypertension and diabetes mellitus, a previous history of cardiac arrhythmias, and in patients with acute infections. Evaluate cardiac history and function at baseline, and monitor patients for cardiac arrhythmias and cardiac function. Obtain further evaluation (e.g., ECG, echocardiogram) as indicated for patients who develop symptoms of arrhythmia (e.g., palpitations, lightheadedness, syncope, chest pain), new onset dyspnea, or other cardiovascular concerns. Manage cardiac arrhythmias and cardiac failure appropriately, follow dose modification guidelines, and consider the risks and benefits of continued IMBRUVICA® treatment. Hypertension: Hypertension occurred in 19% of 1,476 patients who received IMBRUVICA® in clinical trials. Grade 3 or greater hypertension occurred in 8% of patients. Based on data from 1,124 of these patients, the median time to onset was 5.9 months (range, 0.03 to 24 months). Monitor blood pressure in patients treated with IMBRUVICA®, initiate or adjust anti-hypertensive medication throughout treatment with IMBRUVICA® as appropriate, and follow dosage modification guidelines for Grade 3 or higher hypertension. Cytopenias: In 645 patients with B-cell malignancies who received IMBRUVICA® as a single agent, grade 3 or 4 neutropenia occurred in 23% of patients, grade 3 or 4 thrombocytopenia in 8% and grade 3 or 4 anemia in 2.8%, based on laboratory measurements. Monitor complete blood counts monthly. Second Primary Malignancies: Other malignancies (10%), including non-skin carcinomas (3.9%), occurred among the 1,476 patients who received IMBRUVICA® in clinical trials. The most frequent second primary malignancy was non-melanoma skin cancer (6%). Tumor Lysis Syndrome: Tumor lysis syndrome has been infrequently reported with IMBRUVICA®. Assess the baseline risk (e.g., high tumor burden) and take appropriate precautions. Monitor patients closely and treat as appropriate. Embryo-Fetal Toxicity: Based on findings in animals, IMBRUVICA® can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with IMBRUVICA® and for 1 month after the last dose. Advise males with female partners of reproductive potential to use effective contraception during the same time period. ADVERSE REACTIONS B-cell malignancies: The most common adverse reactions (≥30%) in patients with B-cell malignancies (MCL, CLL/SLL, WM and MZL) were thrombocytopenia (54.5%), diarrhea (43.8%), fatigue (39.1%), musculoskeletal pain (38.8%), neutropenia (38.6%), rash (35.8%), anemia (35.0%), and bruising (32.0%). The most common Grade ≥ 3 adverse reactions (≥5%) in patients with B-cell malignancies (MCL, CLL/SLL, WM and MZL) were neutropenia (20.7%), thrombocytopenia (13.6%), pneumonia (8.2%), and hypertension (8.0%). Approximately 9% (CLL/SLL), 14% (MCL), 14% (WM) and 10% (MZL) of patients had a dose reduction due to adverse reactions. Approximately 4-10% (CLL/SLL), 9% (MCL), and 7% (WM [5%] and MZL [13%]) of patients discontinued due to adverse reactions. cGVHD: The most common adverse reactions (≥20%) in patients with cGVHD were fatigue (57%), bruising (40%), diarrhea (36%), thrombocytopenia (33%), muscle spasms (29%), stomatitis (29%), nausea (26%), hemorrhage (26%), anemia (24%), and pneumonia (21%). The most common Grade 3 or higher adverse reactions (≥5%) reported in patients with cGVHD were pneumonia (14%), fatigue (12%), diarrhea (10%), neutropenia (10%), sepsis (10%), hypokalemia (7%), headache (5%), musculoskeletal pain (5%), and pyrexia (5%). Twenty-four percent of patients receiving IMBRUVICA® in the cGVHD trial discontinued treatment due to adverse reactions. Adverse reactions leading to dose reduction occurred in 26% of patients. Treatment-emergent decreases (all grades) were based on laboratory measurements. DRUG INTERACTIONS CYP3A Inhibitors: Co-administration of IMBRUVICA® with strong or moderate CYP3A inhibitors may increase ibrutinib plasma concentrations. Increased ibrutinib concentrations may increase the risk of drug-related toxicity. Dose modifications of IMBRUVICA® are recommended when used concomitantly with posaconazole, voriconazole, and moderate CYP3A inhibitors. Avoid concomitant use of other strong CYP3A inhibitors. Interrupt IMBRUVICA® if strong inhibitors are used short-term (e.g., for ≤ 7 days). Avoid grapefruit and Seville oranges during IMBRUVICA® treatment, as these contain strong or moderate inhibitors of CYP3A. See dose modification guidelines in USPI sections 2.3 and 7.1. CYP3A Inducers: Avoid coadministration with strong CYP3A inducers. SPECIFIC POPULATIONS Hepatic Impairment (based on Child-Pugh criteria): Avoid use of IMBRUVICA® in patients with severe hepatic impairment. In patients with mild or moderate impairment, reduce recommended IMBRUVICA® dose and monitor more frequently for adverse reactions of IMBRUVICA®. Please click here to see the full Prescribing Information. DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) INDICATIONS AND IMPORTANT SAFETY INFORMATION INDICATIONS DARZALEX® (daratumumab) is indicated for the treatment of adult patients with multiple myeloma: - In combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy - In combination with bortezomib, melphalan, and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant - In combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant - In combination with bortezomib and dexamethasone in patients who have received at least one prior therapy - In combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy - In combination with pomalidomide and dexamethasone in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (PI) - As monotherapy in patients who have received at least three prior lines of therapy including a PI and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) is indicated for the treatment of adult patients with multiple myeloma: - In combination with bortezomib, melphalan, and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant - In combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy - In combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant - In combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor (PI) - In combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy - In combination with bortezomib and dexamethasone in patients who have received at least one prior therapy - As monotherapy in patients who have received at least three prior lines of therapy including a PI and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent DARZALEX® AND DARZALEX FASPRO®: CONTRAINDICATIONS DARZALEX® and DARZALEX FASPRO® are contraindicated in patients with a history of severe hypersensitivity to daratumumab, hyaluronidase (for DARZALEX FASPRO®), or any of the components of the formulations. DARZALEX®: Infusion-Related Reactions DARZALEX® can cause severe and/or serious infusion-related reactions including anaphylactic reactions. These reactions can be life-threatening, and fatal outcomes have been reported. In clinical trials (monotherapy and combination: N=2066), infusion-related reactions occurred in 37% of patients with the Week 1 (16 mg/kg) infusion, 2% with the Week 2 infusion, and cumulatively 6% with subsequent infusions. Less than 1% of patients had a Grade 3/4 infusion-related reaction at Week 2 or subsequent infusions. The median time to onset was 1.5 hours (range: 0 to 73 hours). Nearly all reactions occurred during infusion or within 4 hours of completing DARZALEX®. Severe reactions have occurred, including bronchospasm, hypoxia, dyspnea, hypertension, tachycardia, headache, laryngeal edema, pulmonary edema, and ocular adverse reactions, including choroidal effusion, acute myopia, and acute angle closure glaucoma. Signs and symptoms may include respiratory symptoms, such as nasal congestion, cough, throat irritation, as well as chills, vomiting, and nausea. Less common signs and symptoms were wheezing, allergic rhinitis, pyrexia, chest discomfort, pruritus, hypotension, and blurred vision. When DARZALEX® dosing was interrupted in the setting of ASCT (CASSIOPEIA) for a median of 3.75 months (range: 2.4 to 6.9 months), upon re-initiation of DARZALEX®, the incidence of infusion-related reactions was 11% for the first infusion following ASCT. Infusion-related reactions occurring at re-initiation of DARZALEX® following ASCT were consistent in terms of symptoms and severity (Grade 3 or 4: <1%) with those reported in previous studies at Week 2 or subsequent infusions. In EQUULEUS, patients receiving combination treatment (n=97) were administered the first 16 mg/kg dose at Week 1 split over two days, i.e., 8 mg/kg on Day 1 and Day 2, respectively. The incidence of any grade infusion-related reactions was 42%, with 36% of patients experiencing infusion-related reactions on Day 1 of Week 1, 4% on Day 2 of Week 1, and 8% with subsequent infusions. Pre-medicate patients with antihistamines, antipyretics, and corticosteroids. Frequently monitor patients during the entire infusion. Interrupt DARZALEX® infusion for reactions of any severity and institute medical management as needed. Permanently discontinue DARZALEX® therapy if an anaphylactic reaction or life-threatening (Grade 4) reaction occurs and institute appropriate emergency care. For patients with Grade 1, 2, or 3 reactions, reduce the infusion rate when re-starting the infusion. To reduce the risk of delayed infusion-related reactions, administer oral corticosteroids to all patients following DARZALEX® infusions. Patients with a history of chronic obstructive pulmonary disease may require additional post-infusion medications to manage respiratory complications. Consider prescribing short and long-acting bronchodilators and inhaled corticosteroids for patients with chronic obstructive pulmonary disease. Ocular adverse reactions, including acute myopia and narrowing of the anterior chamber angle due to ciliochoroidal effusions with potential for increased intraocular pressure or glaucoma, have occurred with DARZALEX® infusion. If ocular symptoms occur, interrupt DARZALEX® infusion and seek immediate ophthalmologic evaluation prior to restarting DARZALEX®. DARZALEX FASPRO®: Hypersensitivity and Other Administration Reactions Both systemic administration-related reactions, including severe or life-threatening reactions, and local injection-site reactions can occur with DARZALEX FASPRO®. Fatal reactions have been reported with daratumumab-containing products, including DARZALEX FASPRO®. Systemic Reactions In a pooled safety population of 898 patients with multiple myeloma (N=705) or light chain (AL) amyloidosis (N=193) who received DARZALEX FASPRO® as monotherapy or in combination, 9% of patients experienced a systemic administration-related reaction (Grade 2: 3.2%, Grade 3: 1%). Systemic administration-related reactions occurred in 8% of patients with the first injection, 0.3% with the second injection, and cumulatively 1% with subsequent injections. The median time to onset was 3.2 hours (range: 4 minutes to 3.5 days). Of the 140 systemic administration-related reactions that occurred in 77 patients, 121 (86%) occurred on the day of DARZALEX FASPRO® administration. Delayed systemic administration-related reactions have occurred in 1% of the patients. Severe reactions included hypoxia, dyspnea, hypertension, tachycardia, and ocular adverse reactions, including choroidal effusion, acute myopia, and acute angle closure glaucoma. Other signs and symptoms of systemic administration-related reactions may include respiratory symptoms, such as bronchospasm, nasal congestion, cough, throat irritation, allergic rhinitis, and wheezing, as well as anaphylactic reaction, pyrexia, chest pain, pruritus, chills, vomiting, nausea, hypotension, and blurred vision. Pre-medicate patients with histamine-1 receptor antagonist, acetaminophen, and corticosteroids. Monitor patients for systemic administration-related reactions, especially following the first and second injections. For anaphylactic reaction or life-threatening (Grade 4) administration-related reactions, immediately and permanently discontinue DARZALEX FASPRO®. Consider administering corticosteroids and other medications after the administration of DARZALEX FASPRO® depending on dosing regimen and medical history to minimize the risk of delayed (defined as occurring the day after administration) systemic administration-related reactions. Ocular adverse reactions, including acute myopia and narrowing of the anterior chamber angle due to ciliochoroidal effusions with potential for increased intraocular pressure or glaucoma, have occurred with daratumumab-containing products. If ocular symptoms occur, interrupt DARZALEX FASPRO® and seek immediate ophthalmologic evaluation prior to restarting DARZALEX FASPRO®. Local Reactions In this pooled safety population, injection-site reactions occurred in 8% of patients, including Grade 2 reactions in 0.7%. The most frequent (>1%) injection-site reaction was injection-site erythema. These local reactions occurred a median of 5 minutes (range: 0 minutes to 6.5 days) after starting administration of DARZALEX FASPRO®. Monitor for local reactions and consider symptomatic management. DARZALEX® and DARZALEX FASPRO®: Neutropenia and Thrombocytopenia DARZALEX® and DARZALEX FASPRO® may increase neutropenia and thrombocytopenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Monitor patients with neutropenia for signs of infection. Consider withholding DARZALEX® or DARZALEX FASPRO® until recovery of neutrophils or for recovery of platelets. In lower body weight patients receiving DARZALEX FASPRO®, higher rates of Grade 3-4 neutropenia were observed. DARZALEX® and DARZALEX FASPRO®: Interference With Serological Testing Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive indirect antiglobulin test (indirect Coombs test). Daratumumab-mediated positive indirect antiglobulin test may persist for up to 6 months after the last daratumumab administration. Daratumumab bound to RBCs masks detection of antibodies to minor antigens in the patient's serum. The determination of a patient's ABO and Rh blood type are not impacted. Notify blood transfusion centers of this interference with serological testing and inform blood banks that a patient has received DARZALEX® and DARZALEX FASPRO®. Type and screen patients prior to starting DARZALEX® and DARZALEX FASPRO®. DARZALEX® and DARZALEX FASPRO®: Interference With Determination of Complete Response Daratumumab is a human immunoglobulin G (IgG) kappa monoclonal antibody that can be detected on both the serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for the clinical monitoring of endogenous M-protein. This interference can impact the determination of complete response and of disease progression in some patients with IgG kappa myeloma protein. DARZALEX® and DARZALEX FASPRO®: Embryo-Fetal Toxicity Based on the mechanism of action, DARZALEX® and DARZALEX FASPRO® can cause fetal harm when administered to a pregnant woman. DARZALEX® and DARZALEX FASPRO® may cause depletion of fetal immune cells and decreased bone density. Advise pregnant women of the potential risk to a fetus. Advise females with reproductive potential to use effective contraception during treatment with DARZALEX® or DARZALEX FASPRO® and for 3 months after the last dose. The combination of DARZALEX® or DARZALEX FASPRO® with lenalidomide, pomalidomide, or thalidomide is contraindicated in pregnant women because lenalidomide, pomalidomide, and thalidomide may cause birth defects and death of the unborn child. Refer to the lenalidomide, pomalidomide, or thalidomide prescribing information on use during pregnancy. DARZALEX®: ADVERSE REACTIONS The most frequently reported adverse reactions (incidence ≥20%) were upper respiratory infection, neutropenia, infusion-related reactions, thrombocytopenia, diarrhea, constipation, anemia, peripheral sensory neuropathy, fatigue, peripheral edema, nausea, cough, pyrexia, dyspnea, and asthenia. The most common hematologic laboratory abnormalities (≥40%) with DARZALEX® are neutropenia, lymphopenia, thrombocytopenia, leukopenia, and anemia. DARZALEX FASPRO®: ADVERSE REACTIONS In multiple myeloma, the most common adverse reaction (≥20%) with DARZALEX FASPRO® monotherapy is upper respiratory tract infection. The most common adverse reactions with combination therapy (≥20% for any combination) include fatigue, nausea, diarrhea, dyspnea, insomnia, headache, pyrexia, cough, muscle spasms, back pain, vomiting, hypertension, upper respiratory tract infection, peripheral sensory neuropathy, constipation, pneumonia, and peripheral edema. The most common hematologic laboratory abnormalities (≥40%) with DARZALEX FASPRO® are decreased leukocytes, decreased lymphocytes, decreased neutrophils, decreased platelets, and decreased hemoglobin. Please read full Prescribing Information for DARZALEX®. Please read full Prescribing Information for DARZALEX FASPRO®. CARVYKTI™ IMPORTANT SAFETY INFORMATION INDICATIONS AND USAGE CARVYKTI™ (ciltacabtagene autoleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma, after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. WARNINGS AND PRECAUTIONS Cytokine Release Syndrome (CRS) including fatal or life-threatening reactions, occurred following treatment with CARVYKTI™ in 95% (92/97) of patients receiving ciltacabtagene autoleucel. Grade 3 or higher CRS (2019 ASTCT grade) occurred in 5% (5/97) of patients, with Grade 5 CRS reported in 1 patient. The median time to onset of CRS was 7 days (range: 1-12 days). The most common manifestations of CRS included pyrexia (100%), hypotension (43%), increased aspartate aminotransferase (AST) (22%), chills (15%), increased alanine aminotransferase (14%) and sinus tachycardia (11%). Grade 3 or higher events associated with CRS included increased AST and ALT, hyperbilirubinemia, hypotension, pyrexia, hypoxia, respiratory failure, acute kidney injury, disseminated intravascular coagulation, HLH/MAS, angina pectoris, supraventricular and ventricular tachycardia, malaise, myalgias, increased C-reactive protein, ferritin, blood alkaline phosphatase and gamma-glutamyl transferase. Identify CRS based on clinical presentation. Evaluate for and treat other causes of fever, hypoxia, and hypotension. CRS has been reported to be associated with findings of HLH/MAS, and the physiology of the syndromes may overlap. HLH/MAS is a potentially life-threatening condition. In patients with progressive symptoms of CRS or refractory CRS despite treatment, evaluate for evidence of HLH/MAS. Sixty-nine of 97 (71%) patients received tocilizumab and/or a corticosteroid for CRS after infusion of ciltacabtagene autoleucel. Forty-four (45%) patients received only tocilizumab, of whom 33 (34%) received a single dose and 11 (11%) received more than one dose; 24 patients (25%) received tocilizumab and a corticosteroid, and one patient (1%) received only corticosteroids. Ensure that a minimum of two doses of tocilizumab are available prior to infusion of CARVYKTI™. Monitor patients at least daily for 10 days following CARVYKTI™ infusion at a REMS-certified healthcare facility for signs and symptoms of CRS. Monitor patients for signs or symptoms of CRS for at least 4 weeks after infusion. At the first sign of CRS, immediately institute treatment with supportive care, tocilizumab, or tocilizumab and corticosteroids. Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur at any time. Neurologic toxicities, which may be severe, life-threatening or fatal, occurred following treatment with CARVYKTI™. Neurologic toxicities included ICANS, neurologic toxicity with signs and symptoms of parkinsonism, Guillain-Barré Syndrome, peripheral neuropathies, and cranial nerve palsies. Counsel patients on the signs and symptoms of these neurologic toxicities, and on the delayed nature of onset of some of these toxicities. Instruct patients to seek immediate medical attention for further assessment and management if signs or symptoms of any of these neurologic toxicities occur at any time. Overall, one or more subtypes of neurologic toxicity described below occurred following ciltacabtagene autoleucel in 26% (25/97) of patients, of which 11% (11/97) of patients experienced Grade 3 or higher events. These subtypes of neurologic toxicities were also observed in two ongoing studies. Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS): Patients may experience fatal or life-threatening ICANS following treatment with CARVYKTI™, including before CRS onset, concurrently with CRS, after CRS resolution, or in the absence of CRS. ICANS occurred in 23% (22/97) of patients receiving ciltacabtagene autoleucel including Grade 3 or 4 events in 3% (3/97) and Grade 5 (fatal) events in 2% (2/97). The median time to onset of ICANS was 8 days (range 1-28 days). All 22 patients with ICANS had CRS. The most frequent (≥5%) manifestation of ICANS included encephalopathy (23%), aphasia (8%) and headache (6%). Monitor patients at least daily for 10 days following CARVYKTI™ infusion at the REMS-certified healthcare facility for signs and symptoms of ICANS. Rule out other causes of ICANS symptoms. Monitor patients for signs or symptoms of ICANS for at least 4 weeks after infusion and treat promptly. Neurologic toxicity should be managed with supportive care and/or corticosteroids as needed. Parkinsonism: Of the 25 patients in the CARTITUDE-1 study experiencing any neurotoxicity, five male patients had neurologic toxicity with several signs and symptoms of parkinsonism, distinct from immune effector cell-associated neurotoxicity syndrome (ICANS). Neurologic toxicity with parkinsonism has been reported in other ongoing trials of ciltacabtagene autoleucel. Patients had parkinsonian and non-parkinsonian symptoms that included tremor, bradykinesia, involuntary movements, stereotypy, loss of spontaneous movements, masked facies, apathy, flat affect, fatigue, rigidity, psychomotor retardation, micrographia, dysgraphia, apraxia, lethargy, confusion, somnolence, loss of consciousness, delayed reflexes, hyperreflexia, memory loss, difficulty swallowing, bowel incontinence, falls, stooped posture, shuffling gait, muscle weakness and wasting, motor dysfunction, motor and sensory loss, akinetic mutism, and frontal lobe release signs. The median onset of parkinsonism in the 5 patients in CARTITUDE-1 was 43 days (range 15-108) from infusion of ciltacabtagene autoleucel. Monitor patients for signs and symptoms of parkinsonism that may be delayed in onset and managed with supportive care measures. There is limited efficacy information with medications used for the treatment of Parkinson's disease, for the improvement or resolution of parkinsonism symptoms following CARVYKTI™ treatment. Guillain-Barré Syndrome: A fatal outcome following Guillain-Barré Syndrome (GBS) has occurred in another ongoing study of ciltacabtagene autoleucel despite treatment with intravenous immunoglobulins. Symptoms reported include those consistent with Miller-Fisher variant of GBS, encephalopathy, motor weakness, speech disturbances and polyradiculoneuritis. Monitor for GBS. Evaluate patients presenting with peripheral neuropathy for GBS. Consider treatment of GBS with supportive care measures and in conjunction with immunoglobulins and plasma exchange, depending on severity of GBS. Peripheral Neuropathy: Six patients in CARTITUDE-1 developed peripheral neuropathy. These neuropathies presented as sensory, motor or sensorimotor neuropathies. Median time of onset of symptoms was 62 days (range 4-136 days), median duration of peripheral neuropathies was 256 days (range 2-465 days) including those with ongoing neuropathy. Patients who experienced peripheral neuropathy also experienced cranial nerve palsies or GBS in other ongoing trials of ciltacabtagene autoleucel. Cranial Nerve Palsies: Three patients (3.1%) experienced cranial nerve palsies in CARTITUDE-1. All three patients had 7th cranial nerve palsy; one patient had 5th cranial nerve palsy as well. Median time to onset was 26 days (range 21-101 days) following infusion of ciltacabtagene autoleucel. Occurrence of 3rd and 6th cranial nerve palsy, bilateral 7th cranial nerve palsy, worsening of cranial nerve palsy after improvement, and occurrence of peripheral neuropathy in patients with cranial nerve palsy have also been reported in ongoing trials of ciltacabtagene autoleucel. Monitor patients for signs and symptoms of cranial nerve palsies. Consider management with systemic corticosteroids, depending on the severity and progression of signs and symptoms. Hemophagocytic Lymphohistiocytosis (HLH)/Macrophage Activation Syndrome (MAS): Fatal HLH occurred in one patient (1%), 99 days after ciltacabtagene autoleucel. The HLH event was preceded by prolonged CRS lasting 97 days. The manifestations of HLH/MAS include hypotension, hypoxia with diffuse alveolar damage, coagulopathy, cytopenia, and multi-organ dysfunction, including renal dysfunction. HLH is a life-threatening condition with a high mortality rate if not recognized and treated early. Treatment of HLH/MAS should be administered per institutional standards. CARVYKTI™ REMS: Because of the risk of CRS and neurologic toxicities, CARVYKTI™ is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the CARVYKTI™ REMS. Further information is available at www.CARVYKTIrems.com or 1-844-672-0067. Prolonged and Recurrent Cytopenias: Patients may exhibit prolonged and recurrent cytopenias following lymphodepleting chemotherapy and CARVYKTI™ infusion. One patient underwent autologous stem cell therapy for hematopoietic reconstitution due to prolonged thrombocytopenia. In CARTITUDE-1, 30% (29/97) of patients experienced prolonged Grade 3 or 4 neutropenia and 41% (40/97) of patients experienced prolonged Grade 3 or 4 thrombocytopenia that had not resolved by Day 30 following ciltacabtagene autoleucel infusion. Recurrent Grade 3 or 4 neutropenia, thrombocytopenia, lymphopenia and anemia were seen in 63% (61/97), 18% (17/97), 60% (58/97), and 37% (36/97) after recovery from initial Grade 3 or 4 cytopenia following infusion. After Day 60 following ciltacabtagene autoleucel infusion, 31%, 12% and 6% of patients had a recurrence of Grade 3 or higher lymphopenia, neutropenia and thrombocytopenia, respectively, after initial recovery of their Grade 3 or 4 cytopenia. Eighty-seven percent (84/97) of patients had one, two, or three or more recurrences of Grade 3 or 4 cytopenias after initial recovery of Grade 3 or 4 cytopenia. Six and 11 patients had Grade 3 or 4 neutropenia and thrombocytopenia, respectively, at the time of death. Monitor blood counts prior to and after CARVYKTI™ infusion. Manage cytopenias with growth factors and blood product transfusion support according to local institutional guidelines. Infections: CARVYKTI™ should not be administered to patients with active infection or inflammatory disorders. Severe, life-threatening or fatal infections occurred in patients after CARVYKTI™ infusion. Infections (all grades) occurred in 57 (59%) patients. Grade 3 or 4 infections occurred in 23% (22/97) of patients; Grade 3 or 4 infections with an unspecified pathogen occurred in 17%, viral infections in 7%, bacterial infections in 1%, and fungal infections in 1% of patients. Overall, four patients had Grade 5 infections: lung abscess (n=1), sepsis (n=2) and pneumonia (n=1). Monitor patients for signs and symptoms of infection before and after CARVYKTI™ infusion and treat patients appropriately. Administer prophylactic, pre-emptive and/or therapeutic antimicrobials according to the standard institutional guidelines. Febrile neutropenia was observed in 10% of patients after ciltacabtagene autoleucel infusion, and may be concurrent with CRS. In the event of febrile neutropenia, evaluate for infection and manage with broad-spectrum antibiotics, fluids and other supportive care, as medically indicated. Viral Reactivation: Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure and death, can occur in patients with hypogammaglobulinemia. Perform screening for Cytomegalovirus (CMV), HBV, hepatitis C virus (HCV), and human immunodeficiency virus (HIV), or any other infectious agents if clinically indicated in accordance with clinical guidelines before collection of cells for manufacturing. Consider antiviral therapy to prevent viral reactivation per local institutional guidelines/clinical practice. Hypogammaglobulinemia was reported as an adverse event in 12% (12/97) of patients; laboratory IgG levels fell below 500 mg/dL after infusion in 92% (89/97) of patients. Monitor immunoglobulin levels after treatment with CARVYKTI™ and administer IVIG for IgG <400 mg/dL. Manage per local institutional guidelines, including infection precautions and antibiotic or antiviral prophylaxis. Use of Live Vaccines: The safety of immunization with live viral vaccines during or following CARVYKTI™ treatment has not been studied. Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during CARVYKTI™ treatment, and until immune recovery following treatment with CARVYKTI™. Hypersensitivity Reactions have occurred in 5% (5/97) of patients following ciltacabtagene autoleucel infusion. Serious hypersensitivity reactions, including anaphylaxis, may be due to the dimethyl sulfoxide (DMSO) in CARVYKTI™. Patients should be carefully monitored for 2 hours after infusion for signs and symptoms of severe reaction. Treat promptly and manage appropriately according to the severity of the hypersensitivity reaction. Secondary Malignancies: Patients may develop secondary malignancies. Monitor life-long for secondary malignancies. In the event that a secondary malignancy occurs, contact Janssen Biotech, Inc., at 1-800-526-7736 for reporting and to obtain instructions on collection of patient samples for testing of secondary malignancy of T cell origin. Effects on Ability to Drive and Use Machines: Due to the potential for neurologic events, including altered mental status, seizures, neurocognitive decline, or neuropathy, patients are at risk for altered or decreased consciousness or coordination in the 8 weeks following CARVYKTI™ infusion. Advise patients to refrain from driving and engaging in hazardous occupations or activities, such as operating heavy or potentially dangerous machinery during this initial period, and in the event of new onset of any neurologic toxicities. ADVERSE REACTIONS The most common non-laboratory adverse reactions (incidence greater than 20%) are pyrexia, cytokine release syndrome, hypogammaglobulinemia, hypotension, musculoskeletal pain, fatigue, infections of unspecified pathogen, cough, chills, diarrhea, nausea, encephalopathy, decreased appetite, upper respiratory tract infection, headache, tachycardia, dizziness, dyspnea, edema, viral infections, coagulopathy, constipation, and vomiting. The most common laboratory adverse reactions (incidence greater than or equal to 50%) include thrombocytopenia, neutropenia, anemia, aminotransferase elevation, and hypoalbuminemia. Please read full Prescribing Information including Boxed Warning for CARVYKTI™. BALVERSA® IMPORTANT SAFETY INFORMATION Warnings and Precautions Ocular Disorders – BALVERSA® can cause ocular disorders, including central serous retinopathy/retinal pigment epithelial detachment (CSR/RPED) resulting in visual field defect. CSR/RPED was reported in 25% of patients treated with BALVERSA®, with a median time to first onset of 50 days. Grade 3 CSR/RPED, involving central field of vision, was reported in 3% of patients. CSR/RPED resolved in 13% of patients and was ongoing in 13% of patients at the study cutoff. CSR/RPED led to dose interruptions and reductions in 9% and 14% of patients, respectively, and 3% of patients discontinued BALVERSA®. Dry eye symptoms occurred in 28% of patients during treatment with BALVERSA® and were Grade 3 in 6% of patients. All patients should receive dry eye prophylaxis with ocular demulcents as needed. Perform monthly ophthalmological examinations during the first 4 months of treatment and every 3 months afterwards, and urgently at any time for visual symptoms. Ophthalmological examination should include assessment of visual acuity, slit lamp examination, fundoscopy, and optical coherence tomography. Withhold BALVERSA® when CSR occurs and permanently discontinue if it does not resolve within 4 weeks or if Grade 4 in severity. For ocular adverse reactions, follow the dose modification guidelines [see Dosage and Administration (2.3)]. Hyperphosphatemia and Soft Tissue Mineralization – BALVERSA® can cause hyperphosphatemia leading to soft tissue mineralization, cutaneous calcinosis, non-uremic calciphylaxis and vascular calcification. Increases in phosphate levels are a pharmacodynamic effect of BALVERSA® [see Pharmacodynamics (12.2)]. Hyperphosphatemia was reported as adverse reaction in 76% of patients treated with BALVERSA®. The median onset time for any grade event of hyperphosphatemia was 20 days (range: 8–116) after initiating BALVERSA®. Thirty-two percent of patients received phosphate binders during treatment with BALVERSA®. Cutaneous calcinosis, non-uremic calciphylaxis and vascular calcification have been observed in 0.3% of patients treated with BALVERSA®. Monitor for hyperphosphatemia throughout treatment. In all patients, restrict phosphate intake to 600-800 mg daily. If serum phosphate is above 7.0 mg/dL, consider adding an oral phosphate binder until serum phosphate level returns to <5.5 mg/dL. Withhold, dose reduce, or permanently discontinue BALVERSA® based on duration and severity of hyperphosphatemia [see Dosage and Administration (2.3), Table 2: Dose Modifications for Adverse Reactions]. Embryo-fetal Toxicity – Based on the mechanism of action and findings in animal reproduction studies, BALVERSA® can cause fetal harm when administered to a pregnant woman. In a rat embryo-fetal toxicity study, erdafitinib was embryotoxic and teratogenic at exposures less than the human exposures at all doses studied. Advise pregnant women of the potential risk to the fetus. Advise female patients of reproductive potential to use effective contraception during treatment with BALVERSA® and for one month after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with BALVERSA® and for one month after the last dose [see Use in Specific Populations (8.1, 8.3) and Clinical Pharmacology (12.1)]. Most common adverse reactions including laboratory abnormalities ≥20%: Phosphate increased (76%), stomatitis (56%), fatigue (54%), creatinine increased (52%), diarrhea (47%), dry mouth (45%), onycholysis (41%), alanine aminotransferase increased (41%), alkaline phosphatase increased (41%), sodium decreased (40%), decreased appetite (38%), albumin decreased (37%), dysgeusia (37%), hemoglobin decreased (35%), dry skin (34%), aspartate aminotransferase increased (30%), magnesium decreased (30%), dry eye (28%), alopecia (26%), palmar-plantar erythrodysesthesia syndrome (26%), constipation (28%), phosphate decreased (24%), abdominal pain (23%), calcium increased (22%), nausea (21%), and musculoskeletal pain (20%). The most common Grade 3 or greater adverse reactions (>1%) were stomatitis (9%), nail dystrophy, palmar-plantar erythrodysesthesia syndrome (6%), paronychia (3%), nail disorder, keratitis†, onycholysis (10%), and hyperphosphatemia. *Included within onycholysis. †Included within dry eye. - An adverse reaction with a fatal outcome in 1% of patients was acute myocardial infarction. - Serious adverse reactions occurred in 41% of patients, including eye disorders (10%). - Permanent discontinuation due to an adverse reaction occurred in 13% of patients. The most frequent reasons for permanent discontinuation included eye disorders (6%). - Dosage interruptions occurred in 68% of patients. The most frequent adverse reactions requiring dosage interruption included hyperphosphatemia (24%), stomatitis (17%), eye disorders (17%), and palmar-plantar erythrodysesthesia syndrome (8%). - Dose reductions occurred in 53% of patients. The most frequent adverse reactions for dose reductions included eye disorders (23%), stomatitis (15%), hyperphosphatemia (7%), palmar-plantar erythrodysesthesia syndrome (7%), paronychia (7%), and nail dystrophy (6%). Drug Interactions - Moderate CYP2C9 or strong CYP3A4 Inhibitors: Consider alternative agents or monitor closely for adverse reactions. (7.1) - Strong CYP2C9 or CYP3A4 inducers: Avoid concomitant use with BALVERSA®. (7.1) - Moderate CYP2C9 or CYP3A4 inducers: Increase BALVERSA® dose up to 9 mg. (7.1) - Serum phosphate level-altering agents: Avoid concomitant use with agents that can alter serum phosphate levels before the initial dose modification period. (2.3, 7.1) - CYP3A4 substrates: Avoid concomitant use with sensitive CYP3A4 substrates with narrow therapeutic indices. (7.2) - OCT2 substrates: Consider alternative agents or consider reducing the dose of OCT2 substrates based on tolerability. (7.2) - P-gp substrates: Separate BALVERSA® administration by at least 6 hours before or after administration of P-gp substrates with narrow therapeutic indices. (7.2) Use in Specific Populations Lactation – Because of the potential for serious adverse reactions from erdafitinib in a breastfed child, advise lactating women not to breastfeed during treatment with BALVERSA® and for one month following the last dose. Please see the full Prescribing Information for BALVERSA®. RYBREVANT® IMPORTANT SAFETY INFORMATION19 WARNINGS AND PRECAUTIONS Infusion Related Reactions19 RYBREVANT® can cause infusion related reactions (IRR); signs and symptoms of IRR include dyspnea, flushing, fever, chills, nausea, chest discomfort, hypotension, and vomiting. Based on the safety population, IRR occurred in 66% of patients treated with RYBREVANT®. Among patients receiving treatment on Week 1 Day 1, 65% experienced an IRR, while the incidence of IRR was 3.4% with the Day 2 infusion, 0.4% with the Week 2 infusion, and cumulatively 1.1% with subsequent infusions. Of the reported IRRs, 97% were Grade 1-2, 2.2% were Grade 3, and 0.4% were Grade 4. The median time to onset was 1 hour (range 0.1 to 18 hours) after start of infusion. The incidence of infusion modifications due to IRR was 62% and 1.3% of patients permanently discontinued RYBREVANT® due to IRR. Premedicate with antihistamines, antipyretics, and glucocorticoids and infuse RYBREVANT® as recommended. Administer RYBREVANT® via a peripheral line on Week 1 and Week 2. Monitor patients for any signs and symptoms of infusion reactions during RYBREVANT® infusion in a setting where cardiopulmonary resuscitation medication and equipment are available. Interrupt infusion if IRR is suspected. Reduce the infusion rate or permanently discontinue RYBREVANT® based on severity. Interstitial Lung Disease/Pneumonitis19 RYBREVANT® can cause interstitial lung disease (ILD)/pneumonitis. Based on the safety population, ILD/pneumonitis occurred in 3.3% of patients treated with RYBREVANT®, with 0.7% of patients experiencing Grade 3 ILD/pneumonitis. Three patients (1%) discontinued RYBREVANT® due to ILD/pneumonitis. Monitor patients for new or worsening symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever). Immediately withhold RYBREVANT® in patients with suspected ILD/pneumonitis and permanently discontinue if ILD/pneumonitis is confirmed. Dermatologic Adverse Reactions19 RYBREVANT® can cause rash (including dermatitis acneiform), pruritus and dry skin. Based on the safety population, rash occurred in 74% of patients treated with RYBREVANT®, including Grade 3 rash in 3.3% of patients. The median time to onset of rash was 14 days (range: 1 to 276 days). Rash leading to dose reduction occurred in 5% of patients, and RYBREVANT® was permanently discontinued due to rash in 0.7% of patients. Toxic epidermal necrolysis occurred in one patient (0.3%) treated with RYBREVANT®. Instruct patients to limit sun exposure during and for 2 months after treatment with RYBREVANT®. Advise patients to wear protective clothing and use broad spectrum UVA/UVB sunscreen. Alcohol free emollient cream is recommended for dry skin. If skin reactions develop, start topical corticosteroids and topical and/or oral antibiotics. For Grade 3 reactions, add oral steroids and consider dermatologic consultation. Promptly refer patients presenting with severe rash, atypical appearance or distribution, or lack of improvement within 2 weeks to a dermatologist. Withhold, dose reduce or permanently discontinue RYBREVANT® based on severity. Ocular Toxicity19 RYBREVANT® can cause ocular toxicity including keratitis, dry eye symptoms, conjunctival redness, blurred vision, visual impairment, ocular itching, and uveitis. Based on the safety population, keratitis occurred in 0.7% and uveitis occurred in 0.3% of patients treated with RYBREVANT®. All events were Grade 1-2. Promptly refer patients presenting with eye symptoms to an ophthalmologist. Withhold, dose reduce or permanently discontinue RYBREVANT® based on severity. Embryo Fetal Toxicity19 Based on its mechanism of action and findings from animal models, RYBREVANT® can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the potential risk to the fetus. Advise female patients of reproductive potential to use effective contraception during treatment and for 3 months after the final dose of RYBREVANT®. Adverse Reactions19 The most common adverse reactions (≥20%) were rash (84%), IRR (64%), paronychia (50%), musculoskeletal pain (47%), dyspnea (37%), nausea (36%), fatigue (33%), edema (27%), stomatitis (26%), cough (25%), constipation (23%), and vomiting (22%). The most common Grade3 to 4 laboratory abnormalities (≥2%) were decreased lymphocytes (8%), decreased albumin (8%), decreased phosphate (8%), decreased potassium (6%), increased alkaline phosphatase (4.8%), increased glucose (4%), increased gamma-glutamyl transferase (4%), and decreased sodium (4%). Please read full Prescribing Information for RYBREVANT®. ERLEADA® IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS Cerebrovascular and Ischemic Cardiovascular Events — In a randomized study (SPARTAN) of patients with nmCRPC, ischemic cardiovascular events occurred in 3.7% of patients treated with ERLEADA® and 2% of patients treated with placebo. In a randomized study (TITAN) in patients with mCSPC, ischemic cardiovascular events occurred in 4.4% of patients treated with ERLEADA® and 1.5% of patients treated with placebo. Across the SPARTAN and TITAN studies, 4 patients (0.3%) treated with ERLEADA® and 2 patients (0.2%) treated with placebo died from an ischemic cardiovascular event. Patients with history of unstable angina, myocardial infarction, congestive heart failure, stroke, or transient ischemic attack within 6 months of randomization were excluded from the SPARTAN and TITAN studies. In the SPARTAN study, cerebrovascular events occurred in 2.5% of patients treated with ERLEADA® and 1% of patients treated with placebo. In the TITAN study, cerebrovascular events occurred in 1.9% of patients treated with ERLEADA® and 2.1% of patients treated with placebo. Across the SPARTAN and TITAN studies, 3 patients (0.2%) treated with ERLEADA®, and 2 patients (0.2%) treated with placebo died from a cerebrovascular event. Cerebrovascular and ischemic cardiovascular events, including events leading to death, occurred in patients receiving ERLEADA®. Monitor for signs and symptoms of ischemic heart disease and cerebrovascular disorders. Optimize management of cardiovascular risk factors, such as hypertension, diabetes, or dyslipidemia. Consider discontinuation of ERLEADA® for Grade 3 and 4 events. Fractures — In a randomized study (SPARTAN) of patients with nmCRPC, fractures occurred in 12% of patients treated with ERLEADA® and in 7% of patients treated with placebo. In a randomized study (TITAN) of patients with mCSPC, fractures occurred in 9% of patients treated with ERLEADA® and in 6% of patients treated with placebo. Evaluate patients for fracture risk. Monitor and manage patients at risk for fractures according to established treatment guidelines and consider use of bone-targeted agents. Falls — In a randomized study (SPARTAN), falls occurred in 16% of patients treated with ERLEADA® compared with 9% of patients treated with placebo. Falls were not associated with loss of consciousness or seizure. Falls occurred in patients receiving ERLEADA® with increased frequency in the elderly. Evaluate patients for fall risk. Seizure — In two randomized studies (SPARTAN and TITAN), 5 patients (0.4%) treated with ERLEADA® and 1 patient treated with placebo (0.1%) experienced a seizure. Permanently discontinue ERLEADA® in patients who develop a seizure during treatment. It is unknown whether anti-epileptic medications will prevent seizures with ERLEADA®. Advise patients of the risk of developing a seizure while receiving ERLEADA® and of engaging in any activity where sudden loss of consciousness could cause harm to themselves or others. Embryo-Fetal Toxicity — The safety and efficacy of ERLEADA® have not been established in females. Based on findings from animals and its mechanism of action, ERLEADA® can cause fetal harm and loss of pregnancy when administered to a pregnant female. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of ERLEADA® [see Use in Specific Populations (8.1, 8.3)]. ADVERSE REACTIONS The most common adverse reactions (≥10%) that occurred more frequently in the ERLEADA®-treated patients (≥2% over placebo) from the randomized placebo-controlled clinical trials (TITAN and SPARTAN) were fatigue, arthralgia, rash, decreased appetite, fall, weight decreased, hypertension, hot flush, diarrhea, and fracture. Laboratory Abnormalities — All Grades (Grade 3-4) - Hematology — In the TITAN study: white blood cell decreased ERLEADA® 27% (0.4%), placebo 19% (0.6%). In the SPARTAN study: anemia ERLEADA® 70% (0.4%), placebo 64% (0.5%); leukopenia ERLEADA® 47% (0.3%), placebo 29% (0%); lymphopenia ERLEADA® 41% (1.8%), placebo 21% (1.6%) - Chemistry — In the TITAN study: hypertriglyceridemia ERLEADA® 17% (2.5%), placebo 12% (2.3%). In the SPARTAN study: hypercholesterolemia ERLEADA® 76% (0.1%), placebo 46% (0%); hyperglycemia ERLEADA® 70% (2%), placebo 59% (1.0%); hypertriglyceridemia ERLEADA® 67% (1.6%), placebo 49% (0.8%); hyperkalemia ERLEADA® 32% (1.9%), placebo 22% (0.5%) - Rash — In 2 randomized studies (SPARTAN and TITAN), rash was most commonly described as macular or maculopapular. Adverse reactions of rash were 26% with ERLEADA® vs 8% with placebo. Grade 3 rashes (defined as covering >30% body surface area [BSA]) were reported with ERLEADA® treatment (6%) vs placebo (0.5%) The onset of rash occurred at a median of 83 days. Rash resolved in 78% of patients within a median of 78 days from onset of rash. Rash was commonly managed with oral antihistamines, topical corticosteroids, and 19% of patients received systemic corticosteroids. Dose reduction or dose interruption occurred in 14% and 28% of patients, respectively. Of the patients who had dose interruption, 59% experienced recurrence of rash upon reintroduction of ERLEADA®. Hypothyroidism — In 2 randomized studies (SPARTAN and TITAN), hypothyroidism was reported for 8% of patients treated with ERLEADA® and 1.5% of patients treated with placebo based on assessments of thyroid-stimulating hormone (TSH) every 4 months. Elevated TSH occurred in 25% of patients treated with ERLEADA® and 7% of patients treated with placebo. The median onset was at the first scheduled assessment. There were no Grade 3 or 4 adverse reactions. Thyroid replacement therapy, when clinically indicated, should be initiated or dose-adjusted. DRUG INTERACTIONS Effect of Other Drugs on ERLEADA® — Co-administration of a strong CYP2C8 or CYP3A4 inhibitor is predicted to increase the steady-state exposure of the active moieties. No initial dose adjustment is necessary; however, reduce the ERLEADA® dose based on tolerability [see Dosage and Administration (2.2)]. Effect of ERLEADA® on Other Drugs CYP3A4, CYP2C9, CYP2C19, and UGT Substrates — ERLEADA® is a strong inducer of CYP3A4 and CYP2C19, and a weak inducer of CYP2C9 in humans. Concomitant use of ERLEADA® with medications that are primarily metabolized by CYP3A4, CYP2C19, or CYP2C9 can result in lower exposure to these medications. Substitution for these medications is recommended when possible or evaluate for loss of activity if medication is continued. Concomitant administration of ERLEADA® with medications that are substrates of UDP-glucuronosyl transferase (UGT) can result in decreased exposure. Use caution if substrates of UGT must be co-administered with ERLEADA® and evaluate for loss of activity. P-gp, BCRP, or OATP1B1 Substrates — Apalutamide is a weak inducer of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and organic anion transporting polypeptide 1B1 (OATP1B1) clinically. Concomitant use of ERLEADA® with medications that are substrates of P-gp, BCRP, or OATP1B1 can result in lower exposure of these medications. Use caution if substrates of P-gp, BCRP, or OATP1B1 must be co-administered with ERLEADA® and evaluate for loss of activity if medication is continued. Please see the full Prescribing Information for ERLEADA®. About the Janssen Pharmaceutical Companies of Johnson & Johnson At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension. Learn more at www.janssen.com. Follow us at @JanssenUS and @JanssenGlobal. Janssen Research & Development, LLC and Janssen Biotech, Inc. are part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Cautions Concerning Forward-Looking Statements This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of IMBRUVICA® (ibrutinib), DARZALEX® (daratumumab), DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), CARVYKTITM (ciltacabtagene autoleucel), teclistamab, talquetamab, BALVERSA® (erdafitinib), RYBREVANT® (amivantamab-vmjw), niraparib and ERLEADA® (apalutamide). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC or any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Reports on Form 10-Q, and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments. Media Contacts: Brian Kenney +1 215-620-0111 Caroline Pavis +1 610-357-3121 Investor Relations: Raychel Kruper +1 732-524-6164 U.S. Medical Inquiries: +1 800-526-7736 SOURCE The Janssen Pharmaceutical Companies of Johnson & Johnson	https://www.prnewswire.com/news-releases/janssen-to-highlight-science-innovation-and-advances-in-robust-oncology-portfolio-and-pipeline-through-more-than-60-data-presentations-at-asco-and-eha-301557740.html	2022-05-31T12:45:54	en	0.896388
- Cabin Awareness concept uses millimeter-wave radar to detect people and pets throughout the vehicle cabin - Patent-pending concept introduced in prototype Toyota Sienna minivan and May Mobility Sienna AutonoMaaS shuttle - Cabin Awareness technology could help prevent heatstroke deaths by alerting drivers about occupants left behind PLANO, Texas, May 31, 2022 /PRNewswire/ -- Toyota Connected North America (TCNA), an independent software and innovation center of excellence, today introduced its Cabin Awareness concept technology that uses millimeter-wave, high-resolution 4D imaging radar to help detect occupants (including certain pets) in cars and has the potential to detect them if ever they're left behind. The Cabin Awareness concept takes a unique approach to in-vehicle occupant detection using a 4D imaging radar sensor, mounted out of sight above a vehicle's headliner that can detect presence of a life form in the vehicle, even after a driver exits. Specifically, the Cabin Awareness concept has the capability to sense micro movements, such as a heartbeat, motion and respiration of occupants across three full seating rows, the cargo area and footwells. It also classifies all occupants according to size, posture and position – supporting advanced safety applications. The platform provides robust sensing even if the occupant is covered with a blanket, a scenario which a passerby would be unable to see the occupant. It differs from other technologies on the market such as weight sensors, that can be prone to false alerts and mis-detects, cameras limited by blind spots or other radar systems with a limited range of passenger detection. "Toyota Connected's talented software engineers and data scientists are leveraging cutting-edge technology to bring innovation and advanced technologies to customers' vehicles," said Zack Hicks, CEO and president, TCNA and executive vice president and chief digital officer, TMNA. "We are extremely proud of our efforts to take this idea from the drawing board to a full-blown concept, and, hopefully, developing a technology that has the potential to save lives." Real-World Testing While Cabin Awareness is currently a concept, the feature is getting a real-world trial through Toyota's partner May Mobility. The autonomous-vehicle company is testing the technology in its fleet of Toyota Sienna AutonoMaaS (Autonomous Mobility as a Service) minivans at its headquarters in Michigan and will soon begin testing in public AV deployments in Arlington, Texas, and Ann Arbor, Michigan, with additional deployments coming in late 2022. Recently, May Mobility announced that a portion of the fleet will be modified to become ADA-compliant and accommodate passengers in wheelchairs. "May Mobility was founded with a mission of making roads safer through autonomous technology – and we've kept safety as our top priority as we've advanced our technology and worked with key strategic partners like Toyota," said Edwin Olson, CEO, May Mobility. "As we move closer to driver-out operations next year and continue to scale our global business with more public AV deployments, technology like the Cabin Awareness concept is essential for our riders." In the future, one possible application for autonomous shuttles is alerting parents when their children complete a ride. Conversely, a shuttle may delay driving to its next stop if it senses someone is still in the vehicle upon reaching its destination. "The key difference with this system is the improved resolution and accuracy, full-cabin detection and scope of functionality Cabin Awareness provides," said Simon Roberts, managing engineer, TCNA, who has spearheaded the development process. "With the precision of these sensors, we're designing Cabin Awareness with the aim of reducing false positives and false negatives." Applying Technology to Alert Drivers In 2021 in the U.S., 23 children died from heat stroke after being left in vehicles, according to the nonprofit Kids and Cars. On average, one in four children that die in a hot car obtained access to the car while it was unattended or not operational. Depending on the circumstances, the inside of a car can get up to 125° F in minutes even when outside temperature is as low as 60° F. Studies show children's body temperatures rise three to five times faster than adults. If left in a vehicle during the summer, the inside cabin temperature can reach dangerous levels in just 10 minutes. "We are excited to explore and leverage new technologies, connected intelligence and existing safety platforms, with the ultimate goal of reducing child fatalities in hot cars. This Cabin Awareness concept has the potential to do exactly that," said Brian Kursar, chief technology officer, TCNA and group vice president, chief technology officer and chief data officer, Toyota Motor North America (TMNA). "I'm so proud of the Toyota Connected and TMNA's Connected Technologies teams for developing this concept and believe in the talent and dedication of our engineers." As currently designed, the Cabin Awareness concept provides an array of warnings to help alert the driver (and potentially, passersby) to check the back of the vehicle if a living being is detected. First, a warning light signals on the instrument cluster. Then, the horn honks. Emergency lights flash. Following all the early warnings, the owner may get a notification on their phone through the Toyota app as well as text messages. If programmed, Cabin Awareness could even send alerts through smart home devices or send text messages to designated emergency contacts assigned by the primary user. Further alert options include having Toyota's Safety Connect® emergency assistance system contact first responders through the integrated SOS vehicle function. The team is continuing to explore additional notification alerts such as vehicle-to-vehicle (V2V) communications and the incorporation of smart infrastructure retail signage to further expand the reach of this alert. Born from Innovation The idea for Cabin Awareness was born in 2019 out of the inaugural Toyota Connected Hackathon, a 36-hour innovation event that challenged teams of software designers and engineers to ideate, develop and test real-world solutions. This winning idea quickly grew support following the Hackathon, allowing Roberts to assemble a team of engineers and further develop the technology. The Cabin Awareness concept also allowed Toyota Connected to evaluate and develop hardware for the first time in addition to building innovative software systems and creating new processes. The Toyota Connected team evaluated millimeter-wave suppliers and began working with technology provider Vayyar Imaging's in-cabin monitoring platform. Vayyar's high-resolution, single chip, 4D imaging radar is the only solution on the market that has the capability to monitor an entire vehicle cabin with a single sensor. The platform provides exceptionally dense point cloud imaging, enabling developers to independently develop a wide range of advanced applications and deploy them remotely using over-the-air software updates. Inspired by Space Technology Inspiration for the Cabin Awareness concept came from microwave radar technology created by NASA's Jet Propulsion Laboratory to support underground rescues after a 7.8-magnitude earthquake struck Nepal in 2015. In this application, NASA engineers and rescuers were able to detect human breathing and heartbeats under more than 30 feet of rubble, helping responders know where to dig holes. "NASA's use of radar technology was inspiring," said Kursar. "The idea that you can listen to heartbeats using contact-less technology opens up new possibilities to give Toyota the potential to produce a service that is beneficial to the evolution of our in-vehicle services." "The Cabin Awareness program is an innovation first for Toyota Connected and Toyota in so many ways," said Roberts. "The most important goal we're working on, though, is to build technologies that empower occupants and give them greater peace of mind." About Toyota Connected, Inc. Based in Plano, Texas, Toyota Connected North America (TCNA) was established in 2016 to drive Toyota's global efforts for an intelligent mobile society. With big data collected from vehicles and analyzed on a cloud platform, Toyota Connected humanizes the driving experience by providing customers secure, seamless and contextual services, elevating the customer experience while benefitting dealers, distributors, and partners. At the heart of TCNA is Toyota's belief in human-centered mobility and a fundamental commitment to personal privacy. About Toyota Toyota (NYSE:TM) has been a part of the cultural fabric in the U.S. for more than 60 years, and is committed to advancing sustainable, next-generation mobility through our Toyota and Lexus brands, plus our nearly 1,500 dealerships. Toyota directly employs more than 39,000 people in the U.S. who have contributed to the design, engineering, and assembly of nearly 32 million cars and trucks at our nine manufacturing plants. By 2025, Toyota's 10th plant in North Carolina will begin to manufacture automotive batteries for electrified vehicles. With more electrified vehicles on the road than any other automaker, a quarter of the company's 2021 U.S. sales were electrified. To help inspire the next generation for a career in STEM-based fields, including mobility, Toyota launched its virtual education hub at www.TourToyota.com with an immersive experience and chance to virtually visit many of our U.S. manufacturing facilities. The hub also includes a series of free STEM-based lessons and curriculum through Toyota USA Foundation partners, virtual field trips and more. For more information about Toyota, visit www.ToyotaNewsroom.com. About Vayyar Vayyar's automotive-grade 4D imaging radar platform creates holistic safety solutions for in-cabin, ADAS and motorcycle safety. Powered by a single radar-on-chip, it delivers exceptional resolution across an ultra-wide field of view, enabling it to replace multiple existing single-function sensors. The platform provides comprehensive detection in and around the vehicle, simultaneously tracking multiple static and dynamic targets. Inside the cabin, the 60 GHz configuration detects the presence, position and size of each occupant, classifying children and adults. This enables Child Presence Detection, enhanced Seat Belt Reminders, optimized airbag deployment, out-of-position alerts, intruder detection and more. Outside the car (or motorcycle), the 79 GHz system supports most SRR, MRR and LRR applications including parking assistance, Autonomous Emergency Braking, Lane Change Assist, Blind Spot Detection, Cross Traffic Alerts, Adaptive Cruise Control and more, with an effective range from 20cm to 300m. Vayyar technology is multifunctional, affordable and available for mass production. The radar-based platform is robust in all road conditions, while protecting user privacy at all times. About May Mobility May Mobility, established in Ann Arbor, Michigan in 2017, is building the world's best autonomy system. Their proprietary Multi-Policy Decision Making (MPDM) system is at the core of their mission to help make cities safer, greener, and more accessible. MPDM's proven track record has delivered more than 315,000 autonomy-enabled rides to date in several public transit applications across the U.S. and Japan. With key strategic partnerships including some of the world's most innovative automotive and transportation companies, such as Toyota Motor Corporation, May Mobility aims to achieve the highest standard in rider safety, sustainability, and transportation equity. For more information, visit www.maymobility.com. Media Contacts: Corey Proffitt Corey.proffitt@toyotaconnected.com Jacob Brown Jacob.Brown@toyotaconnected.com View original content to download multimedia: SOURCE Toyota Connected North America	https://www.wlbt.com/prnewswire/2022/05/31/toyota-connected-cabin-awareness-concept-uses-new-tech-detect-occupants/	2022-05-31T12:46:00	en	0.940471
Karimoku at Salone del Mobile 2022 - Exhibition & Launch Karimoku Showcases the Wide Variety and High Quality of Its Bespoke Furniture Collections in a Comprehensive Interior Resembling an Apartment Designed by Norm Architects and Keiji Ashizawa Design. Two New Designs Are to Be Launched. AICHI, Japan, May 31, 2022 /PRNewswire/ -- Japanese lifestyle brand Karimoku exhibits at Salone del Mobile, showcasing the wide variety and high quality of its bespoke contemporary furniture collections to an international audience. Referencing the concept of the brand, the versatility of the bespoke collections is displayed in a comprehensive, thoughtfully curated interior resembling an apartment. Designed by the brand's co-founders, Danish architecture and design studio Norm Architects and Japanese architecture and design practice Keiji Ashizawa Design, the interior concept is a representation of Japanese and Danish design principles. The presentation at Salone del Mobile also sees the debut of several new, bespoke products to the collection. SALONE DEL MOBILE 2022 JUNE 7TH TO 12TH 9:30- 18:30 RHO FIERA, HALL 1 3, BOOTH E09 [email protected] KARIMOKU.COM Emerging from shared design values, Karimoku is a contemporary lifestyle brand based in Japan and born out of admiration and love for serene beauty, material richness and timeless appeal. The collection is brought to life by the world's leading architects through individual cases, and the story of each collection is told through its native setting. The origins of Karimoku Furniture date back to 1940, when Shohei Kato took over a longstanding timber company and established a small woodworking shop in the town of Kariya, Aichi. The company produced various wooden parts in the ensuing decades, developing a range of techniques before launching its own line of wooden furniture in the 1960s. Building upon the concept of manufacturing high-tech and high-touch products, the company established bases in timber production areas and soon developed into one of Japan's leading manufacturers of wooden furniture. Media contact: Yuki Fukushima [email protected] 08091226929 SOURCE Karimoku Furniture Inc.	https://www.prnewswire.com/news-releases/karimoku-at-salone-del-mobile-2022--exhibition--launch-301557735.html	2022-05-31T12:46:00	en	0.929867
- The Corporation recorded revenues of $4.6 million in Q1 2022, a 65% increase from Q1 2021, and a 28% increase from Q4 2021 - Record revenue in medical cannabis of over $2.6 million in Q1 2022, a 470% increase from the prior year and 32% increase from Q4 2021 - Gross profit before fair value adjustments grew to $2.1 million, up 96% from Q1 2021, driven primarily by its 75% gross margin medical cannabis business, compared to 49% in Q4 2021. - In Q1 2022, Europe (the UK and Germany) represented 53% of all medical cannabis revenue, compared to 10% in Q1 2021. - The net change in cash and cash equivalents of -$3.3 million, compared to -$8.6 million in Q1 2022, ending Q1 2022 with $5.1 million in cash TORONTO, May 31, 2022 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Corporation") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a global leader in medical cannabis throughout Latin America and Europe, announced today its financial results for the quarter ended March 31, 2022, reporting record revenue in the medical cannabis business. These filings are available for review on the Corporation's SEDAR profile at www.sedar.com. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated. Summary of Key Financial Results: Q1 2022 operating highlights and subsequent events: - Khiron's unique patient-focused medical cannabis segment posted 7th quarter of consecutive revenue growth in Q1 2022, and now represents 57% of the Corporation´s revenue and 92% of its total gross profits. In the month of March 2022, Khiron had surpassed $1 million in monthly revenues in medical cannabis alone. - Khiron's unique business model is already beginning to yield positive financial results during Q1 2022. ILANS SAS (Khiron's health service business in Colombia) has been instrumental in driving higher gross margin medical cannabis and clinical services. - Both Khiron's European expansion and continued growth in Colombia, is driving the medical cannabis segment growth in Q1 2022. In Q1 2022, Khiron surpassed $1 million in medical cannabis revenues in the United Kingdom. - In Colombia, Khiron continues to be a market leader in medical cannabis with its unique vertically integrated approach and leverage of insurance coverage on its clinics. Over 82% of sales were sold through insurance coverage, and over 84% of the sales were sold to returning patients, who are now purchasing up to 1.8 bottles per month. - At the end of Q1 2022, the Corporation had $37.6 million in total assets (excluding goodwill), with more than $9.4 million in land and buildings, high-quality medical cannabis inventory of $8.1 million, healthy Accounts Receivables with credit-worthy clients in Colombia and Europe of $4.4 million and $0.8 million in financial debt. - The Corporation's cash used in operating activities for Q1 2022 was $2.8 million, compared to -$8.2 million in Q1 2021 and approximately -$5.4 million in Q4 2021, resulting in net cash of $5.1 million at the end of Q1 2022. This is a result of actively managing the working capital cycle, improving collection times for the Corporation´s Accounts Receivable, and extending payment terms on its Accounts Payables while reducing overall general and administrative costs and increasing its high gross margin medical cannabis business. Management commentary: Alvaro Torres, Khiron CEO and Director, comments, "Khiron is the top-selling medical cannabis brand in Latin America and one of the top-selling brands in the United Kingdom. Our unique approach will continue to generate double-digit revenue and gross profits quarter over quarter in markets poised to become significant in the coming years. Our focus is to leverage the infrastructure we have built to continue driving sales in our target markets while maintaining discipline in our expenses so we can achieve profitability in the near future, and then continue to look for more growth opportunities in Latin America and Europe." Mr. Torres added, "The results of Q1 2022 continue to showcase the success of Khiron's global expansion and the Corporation's unique "patient-first" strategy. Webcast Details: Khiron invites individual and institutional investors, as well as advisors and analysts, to attend the Corporation's First Quarter 2022 Conference Call, followed by a Q&A session. DATE: Tuesday, May 31th, 2022 TIME: 10:00am ET PRESENTERS: Alvaro Torres, Khiron Chief Executive Officer and Director, Swapan Kakumanu, Khiron Chief Financial Officer, and Franziska Katterbach, President of Khiron Europe. FORMAT: Live 45 minute presentation & Q&A session REGISTER LINK: https://us02web.zoom.us/webinar/register/WN_VVgAryILSl-W9at7iftkCQ About Khiron Life Sciences Corp. Khiron is a leading vertically integrated international medical cannabis corporation with core operations in Latin America and Europe. Leveraging medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific, product innovation, and cannabis operations expertise to drive prescriptions and brand loyalty with patients worldwide. The Corporation has a sales presence in Colombia, Peru, Germany, United Kingdom, and Brazil and is positioned to commence sales in Mexico. The Corporation is led by co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and board of directors. Visit Khiron online at https://investors.khiron.ca. Linkedin https://www.linkedin.com/company/khiron-life-sciences-corp/ Non-IFRS Financial Measures This press release includes references to Adjusted EBITDA, which is a financial measure that does not have a standardized meaning prescribed by IFRS. Adjusted EBITDA is calculated as net loss before tax as reported under IFRS and adding back share-based compensation expense, transaction fees, unrealized gain on changes in fair value of biological assets, depreciation and non-recurring items. Adjusted EBITDA provides an indication of the results generated by the Corporation's principal business activities prior to how these activities and assets are financed (including mark-to-market movements of the warrant value), depreciated and amortized or how the results are taxed in various jurisdictions, impairment of property, plant, and equipment, impairment of intangible assets, changes in fair value of inventory, unrealized changes in fair value of biological assets, prior to the effect of foreign exchange, other income and expenses, and non-cash share-based payment expense. The term Adjusted EBITDA does not have any standardized meaning and therefore may not be comparable to similar measures presented by other issuers. The Corporation believes Adjusted EBITDA not only provides management with comparable financial data for internal financial analysis but also provides meaningful supplemental information to investors. In particular, management believes that this financial measure can provide information useful to its shareholders in understanding the performance of the Corporation and may assist in the evaluation of its business relative to that of its peers. Investors are cautioned that this non-IFRS measure should not be considered in isolation or construed as an alternative to the measurements of performance calculated in accordance with IFRS as, given the non-standardized meaning, it may not be comparable to similar measures presented by other issuers. Existing Adjusted EBITDA is not necessarily predictive of the Corporation's future performance or the Adjusted EBITDA of the Corporation as at any future date. Calculation and Reconciliation of Adjusted EBITDA The following table provides a reconciliation of net loss to Adjusted EBITDA. Cautionary Statement Regarding Forward-Looking Statements This press release may contain "forward-looking information" within the meaning of applicable securities legislation. All information contained herein that is not historical in nature constitutes forward-looking information. Forward-looking information contained in this news release include, without limitation, statements pertaining to the Corporation's business plans and goals, including its goal of achieving profitability in the near future and improving revenue collections, reducing cash outflows, and leveraging the Corporation's assets to generate more working capital. Forward-looking information and statements contained in this news release reflect management's current beliefs and is based on information currently available and on assumptions that management believes to be reasonable. These assumptions include, but are not limited to, assumptions regarding the future regulatory developments and economic conditions, the Corporation's ability to continue its growth and reduce costs. Although management believes that its expectations and assumptions to be reasonable, forward-looking information is always subject to known and unknown risks, uncertainties and other factors, many of which are beyond the control of management, that may cause actual results to differ materially from those expressed or implied in such forward-looking information. Such risks and uncertainties include but are not limited to the following: risks relating to general economic conditions and capital markets; risks relating to the availability of financing on satisfactory terms; risks relating to the COVID-19 pandemic or other health crises; risks relating to regulatory, legislative, competitive and political conditions; as well as those other risk factors discussed in Khiron's most recent annual information form which is available on Khiron's SEDAR profile at www.sedar.com. As a result of the foregoing and other risks and uncertainties, readers are cautioned not to place undue reliance on forward-looking information contained in this press release. Readers are further cautioned that the foregoing risks and uncertainties is not exhaustive, and there may be other risks and uncertainties, presently unknown to management of the Corporation, that may cause actual results to differ materially from those expressed or implied in forward-looking statements contained in this press release. The forward-looking information contained in this press release is expressly qualified by this cautionary statement. Khiron disclaims any intention to update or revise any forward-looking information disclosed herein, whether as a result of new information, future events or otherwise, except as required by law. SOURCE Khiron Life Sciences Corp.	https://www.prnewswire.com/news-releases/khiron-life-sciences-reports-first-quarter-2022-financial-results-with-record-revenue-in-medical-cannabis-301557742.html	2022-05-31T12:46:06	en	0.934253
OMAHA, Neb., May 31, 2022 /PRNewswire/ -- Jennifer Hamann, executive vice president and chief financial officer, and Kenny Rocker, executive vice president – marketing and sales, of Union Pacific Corporation (NYSE: UNP), will address the UBS Global Industrials and Transportation Conference on Tuesday, June 7, 2022, at 8:00 a.m. ET. A live webcast of the presentation will be available in the investor relations section of Union Pacific's website at www.up.com/investor. A replay of the audio webcast will be available shortly thereafter. ABOUT UNION PACIFIC Union Pacific (NYSE: UNP) delivers the goods families and businesses use every day with safe, reliable and efficient service. Operating in 23 western states, the company connects its customers and communities to the global economy. Trains are the most environmentally responsible way to move freight, helping Union Pacific protect future generations. More information about Union Pacific is available at www.up.com. View original content to download multimedia: SOURCE Union Pacific Corporation	https://www.wlbt.com/prnewswire/2022/05/31/union-pacific-corporation-executives-address-ubs-global-industrials-transportation-conference/	2022-05-31T12:46:06	en	0.904584
WA Pendleton OR Zone Forecast for Monday, May 30, 2022 _____ 944 FPUS56 KPDT 311058 ZFPPDT Zone Forecast Product for Northeast Oregon and South Central Washington National Weather Service Pendleton OR 358 AM PDT Tue May 31 2022 WAZ026-312300- Kittitas Valley- Including the cities of Ellensburg and Thorp 358 AM PDT Tue May 31 2022 .TODAY...Mostly cloudy in the morning, then partly cloudy with a 20 percent chance of rain showers in the afternoon. Highs in the lower to mid 70s. Northeast wind 5 to 15 mph. .TONIGHT...Partly cloudy. A 20 percent chance of rain showers in the evening. Lows in the upper 40s to mid 50s. Northeast wind 5 to 10 mph. .WEDNESDAY...Mostly cloudy. A 20 percent chance of showers and thunderstorms in the afternoon. Highs in the lower 70s to lower 80s. Northeast wind 5 to 15 mph. .WEDNESDAY NIGHT...Mostly cloudy with a 20 percent chance of rain showers. Lows in the mid 50s to lower 60s. North wind 5 to 10 mph. .THURSDAY...Mostly cloudy with a chance of showers and thunderstorms. Highs in the mid 70s to lower 80s. Northeast wind 5 to 10 mph. Chance of precipitation 50 percent. .THURSDAY NIGHT...Mostly cloudy with a chance of showers and thunderstorms. Lows in the 50s. Chance of precipitation 50 percent. .FRIDAY...Mostly cloudy with a chance of showers and thunderstorms. Some thunderstorms may produce heavy rainfall. Highs in the lower to mid 70s. Chance of precipitation 40 percent. .FRIDAY NIGHT...Mostly cloudy with a 20 percent chance of rain showers. Lows in the lower to mid 50s. .SATURDAY THROUGH SUNDAY...Mostly cloudy with a 50 percent chance of rain showers. Highs in the 60s. Lows in the upper 40s to mid 50s. .SUNDAY NIGHT AND MONDAY...Partly cloudy with a 20 percent chance of rain showers. Lows in the mid 40s to lower 50s. Highs in the 60s. $$ WAZ027-312300- Yakima Valley- Including the cities of Naches, Sunnyside, Toppenish, and Yakima 358 AM PDT Tue May 31 2022 .TODAY...Mostly cloudy in the morning then clearing. Highs in the lower to mid 70s. Light wind, becoming east 5 to 10 mph in the afternoon. .TONIGHT...Mostly clear. Lows in the upper 40s to mid 50s. Southeast wind 5 to 10 mph in the evening, becoming light. .WEDNESDAY...Mostly cloudy. Highs in the mid 70s to lower 80s. Northeast wind 5 to 10 mph. .WEDNESDAY NIGHT...Mostly cloudy with a 20 percent chance of rain showers. Lows in the mid to upper 50s. Northwest wind 5 to 10 mph. .THURSDAY...Mostly cloudy with a chance of showers and thunderstorms. Highs in the upper 70s to lower 80s. Northeast wind 5 to 10 mph. Chance of precipitation 50 percent. .THURSDAY NIGHT...Mostly cloudy with a chance of showers and thunderstorms. Lows in the mid to upper 50s. Chance of precipitation 40 percent. .FRIDAY AND FRIDAY NIGHT...Mostly cloudy with a 20 percent chance of rain showers. Highs in the mid 70s to lower 80s. Lows in the 50s. .SATURDAY THROUGH SUNDAY...Mostly cloudy with a 50 percent chance of rain showers. Highs in the mid 60s to lower 70s. Lows in the lower to mid 50s. .SUNDAY NIGHT AND MONDAY...Partly cloudy with a 20 percent chance of rain showers. Lows in the mid 40s to lower 50s. Highs in the mid 60s to lower 70s. $$ WAZ028-312300- Lower Columbia Basin of Washington- Including the cities of Connell, Prosser, and Tri-Cities 358 AM PDT Tue May 31 2022 .TODAY...Mostly cloudy in the morning then clearing. Highs in the lower to mid 70s. East wind 5 to 10 mph. .TONIGHT...Mostly clear. Lows in the lower to mid 50s. East wind 5 to 10 mph. .WEDNESDAY...Mostly cloudy in the morning, becoming partly cloudy. Highs in the upper 70s to lower 80s. Northeast wind 5 to 10 mph. .WEDNESDAY NIGHT...Mostly cloudy with a 20 percent chance of rain showers. Lows in the upper 50s to lower 60s. Northeast wind 5 to 10 mph. .THURSDAY...Mostly cloudy with a chance of showers and thunderstorms. Highs in the lower to mid 80s. North wind 5 to 10 mph. Chance of precipitation 40 percent. .THURSDAY NIGHT...Mostly cloudy with a chance of showers and thunderstorms. Lows in the mid 50s to lower 60s. Chance of precipitation 40 percent. .FRIDAY...Mostly cloudy with a chance of showers and thunderstorms. Some thunderstorms may produce heavy rainfall. Highs in the upper 70s to lower 80s. Chance of precipitation 50 percent. .FRIDAY NIGHT...Mostly cloudy with a 20 percent chance of rain showers. Lows in the mid to upper 50s. .SATURDAY AND SATURDAY NIGHT...Mostly cloudy with a 50 percent chance of rain showers. Highs in the upper 60s to lower 70s. Lows in the 50s. .SUNDAY...Mostly cloudy with a chance of showers and thunderstorms. Highs in the upper 60s to lower 70s. Chance of precipitation 50 percent. .SUNDAY NIGHT AND MONDAY...Partly cloudy with a 20 percent chance of rain showers. Lows in the upper 40s to lower 50s. Highs in the upper 60s to lower 70s. $$ WAZ029-312300- Foothills of the Blue Mountains of Washington- Including the cities of Dayton, Waitsburg, and Walla Walla 358 AM PDT Tue May 31 2022 .TODAY...Mostly cloudy in the morning then clearing. Highs in the lower to mid 70s. Northeast wind 5 to 10 mph. .TONIGHT...Partly cloudy. Lows in the upper 40s to lower 50s. East wind 5 to 10 mph. .WEDNESDAY...Partly cloudy. Highs in the upper 70s to lower 80s. Southeast wind 5 to 10 mph shifting to the north in the afternoon. .WEDNESDAY NIGHT...Mostly cloudy with a 20 percent chance of rain showers. Lows in the mid to upper 50s. East wind 5 to 10 mph. .THURSDAY...Mostly cloudy with a chance of showers and thunderstorms. Highs around 80. Northeast wind 5 to 10 mph. Chance of precipitation 50 percent. .THURSDAY NIGHT...Mostly cloudy with a chance of showers and thunderstorms. Lows in the mid to upper 50s. Chance of precipitation 50 percent. .FRIDAY...Mostly cloudy with a chance of showers and thunderstorms. Some thunderstorms may produce heavy rainfall. Highs in the mid to upper 70s. Chance of precipitation 50 percent. .FRIDAY NIGHT...Mostly cloudy with a chance of showers and thunderstorms. Lows in the mid to upper 50s. Chance of precipitation 40 percent. .SATURDAY...Mostly cloudy with a 50 percent chance of rain showers. Highs in the upper 60s to lower 70s. .SATURDAY NIGHT...Rain showers likely. Lows in the lower to mid 50s. Chance of precipitation 60 percent. .SUNDAY...Rain showers likely and a chance of thunderstorms. Highs in the upper 60s to lower 70s. Chance of precipitation 70 percent. .SUNDAY NIGHT...Mostly cloudy with a 50 percent chance of rain showers. Lows in the lower 50s. .MONDAY...Partly cloudy with a 20 percent chance of rain showers. Highs in the upper 60s to lower 70s. $$ WAZ030-312300- Northwest Blue Mountains- Including the city of Ski Bluewood Resort 358 AM PDT Tue May 31 2022 .TODAY...Mostly cloudy in the morning, then partly cloudy with a 20 percent chance of showers and thunderstorms in the afternoon. Highs in the mid to upper 50s, except in the lower to mid 60s valleys. .TONIGHT...Partly cloudy. A 20 percent chance of showers and thunderstorms in the evening. Lows in the 40s. .WEDNESDAY...Partly cloudy in the morning, then mostly cloudy with a 20 percent chance of showers and thunderstorms in the afternoon. Highs in the lower 60s to lower 70s. .WEDNESDAY NIGHT...Mostly cloudy with a 20 percent chance of showers and thunderstorms. Lows in the upper 40s to mid 50s. .THURSDAY...Mostly cloudy with a chance of showers and thunderstorms. Highs in the lower to mid 60s, except in the upper 60s to mid 70s valleys. Chance of precipitation 50 percent. .THURSDAY NIGHT...Mostly cloudy with a chance of showers and thunderstorms. Lows in the upper 40s to mid 50s. Chance of precipitation 50 percent. .FRIDAY...Rain showers likely and a chance of thunderstorms. Some thunderstorms may produce heavy rainfall. Highs in the upper 50s to lower 60s, except in the mid 60s to lower 70s valleys. Chance of precipitation 60 percent. .FRIDAY NIGHT...Mostly cloudy with a chance of showers and thunderstorms. Lows in the upper 40s to lower 50s. Chance of precipitation 40 percent. .SATURDAY...Mostly cloudy with a 50 percent chance of rain showers. Highs in the mid to upper 50s, except in the lower to mid 60s valleys. .SATURDAY NIGHT...Rain showers likely. Lows in the mid 40s to lower 50s. Chance of precipitation 70 percent. .SUNDAY...Rain showers likely and a chance of thunderstorms. Highs in the lower 50s to lower 60s. Chance of precipitation 70 percent. .SUNDAY NIGHT...Mostly cloudy with a 20 percent chance of showers and thunderstorms. Lows in the 40s. .MONDAY...Mostly cloudy with a 40 percent chance of rain showers. Highs in the lower 50s to lower 60s. $$ WAZ520-312300- East Slopes of the Washington Cascades- Including the cities of Appleton, Cle Elum, and Cliffdell 358 AM PDT Tue May 31 2022 .TODAY...Mostly cloudy in the morning, then partly cloudy with a chance of showers and thunderstorms in the afternoon. Highs in the upper 50s to upper 60s, except in the mid 60s to lower 70s valleys. Chance of precipitation 40 percent. .TONIGHT...Partly cloudy. A 20 percent chance of showers and thunderstorms in the evening. Lows in the 40s. .WEDNESDAY...Mostly cloudy. A 20 percent chance of showers and thunderstorms in the afternoon. Highs in the lower 60s to lower 70s. .WEDNESDAY NIGHT...Mostly cloudy with a chance of showers and thunderstorms. Lows in the lower 40s to lower 50s. Chance of precipitation 40 percent. .THURSDAY...Mostly cloudy with a chance of showers and thunderstorms. Highs in the lower 60s to lower 70s, except in the lower to mid 70s valleys. Chance of precipitation 50 percent. .THURSDAY NIGHT...Mostly cloudy with a chance of showers and thunderstorms. Lows in the lower 40s to lower 50s. Chance of precipitation 50 percent. .FRIDAY...Mostly cloudy with a chance of showers and thunderstorms. Some thunderstorms may produce heavy rainfall. Highs in the mid 50s to mid 60s, except in the mid 60s to lower 70s valleys. Chance of precipitation 50 percent. .FRIDAY NIGHT...Mostly cloudy with a 20 percent chance of rain showers. Lows in the 40s. .SATURDAY...Mostly cloudy with a 50 percent chance of rain showers. Highs in the upper 40s to upper 50s, except in the upper 50s to mid 60s valleys. .SATURDAY NIGHT...Rain showers likely. Lows in the 40s. Chance of precipitation 70 percent. .SUNDAY...Rain showers likely and a chance of thunderstorms. Highs in the upper 40s to upper 50s, except in the upper 50s to mid 60s valleys. Chance of precipitation 70 percent. .SUNDAY NIGHT...Mostly cloudy with a 50 percent chance of rain showers. Lows in the upper 30s to mid 40s. .MONDAY...Partly cloudy with a 20 percent chance of rain showers. Highs in the lower 50s to lower 60s, except in the upper 50s to mid 60s valleys. $$ WAZ521-312300- Simcoe Highlands- Including the cities of Goldendale and Bickleton 358 AM PDT Tue May 31 2022 .TODAY...Mostly cloudy in the morning, becoming partly cloudy. Highs in the upper 60s to lower 70s. .TONIGHT...Mostly clear. Lows in the mid 40s to lower 50s. .WEDNESDAY...Mostly cloudy. A 20 percent chance of showers and thunderstorms in the afternoon. Highs in the 70s. East wind 5 to 15 mph in the afternoon. .WEDNESDAY NIGHT...Mostly cloudy with a 20 percent chance of rain showers. Lows in the 50s. .THURSDAY...Mostly cloudy with a chance of showers and thunderstorms. Highs in the 70s. Chance of precipitation 50 percent. .THURSDAY NIGHT...Mostly cloudy with a chance of showers and thunderstorms. Lows in the upper 40s to upper 50s. Chance of precipitation 40 percent. .FRIDAY AND FRIDAY NIGHT...Mostly cloudy with a 20 percent chance of rain showers. Highs in the upper 60s to mid 70s. Lows in the upper 40s to upper 50s. .SATURDAY AND SATURDAY NIGHT...Mostly cloudy with a 50 percent chance of rain showers. Highs in the upper 50s to upper 60s. Lows in the upper 40s to mid 50s. .SUNDAY...Rain showers likely and a chance of thunderstorms. Highs in the upper 50s to upper 60s. Chance of precipitation 70 percent. .SUNDAY NIGHT AND MONDAY...Partly cloudy with a 20 percent chance of rain showers. Lows in the 40s. Highs in the upper 50s to upper 60s. $$ _____ Copyright 2022 AccuWeather	https://www.theheraldreview.com/weather/article/WA-Pendleton-OR-Zone-Forecast-17209001.php	2022-05-31T12:46:09	en	0.901211
USANA wins four Best of State Award Medals SALT LAKE CITY, May 31, 2022 /PRNewswire/ -- USANA, a leader in global nutrition, was honored last week at the Best of State Gala in Salt Lake City, Utah for its excellence in product quality and innovation. USANA brought home four awards for Celavive, Rev3, CellSentials, and its Nutritional product line. To learn more about USANA and its award-winning products, please visit USANA.com. "For over a decade, USANA has been a mainstay at the Best of State Awards—a great feat when you consider the competitive health and wellness landscape in Utah," says Dan Macuga, USANA's chief communications & marketing officer. "USANA celebrates its 30th anniversary this year. From day one, we've prided ourselves in providing people around the world wanting to start their health improvement journey, with high-quality, science-based supplements. Looking forward, we are excited for the next 30 years where our world class research and innovation will take us." USANA took home four Best of State medals in the following categories: - USANA's Celavive skincare system won its fifth consecutive Best of State award in the Personal Care Products category - Rev3 Energy won best beverage for its fourteenth consecutive year - USANA CellSentials took home best dietary supplement for its sixth win in a row - USANA's Nutritionals won in the Health/Nutrition Products category for the fifth time The Best of State Awards were created in 2003 to recognize outstanding individuals, organizations, and businesses in Utah. Best of State candidates are evaluated by a panel of more than 100 judges based on three criteria: achievement in the field of endeavor; innovation or creativity in approaches, techniques, methods, or processes; and contribution to improving the quality of life in Utah. Since 1992, USANA has won more than 850 local, national, and international awards. USANA (NYSE: USNA) prides itself in providing consumers the highest quality nutritional products in the world. From its award-winning supplements to its innovative Celavive skincare and Active Nutrition lines, USANA has proven for nearly 30 years why it's a company you can trust. How about giving us a try? Shop at USANA.com or learn more at whatsupUSANA.com. Media Contact: Amy Haran Executive Vice President of Communications (801) 954-7641 media(at)USANAinc(dot)com View original content to download multimedia: SOURCE USANA	https://www.wlbt.com/prnewswire/2022/05/31/utah-company-brings-home-four-awards-prestigious-local-organization/	2022-05-31T12:46:13	en	0.955297
VANCOUVER, BC, May 31, 2022 /PRNewswire/ - The Very Good Food Company Inc. (NASDAQ: VGFC) (TSXV: VERY.V) (FSE: OSI) ("VERY GOOD" or the "Company"), is pleased to announce that the Company has entered into a securities purchase agreement with an institutional investor, for expected gross proceeds of USD$6,500,000 in a private placement of its equity securities (the "Offering"), comprised of 32,500,000 common shares of the Company ("Shares") (or common share equivalents) and warrants to purchase up to 32,500,000 Shares ("Warrants"), at a purchase price of USD $0.20 per Share and associated Warrant. Each Warrant entitles the holder to acquire one Share at an exercise price of USD $0.2582 per Share for a period five years from the issuance date. The Shares, common share equivalents, the Warrants and the Shares issuable thereunder may be collectively referred to herein as the "Securities". The net proceeds of the Offering will be used by the Company for general working capital purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for the Offering. The Offering is expected to close on or about June 2, 2022, subject to satisfaction of customary closing conditions, including the approval of the TSX Venture Exchange. The Securities sold in the Offering have not been registered under the Securities Act of 1933, as amended, or state securities laws as of the time of issuance and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ("SEC") or an applicable exemption from such registration requirements. The Company has agreed to file one or more registration statements with the SEC registering the resale of the Securities within thirty (30) days of the date of the securities purchase agreement and shall use commercially reasonable efforts to cause a registration statement to be declared effective under the Securities Act of 1933 within forty five (45) days of the date of the securities purchase agreement (or, in the event of a "full review" by the SEC, within seventy five (75) days of the date of the securities purchase agreement). No Securities were offered or sold to Canadian residents in connection with the Offering. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This news release shall not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent registration under U.S. federal and state securities laws or an applicable exemption from such U.S. registration requirements. The Very Good Food Company Inc. is an emerging plant-based food technology company that produces nutritious and delicious plant-based meat and cheese products under VERY GOOD's core brands: The Very Good Butchers and The Very Good Cheese Co. www.verygoodfood.com. OUR MISSION IS LOFTY BUT BEAUTIFULLY SIMPLE: GET MILLIONS TO RETHINK THEIR FOOD CHOICES WHILE HELPING THEM DO THE WORLD A WORLD OF GOOD. BY OFFERING PLANT-BASED FOOD OPTIONS SO DELICIOUS AND NUTRITIOUS, WE'RE HELPING THIS KIND OF DIET BECOME THE NORM. ON BEHALF OF THE VERY GOOD FOOD COMPANY INC. Matthew Hall Interim Chief Executive Officer This news release contains "forward-looking information" within the meaning of applicable securities laws in Canada and "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, including Section 21E of the Securities Exchange Act of 1934, as amended (collectively referred to as "forward-looking information"), for the purpose of providing information about management's current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes. Forward-looking information may be identified by words such as "plans", "proposed", "expects", "anticipates", "intends", "estimates", "may", "will", and similar expressions. Forward-looking information contained or referred to in this news release includes, but is not limited to, relating to the terms and conditions of the Offering; closing of the Offering and satisfaction of closing conditions; use of proceeds from the Offering and Very Good's intention to obtain an effective registration statement from the SEC registering the resale of the Securities and the timing thereof. Forward-looking information is based on a number of factors and assumptions which have been used to develop such information, but which may prove to be incorrect including, but not limited to, material assumptions with respect to the Company's ability to continue as a going concern; the Company's ability to manage recent personnel changes; and the Company's ability to successfully execute on its updated business strategy outlined in its most recently filed interim Management's Discussion and Analysis for the three months ended March 31, 2022, which is available at www.sedar.com and www.sec.gov. The Company's ability to execute on its strategy may also depend on the Company's ability to accurately forecast customer demand for its products and manage its inventory levels, continued demand for VERY GOOD's products, continued growth of the popularity of meat alternatives and the plant-based food industry, no material deterioration in general business and economic conditions, the successful placement of VERY GOOD's products in retail stores, the Company's ability to remain listed on the Nasdaq, VERY GOOD's ability to successfully enter new markets and manage its international expansion, VERY GOOD's ability to obtain necessary production equipment and human resources as needed, VERY GOOD's relationship with its suppliers, distributors and third-party logistics providers, and management's ability to position VERY GOOD competitively. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, undue reliance should not be placed on forward-looking information because VERY GOOD can give no assurance that such expectations will prove to be correct. Risks and uncertainties that could cause actual results, performance or achievements of VERY GOOD to differ materially from those expressed or implied in such forward-looking information include, among others, the impact of, uncertainties and risks associated with negative cash flow and future financing requirements to sustain and grow operations, limited history of operations and revenues and no history of earnings or dividends, competition, risks relating to the availability of raw materials, risks relating to regulation on social media, expansion of facilities, risks related to credit facilities, dependence on senior management and key personnel, availability of labor, general business risk and liability, regulation of the food industry, change in laws, regulations and guidelines, compliance with laws, risks related to third party logistics providers, unfavorable publicity or consumer perception, increased costs as a result of being a United States public company, product liability and product recalls, risks related to intellectual property, risks relating to co-manufacturing, risks related to expansion into the United States; risks related to our acquisition strategy, taxation risks, difficulties with forecasts, management of growth and litigation as well as the risks associated with the ongoing COVID-19 pandemic. For a more comprehensive discussion of the risks faced by VERY GOOD, please refer to VERY GOOD's most recent Annual Information Form filed with Canadian securities regulatory authorities at www.sedar.com and as an exhibit to the Form 20-F filed with the SEC on May 26, 2022 and available at www.sec.gov. The forward-looking information in this news release reflects the current expectations, assumptions and/or beliefs of the Company based on information currently available. Any forward-looking information speaks only as of the date of this news release. VERY GOOD undertakes no obligation to publicly update or revise any forward-looking information whether because of new information, future events or otherwise, except as otherwise required by law. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. None of the Nasdaq Stock Market LLC, TSX Venture Exchange, the SEC or any other securities regulator has either approved or disapproved the contents of this news release. None of the Nasdaq, the TSX Venture Exchange or its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), the SEC or any other securities regulator accepts responsibility for the adequacy or accuracy of this news release. View original content to download multimedia: SOURCE The Very Good Food Company Inc.	https://www.wlbt.com/prnewswire/2022/05/31/very-good-food-company-inc-announces-usd-65-million-private-placement/	2022-05-31T12:46:19	en	0.935829
Funds will support programmatic audio advertising expansion, tripling locations in next 18 months INDIANAPOLIS, May 31, 2022 /PRNewswire/ -- Fueled by rising momentum in programmatic technology, national premier retail audio advertising provider Vibenomics has raised $12.3 million in Series B funding to support the launch of additional national networks in grocery stores, pharmacies, and convenience stores. The round is led by Panoramic Ventures, one of the largest and most active tech venture funds in the Southeast. Vibenomics established itself as a formidable player in the Audio-Out-of-Home (AOOH) market after partnering with Kroger in May 2020. Last year, the company experienced its most significant growth, launching its first proprietary media player to deliver music, messaging and programmatic advertisements to each of its network partners' individual locations. By mid-2021, Vibenomics introduced multiple Demand Side Platforms (DSPs) to become the first — and only — programmatic digital AOOH solution for advertisers. "This funding validates our investors' belief in the future of Vibenomics and what we're building," said Brent Oakley, CEO of Vibenomics. "AOOH's value, impact and ability to scale allows retailers to provide a positive, in-store customer experience. We're anticipating another record-breaking year in 2022 and these funds will enable us to continue innovating and accelerating product developments, building on our momentum." Vibenomics continues to expand its national footprint in programmatic retail advertising. Earlier this year, the company partnered with Hy-Vee, adding an additional 400 locations across the Midwest. In the coming months, Vibenomics has a line of sight to expand to over 20,000 locations by the end of 2023. "Vibenomics directs the majority of its efforts toward consumer packaged goods (CPGs), a massive and highly competitive advertising sector eager to invest in innovative marketing strategies, particularly within retail locations," said Paul Iaffaldano, general partner for Panoramic Ventures. "We believe that Vibenomics's innovative approach to in-store audio advertisements in that industry gives us significant leverage to capitalize on a growing market." Vibenomics has nearly 40 employees, about 90% of whom live in the Indianapolis area and 10% work remotely. The company expects to increase its workforce by 25%, specifically in its sales and marketing departments, by the end of 2022. To learn more about Vibenomics, visit https://www.vibenomics.com. About Vibenomics Vibenomics, Inc. is a location-based Audio Out-of-Home™ advertising and experience company that powers audio channels for retailers, giving brands the ability to talk to shoppers directly at the point of sale. With its powerful cloud-based technology, licensed background music library, data integration capabilities, full-service team of audio experience experts, and network of on-demand professional voice talent, the company provides the right revenue-enhancing vibe for over 180 advertisers in more than 15,000 locations across 49 states, reaching more than 250 million unique monthly listeners. Vibenomics dynamically broadcasts hyper-targeted, on-demand audio advertisements within any combination of locations across its swiftly growing national footprint, unlocking a powerful new shopper marketing channel for reaching consumers during the critical final footsteps along the path to purchase. Through a first-of-its-kind partner program, retailers can receive a portion of revenue for advertisements sold by Vibenomics that play within their locations, giving them the ability to monetize their private airwaves and transform a legacy expense into a new profit center. About Panoramic Ventures: Panoramic Ventures is a venture capital firm based in Atlanta that takes a "wider-view" approach to investing by targeting the Southeast and Midwest and placing a focus on diverse founders and university startups. Panoramic opens new doors for overlooked founders, giving more entrepreneurs access to capital to build leading tech companies. For more information, visit www.panoramic.vc or follow Panoramic Ventures on LinkedIn, Instagram, or Twitter @panoramicvc. Media Contact: Abby Lewis BLASTmedia for Vibenomics 317.806.1900 x 136 Abby@blastmedia.com View original content to download multimedia: SOURCE Vibenomics	https://www.wlbt.com/prnewswire/2022/05/31/vibenomics-announces-123m-series-b-funding-with-plans-expand-its-network-advertising-reach/	2022-05-31T12:46:26	en	0.925983
LINDBLAD EXPEDITIONS HOLDINGS, INC. APPOINTS NOAH BRODSKY AS CHIEF COMMERCIAL OFFICER NEW YORK, May 31, 2022 /PRNewswire/ -- Lindblad Expeditions Holdings, Inc. (NASDAQ: LIND) a global leader of expedition cruises and adventure travel experiences, announced today it has named Noah Brodsky as its Chief Commercial Officer, effective today. Mr. Brodsky has built a 20+ year career focused on inspirational travel experiences and premium guest service through a succession of sales, marketing and operating roles at leading global hospitality companies. He is a demonstrated leader in innovative marketing strategies, revenue growth and digital transformation. Most recently, Mr. Brodsky served as the President of the Travel + Leisure Group and Chief Brand Officer for Travel + Leisure Co., the world's leading membership and leisure travel company. During his tenure, he led the rebranding of the Company, substantially grew the rental division, and created and launched multiple branded products, including a full-service travel agency, a subscription travel club, and a licensed goods business. Previously, Mr. Brodsky served as Chief Brand Officer for Wyndham Destinations, the world's largest vacation ownership and exchange business with more than $4B in annual revenue. While there, he led the enterprise level digital, brand, CRM, Partnership and PR departments. Earlier roles included SVP of Worldwide Loyalty and Engagement for Wyndham Hotels & Resorts, Chief Experience Officer at WeWork, and various marketing and operations roles at Starwood Hotels and Four Seasons Resorts. In his role with Lindblad Expeditions, Mr. Brodsky will be responsible for all revenue production and will lead marketing, sales, digital product development and strategic partnerships for the Company. "Lindblad Expeditions is poised for continued growth, as we expand our reach to provide our guests with more ways to discover the world. Noah's proven leadership skills in marketing, digital transformation and team building will be vital as we further build out a world class sales and marketing platform to support our growing fleet and inspiring new experiences for guests across the globe," shared Dolf Berle, CEO of Lindblad Expeditions. "Travelers today are seeking out extraordinary experiences that offer a sense of exploration and discovery and Lindblad Expeditions leads the category in sought-after, remote destinations. I am excited and honored to join the team that is building upon the Company's rich legacy of adventure, excellence and life-changing travel experiences for the next generation of Lindblad Expeditions' guests," said Brodsky. Lindblad Expeditions Holdings, Inc. is a global provider of small ship expeditions and adventure travel experiences recognized as the category leader for its pioneering, cutting edge programming and conservation commitment. Lindblad focuses on ship-based voyages through its Lindblad Expeditions brand and on land-based travel through its subsidiaries, Natural Habitat, Inc., Off the Beaten Path LLC, DuVine Cycling + Adventure Co. and Classic Journeys, LLC. Lindblad works in partnership with National Geographic to inspire people to explore and care about the planet. The organizations work in tandem to produce innovative marine expedition programs and to promote conservation and sustainable tourism around the world. Guests interact with and learn from leading scientists, naturalists and researchers while discovering stunning natural environments, above and below the sea, through state-of-the-art exploration tools. Photo of Noah Brodsky: here SOURCE Lindblad Expeditions Holdings, Inc.	https://www.prnewswire.com/news-releases/lindblad-expeditions-holdings-inc-appoints-noah-brodsky-as-chief-commercial-officer-301557545.html	2022-05-31T12:46:30	en	0.936828
Efficacy and safety results were based on analyses at week 109 from the open-label extension trial of a VILTEPSO Phase 2 study. These data from the open-label extension study of VILTEPSO were previously presented at medical congresses and scientific meetings. PARAMUS, N.J., May 31, 2022 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru Nakai), announced the publication of long-term efficacy and safety data based on analyses at 109 weeks from the 192-week open-label extension trial of a Phase 2 study of VILTEPSO® (viltolarsen) injection in the Journal of Neuromuscular Diseases. The article, "Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy," is freely available under open access (click here). "In this VILTEPSO open-label, long-term extension study, evaluation of functional clinical endpoints demonstrated maintenance of motor function versus functional decline in a historical control group over two years," said Leslie Magnus, MD, Vice President, Medical Affairs. "These encouraging interim results with VILTEPSO support the continued need to research its clinical profile and its potential impact on maintaining mobility." Data published in the Journal of Neuromuscular Diseases are from an open-label trial (N=16) that is the extension of a previous 24-week Phase 2 trial in North America. All 16 patients aged 4 to <10 years with DMD amenable to exon 53 skipping in the 24-week study elected to enroll in this long-term trial to continue evaluation of motor function and safety. Assessments of timed function tests (Time to Stand, Time to Run/Walk, 6-Minute Walk Test) were compared to a matched DMD historical control group (Cooperative International Neuromuscular Research Group Duchenne Natural History Study). In addition to this Phase 2 open-label extension study, NS Pharma continues to investigate the efficacy and safety of VILTEPSO in the confirmatory Phase 3 RACER53 trial. This study was initiated in October 2019 and is currently enrolling patients. The purpose of this Phase 3 randomized, double-blind, placebo-controlled trial is to evaluate the efficacy of viltolarsen on functional motor endpoints compared to placebo in DMD patients amenable to exon 53 skipping. Continued approval of VILTEPSO is dependent on verification of clinical benefit. Prior to its approval in the U.S. in August 2020, VILTEPSO was granted Priority Review as well as Rare Pediatric Disease, Orphan Drug and Fast Track Designations. In March 2020, VILTEPSO was approved in Japan for the treatment of patients with DMD who are amenable to exon 53 skipping therapy. Prior to its approval in Japan, VILTEPSO was granted with the SAKIGAKE designation, Orphan Drug designation, and designation of Conditional Early Approval System. VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Warnings and Precautions: Kidney toxicity was observed in animals who received viltolarsen. Although kidney toxicity was not observed in the clinical studies with VILTEPSO, the clinical experience with VILTEPSO is limited, and kidney toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. Kidney function should be monitored in patients taking VILTEPSO. Serum creatinine may not be a reliable measure of kidney function in DMD patients. Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting VILTEPSO. Consider also measuring glomerular filtration rate before starting VILTEPSO. During treatment, monitor urine dipstick every month, and serum cystatin C and urine protein-to-creatinine ratio every three months. Urine should be free of excreted VILTEPSO for monitoring of urine protein. Obtain urine either prior to VILTEPSO infusion, or at least 48 hours after the most recent infusion. Alternatively, use a laboratory test that does not use the reagent pyrogallol red, which has the potential to generate a false positive result due to cross reaction with any VILTEPSO in the urine. If a persistent increase in serum cystatin C or proteinuria is detected, refer to a pediatric nephrologist for further evaluation. Adverse Reactions: The most common adverse reactions include upper respiratory tract infection, injection site reaction, cough, and pyrexia. To report an adverse event, or for general inquiries, please call NS Pharma Medical Information at 1-866-NSPHARM (1-866-677-4276) For more information about VILTEPSO, see full Prescribing Information. NS Pharma, Inc., is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. For more information, please visit http://www.nspharma.com. NS Pharma is a registered trademark of the Nippon Shinyaku group of companies. Contact U.S. Media Contact: media@nspharma.com View original content: SOURCE NS Pharma	https://www.wlbt.com/prnewswire/2022/05/31/viltepso-viltolarsen-injection-long-term-efficacy-safety-data-published-journal-neuromuscular-diseases/	2022-05-31T12:46:33	en	0.92021
TSX-V: MKO; OTCQX: MAKOF VANCOUVER, BC, May 31, 2022 /PRNewswire/ - Mako Mining Corp. (TSXV: MKO) (OTCQX: MAKOF) ("Mako" or the "Company") is pleased to provide financial results for the three months ended March 31, 2022 ("Q1 2022"), which is the third full quarter of financial results since declaring commercial production on July 1, 2021 at its San Albino gold mine ("San Albino") in northern Nicaragua. For detailed Q1 2022 operating results, please see the press release dated April 27, 2022. All dollar amounts referred to herein are expressed in United States dollars unless otherwise stated. - $17.3 million in Revenue - $8.3 million in Adjusted EBITDA(1) - $8.7 million in Mine Operating Cash Flow ("Mine OCF") (1) (3) - $1.0 million in Net Loss - $797 Cash Costs ($/oz sold) (1) (2) - $862 Total Cash Costs ($/oz sold) (1) (2) - $1,104 All-In Sustaining Costs ("AISC") ($/oz sold) (1) (2) - $4.6 million of principal repayments during Q1 2022 - $1.9 million in exploration and evaluation expenses ($1.4 million at San Albino and $0.4 million at Las Conchitas) - $2.1 million of surface rights for regional expansion added this quarter - 401,500 shares purchased under the normal course issuer bid for total consideration of $94,340 (C$121,770) - Two monthly repayment installments totaling $0.8 million were made on the Sailfish Loan - Principal repayments of $0.5 million were made on the Wexford Loan - Total principal repayment of approximately $9.0 million since the beginning of Q4 2021 to Wexford and Sailfish Akiba Leisman, Chief Executive Officer, states that, "Q1 2022 was the third full quarter of financial results since declaring commercial production at San Albino at our initial 500 tonnes per day mine and processing plant, where 9,580 ounces were sold at $797/oz Cash Costs and $1,104/oz AISC. Costs are higher than Q4 due to an increase in diesel and other key reagents as well as an increase in waste development tonnage. The processing plant was operating at 596 tonnes per day at 87% availability (104% of nameplate capacity), as the plant has now been fully debottlenecked. The Company generated $8.3 million in Adjusted EBITDA, which excludes $1.9 million in exploration expenditures incurred in the quarter. As a result, approximately $9 million of principal has been repaid since the beginning of Q4 2021, including $4.6 million repaid in Q1 2022, and $1.3 million repaid on outstanding loans subsequent to quarter end. In addition, the $17.2 million exploration program announced in March 2022 is being funded out of cash flow, with the focus on discovering new veins and mineralization elsewhere on our property. The first results from this program are expected to be announced later this week. These extraordinary cash flows from our relatively small scale mine are expected to allow us to fund our growth with the ultimate objective of doubling capacity to 1,000 tonnes per day by next year." Table 1 – Revenue Table 2 – Operating and Financial Data Table 3 – EBITDA Reconciliation Q1 2022 - Mine OCF Calculation and Cash Reconciliation (in $ millions) For complete details, please refer to the Consolidated Financial Statements and the associated Management Discussion and Analysis for the three months ended March 31, 2022, available on SEDAR (www.sedar.com) or on the Company's website (www.makominingcorp.com). The Company has included certain non-GAAP financial measures and non-GAAP ratios in this press release such as EBITDA, Adjusted EBITDA, Mine Operating Cash Flow cash cost per ounce sold, total cash cost per ounce sold, AISC per ounce sold. These non-GAAP measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. In the gold mining industry, these are commonly used performance measures and ratios, but do not have any standardized meaning prescribed under IFRS and therefore may not be comparable to other issuers. The Company believes that, in addition to conventional measures prepared in accordance with IFRS, certain investors use this information to evaluate the Company's underlying performance of its core operations and its ability to generate cash flow. "EBITDA" represents earnings before interest (including non-cash accretion of financial obligation and lease obligations), income taxes and depreciation, depletion and amortization. "Adjusted EBITDA" represents EBITDA, adjusted to exclude exploration activities, share-based compensation and change in provision for reclamation and rehabilitation. "Cash costs per ounce sold" is calculated by deducting revenues from silver sales and dividing the sum of mining, milling and mine site administration cost. "Total cash costs per ounce sold" is calculated by deducting revenues from silver sales from production cash costs and production taxes and royalties and dividing the sum by the number of gold ounces sold. Production cash costs include mining, milling, mine site security and mine site administration costs. "AISC per ounce sold" includes total cash costs (as defined above) and adds the sum of G&A, sustaining capital and certain exploration and evaluation ("E&E") costs, sustaining lease payments, provision for environmental fees, if applicable, and rehabilitation costs paid, all divided by the number of ounces sold. As this measure seeks to reflect the full cost of gold production from current operations, capital and E&E costs related to expansion or growth projects are not included in the calculation of AISC per ounce. Additionally, certain other cash expenditures, including income and other tax payments, financing costs and debt repayments, are not included in AISC per ounce. "Mine OCF" represents operating cash flow, excluding Nicaraguan taxes and royalties, changes in non-cash working capital and exploration expenses. On behalf of the Board, Akiba Leisman Chief Executive Officer Mako Mining Corp. is a publicly listed gold mining, development and exploration company. The Company operates the high-grade San Albino gold mine in Nueva Segovia, Nicaragua, which ranks as one of the highest-grade open pit gold mines globally. Mako's primary objective is to operate San Albino profitably and fund exploration of prospective targets on its district-scale land package. Forward-Looking Information: Some of the statements contained herein may be considered "forward-looking information" within the meaning of applicable securities laws. Forward-looking information can be identified by words such as, without limitation, "estimate", "project", "believe", "anticipate", "intend", "expect", "plan", "predict", "may" or "should" or variations thereon or comparable terminology. The forward-looking information contained herein reflects the Company's current beliefs and expectations, based on management's reasonable assumptions, and includes, without limitation, that, based on the financial results, the Company intends to announce the first results from its previously announced exploration results later this week; the Company expects to fund its growth with the ultimate objective of doubling capacity to 1,000 tonnes per day by next year and Mako's primary objective to operate San Albino profitably and fund exploration of prospective targets on its district-scale land package. Such forward-looking information is subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking information, including, without limitation, changes in the Company's exploration and development plans and growth parameters and its ability to fund its growth to reach its stated target capacity; unanticipated costs; and other risks and uncertainties as disclosed in the Company's public disclosure filings on SEDAR at www.sedar.com. Such information contained herein represents management's best judgment as of the date hereof, based on information currently available and is included for the purposes of providing investors with information regarding the Company's Q1 2022 financial results and may not be appropriate for other purposes. Mako does not undertake to update any forward-looking information, except in accordance with applicable securities laws. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE Mako Mining Corp.	https://www.prnewswire.com/news-releases/mako-mining-provides-q1-2022-financial-results-301557611.html	2022-05-31T12:46:37	en	0.941761
to aid the detection and evaluation of diseases associated with NETosis AUSTIN, Texas, May 31, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced that its Nu.Q® NETs test has been CE marked for the detection and evaluation of NETosis, enabling clinical use in more than 27 countries across Europe. NETosis is a unique form of cell death that is characterized by the release of neutrophil extracellular traps ("NETs"), composed of decondensed chromatin, that trap and kill bacteria and viral particles. Although NETs play an important role in our immune system, excessive production can lead to tissue damage and, in severe cases, sepsis, shock, and death. Through routine blood tests, Volition's simple, low cost, accessible technology can detect NETosis, predict disease severity, and monitor its progression and response to treatment. Nu.Q® NETs is the first biomarker approved to measure NETs for patient management. Its broad intended use as a diagnostic tool to aid the detection and evaluation of diseases associated with NETosis offers a substantial commercial opportunity, with Volition's estimated Total Addressable Market in Europe, for sepsis alone, amounting to almost $6.5 billion on an annualized basis. Jake Micallef, Chief Scientific Officer at Volition explained: "NETosis has become a huge focus for medics in recent years, given elevated levels of NETs are associated with poor patient outcomes in a range of diseases, such as COVID-19, but also including sepsis and cancer. As NETs contain nucleosomes, we believe that our Nu.Q® NETs test is a groundbreaking diagnostic solution for the detection and monitoring of NETosis. With CE marking, it can now be used within European clinical settings to identify patients with a high level of NETs and allow physicians to rapidly triage these patients, then monitor their disease progression and response to treatment." Gael Forterre, Chief Commercial Officer at Volition added: "The role of NETs in the progression of acute, chronic, and debilitating conditions cannot be understated. As the only analytically validated test for NETs, we believe that there is enormous potential for Nu.Q® NETs to support clinical decision-making, enabling physicians to act quickly, and improve patient outcomes. We expect this to be a significant commercial opportunity for Volition. "Achieving CE marking is a critical regulatory milestone for us. Nu.Q® NETs is now registered for use in Europe in both ELISA (enzyme-linked immunoassay) and automated ChLIA (ChemiLuminescence ImmunoAssay) formats. We are now gearing up for commercialization and expect to drive sales from the first half of 2023." Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals. For more information about Volition's Nu.Q® technology go to: www.volition.com Note to editor: For more information about NETosis, watch our video or go to our Nu.Q® NETs webpage. About Volition Volition is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients but also improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring. Volition's research and development activities are centered in Belgium, with an innovation laboratory in California and additional offices in Texas, London, and Singapore, as the company focuses on bringing its diagnostic and disease monitoring products to market. For more information about Volition, visit www.volition.com The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. The address for Volition's website is included in this document as an inactive textual reference only. Media Enquiries: Louise Batchelor/Debra Daglish, Volition, mediarelations@volition.com +44 (0)7557 774620 Investor Enquiries: Scott Powell, Volition, investorrelations@volition.com +1 (646) 650 1351 Joseph Green, Edison Advisors, jgreen@edisongroup.com +1 (646) 653 7030 Safe Harbor Statement Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to the potential uses, benefits and effectiveness of its Nu.Q® NETs test, the size of Volition's addressable market for such test, Volition's ability to successfully commercialize such test platform, and expectations regarding Volition's ability to transition to a commercial products company, including its future financial performance. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including a failure by the marketplace to accept Volition's Nu.Q® NETs test; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and its intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring markets and their rapid technological change; downturns in domestic and foreign economies; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances. Nucleosomics™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All references to "$" refer to the legal currency of the United States of America. View original content: SOURCE VolitionRx Limited	https://www.wlbt.com/prnewswire/2022/05/31/volition-achieves-ce-mark-nuq-nets-test/	2022-05-31T12:46:39	en	0.94737
MatchCraft Recognized for its "Powered by" Technology at SIINDA Live Conference Creator of award-winning digital ad platform, adVantage™, awarded for its API suite used to power paid search, social and display advertising. LOS ANGELES, May 31, 2022 /PRNewswire/ -- At the Search & Information Industry Association (SIINDA) Live Conference held in Mallorca, MatchCraft was awarded the Silver Award for Technical Innovation Supporting SMBs During COVID. The Siinda Digital Marketing and Innovation Awards recognize excellence in support of local businesses and the conference is considered Europe's most prestigious local media event. The recognition highlight's MatchCraft's ongoing dedication to providing partners and their local business advertisers with industry leading solutions. "As a long standing parter with SIINDA, we appreciate how valuable their recognition is and are thrilled to have our solutions named among the best of the best," said MatchCraft CEO, Sandy Lohr. The recently launched "Powered by" suite of APIs offers partners access tot he technology used by AdVantage to power paid search, social and display campaigns fro local businesses across the globe. The result of more than 20 years of research and development, the solution provides immediate access to mature technology that is both affordable and scalable. MatchCraft welcomes the opportunity to discuss our "Powered by" solution. Schedule a demo with us or get directly in touch with our Business Development team: in the US or APAC call Brad Petersen, at +1 888 502-7238, In EMEA or LATAM call Jeff Chew at +31 10 3100 881. We look forward to learning more about your digital marketing needs and how we may be a match for you to scale your business with the efficiencies and performance of "Powered by". MatchCraft, a Vendasta owned company, provides a best-in-class marketing platform that enables companies to successfully sell and manage search, display, and social campaigns for their advertisers. Unlike other advertising technology platforms, MatchCraft's platform adVantage™ helps organizations efficiently manage campaigns of all sizes, enabling clients to deliver spectacular results to their advertisers. MatchCraft's sophisticated real-time bidding algorithms, and a team of digital marketing enthusiasts, work relentlessly to deliver exceptional ROI for merchants around the world. MatchCraft is a fully remote company with team members across the US, Europe, Mexico, and India. For digital marketing news, advice and to stay in the loop on product rollouts, follow MatchCraft on Facebook, MatchCraft on Twitter, MatchCraft on LinkedIn or visit www.MatchCraft.com SIINDA (Search & Information Industry Association) is the leading Europe based non-profit association bringing together companies in the search (digital, mobile, print, vertical directories and platforms), information, and telecommunication sectors as well as businesses providing "on demand" services. They have global members and SIINDA's Live Conference Series explores matters relevant to local businesses and includes presenters and attendees from some of Europe's mose respected digital companies and thought leaders. SOURCE MatchCraft	https://www.prnewswire.com/news-releases/matchcraft-recognized-for-its-powered-by-technology-at-siinda-live-conference-846064889.html	2022-05-31T12:46:43	en	0.919346
PAGOSA SPRINGS, Colo. , May 31, 2022 /PRNewswire/ -- VOORMI®, manufacturer of the world's most innovative technical apparel, has just announced the next horizon in the future of CORE CONSTRUCTION® Technology. Following a multi-year investment in advanced machinery, the company's affiliate technology provider (SWNR Technologies) is now offering its first glimpse into the future of textiles with advanced functional cores. "When we launched the first generation of CORE CONSTRUCTION® Technology, there was so much excitement and speculation about where the technology could go," said Timm Smith, CTO at VOORMI. "From Outside Magazine's vision for membranes in everything we wear, to Wired magazine deeming it the biggest advancement in Outerwear in the last 40 years, the opportunities out there felt boundless. What followed was a multi-year development project aimed at realizing the full potential of core-knitted textiles." According to Smith, while the first generation of CORE CONSTRUCTION® products were designed to bring superior performance and weather protection to fleece and other thermal layers, the long-term vision has always been to enable the insertion of even more complex functional substrates into the broader knitwear market, as well as the explore the vast world of opportunities beyond apparel. "From the beginning, fine-gauge knits, technical yarns, and the insertion of advanced substrates have all been key areas of focus for us," said Smith. "As is the case with most new 'methods of make' – it ultimately came down to equipment limitations. This Gen2 machinery truly opens up the world for us in terms of capability. With brand new patterning and multi-core insertion capabilities, there's no reason why every yard of knitted fabric in the world shouldn't contain a multi-functional core." In addition to a host of new products to be released over the coming year under the VOORMI brand, the company has kicked off a number of pilot projects in non-apparel sectors, providing enhanced functionality in industries ranging from automotive applications to e-textiles. "Given that textiles and apparel surround us in every aspect of our lives, it's our belief that that they should provide functionality to meet tomorrow's expectations" says Dan English, CEO at VOORMI. "This machinery, and the multi-million dollar investment we've made around it, finally provides the tools to enable truly new levels of performance in fabric. We're so excited for where this goes next." For more information on CORE CONSTRUCTION® Technology and/or opportunities for partnership, contact techpartners@swnrtechnologies.com. The future of Clothing Located in Southwest CO and Bozeman MT, VOORMI is on a mission to build the next generation of outdoor clothing. Clothing for a world where technology and textiles converge in the ultimate expression of simplicity and sophistication. VOORMI's products are designed to elevate the full human powered experience, wherever in the world that road may lead. For more information on VOORMI and SWNR Technologies, visit voormi.com. View original content: SOURCE VOORMI	https://www.wlbt.com/prnewswire/2022/05/31/voormi-unveils-next-generation-core-construction-technology/	2022-05-31T12:46:46	en	0.937584
NEW YORK, May 31, 2022 /PRNewswire/ -- The "Mattress Market by Product, Distribution Channel, and Geography - Forecast and Analysis 2021-2025" report has been added to Technavio's offering. According to the report, the market size will increase by USD 14.36 billion between 2020 and 2025, expanding at a CAGR of 7.73% during the forecast period. APAC will have the largest share of the market. The continuous expansion in the urban population is creating significant demand for mattresses in the region. Download Our Sample Report for more highlights on the market size, YOY growth rates, growth momentum, and other important statistics. Vendor Landscape The global mattress market is fragmented. The market is characterized by the presence of numerous large, small, and medium-sized manufacturers. Most of the large and established players have extensive sales and distribution networks globally, whereas small players are concentrated in the regional markets. Vendors are competing based on parameters such as price, quality, technology, brand identity, and distribution. Technavio identifies Casper Sleep Inc., King Koil Licensing Co. Inc., Kingsdown Inc., Kurlon Enterprise Ltd., Leggett & Platt Inc., Paramount Bed Holdings Co. Ltd., Saatva Inc., Serta Simmons Bedding LLC, Sleep Number Corp., and Tempur Sealy International Inc. are some of the major market participants. Although the expansion of commercial end-users, growing demand for smart mattresses, and the rising popularity of eco-friendly mattresses will offer immense growth opportunities, fluctuating raw material prices and high manufacturing costs, the growing threat from counterfeit mattresses, and stringent government regulations for manufacturing mattresses will challenge the growth of the market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments. For additional insights on the vendor landscape, View Our Sample Report Mattress Market 2021-2025: Segmentation The global mattress market is segmented as below: - Product - Innerspring Mattress - Memory Foam Mattress - Latex Mattress - Other Mattresses The innerspring mattress segment will have the largest share of the market. The growth of the segment can be attributed to the increased demand and affordability of innerspring mattresses. - Distribution Channel - Offline - Online The offline segment accounted for maximum sales in the market. The market growth in the segment will be significant over the forecast period. - Geography - APAC - North America - Europe - South America About 52% of the market growth will originate from APAC during the forecast period. The rise in the sales of household products via e-commerce channels and expansion of geographical presence by key vendors are driving the growth of the segment. Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our mattress market report covers the following areas: Mattress Market 2021-2025: Vendor Analysis We provide a detailed analysis of around 25 vendors operating in the mattress market. Backed with competitive intelligence and benchmarking, our research report on the mattress market is designed to provide entry support, customer profile, and M&As as well as go-to-market strategy support. Mattress Market 2021-2025: Key Highlights - CAGR of the market during the forecast period 2021-2025 - Detailed information on factors that will assist mattress market growth during the next five years - Estimation of the mattress market size and its contribution to the parent market - Predictions on upcoming trends and changes in consumer behavior - The growth of the mattress market - Analysis of the market's competitive landscape and detailed information on vendors - Comprehensive details of factors that will challenge the growth of mattress market vendors Related Reports: - Latex Pillow Market by Distribution Channel and Geography - Forecast and Analysis 2022-2026 - Latex Mattress Market by Distribution Channel and Geography - Forecast and Analysis 2021-2025 Table Of Contents : 1 Executive Summary 2 Market Landscape - 2.1 Market ecosystem - Exhibit 01: Parent market - Exhibit 02: Market characteristics - 2.2 Value chain analysis 3 Market Sizing - 3.1 Market definition - Exhibit 03: Offerings of vendors included in the market definition - 3.2 Market segment analysis - Exhibit 04: Market segments - 3.3 Market size 2020 - 3.4 Market outlook: Forecast for 2020 - 2025 - Exhibit 05: Global - Market size and forecast 2020 - 2025 ($ million) - Exhibit 06: Global market: Year-over-year growth 2020 - 2025 (%) 4 Five Forces Analysis - 4.1 Five Forces Analysis - Exhibit 07: Five forces analysis 2020 & 2025 - 4.2 Bargaining power of buyers - Exhibit 08: Bargaining power of buyers - 4.3 Bargaining power of suppliers - Exhibit 09: Bargaining power of suppliers - 4.4 Threat of new entrants - Exhibit 10: Threat of new entrants - 4.5 Threat of substitutes - Exhibit 11: Threat of substitutes - 4.6 Threat of rivalry - Exhibit 12: Threat of rivalry - 4.7 Market condition - Exhibit 13: Market condition - Five forces 2020 5 Market Segmentation by Product - 5.1 Market segments - Exhibit 14: Product - Market share 2020-2025 (%) - 5.2 Comparison by Product - Exhibit 15: Comparison by Product - 5.3 Innerspring mattress - Market size and forecast 2020-2025 - Exhibit 16: Innerspring mattress - Market size and forecast 2020-2025 ($ million) - Exhibit 17: Innerspring mattress - Year-over-year growth 2020-2025 (%) - 5.4 Memory foam mattress - Market size and forecast 2020-2025 - Exhibit 18: Memory foam mattress - Market size and forecast 2020-2025 ($ million) - Exhibit 19: Memory foam mattress - Year-over-year growth 2020-2025 (%) - 5.5 Latex mattress - Market size and forecast 2020-2025 - Exhibit 20: Latex mattress - Market size and forecast 2020-2025 ($ million) - Exhibit 21: Latex mattress - Year-over-year growth 2020-2025 (%) - 5.6 Other mattresses - Market size and forecast 2020-2025 - Exhibit 22: Other mattresses - Market size and forecast 2020-2025 ($ million) - Exhibit 23: Other mattresses - Year-over-year growth 2020-2025 (%) - 5.7 Market opportunity by Product - Exhibit 24: Market opportunity by Product 6 Market Segmentation by Distribution channel - 6.1 Market segments - Exhibit 25: Distribution channel - Market share 2020-2025 (%) - 6.2 Comparison by Distribution channel - Exhibit 26: Comparison by Distribution channel - 6.3 Offline - Market size and forecast 2020-2025 - Exhibit 27: Offline - Market size and forecast 2020-2025 ($ million) - Exhibit 28: Offline - Year-over-year growth 2020-2025 (%) - 6.4 Online - Market size and forecast 2020-2025 - Exhibit 29: Online - Market size and forecast 2020-2025 ($ million) - Exhibit 30: Online - Year-over-year growth 2020-2025 (%) - 6.5 Market opportunity by Distribution channel - Exhibit 31: Market opportunity by Distribution channel 7 Customer landscape - 7.1 Customer landscape - Exhibit 32: Customer landscape 8 Geographic Landscape - 8.1 Geographic segmentation - Exhibit 33: Market share by geography 2020-2025 (%) - 8.2 Geographic comparison - Exhibit 34: Geographic comparison - 8.3 APAC - Market size and forecast 2020-2025 - Exhibit 35: APAC - Market size and forecast 2020-2025 ($ million) - Exhibit 36: APAC - Year-over-year growth 2020-2025 (%) - 8.4 North America - Market size and forecast 2020-2025 - Exhibit 37: North America - Market size and forecast 2020-2025 ($ million) - Exhibit 38: North America - Year-over-year growth 2020-2025 (%) - 8.5 Europe - Market size and forecast 2020-2025 - Exhibit 39: Europe - Market size and forecast 2020-2025 ($ million) - Exhibit 40: Europe - Year-over-year growth 2020-2025 (%) - 8.6 South America - Market size and forecast 2020-2025 - Exhibit 41: South America - Market size and forecast 2020-2025 ($ million) - Exhibit 42: South America - Year-over-year growth 2020-2025 (%) - 8.7 MEA - Market size and forecast 2020-2025 - Exhibit 43: MEA - Market size and forecast 2020-2025 ($ million) - Exhibit 44: MEA - Year-over-year growth 2020-2025 (%) - 8.8 Key leading countries - Exhibit 45: Key leading countries - 8.9 Market opportunity by geography - Exhibit 46: Market opportunity by geography ($ million) 9 Drivers, Challenges, and Trends - 9.1 Market drivers - 9.2 Market challenges - 9.3 Market trends 10 Vendor Landscape - 10.1 Vendor landscape - Exhibit 48: Vendor landscape - 10.2 Competitive scenario - 10.3 Landscape disruption - Exhibit 49: Landscape disruption - Exhibit 50: Industry risks 11 Vendor Analysis - 11.1 Vendors covered - Exhibit 51: Vendors covered - 11.2 Market positioning of vendors - Exhibit 52: Market positioning of vendors - 11.3 Casper Sleep Inc. - Exhibit 53: Casper Sleep Inc. - Overview - Exhibit 54: Casper Sleep Inc. - Product and service - Exhibit 55: Casper Sleep Inc. - Key offerings - 11.4 King Koil Licensing Co. Inc. - Exhibit 56: King Koil Licensing Co. Inc. - Overview - Exhibit 57: King Koil Licensing Co. Inc. - Product and service - Exhibit 58: King Koil Licensing Co. Inc. - Key offerings - 11.5 Kingsdown Inc. - Exhibit 59: Kingsdown Inc. - Overview - Exhibit 60: Kingsdown Inc. - Product and service - Exhibit 61: Kingsdown Inc. - Key offerings - 11.6 Kurlon Enterprise Ltd. - Exhibit 62: Kurlon Enterprise Ltd. - Overview - Exhibit 63: Kurlon Enterprise Ltd. - Product and service - Exhibit 64: Kurlon Enterprise Ltd. - Key offerings - 11.7 Leggett & Platt Inc. - Exhibit 65: Leggett & Platt Inc. - Overview - Exhibit 66: Leggett & Platt Inc. - Business segments - Exhibit 67: Leggett & Platt Inc. - Key offerings - Exhibit 68: Leggett & Platt Inc. - Segment focus - 11.8 PARAMOUNT BED HOLDINGS CO. LTD. - Exhibit 69: PARAMOUNT BED HOLDINGS CO. LTD. - Overview - Exhibit 70: PARAMOUNT BED HOLDINGS CO. LTD. - Business segments - Exhibit 71: PARAMOUNT BED HOLDINGS CO. LTD. - Key offerings - Exhibit 72: PARAMOUNT BED HOLDINGS CO. LTD. - Segment focus - 11.9 Saatva Inc. - Exhibit 73: Saatva Inc. - Overview - Exhibit 74: Saatva Inc. - Product and service - Exhibit 75: Saatva Inc. - Key offerings - 11.10 Serta Simmons Bedding LLC - Exhibit 76: Serta Simmons Bedding LLC - Overview - Exhibit 77: Serta Simmons Bedding LLC - Product and service - Exhibit 78: Serta Simmons Bedding LLC - Key news - Exhibit 79: Serta Simmons Bedding LLC - Key offerings - 11.11 Sleep Number Corp. - Exhibit 80: Sleep Number Corp. - Overview - Exhibit 81: Sleep Number Corp. - Product and service - Exhibit 82: Sleep Number Corp. - Key offerings - 11.12 Tempur Sealy International Inc. - Exhibit 83: Tempur Sealy International Inc. - Overview - Exhibit 84: Tempur Sealy International Inc. - Product and service - Exhibit 85: Tempur Sealy International Inc. - Key news - Exhibit 86: Tempur Sealy International Inc. - Key offerings - Exhibit 87: Tempur Sealy International Inc. – Segment focus 12 Appendix - 12.1 Scope of the report - 12.2 Currency conversion rates for US$ - Exhibit 88: Currency conversion rates for US$ - 12.3 Research methodology - Exhibit 89: Research Methodology - Exhibit 90: Validation techniques employed for market sizing - Exhibit 91: Information sources - 12.4 List of abbreviations - Exhibit 92: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: www.technavio.com/ SOURCE Technavio	https://www.prnewswire.com/news-releases/mattress-market-size-to-increase-by-usd-14-36-bn--driven-by-the-expansion-of-commercial-end-users--technavio-301557310.html	2022-05-31T12:46:49	en	0.836978
CALGARY, AB and MOUNTAIN VIEW, Calif., May 31, 2022 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients is pleased to announce today that is has been engaged by a specialty pharmaceutical company (the "Counterparty") to optimize an enzyme vital to the development of a large volume Active Pharmaceutical Ingredient (API) used in nutraceutical and pharmaceutical products. The Counterparty is partnered with a large-cap, multi-national healthcare company. "This is a significant step forward in the evolution of Willow's business", said Trevor Peters, Willow's President and Chief Executive Officer. "This new partnership highlights the capabilities of our scientific team, and demonstrates to our stakeholders the wide array of opportunities accessible to Willow's comprehensive FutureGrownTM technology platform. As Willow continues to expand its capabilities and add new partnerships, Willow is on a path to becoming the premier name in biobased manufacturing." The project consists of research & development and commercialization phases, with revenue coming from both research fees and milestone payments. Following commercialization, Willow anticipates an on-going revenue stream from license payments. Willow develops and produces high-purity ingredients for the personal care, food and beverage, and pharmaceutical markets. Willow's FutureGrownTM biotechnology platform allows large-scale production with sustainability at its core. Willow's R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products to benefit our B2B partners and their customers. For further information, please visit our website at www.willowbio.com This news release may include forward-looking statements including opinions, assumptions, estimates and the Company's assessment of future plans and operations, and, more particularly, statements concerning: the ability to accommodate new programs and to expand capabilities, including in respect of a new partnered pharmaceutical project; the demand and market size potential of the synthetic cannabinoid industry; and the business plan of the Company, generally, including becoming a leader in precision fermentation, cannabinoid research and production. When used in this news release, the words "will," "anticipate," "believe," "estimate," "expect," "intent," "may," "project," "should," and similar expressions are intended to be among the statements that identify forward-looking statements. The forward-looking statements are founded on the basis of expectations and assumptions made by the Company which include, but are not limited to: the success of Willow's strategic partnerships, including the development of future strategic partnerships; the financial strength of the Company; the ability of the Company to fund its business plan using cash on hand and existing resources; the market for Willow's products; the ability of the Company to obtain and retain applicable licences; the ability of the Company to obtain suitable manufacturing partners and other strategic relationships; and the successful implementation of Willow's commercialization and production strategy, generally. Forward-looking statements are subject to a wide range of risks and uncertainties, and although the Company believes that the expectations represented by such forward-looking statements are reasonable, there can be no assurance that such expectations will be realized. Any number of important factors could cause actual results to differ materially from those in the forward-looking statements including, but not limited to, risks associated with: the cannabinoid industry in general; the success of the Company's research and development strategies; infringement on intellectual property; failure to benefit from partnerships or successfully integrate acquisitions; actions and initiatives of federal and provincial governments and changes to government policies and the execution and impact of these actions, initiatives and policies; import/export and research restrictions for cannabinoid-based operations; the size of the medical-use and adult-use cannabinoid market; competition from other industry participants; adverse U.S., Canadian and global economic conditions; adverse global events and public-health crises, including the current COVID-19 outbreak; failure to comply with certain regulations; departure of key management personnel or inability to attract and retain talent; and other factors more fully described from time to time in the reports and filings made by the Company with securities regulatory authorities. Please refer to the Company's most recent annual information form and management's discussion and analysis for additional risk factors relating to Willow, which can be accessed either on Willow's website at www.willowbio.com or under the Company's profile on www.sedar.com. Any financial outlook and future-oriented financial information contained in this document regarding prospective financial performance, financial position, cash balances or revenue is based on assumptions about future events, including economic conditions and proposed courses of action based on management's assessment of the relevant information that is currently available. Projected operational information contains forward-looking information and is based on a number of material assumptions and factors, as are set out above. These projections may also be considered to contain future-oriented financial information or a financial outlook. The actual results of the Company's operations for any period will likely vary from the amounts set forth in these projections and such variations may be material. Actual results will vary from projected results. Readers are cautioned that any such financial outlook and future-oriented financial information contained herein should not be used for purposes other than those for which it is disclosed herein. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement. View original content to download multimedia: SOURCE Willow Biosciences Inc.	https://www.wlbt.com/prnewswire/2022/05/31/willow-biosciences-expands-its-portfolio-with-new-partnered-pharmaceutical-project/	2022-05-31T12:46:53	en	0.940591
Customers will be able to transact faster and cheaper with USDC on the Stellar network SAN FRANCISCO, May 31, 2022 /PRNewswire/ -- As of today, customers of Mercado Bitcoin, the largest platform for digital assets in Latin America, will have access to USDC issued on the Stellar network, which offers fast and affordable transactions. It is the first time that the Mercado Bitcoin platform has offered the same asset issued by different networks. Now, with the possibility of transacting using USDC with lower fees, a fraction of one cent per transaction, the customer will be able to choose the network most suitable for their needs. Since 2014, the Stellar network has been offering safe and cheap transactions. In the first quarter of 2022, it processed an average of $8.6 million a day in payments. Currently, it has also been one of the most chosen networks for payments, tokenization, and issuance of real assets. "USDC on Stellar provides Mercado Bitcoin customers both valuable interoperability and a truly borderless digital dollar," said Denelle Dixon, CEO of Stellar Development Foundation. "As we continue our mission of creating equitable access to the global financial system, this integration is a mutually beneficial step forward. MB is one of the largest digital assets exchanges in the southern hemisphere, with the potential to bring significant volume and liquidity to the Stellar network." By the end of 2022, the network plans to launch native smart contracts that will unlock the creation of numerous applications, which will further increase the utility of USDC on Stellar. Stellar is a decentralized, fast, scalable, and uniquely sustainable network for financial products and services. It is both a cross-currency transaction system and a platform for digital asset issuance, designed to connect the world's financial infrastructure. Dozens of financial institutions worldwide issue assets and settle payments on the Stellar network, which has grown to over 6 million accounts. For more information, visit stellar.org. The Stellar Development Foundation (SDF) is a non-profit organization that supports the development and growth of Stellar, an open-source network that connects the world's financial infrastructure. Founded in 2014, the Foundation helps maintain Stellar's codebase, supports the technical and business communities building on the network, and serves as a voice to regulators and institutions. The Foundation seeks to create equitable access to the global financial system, using the Stellar network to unlock the world's economic potential through blockchain technology. For more information, visit stellar.org/foundation. About Mercado Bitcoin - Mercado Bitcoin is the largest cryptocurrency and alternative asset trading platform in Latin America. The company, which offers freedom, security, and liquidity in trading, is among the 25 most trusted exchanges in the world to trade cryptoassets, according to a study conducted by the Blockchain Transparency Institute (BTI). With more than 3.5 million customers and more than R$40 billion traded since its creation in 2013, the company is transforming people's relationships with their own money and democratizing access to alternative assets with liquidity and security. SOURCE The Stellar Development Foundation	https://www.prnewswire.com/news-releases/mercado-bitcoin-integrates-usdc-on-stellar-301557574.html	2022-05-31T12:46:55	en	0.931052
BEIJING, May 31, 2022 /PRNewswire/ -- WiMi Hologram Cloud Inc. (Nasdaq: WIMI) ("WiMi" or the "Company"), a leading global Hologram Augmented Reality ("AR") Technology provider, today announced that it had joined the Information Technology Innovation Committee of China Communications Industry Association (CCIAITIC) after a three-month rigorous evaluation of technical indicators. WiMi had become a member of the committee and obtained the member unit certification issued by the China Communications Industry Association, which again demonstrated that the Company has a solid ability to engage in holographic AR and information software services. China Communications Industry Association ("CCIA" or the "Association") is registered with the Ministry of Civil Affairs of the People's Republic of China (MCA). It is guided by the Ministry of Industry and Information Technology (MIIT) in its business. It plays the role of a bridge and an assistant between enterprises and the government, continuously promotes the technological innovation of China's communication industry, and goes out of the country. It promotes the development of the industry and makes continuous efforts to prosper the economic development of China's communication sector. The Association is in the charge of MIIT. Under the guidance of MIIT, the Association carries out industry management, information exchange, business training, international cooperation, and consulting services. It aims to promote the technical progress of the industry, improve product quality, strengthen economic and technical cooperation between enterprises and institutions, tighten the connections and improve the quality of member units and their economic benefits. The Association also promotes communication products to meet the growing demand at home and abroad to enhance the competitiveness in the international market. To promote the development of China's communications industry in the field of national information technology innovation, and to accelerate the integration and growth of new-generation information technology and its innovation, such as 5G communications and metaverse, Internet of Things, East Digital West Computing, blockchain, artificial intelligence, the establishment of CCIAITIC has been approved by MCA and MIIT. CCIAITIC is a subsidiary organization. WiMi's admittance to CCIAITIC proves its overall comprehensive strength. WiMi is currently the leading holographic platform in China and has established a complete holographic technology research and development system, holographic content production and reserve system, and holographic commercialization system. The Company has 195 technology patents related to image processing and display, model input/output, 3D modeling, and 325 software copyrights. It has produced more than 4,600 high-quality, high-fidelity holographic contents. WiMi's Holographic XR Head-Mounted Display Device "WiMi Hologram SoftLight", Holographic AR Head-Mounted Display Device "WiMi HoloAR Lens", and its Holographic Lidar "WiMi HoloPulse LiDAR", have all been licensed and approved by the Federal Communications Commission to enter the U.S. market. In the future, WiMi will seize this opportunity to further strengthen and accelerate the continuous innovation in 5G communication, holographic AR, metaverse, artificial intelligence, and information software development. About WIMI Hologram Cloud WiMi Hologram Cloud, Inc. (NASDAQ: WIMI), whose commercial operations began in 2015, is a holographic cloud comprehensive technical solution provider that focuses on professional areas including holographic AR automotive HUD software, 3D holographic pulse LiDAR, head-mounted light field holographic equipment, holographic semiconductor, holographic cloud software, holographic car navigation, metaverse holographic AR/VR equipment, metaverse holographic cloud software, and others. Its services and holographic AR technologies include holographic AR automotive application, 3D holographic pulse LiDAR technology, holographic vision semiconductor technology, holographic software development, holographic AR advertising technology, holographic AR entertainment technology, holographic ARSDK payment, interactive holographic communication, metaverse holographic AR technology, metaverse virtual cloud service and other holographic AR technologies. For more information, please visit http://ir.wimiar.com. Safe Harbor Statements This press release contains "forward-looking statements" within the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will,""expects,""anticipates,""future,""intends,""plans,""believes,""estimates" and similar statements. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Among other things, the business outlook and quotations from management in this press release and the Company's strategic and operational plans contain forward−looking statements. The Company may also make written or oral forward−looking statements in its periodic reports to the US Securities and Exchange Commission ("SEC") on Forms 20−F and 6−K, in its annual report to shareholders, in press releases, and other written materials, and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. Several factors could cause actual results to differ materially from those contained in any forward−looking statement, including but not limited to the following: the Company's goals and strategies; the Company's future business development, financial condition, and results of operations; the expected growth of the AR holographic industry; and the Company's expectations regarding demand for and market acceptance of its products and services. Further information regarding these and other risks is included in the Company's annual report on Form 20-F and the current report on Form 6-K and other documents filed with the SEC. All information provided in this press release is as of the date of this press release. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable laws. View original content: SOURCE WiMi Hologram Cloud Inc.	https://www.wlbt.com/prnewswire/2022/05/31/wimi-hologram-cloud-joins-information-technology-innovation-committee-china-communications-industry-association/	2022-05-31T12:46:59	en	0.923742
New Analysis from Global Industry Analysts Reveals Steady Growth for Machine Tools, with the Market to Reach $98.3 Billion Worldwide by 2026 SAN FRANCISCO, May 31, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Machine Tools - Global Market Trajectory & Analytics". The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace. FACTS AT A GLANCE What's New for 2022? - Global competitiveness and key competitor percentage market shares - Market presence across multiple geographies - Strong/Active/Niche/Trivial - Online interactive peer-to-peer collaborative bespoke updates - Access to our digital archives and MarketGlass Research Platform - Complimentary updates for one year Edition: 19; Released: May 2022 Executive Pool: 33272 Companies: 617 - Players covered include Ace Micromatic Group; Allied Machine & Engineering Corporation; Amada Co, Ltd.; Amada Machine Tools America, Inc.; Chiron Group SE; Dalian Machine Tool Group Corporation; DMG Mori Co., Ltd.; Doosan Machine Tools Co. Ltd.; Electronica Hitech Engineering Pvt. Ltd.; FANUC Corporation; FANUC America Corporation; GF Machining Solutions Management SA; Gleason Corporation; GROB-WERKE GmbH & Co. KG; Hardinge, Inc.; Jones & Shipman Hardinge Ltd.; Haas Automation, Inc.; Hyundai WIA Co. Ltd.; JTEKT Corporation; Kennametal Inc.; Komatsu Ltd.; Makino Milling Machine Co. Ltd.; Okuma Corporation; Otto Bihler Maschinenfabrik GmbH & Co. KG; Sandvik AB; Sandvik Coromant; Schuler AG; Shanghai Machine Tool Works Ltd.; Shape Technologies Group; Sodick; Spinner Machine Tools GmbH; TAJMAC-ZPS, a.s.; Trumpf Group; Walter AG; Yamazaki Mazak Corporation and Others. Coverage: All major geographies and key segments Segments: Product Segment (Machining Centers; Lathe Machines; Bending & Forming Machines; Grinding, Honing, Lapping, Polishing & Buffing Machines; Milling Machines; Electrical Discharge Machines; Punching & Shearing Machines; High Power Laser Cutting Machines; Metal Working Presses; Waterjet Cutting Machines; Other Product Segments); End-Use (Automotive, Aerospace / Defense, Industrial Machinery, Other End-Uses) Geographies: World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; India; South Korea; Taiwan; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Africa. Complimentary Project Preview - This is an ongoing global program. Preview our research program before you make a purchase decision. We are offering a complimentary access to qualified executives driving strategy, business development, sales & marketing, and product management roles at featured companies. Previews provide deep insider access to business trends; competitive brands; domain expert profiles; and market data templates and much more. You may also build your own bespoke report using our MarketGlass™ Platform which offers thousands of data bytes without an obligation to purchase our report. Preview Registry ABSTRACT- Amid the COVID-19 crisis, the global market for Machine Tools estimated at US$77.1 Billion in the year 2022, is projected to reach a revised size of US$98.3 Billion by 2026, growing at a CAGR of 5.8% over the analysis period. Machining Centers, one of the segments analyzed in the report, is projected to grow at a 5.5% CAGR, while growth in the Lathe Machines segment is readjusted to a revised 6.2% CAGR. Despite receiving a major blow in the form of COVID-19 coronavirus outbreak, China is forecast to continue to remain among the world's largest manufacturing hubs in the medium term despite the rising domestic production costs. In the United States, manufacturing renaissance and reshoring of manufacturing are forecast to benefit the machine tools market in the long-term. The latter half of the previous decade saw automotive manufacturing making a comeback to domestic shores as cost advantages of moving plants overseas to countries like China gradually shrunk. Spiraling labor costs in China and increasing shipping costs are fast eroding China's edge as a low cost manufacturing hub. In addition, the shale gas revolution in the United States and the ensuing availability of cheap energy and fuel sources is expected to reduce manufacturing costs in the country. Interestingly, cheap shale gas is attracting industrial companies back into the US, boding a possible return to industrialization after decades of consumption led growth. Surplus of shale gas reserves and production results in significantly lower feedstock and energy costs, helping narrow further the country's production cost gap with China and other lower cost Asian countries. Manufacturing in Europe over the last couple of decades has been slow and stagnant largely as a result of de-localization of manufacturing activities of most companies in the EU zone. Japan over the last decade played an instrumental role in chipping away at EU manufacturing strength through radical improvements in design, performance and engineering skills. Manufacturing industry in the region has been facing steady loss of loss of knowledge capital as a result of labor market rigidities. Projected rise in demand for fabricated metals from major sectors like machinery and construction in 2022 and beyond would favor market expansion, globally. Fabricated metals such as small arms, ammunition, building products, cutlery, utensils, springs, stamped-metal products, cranes, tanks, fasteners and other hardware are manufactured using various machine tools. Likely increase in demand for these fabricated metals therefore would drive the future demand for machine tools. Going forward, additive manufacturing is expected to wield a major positive impact on the market. Several manufacturers of machine tools are aiming to capitalize on the growing popularity of 3D printing by integrating the technology in their tools. 3D printing enables quicker delivery of products and reduces development costs and raw material costs drastically. Ongoing advancements in 3D printing in making a plethora of products, ranging from small parts & components to multi-storey buildings and mid-sized boats in very less time and resources, has grabbed the attention of enterprises across different industries, while pointing towards active integration of the technology in machine tools vertical. At the same time, the trend of high demand for advanced technology based machine tools, especially those integrated with IoT, AI, ML, and smart functionalities, would continue with the same fervor. Five and four-axis machines, multitasking machines and a few other advanced machine tool segments are expected to witness strong demand growth across the world but commodity type machine tools are expected to be in less demand. The market for machine tools has been witnessing continuous technological advancements for long but the sophistications of the recent years are a class apart from the many previous advancements. These include multi-axis arms and robotic arms among a few others. This combined with the factor of constant and rapid growth of the manufacturing industry worldwide is the major factor driving growth for the market for machine tools currently. All industrial sectors seek innovative means for increasing productivity and reducing downtime. This increased the proliferation of automated machine tools. Demand has also been high over the past many years for high accuracy and high precision components among various industrial sectors which has been encouraging machine tool companies to develop more advanced and feature-rich tools that can handle heavy and more complicated parts with increased accuracy and flexibility. CNC (Computer Numerical Control) machine tools for instance, provide the finest cuts for metal workpieces. When workpieces have the perfect finishes, it greatly improves quality of final product. Wastage is also greatly reduced with such high accuracy in cutting. Automation, machine learning and such other advances led to the development of CNC systems. In the current scenario, CNC machine tools are being increasingly employed in machining operations where they help in reducing machining time of various components by following a completely automated process. There are several advantages with CNC machines including enhanced capability, uniformity in product delivery, and reduced operating and labor costs among others. Advanced software is also being integrated in CNC machine tools. With the help of the software, users would be able to produce components seamlessly, in the required sizes, textures and shapes. CAD-CAM in product designing as well as prototyping is also implemented in CNC machines. These enable customers provide better finishes for their products. CNC systems are also being integrated with automatic tool changers. The automation of such tool changers allows conducting of multiple operations with just one command. All high-speed CNC machining centers also have tool magazines as the most common parts along with the automatic tool changers. Machine tool manufacturers currently are totally invested in developing advanced and fully-automated machine tools. Okuma Corporation for instance, a provider of CNC lathe machines, recently launched its new large vertical CNC lathe, VT1000EX, capable of achieving improved productivity, especially in machining materials that are difficult to cut. The lathe machine offers exceptional machining capability due to its mechanical configuration which is highly rigid. Difficult-to-cut materials can be given the finest cuts with reduced cycle times. More MarketGlass™ Platform Our MarketGlass™ Platform is a free full-stack knowledge center that is custom configurable to today`s busy business executive`s intelligence needs! This influencer driven interactive research platform is at the core of our primary research engagements and draws from unique perspectives of participating executives worldwide. Features include - enterprise-wide peer-to-peer collaborations; research program previews relevant to your company; 3.4 million domain expert profiles; competitive company profiles; interactive research modules; bespoke report generation; monitor market trends; competitive brands; create & publish blogs & podcasts using our primary and secondary content; track domain events worldwide; and much more. Client companies will have complete insider access to the project data stacks. Currently in use by 67,000+ domain experts worldwide. Our platform is free for qualified executives and is accessible from our website www.StrategyR.com or via our just released mobile application on iOS or Android About Global Industry Analysts, Inc. & StrategyR™ Global Industry Analysts, Inc., (www.strategyr.com) is a renowned market research publisher the world`s only influencer driven market research company. Proudly serving more than 42,000 clients from 36 countries, GIA is recognized for accurate forecasting of markets and industries for over 33 years. CONTACTS: Zak Ali Director, Corporate Communications Global Industry Analysts, Inc. Phone: 1-408-528-9966 www.StrategyR.com Email: [email protected] LINKS Join Our Expert Panel https://www.strategyr.com/Panelist.asp Connect With Us on LinkedIn https://www.linkedin.com/company/global-industry-analysts-inc./ Follow Us on Twitter https://twitter.com/marketbytes Journalists & Media [email protected] SOURCE Global Industry Analysts, Inc.	https://www.prnewswire.com/news-releases/new-analysis-from-global-industry-analysts-reveals-steady-growth-for-machine-tools-with-the-market-to-reach-98-3-billion-worldwide-by-2026--301557154.html	2022-05-31T12:47:01	en	0.910151
New Study from StrategyR Highlights a $12.1 Billion Global Market for Ferrosilicon by 2026 SAN FRANCISCO, May 31, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Ferrosilicon - Global Market Trajectory & Analytics". The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace. FACTS AT A GLANCE What's New for 2022? - Global competitiveness and key competitor percentage market shares - Market presence across multiple geographies - Strong/Active/Niche/Trivial - Online interactive peer-to-peer collaborative bespoke updates - Access to our digital archives and MarketGlass Research Platform - Complimentary updates for one year Edition: 21; Released: May 2022 Executive Pool: 1197 Companies: 50 - Players covered include China National BlueStar (Group) Co., Ltd.; Elkem AS; Ferroglobe PLC; The Rima Group; M & M Alloys Limited; Imexsar; Sinoferro Dense Medium Powders Limited; Anyang Xinchuang Metallurgy Material Co., Ltd.; DMS Powders (Pty) Ltd; Westbrook Resources Ltd; Eurasian Resources Group; Ferro Alloys Corporation Limited (FACOR); Mechel PAO; Finnfjord AS and Others. Coverage: All major geographies and key segments Segments: Application (Deoxidizer, Inoculants, Other Applications); End-Use (Carbon & Alloy Steel, Stainless Steel, Electric Steel, Cast Iron, Other End-Uses) Geographies: World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Africa. Complimentary Project Preview - This is an ongoing global program. Preview our research program before you make a purchase decision. We are offering a complimentary access to qualified executives driving strategy, business development, sales & marketing, and product management roles at featured companies. Previews provide deep insider access to business trends; competitive brands; domain expert profiles; and market data templates and much more. You may also build your own bespoke report using our MarketGlass™ Platform which offers thousands of data bytes without an obligation to purchase our report. Preview Registry ABSTRACT- Amid the COVID-19 crisis, the global market for Ferrosilicon estimated at US$10.7 Billion in the year 2022, is projected to reach a revised size of US$12.1 Billion by 2026, growing at a CAGR of 2.9% over the analysis period. Deoxidizer, one of the segments analyzed in the report, is projected to grow at a 2.8% CAGR, while growth in the Inoculants segment is readjusted to a revised 3.3% CAGR. Ferrosilicon is an alloy of silicon, iron, coke, and coal. The content of silicon in ferrosilicon ranges from 15 wt% to 90 wt%. It is primarily used in cast iron and steel applications owing to its superior properties such as hardness, high strength, and resistance to high temperatures and corrosion. Close to 90% of ferrosilicon is used in producing steel and iron. The raw materials required in the production of ferrosilicon are mill scale, quartz, and charcoal. Ferrosilicon is also used in arc welding for electrode coatings. Ferrosilicon is also used in production of ductile iron. It is added to alloys to improve the physical properties such as high temperature, corrosion resistance and heat resistance of the resultant compound. Ferrosilicon is also used in producing semiconductor pure silicon in the electric industry. Growing demand for ferrosilicon as an inoculant and deoxidizer across several end-use industries is anticipated to impact the global ferrosilicon market significantly in the future. Electrical steel, which is also known as silicon steel, utilizes considerable amount of ferrosilicon and silicon to enhance steel's electrical properties such as resistivity. Additionally, increasing demand for electrical steel in manufacturing motors, transformers and other power generating devices is expected to boost the demand for ferrosilicon further during the forecast period. Over the recent past, the consumption of ferrosilicon has declined due to the slowdown in the production of crude steel and growing preference of substitute materials such as crude steel in several countries. In addition, rapid growth of iron castings results in greater utilization of aluminum in manufacturing automobiles. As a result, utilization of substitute materials is considered to be a major challenge in the market. All these factors are expected to hinder the global ferrosilicon market growth during the forecast period. Ferrosilicon is widely applied in metallurgy. It is also extensively used in steel production industries. Corrosion reduces strength and resistance of the surface to fluids. It decreases the chemical and mechanical properties of certain materials. Abrasion and corrosion resistance are other properties of ferrosilicon. The demand for corrosion resistant materials has been growing significantly in the automobile and construction industries. Automotive bodies, structural supports and bridges are required to last long without undergoing corrosion. Hence, several companies have been preferring ferrosilicon in automobile and construction for long lasting quality. Alloying ferrosilicon with other metals makes it useful in producing semiconductors, which are in great demand by the electronics industry. Increasing demand for electronics and rapid industrialization have been resulting in a surge in the use of ferrosilicon. The global impact of COVID-19 on production industries is expected to reduce the use of ferrosilicon temporarily. Furthermore, demand for automotive in Asian countries such as India and Japan is expected to increase in the future once the COVID-19 impact ceases. Increasing adoption of ferrosilicon in manufacturing steel and metal alloys is foreseen to drive the global ferrosilicon market during the analysis period. The demand for steel in industries such as construction, automotive, and manufacturing is very high. Ferrosilicon offers high resistance to corrosion and enhances tensile strength and hardness of steel. Growing investments in the steel sector is a major factor driving the market. For instance, Steel Authority of India Limited is aiming at increasing its steel production capacity from 13 million tons per annum to 50 million tons per annum by 2025. Furthermore, strategic collaborations among key players and entry of international manufacturers into steel production are expected to augment the market growth during the forecast period. Huge demand for renewable energy is another important factor boosting the market. Growing ferrosilicon demand in the cast iron and steel industries is likely to augment growth in the global ferrosilicon market over the analysis period. The steel industry uses ferrosilicon as an essential deoxidizer to prevent carbon loss during steel production. Hence, growth in steel industry investments is likely to spur growth in the global market. For example, POSCO set up a joint venture with HBIS for the production of galvanized steel sheets and started construction work on a plant in Tangshan, Hebei province, China in 2022. With an estimated 900-kiloton production capacity per year, the $600-million plant will ensure a steady galvanized steel sheet supply for the automotive industry. Plumbing applications widely utilize cast iron pipes owing to their remarkable compressive strength and longevity. The silicon alloys market has been evolving rapidly due its ability to impart significant tribiological properties to the alloys, when mixed with aluminum and iron. Excessive use of ferrosilicon alloys in different forms such as steel alloys has benefited the market player to gain consistent revenues. Advancements made in silicon alloys refining have resulted in several materials with desired structural properties, increasing the competition in the silicon alloys market. Increasing adoption of metal forming technologies is expected to keep the landscape more competitive. Increasing utilization of silicon alloys in automotive industry has resulted in market expansion over the recent years. Also, demand for iron and steel in several end-use industries has made the market highly competitive. Advancements made in producing steel and cast iron in the industrialized nations are the major factors boosting the silicon alloys market. Rapid industrialization in such economies has increased the demand significantly. Markets in the rapidly emerging regions such as ASEAN and Brazil have witnessed rise in infrastructural development augmenting the utilization of silicon alloys. New avenues are opening up in the silicon alloys market due to new methods in metal matrix composite formation. These advances are prominently witnessed in the automotive components market, and hence the APAC region is anticipated to witness huge growth in the silicon alloys market in the coming years due to the region's vast strides in the automotive manufacturing. However, the availability of substitute products such as ferrochromium, ferromagnesium, and ferroaluminum and their growing preference over ferrosilicon in the steel industry due to their ease of availability could present challenges for the market. Regular exposure to ferrosilicon is proved to cause cancer among the mining workers, which is another major market restraining factor. More MarketGlass™ Platform Our MarketGlass™ Platform is a free full-stack knowledge center that is custom configurable to today`s busy business executive`s intelligence needs! This influencer driven interactive research platform is at the core of our primary research engagements and draws from unique perspectives of participating executives worldwide. Features include - enterprise-wide peer-to-peer collaborations; research program previews relevant to your company; 3.4 million domain expert profiles; competitive company profiles; interactive research modules; bespoke report generation; monitor market trends; competitive brands; create & publish blogs & podcasts using our primary and secondary content; track domain events worldwide; and much more. Client companies will have complete insider access to the project data stacks. Currently in use by 67,000+ domain experts worldwide. Our platform is free for qualified executives and is accessible from our website www.StrategyR.com or via our just released mobile application on iOS or Android About Global Industry Analysts, Inc. & StrategyR™ Global Industry Analysts, Inc., (www.strategyr.com) is a renowned market research publisher the world`s only influencer driven market research company. Proudly serving more than 42,000 clients from 36 countries, GIA is recognized for accurate forecasting of markets and industries for over 33 years. CONTACTS: Zak Ali Director, Corporate Communications Global Industry Analysts, Inc. Phone: 1-408-528-9966 www.StrategyR.com Email: [email protected] LINKS Join Our Expert Panel https://www.strategyr.com/Panelist.asp Connect With Us on LinkedIn https://www.linkedin.com/company/global-industry-analysts-inc./ Follow Us on Twitter https://twitter.com/marketbytes Journalists & Media [email protected] SOURCE Global Industry Analysts, Inc.	https://www.prnewswire.com/news-releases/new-study-from-strategyr-highlights-a-12-1-billion-global-market-for-ferrosilicon-by-2026--301557150.html	2022-05-31T12:47:07	en	0.907573
Decisions, Decisions: Ten Grand Prize Winners (per trip) Get the Chance to Choose Between Three Once in a Lifetime Adventures CORONA, Calif., May 31, 2022 /PRNewswire/ -- Monster Energy is rewarding their fans this summer with the chance to win an epic trip and all-inclusive backstage pass to either a UFC, MotoGP or Supercross event. All any Monster fan has to do to win a legendary experience is - keep drinking their favorite Monster! The more Monster Energy that fans purchase, the more chances they will have to win the experience of a lifetime. "Monster is known for one-of-a-kind drinks, events and consumer promotions," said Dan McHugh, CMO of Monster Energy. "We're giving our fans the chance to gain access to the best athletes and events all over the world and to experience this up close and personal." Created for the ultimate Monster fan, ten lucky winners (per trip) will be able to experience one of these unbelievable prizes: Meet the UFC Athletes in Las Vegas, tour and workout at a UFC Facility, and experience all of UFC Fight Week with VIP Village Tickets. To make sure the winner arrives in style, they will also be receiving a custom Monster/UFC Gear package prior to their trip, and have their flights covered by Monster Energy. Score the ultimate Monster MotoGP experience at the Monster Energy Barcelona-Catalunya Spanish Grand Prix, which includes VIP Village Tickets, an exclusive invite to the viewing gallery at the Monster compound, private access to a restricted Monster party and dinner in the paddock. The winner will also receive their very own MotoGP helmet. Monster will fly the lucky fan out to Daytona where they receive pit passes to Monster Energy Supercross, track access and attendance to an exclusive Monster concert. Also included is the opportunity to meet the athletes in person and get a custom MEC helmet to take home. Fit for any fan to live out the true Monster Energy life, these trips will provide the winner with a once in a lifetime opportunity. Alongside the grand prize, Monster Energy is also giving out 30 first prizes: 10 Team Yamaha/Monster Gear Packs, 10 Supercross Gear Packs and 10 UFC/Monster Gear Packs. - Scan QR code at POS - Create an account at allaccess.monsterenergy.com - Purchase any Monster Energy product - Upload photo of the receipt to Monster account to earn points - Select the All-Access experience(s) you want to allocate points towards for a chance to win. (limit 24 points per day. 100 points overall.) BONUS: The more you buy, the more chances you have to win! All Monster Energy products are eligible. (Core, Juice, Java, Ultra, Hydro, Rehab) See more about Monster Energy, including all its products, at www.monsterenergy.com. Based in Corona, California, Monster Energy is the leading marketer of energy drinks and alternative beverages. Refusing to acknowledge the traditional, Monster Energy supports the scene and sport. Whether motocross, off-road, NASCAR, MMA, BMX, surf, snowboard, ski, skateboard, eSports or the rock and roll lifestyle, Monster Energy is a brand that believes in authenticity and the core of what its sports, athletes, gamers and musicians represent. More than a drink, it's the way of life lived by athletes, sports, bands, believers and fans. See more about Monster Energy including all of its drinks at www.monsterenergy.com. View original content to download multimedia: SOURCE Monster Energy	https://www.wlbt.com/prnewswire/2022/05/31/win-ufc-motogp-or-supercross-all-access-pass-win-big-with-monster-energys-all-access-pass-promotion/	2022-05-31T12:47:06	en	0.92034
New Study from StrategyR Highlights a 2 Billion Metric Tons Global Market for Steel by 2026 SAN FRANCISCO , May 31, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Steel - Global Market Trajectory & Analytics". The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace. FACTS AT A GLANCE What's New for 2022? - Global competitiveness and key competitor percentage market shares - Market presence across multiple geographies - Strong/Active/Niche/Trivial - Online interactive peer-to-peer collaborative bespoke updates - Access to our digital archives and MarketGlass Research Platform - Complimentary updates for one year Edition: 19; Released: May 2022 Executive Pool: 5173 Companies: 279 - Players covered include Ansteel Group Corporation Ltd.; ArcelorMittal S.A.; China Baowu Steel Group Corporation Limited; EVRAZ plc; EVRAZ NTMK; Gerdau S.A.; HBIS Group; HYUNDAI Steel Company; JFE Steel Corporation; Jiangsu Shagang Group; Nippon Steel Corporation; Nucor Corporation; POSCO; Riva Group; Shandong Iron and Steel Group Co. Ltd.; Shougang Group Co., Ltd.; Tata Steel Group; Tata Steel Europe Ltd.; thyssenkrupp Steel Europe AG; United States Steel Corporation and Others. Coverage: All major geographies and key segments Segments: End-Use (Construction, Machinery, Transportation, Metal Goods, Household Appliances, Other End-Uses) Geographies: World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Turkey; Rest of Europe; Asia-Pacific; India; South Korea; Taiwan; Rest of Asia-Pacific; Latin America; Brazil; Mexico; Rest of Latin America; Middle East; Africa. Complimentary Project Preview - This is an ongoing global program. Preview our research program before you make a purchase decision. We are offering a complimentary access to qualified executives driving strategy, business development, sales & marketing, and product management roles at featured companies. Previews provide deep insider access to business trends; competitive brands; domain expert profiles; and market data templates and much more. You may also build your own bespoke report using our MarketGlass™ Platform which offers thousands of data bytes without an obligation to purchase our report. Preview Registry ABSTRACT- Amid the COVID-19 crisis, the global market for Steel estimated at 1.8 Billion Metric Tons in the year 2022, is projected to reach a revised size of 2 Billion Metric Tons by 2026, growing at a CAGR of 3.2% over the analysis period. Construction, one of the segments analyzed in the report, is projected to grow at a 2.7% CAGR, while growth in the Machinery segment is readjusted to a revised 2.9% CAGR. Steel, one of the most essential engineering materials, is known for its diverse applications in every aspect of human life, ranging from buildings and infrastructure constructions and machinery to metal goods, automobiles, ships and rail, oil & gas infrastructure, and domestic appliances, among others. Steel is the foundation for a number of industries in general and manufacturing industry in particular. Almost all manufacturing plants and machinery is made of, or contains steel. Large families of iron alloys that can be effortlessly malleable are collectively called as steel. Steel is usually made up of iron ore, coal, and limestone. The material is cast in two different ways - either directly to shape, or to ingots, which are heated again and hot worked to bring them to a wrought shape by a number of processes including forging, extrusion and rolling. Wrought steels are available in a wide range of shapes with diverse properties and finishes. Of late, the steel industry's attention shifted towards offering customers lighter, strong, clean, recyclable, flexible, and cost-efficient steel than ever. The effort of the steel industry resulted in the birth of high tech rollers, which transfers the glowing blocks of steel glide, electronic sensors that monitors the progress of steel glide and computer monitors to guarantee quality control. The long-term prospects for the world steel industry remain progressive. Fortunes of finished steel products market depend on health of key end-use markets such as construction sector, automobile and automotive component manufacturing, metal goods fabrication, ship building, machinery manufacturing, oil & gas infrastructure, among others. Given that business cycles in these end-use markets reflect the general economic activity of a nation, demand for steel is highly sensitive to the broader economic variables in a given country or a region. In the post COVID-19 period, anticipated recovery in construction activity, improvement in manufacturing sector and subsequent rise in demand for and production of a range of machinery, rise in fabrication of metal goods, and renewed demand for and production of transportation solutions, in line with improvement in global economy, will therefore drive demand for finished steel. Other megatrends inciting long term growth prospects include ongoing urbanization drive, escalating demand for energy and water. Global outlook for steel remains moderately positive and although not free from downside risks but nevertheless with relatively better growth prospects in certain parts of the world than witnessed in 2020. While China continues to play an influential role, urbanization trends in other countries would drive growth in the construction and automotive markets in the post COVID-19 period. China remains the largest regional market for finished steel products, owing to the huge construction and industrial activity in the region, which generates high demand for a range of steel products. Post COVID-19 growth prospects for finished steel products in other developing markets such as India, Southeast Asia, Latin America, and the Middle East appear promising. Strong pace of economic development, industrialization, rapid urbanization, steady rise in construction activity and robust demand for automobiles among others will help boost demand for steel in these regions in the post COVID-19 environment. Growth will also be driven by other fast developing nations such as Turkey, Ukraine, Kazakhstan, Indonesia, Malaysia, Vietnam, Philippines and Thailand among others. A mature sector now, the steel industry currently is banking on technology innovations and new product developments as key competitive differentiating factors, which makes the industry rife with technology collaborations, partnerships, and alliances as players compete to sharpen their technology prowess both in terms of manufacturing processes, production and marketing. Although the post COVID-19 demand for steel is likely to improve considerably, certain issues and challenges would continue to challenge market prospects. Slow pace of economic growth in core markets such as Europe, overcapacity and oversupply issues, pricing and margin pressures, and volatile global oil prices are likely to wield immense pressure on steel industry in the post COVID-19 period. The raging war between Russia and Ukraine is set to rock various metal commodities and have spiraling impact on prices. The deepening crisis is bound to maintain high pressure on numerous commodities over the near-term, with metal commodities bearing a significant impact. Ongoing conflict involving Russia, a major supplier of aluminum, nickel, oil and natural gas, and Ukraine is expected to stoke inflation and heavily impact supply chains serving diverse industry verticals. The onset of war in February led an upward pricing frenzy for various metal commodities, with aluminum prices touching a record level. The continuing conflict has raised serious concerns pertaining to trade flows, supplies and availability of different commodities. The recent move by Australia to ban export of key raw materials used in production of aluminum to Russia has pushed aluminum prices. The continuing crisis is leading to higher prices of various industrial raw materials, including steel, nickel, crude oil and tin. The conflict is prompting the US, Japan and Europe to impose economic sanctions on Russia, making prices of various commodities dearer. Commodities including nickel, aluminum and palladium are experiencing upward pricing trend and making it challenging for other countries to secure supplies from alternative locations. The ongoing conflict between Ukraine and Russia is bound to influence global trade and demand for steel as both countries represent major exporters of steel-related products. The problem holds specific concerns for industries and countries that have been already struggling with related risk factors, including microchip shortages, slowdown in China and escalating natural resources and energy prices. The Russia-Ukraine war has exacerbated these risks and is anticipated to hold major implications for steel demand. Considering strong positions of Russia and Ukraine in the global steel market, the conflict is bound to impact steel trade. Steel prices are anticipated to continue moving upwards due to strong demand indicators coupled with the impact of ongoing conflict on the supply chain. Prices of steel have already scaled heights and are continuously moving up following the conflict. The Russia-Ukraine war is affecting flow of various raw materials along with finished goods. These factors along with robust steel demand are expected to increase prices. The conflict is also affecting local production of steel as majority of facilities in Ukraine have suspending manufacturing operations owing to safety issues. Resumption of operations would require companies to not only ensure safety, but also secure coking coal supplies. Steel is expected to be also affected by logistics challenges as rising energy prices and port-related issues are leading to high freight rates. More MarketGlass™ Platform Our MarketGlass™ Platform is a free full-stack knowledge center that is custom configurable to today`s busy business executive`s intelligence needs! This influencer driven interactive research platform is at the core of our primary research engagements and draws from unique perspectives of participating executives worldwide. Features include - enterprise-wide peer-to-peer collaborations; research program previews relevant to your company; 3.4 million domain expert profiles; competitive company profiles; interactive research modules; bespoke report generation; monitor market trends; competitive brands; create & publish blogs & podcasts using our primary and secondary content; track domain events worldwide; and much more. Client companies will have complete insider access to the project data stacks. Currently in use by 67,000+ domain experts worldwide. Our platform is free for qualified executives and is accessible from our website www.StrategyR.com or via our just released mobile application on iOS or Android About Global Industry Analysts, Inc. & StrategyR™ Global Industry Analysts, Inc., (www.strategyr.com) is a renowned market research publisher the world`s only influencer driven market research company. Proudly serving more than 42,000 clients from 36 countries, GIA is recognized for accurate forecasting of markets and industries for over 33 years. CONTACTS: Zak Ali Director, Corporate Communications Global Industry Analysts, Inc. Phone: 1-408-528-9966 www.StrategyR.com Email: [email protected] LINKS Join Our Expert Panel https://www.strategyr.com/Panelist.asp Connect With Us on LinkedIn https://www.linkedin.com/company/global-industry-analysts-inc./ Follow Us on Twitter https://twitter.com/marketbytes Journalists & Media [email protected] SOURCE Global Industry Analysts, Inc.	https://www.prnewswire.com/news-releases/new-study-from-strategyr-highlights-a-2-billion-metric-tons-global-market-for-steel-by-2026-301557152.html	2022-05-31T12:47:13	en	0.917108
New Study from StrategyR Highlights a $860.8 Billion Global Market for Digital Advertising and Marketing by 2026 SAN FRANCISCO, May 31, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Digital Advertising and Marketing - Global Market Trajectory & Analytics". The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace. FACTS AT A GLANCE What's New for 2022? - Global competitiveness and key competitor percentage market shares - Market presence across multiple geographies - Strong/Active/Niche/Trivial - Online interactive peer-to-peer collaborative bespoke updates - Access to our digital archives and MarketGlass Research Platform - Complimentary updates for one year Edition: 18; Released: May 2022 Executive Pool: 79739 Companies: 523 - Players covered include Acxiom Corporation; Alibaba Group Holding Limited; Amazon.com, Inc.; Baidu, Inc.; Dentsu International; Eniro AB; Epsilon Data Management, LLC; Facebook, Inc.; Google, Inc.; IAC/InterActiveCorp.; Microsoft Corporation; LinkedIn Corporation; Sohu.com, Inc.; SXM Media; Tencent Holdings Ltd.; TradeDoubler AB; Twitter, Inc.; Xaxis, LLC; Verizon Media and Others. Coverage: All major geographies and key segments Segments: Mode / Format (Display, Search, Other Modes / Formats); Vertical (Retail & Consumer Goods, Automotive, BFSI, IT & Telecom, Media & Entertainment, Tourism, Education, Other Verticals) Geographies: World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa. Complimentary Project Preview - This is an ongoing global program. Preview our research program before you make a purchase decision. We are offering a complimentary access to qualified executives driving strategy, business development, sales & marketing, and product management roles at featured companies. Previews provide deep insider access to business trends; competitive brands; domain expert profiles; and market data templates and much more. You may also build your own bespoke report using our MarketGlass™ Platform which offers thousands of data bytes without an obligation to purchase our report. Preview Registry ABSTRACT- Amid the COVID-19 crisis, the global market for Digital Advertising and Marketing estimated at US$530.9 Billion in the year 2022, is projected to reach a revised size of US$860.8 Billion by 2026, growing at a CAGR of 14.9% over the analysis period. Display, one of the segments analyzed in the report, is projected to grow at a 16.7% CAGR, while growth in the Search segment is readjusted to a revised 13.1% CAGR. The year 2020 has been a challenging year for global marketers as they have been struggling to keep up with the rapid changes occurring due to the COVID-19 pandemic. During the early days of pandemic, marketers across the world were impacted due to the declining ad revenues and budgets. Spending in the advertising industry is directly proportional to the global GDP growth. Due to the crisis, however, the ad spending of companies decline significantly. On an average, spending declined by 8-10% in Europe and by 15% in China. More than a quarter of media planners, buyers and brands paused their spending by the end of Q2 in 2020. With the stay-at-home restrictions due to COVID-19, cinema, out-of-home, and print advertising fell instantly; whereas in-home advertising rose. TV viewership, digital consumption, usage of streaming services, social platforms, and gaming have risen significantly. In response to this growth, advertisers prioritized digital advertising as online environment is always favorable for direct response campaigns. Governments have assumed importance as ad buyers for promoting health messages amidst the COVID crisis. While traditional media formats have recorded substantial declines in spending levels due to the pandemic, buyers have shifted their advertising budgets away from linear TV, radio, print, and out of home (OOH) format towards digital platforms. Social media and paid search have accounted for a large share of the ad spending during this period, thus translating into significant growth for the digital advertising channels. For the year 2021, the advertising landscape for the traditional channels was affected by the resurgence of COVID-19 infections in several countries around the world. However, digital channels will continue to hold prominence for advertising companies as people remain confined to their homes in several countries affected by the pandemic, thus leading to greater consumption of digital and social media content. In Western Europe, ad spend in 2020 slumped, with digital media posting better performance than anticipated during the pandemic. The crisis caused a significant increase in digital media demand and supply. Many small organizations have been leveraging digital media to sustain their businesses in the face of lockdowns. Even in Eastern and Central Europe, ad spend in 2020 declined, but it was lesser than the anticipated rate. Investments in digital formats such as online video, social media, mobile, and desktop is expected to increase in the forthcoming years across Europe. While spend on linear or non-digital advertising is expected to revive, it however is not likely to reach the levels recorded before the pandemic. While in 2021 linear advertising budgets were supported by some televised events and revival in the economy, however digital mediums are expected to continue to be the main focus area. In China, digital ad revenue recorded gains led by rising investments in social media, e-commerce, and short video despite the decline in average media spend during the major part of the year. Digital gained importance among all marketers and will remain critical even in the forthcoming years. In 2020, performance media investments and social KOL (key opinion leaders) registered strong growth, as marketers increasingly concentrated on content to augment conversion and engagement via social commerce. Short video was a key growth driver due to the widespread use of platforms such as Bilibili, Kuaishou, and Douyin. In 2020, short video outpaced e-commerce in terms of digital ad revenue. OOH is also expected to remain strong. Marketers are likely to opt for targeted video on digital rather than conventional TV commercials. The COVID-19 pandemic resulted in people staying at home and/or working remotely from home, resulting in huge increase in online traffic. The large increases in online traffic provide opportunities for companies to keep their target audience engaged through digital marketing initiatives. While overall digital marketing spending declined due the pandemic-induced cuts in marketing and advertising budgets during the lockdown, available budgets have been allocated to digital marketing initiatives. In addition, advertisers are realizing higher returns on their investments owing to lower competition for advertising space. As a result, the pandemic is driving changes to digital marketing strategies at companies, especially at companies where digital marketing initiatives had relatively low priority. Clicks and display ads are among the most prominent forms of digital marketing initiatives. Clicks are expensive compared to display ads, as clicks ensure the customer is directed to the advertiser's website. However, clicks provide a better return on investment. The declines in digital marketing budgets across the spectrum resulted in lower costs per click. As a result, marketers are gaining more clicks for the same cost. Proactive advertisers with long-term outlook are utilizing the lower costs of clicks to improve their marketing plans and stand to gain the most when conditions improve. The continued spending on digital marketing initiatives would ensure that such advertisers have a high recall for their products or services when the conditions improve. In addition, the lower costs of digital marketing, as well as the unfavorable circumstances for other marketing and advertising formats is resulting in advertisers exploring and/or increasing their marketing spends on digital marketing. Digital events are the need of the hour owing to the pandemic crisis. With scope and capabilities for improvement, the number of digital events happening is witnessing growth. Businesses are witnessing immense scope and opportunity for interactive and engaging digital events since most of the physical events stand cancelled owing to the COVID-19 crisis. Digital events are increasingly becoming multi-dimensional owing to things such as greeter videos, breakout sessions, keynotes, panel discussions, open Q&A, Social and gamification, as well as even swag and giveaways. The Netflix model is considered a good example for developing personalized content experiences; however, experiences that are smaller and more personalized, being targeted at few specific individuals, are likely to be witnessed. Content hubs showcase featured content and related content together, all organized on-demand, along with some CTAs that enable visitors in self-selecting their options. Personalized landing pages comprise loads of organized and relevant content that focuses on a specific use case, account, or industry. All interactions could be tracked; while multiple CTAs enable visitors in selecting their options for navigating. The outbreak has encouraged businesses in exploiting digital opportunities and rethinking strategies to adapt towards the transition. Marketing agencies could focus on convincing businesses to use more of digital sphere until normalcy returns and the pandemic crisis passes away. Marketers are likely to develop promotion strategies for encouraging businesses to select new, online efforts. The efforts are likely to enable in finding new clients, and striking new deals. More MarketGlass™ Platform Our MarketGlass™ Platform is a free full-stack knowledge center that is custom configurable to today`s busy business executive`s intelligence needs! This influencer driven interactive research platform is at the core of our primary research engagements and draws from unique perspectives of participating executives worldwide. Features include - enterprise-wide peer-to-peer collaborations; research program previews relevant to your company; 3.4 million domain expert profiles; competitive company profiles; interactive research modules; bespoke report generation; monitor market trends; competitive brands; create & publish blogs & podcasts using our primary and secondary content; track domain events worldwide; and much more. Client companies will have complete insider access to the project data stacks. Currently in use by 67,000+ domain experts worldwide. Our platform is free for qualified executives and is accessible from our website www.StrategyR.com or via our just released mobile application on iOS or Android About Global Industry Analysts, Inc. & StrategyR™ Global Industry Analysts, Inc., (www.strategyr.com) is a renowned market research publisher the world`s only influencer driven market research company. Proudly serving more than 42,000 clients from 36 countries, GIA is recognized for accurate forecasting of markets and industries for over 33 years. CONTACTS: Zak Ali Director, Corporate Communications Global Industry Analysts, Inc. Phone: 1-408-528-9966 www.StrategyR.com Email: [email protected] LINKS Join Our Expert Panel https://www.strategyr.com/Panelist.asp Connect With Us on LinkedIn https://www.linkedin.com/company/global-industry-analysts-inc./ Follow Us on Twitter https://twitter.com/marketbytes Journalists & Media [email protected] SOURCE Global Industry Analysts, Inc.	https://www.prnewswire.com/news-releases/new-study-from-strategyr-highlights-a-860-8-billion-global-market-for-digital-advertising-and-marketing-by-2026--301557144.html	2022-05-31T12:47:19	en	0.932989
NTT Finance Invests in D-ID, World Leader in AI-Driven Creative Media NTT Finance joined recent Series B round to help D-ID expand the horizons of cutting-edge Digital Human and Reenactment technologies TOKYO, May 31, 2022 /PRNewswire/ -- NTT Finance, financial group company of Japanese telecommunications giant NTT, invested in D-ID, the world leader in AI-driven creative media. The funding is part of D-ID's recent $25 million Series B round. The round was led by investment firm Macquarie Capital, with significant investments from Pitango, AXA Venture Partners, OurCrowd, OIF Ventures, Maverick and Marubeni. The new infusion brings D-ID's total funding to $48 million. Investment in D-ID was facilitated by NTT Innovation Laboratory Israel (NTT Israel), a wholly owned subsidiary of NTT that serves as an internal strategic resource to breakthrough innovation from Israel. NTT Israel's mission is to support the evolution of NTT Group customer businesses, promote innovation and digital transformation. NTT Israel collaborates with Israeli companies and academia developing cutting-edge technologies in Cyber Security, Digital Health, AI, Robotics and other various fields, as well as promoting investment opportunities with Israeli companies. The proceeds from this round, from investors across three continents, will allow D-ID to double the number of experts on its world-class deep-learning and computer vision teams, broadening the scope and reach of its pioneering technology as it continues to produce products that transform the digital-human interface. The round will also enable D-ID to expand and support the company's sales and marketing teams in the United States, APAC and EMEA. D-ID uses AI and deep learning to develop reenactment-based products ranging from animating still photos to developing high-quality digital avatars. D-ID's wide range of customers include Warner Bros. Studios, Mondelēz, Publicis and MyHeritage, whom D-ID partnered with to create the viral sensation Deep Nostalgia, which has created nearly 100M animations since its launch, and more recently, LiveStory, which enables the creation of AI-generated biographical videos narrated by photos of users' ancestors. D-ID has also partnered with The Glimpse Group (NASDAQ: VRAR), a diversified virtual reality and augmented reality platform, to develop AI, AR and VR applications for the Metaverse. D-ID is leading the charge to leverage Synthetic Media for good. The company has worked with nonprofit organizations and governments in public awareness campaigns on sensitive issues such as domestic violence and HIV awareness. This new round of funding comes on the heels of a whirlwind of success for D-ID. In early March, the company was named by Fast Company as one of the Most Innovative Companies of 2022 in EMEA. In February, D-ID won best use of AI in the Digiday Marketing and Advertising Awards Europe, and in January, the company's proprietary Live Portrait technology was named a finalist for the prestigious SXSW Innovation Award. "We are grateful for this vote of confidence from NTT group, and thrilled to embark on a meaningful partnership that will enable us to continue expanding and strengthening our relationships and reach within Japan and globally," said Gil Perry, CEO and Co-Founder of D-ID. About NTT Finance NTT FINANCE, which is the first company that NTT established in April 1985 after being privatized, offers financial settlements and finance services. We aim to create new value through our billing solution business that provides billing/collection services and cloud payment services, credit card business, and finance services business that offers various services related to finance and accounting. NTT FINANCE is a wholly owned subsidiary of NTT. Visit us at https://www.ntt-finance.co.jp/eng/ About NTT Israel NTT Innovation Laboratory Israel (NTT Israel) is a strategic focal point to NTT in Israel, a world leader in providing technology and business solutions to people, clients, and communities. With $112B in revenue and more than 320,000 employees in over 80 countries and regions, NTT leads the Japanese communications market, and is a Fortune 100 company. Established on July 2021, NTT Israel facilitates synergies between NTT and the Israeli ecosystem. Company offerings include open innovation processes, consulting with NTT business units, as well as Labs and Tailored services and collaboration with academia. NTT Israel is a wholly owned subsidiary of NTT. NTT Media Contact: [email protected] About D-ID D-ID is a Tel Aviv-based Creative Reality™ startup specializing in patented video reenactment technology using AI and deep learning. D-ID's products range from animating still photos, to facilitating high-quality video productions, and creating viral user experiences. With funding from tier 1 VCs, D-ID aims to radically disrupt the time, hassle and costs involved in video production, allowing for the creation of highly personalized media using AI, specifically in e-learning, corporate training, marcomms, AI assistants, history and the Metaverse. With international customers, D-ID's core competencies in the human face and deep learning enable its partners to create exciting and engaging content that was until now unimaginable. To find out more, visit www.d-id.com. D-ID Media Contact: Gina Shaffer [email protected] SOURCE D-ID	https://www.prnewswire.com/news-releases/ntt-finance-invests-in-d-id-world-leader-in-ai-driven-creative-media-301557680.html	2022-05-31T12:47:25	en	0.935973
Companies operating in France will soon benefit from an integrated cloud payroll system that helps simplify payroll processes AUSTIN, Texas, May 31, 2022 /PRNewswire/ -- Oracle plans to deliver Oracle France Payroll, part of Oracle Fusion Cloud Human Capital Management (HCM). The new cloud payroll solution will help organizations manage compliance, automate workflows, and quickly process payroll for employees working in France. With the addition of Oracle France Payroll, Oracle Cloud HCM will provide built-in payroll support for 13 countries including Bahrain, Canada, China, Kuwait, Mexico, Qatar, Saudi Arabia, United Arab Emirates, United Kingdom, and the United States, with upcoming support for India and Oman. France has one of the most complex payroll processes in Europe, requiring employers to report and withhold income for a variety of taxes on behalf of the country's 30 million workers. Additionally, organizations operating in France experience rapid and continuous legislative and regulatory changes, meaning payroll processes will often vary from one year to the next. To manage this complexity, organizations with employees working in France need the support and flexibility of a cloud-based payroll system that automatically updates to match current payroll and reporting needs. "Payroll is one of the single most important functions for keeping a workforce running smoothly. Employees have zero tolerance for mistakes or delays when it comes to their compensation, no matter how complicated the local rules and regulations are," said Holger Muller, principal analyst, Constellation Research. "It's essential that organizations use a cloud-based payroll system that natively integrates with their core HR systems to automatically stay up to date with changes in regulations and their workforce. The upcoming launch of Oracle France Payroll is a huge opportunity for local and multinational companies operating in France to benefit from that integration in their HR and payroll operations." Oracle France Payroll will help organizations save time and reduce payroll errors by eliminating manual processes and automating complex rules and calculations so customers can easily comply with tax and reporting obligations. Adding France-specific capabilities to Oracle Payroll will allow French companies and multinational organizations operating in France to grow with one global payroll solution. Oracle France Payroll will provide the following benefits to organizations: - Built-in Compliance Rules: Will address regulatory and legislative requirements for processing payroll in France. As Oracle France Payroll is built in the cloud, it can adapt to France's frequently changing rules as needed. It will also give payroll administrators the flexibility to configure pay rules for different collective bargaining agreements, trade union activities, and complex regulations for minimum and variable wages. - Robotic Process Automation: Will help simplify payroll and data entry tasks for payroll administrators, enabling them to calculate payroll faster and more accurately. It will also help reduce errors in more complex work rules that are common in France. - Payroll Unified with Core HR: Will give Oracle France Payroll complete access to workforce data within Oracle Cloud HCM to help ensure that deductions for income, social, and other tax withholdings are managed correctly. This will also help organizations easily onboard new employees and get them paid quickly. "In France, the government and collective bargaining groups are constantly changing the laws and agreements regarding taxes and compensation in hopes of improving working conditions for employees. That can make it challenging for organizations to stay up to date on the latest processes they need to follow to pay their employees accurately and fairly," said Chris Leone, senior vice president of development, Oracle Cloud HCM. "With Oracle France Payroll, local and multinational organizations with employees in France will be able to automate payroll operations to pay their workers quickly and accurately. Frequent and automatic updates will help ensure payroll operations are always in compliance, even as laws and contracts change." See here for more information about Oracle Payroll: https://www.oracle.com/human-capital-management/payroll/ Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at www.oracle.com. Oracle, Java, and MySQL are registered trademarks of Oracle Corporation. SOURCE Oracle	https://www.prnewswire.com/news-releases/oracle-fusion-cloud-hcm-to-add-payroll-support-for-france-301556700.html	2022-05-31T12:47:31	en	0.937958
Oxitec and the Government of Djibouti Announce New Multi-Year Partnership to Fight Invasive Malaria-Transmitting Mosquitoes Threatening the Horn of Africa - With strong support from the Government of Djibouti, this program will pilot a new Friendly™ mosquito control technology to combat the growing threat to the region posed by the rapidly spreading malaria vector, Anopheles stephensi. - Oxitec will work hand-in-hand with the Djibouti Ministry of Health through the national malaria program and with civil society through Association Mutualis, a Djiboutian not-for-profit organisation dedicated to delivering public health impact in Djibouti. - The invasive Anopheles stephensi has caused massive increases in urban malaria in Djibouti's capital city since it was first reported in 2012. It is also rapidly spreading to other countries in the region. - This partnership marks the start of a long-term relationship to validate environmentally sustainable vector control tools, which are urgently needed against this difficult-to-control mosquito. OXFORD, England , May 31, 2022 /PRNewswire/ -- Oxitec Ltd, the leading developer of biological pest control solutions, today announced the launch of a new partnership with the Government of Djibouti and Association Mutualis, a leading not-for-profit organisation serving the public health needs of communities in Djibouti. This exciting partnership was formed in response to a request from the Government of Djibouti to explore how Oxitec's Friendly™ solutions can deliver impact in towns and cities threatened by vector-borne diseases. Recent years have seen unprecedented increases in malaria incidence in Djibouti's capital city and surrounding communities. Where national annual malaria cases previously numbered in their hundreds, public health authorities are now reporting many tens of thousands of cases. This explosion has been ascribed to the arrival, first reported in 2012, of a single invasive mosquito species, Anopheles stephensi. Native to Asia, this malaria vector is highly capable of colonising urban locations, unlike many other malaria-transmitting mosquitoes. In Djibouti, where 70% of people live in the capital city, this urban invasion has exposed most of the country's population to a very new and deadly threat. And it is spreading through the region: it has now been reported in Ethiopia, Sudan, Somalia, and is predicted to spread much further. Leading malaria experts have warned that "urgent action is needed to prevent urban malaria epidemics from emerging and causing a public health disaster". The government of Djibouti has expressed the need for, as part of an integrated approach, innovative solutions to complement existing tools such as mosquito nets, indoor residual spray or environmental management. From that perspective, the Government of Djibouti approached Oxitec in 2018 to explore how the Friendly™ mosquito technology, already proven against the dengue fever mosquito, Aedes aegypti, could serve as a new tool to combat this urban malaria vector. Oxitec recently launched its Friendly™ Aedes as a commercial product for households, communities and businesses in Brazil. Oxitec's malaria program is well under way, and this collaboration heralds a new pilot phase that will enable field validation of the Friendly™ Anopheles stephensi solution under development. Grey Frandsen, CEO of Oxitec, said, "We're excited and honored to be partnering with the Government of Djibouti and Association Mutualis as we work together to pilot Oxitec's newest Friendly™ mosquito technology. It is exactly this type of public-private partnership that unlocks real potential for public health impact to new and growing health challenges. Djibouti's leadership on this front will no doubt serve as an exemplar for how other countries in the region tackle emerging issues, especially in the face of a rapidly changing climate. We are thrilled with our partnership with the Government of Djibouti and Mutualis, as it represents yet another collaboration we undertake to move our technologies to impact." Djibouti's Ministry of Health commented that "As a government, we are focused on delivering safe, effective and sustainable vector control to protect our people from disease-spreading mosquitoes. This new partnership demonstrates our government's commitment to lead the way in changing how malaria-spreading mosquitoes are combated. We're excited about working with Oxitec to explore the impact that this new solution can deliver in our country's malaria-threatened communities. And we believe that this kind of public-private collaboration is the way forward to deliver impact in many fields." A spokesperson for Association Mutualis added, "Current vector management tools are inadequate against Anopheles stephensi and, despite our best efforts, malaria continues to blight people in and around our capital city. We have established a strong partnership with Oxitec, with a shared purpose: to improve management of this invasive mosquito for the benefit of malaria-threatened communities. Their Friendly™ solution represents a promising new tool which we look forward to assessing in Djibouti." About Oxitec Oxitec is the leading developer of biological solutions to control pests that transmit disease, destroy crops and harm livestock. Founded in 2002 at the University of Oxford, Oxitec is led by a passionate team comprised of 15 nationalities and is supported by world-class public, private and non-profit partners. Learn more at oxitec.com. SOURCE Oxitec Ltd	https://www.prnewswire.com/news-releases/oxitec-and-the-government-of-djibouti-announce-new-multi-year-partnership-to-fight-invasive-malaria-transmitting-mosquitoes-threatening-the-horn-of-africa-301557622.html	2022-05-31T12:47:37	en	0.934037
Palladium Promotes Two Managing Directors To Broaden The Firm's Sustainability Framework Deborah Gallegos and Carlos Reyes Promoted to Co-Heads of ESG & Sustainability NEW YORK, May 31, 2022 /PRNewswire/ -- Palladium Equity Partners, LLC (along with its affiliates, "Palladium"), the oldest minority-owned private equity buyout firm in the industry, announced today it has launched the next phase of the firm's sustainability framework to further its mission to be a trusted manager recognized for delivering outstanding returns to all stakeholders. Following Palladium's recent certification as a B-Corp, Palladium today announced the promotion of Deborah Gallegos and Carlos Reyes, both Managing Directors, to lead the Firm's ongoing ESG initiatives as Co-Heads of ESG & Sustainability. Ms. Gallegos and Mr. Reyes will lead Palladium's ESG and sustainability efforts and advance its commitments as a UNPRI signatory and a founding signatory to both ILPA's Diversity in Action Initiative and the Data Convergence Project. Palladium has a robust ESG infrastructure focused on implementing a fully-integrated process for the identification and analysis of ESG factors that seek to drive value creation, reduce costs, and mitigate enterprise risk across the firm. The team has been instrumental in building the program, and will seek to further identify and manage ESG risks throughout the life cycle of Palladium's investments. Ms. Gallegos and Mr. Reyes' deep prior experience in both investment and investor roles has already brought a differentiating factor to Palladium's ESG program, as they are both already embedded into Palladium's funds and work closely with the investment teams and portfolio companies. Ms. Gallegos and Mr. Reyes bring decades of experience investing institutional assets. Ms. Gallegos has more than 25 years of investment experience, including serving as Chief Investment Officer of the New York City Comptroller and as Deputy State Investment Officer for the New Mexico State Investment Council. Mr. Reyes has more than 20 years of experience in private equity, sustainability/ESG, and corporate M&A. Prior to joining Palladium, Mr. Reyes worked at IFC Asset Management Company, a division of IFC – itself a member of the World Bank Group – where he was a Principal in IFC's $1.0 billion African, Latin American and Caribbean Fund, as well as Head of IFC Asset Management Company's Direct Equity Impact Fund. Marcos A. Rodriguez, Palladium's Chairman and CEO, said, "Both Deborah and Carlos are well suited for success in their new roles as Co-Heads of ESG & Sustainability. They are strong leaders who will help us implement the next phase of Palladium's sustainability framework, which we believe will accrue to the benefit of all our investors, our portfolio companies as well as our employees." Eugenie Cesar-Fabian, who formerly held the role of Head of ESG & Sustainability, will be transitioning out of the firm to pursue a senior legal role at a sustainability-focused fintech firm. She noted that, "Deborah and Carlos are exceptionally strong ESG professionals who have achieved significant success already in designing, building and implementing Palladium's internal ESG program. I believe their understanding and passion for ESG will support the firm's position as one of the leading industry voices in this area." Mr. Rodriguez added that, "Genie made a major contribution to Palladium during her decade-plus tenure at the firm. We appreciate her efforts and wish her all the best." Palladium is the oldest minority-owned private equity buyout firm in the industry with over $3 billion of assets under management. The firm seeks to acquire and grow companies in partnership with founders and experienced management teams by providing capital, strategic guidance and operational oversight. Since its founding in 1997, Palladium has invested over $3 billion of capital in 38 platform investments and 153 add-on acquisitions, realizing 23 of these platform investments. The principals of the firm have meaningful experience in consumer, services, industrials, and healthcare businesses, with a special focus on companies they believe will benefit from the growth in the U.S. Hispanic population. Palladium, which is a Certified B Corp, is based in New York City. For more information, visit www.palladiumequity.com. Todd Fogarty or Jeffrey Taufield Kekst CNC [email protected] or [email protected] SOURCE Palladium Equity Partners	https://www.prnewswire.com/news-releases/palladium-promotes-two-managing-directors-to-broaden-the-firms-sustainability-framework-301556971.html	2022-05-31T12:47:43	en	0.954213
NEW YORK, May 31, 2022 /PRNewswire/ -- The Insight Partners published latest research study on "Patient Engagement Technology Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Component (Services, Hardware, and Software), Therapeutic Area (Fitness, Chronic Diseases, Women's Health, and others), Delivery Mode (Cloud-Based and On-Premises), Application (Health Management, Financial Health Management, Home Healthcare Management, and Others), and End User (Patients, Payers, Providers, and Others)", the global patient engagement technology market size is expected to grow from $21.35 billion in 2022 to $59 billion by 2028; it is expected to register a CAGR of 18.5% from 2022 to 2028. The patient engagement technology market growth is driven by the rising adoption of patient-centric engagement solutions, the increasing prevalence of chronic disorders such as cardiovascular disorders, diabetes, and obesity, the surge in government initiatives, and the growing number of start-ups. North America accounts for the major market share of the market in 2022 due to presence of developed healthcare IT infrastructure which led to the high adoption of patient engagement technology. Get Exclusive Access to Sample Pages of Patient Engagement Technology Market Size - COVID-19 Impact and Global Analysis with Strategic Insights at: https://www.theinsightpartners.com/sample/TIPRE00029385/ Patient Engagement Technology Market: Competitive Landscape and Key Developments Allscripts Healthcare, LLC; athenahealth, Inc. (Veritas Capital); Carilex Medi GetWellNetwork, Inc.; AdvancedMD, Inc.; Cerner Corporation; Epic Systems Corporation; Orion Health group of companies; McKESSON CORPORATION; Lincor, Inc.; and Medecision are among the leading companies operating in the global patient engagement technology market. These players are focusing on expanding, diversifying their market presence, and acquiring a new customer base, thereby tapping prevailing business opportunities. In April 2022, Medecision and Clearstep, Inc., —a healthcare technology company—entered into a strategic partnership. The partnership will bring Clearstep's Smart Care Routing to Medecision's current and future health system and health plan customers, enabling an enhanced patient engagement experience. The AI technology will be available through Medecision's HITRUST CSF-certified, SaaS solution, Aerial. Clearstep Smart Care Routing provides patient-consumers with self-service access to the right care and services within a healthcare system or payer network, driving better patient engagement, acquisition, and retention. Place Your Inquiry Before Buying: https://www.theinsightpartners.com/inquiry/TIPRE00029385/ In March 2022, athenahealth plans to launch several new products this year, including an app for patients focused on patient engagement to extend the care experience beyond the clinical encounter. Athenahealth's patient portal works on a phone, although it will be moved beyond that with a more targeted and comprehensive tool. In December 2021, athenahealth, Inc. announced that Allied Digestive Health (ADH), one of the largest gastroenterology groups in the Northeast US, has selected its cloud-based healthcare payments and patient engagement solutions to drive patient relations and revenue cycle excellence and support the organization's growth. ADH leveraged athenahealth's robust patient engagement product to proactively manage patient relations, empowering patients to take an active role in managing their health and clinical information. In February 2021, The Epic Systems MyChart patient portal was ranked Best in KLAS for the fourth year, asserting the health IT vendor's market dominance. The company was also the top Overall Software Suite for the eleventh straight year and the top Overall Physician Practice Vendor. The 2021 Best in KLAS Report included rankings for a few other patient engagement technologies. In 2021, North America dominated the patient engagement technology market. The US holds the largest share of the market in this region. The market growth in the country is attributed to the increasing adoption of advanced medical device technologies, growing digitalization of medical devices, and increasing emphasis on improving treatment outcomes. Moreover, the increasing prevalence of chronic diseases such as diabetes and obesity in the US is likely to create demand for patient engagement technology systems. Connect with Our Research Analyst On: https://www.theinsightpartners.com/speak-to-analyst/TIPRE00029385 According to the Centers for Disease Control and Prevention (CDC), in 2019, almost 6 in 10 people in the US suffered from at least one chronic disease, and 4 in 10 people have two or more chronic diseases. Further, cancer is one of the leading causes of death in the region. Moreover, the rising aging population, the number of accidents, and the number of hospital admissions are major factors driving the number of surgical procedures worldwide. For instance, as per the data provided by Population Reference Bureau, the number of North & South Americans aged 65 and over is projected to nearly double from 52 million (16%) in 2018 to 95 million (23%) by 2060. Hence, the above-mentioned factors are expected to drive the growth of the patient engagement technology market during the forecast period. Rising Adoption of Patient-Centric Engagement Solutions: Patient engagement refers to anything that allows healthcare organizations to communicate with their patients, such as using an online patient portal. However, patient involvement is more than just interactive technology such as a portal or automated message. Moreover, the medical procedure scheduled for patients is critical in assuring patient satisfaction. Technology increases service quality and ensures safety. Wireless technologies have been built around the hospital environments through which patients and healthcare providers can manage personalized data. According to a white paper issued by UbiCare, patient engagement system usage reduces [length of stay (LOS)] by 25% per day for hip replacement patients and 13% for knee replacement patients. For instance, in 2021, an innovative patient engagement program, enhanced recovery after surgery (ERAS), was implemented at university hospitals (UH), which yielded notable results. According to a news release from National Library of Medicine, it led to shorter hospital stays, less use of opioids, fewer post-surgical infections, and lower costs for patients. The program included pre-operative counseling to set expectations with patients and families, optimizing pre-operative and post-operative nutrition, minimizing the use of narcotic pain relievers after surgery, promoting early mobility after surgery, and getting patients healthier. ERAS was first implemented at UH Cleveland Medical Center and used at all hospitals across the UH system. Further, in May 2022, the program won the Patient Engagement Best Practice Award from the Ohio Patient Safety Institute for 2021. Patient empowerment through enhanced health knowledge, timely appointment scheduling with doctors/caregivers, increasing adherence to recommended medical treatments, and rising interaction with providers via online tools are advantages of patient engagement technology solutions. These solutions are adopted based on the level of patient empowerment they provide. When patients access their medical records and track their progress, they become more engaged in their care. Thus, benefits associated with the patient engagement system are promoting the patient engagement technology market growth. Patient Engagement Technology Market: Segmental Overview Based on component, the patient engagement technology market is segmented into software, hardware, and services. The software segment held the largest market share in 2021, and it is anticipated to register the highest CAGR during the forecast period. Therapeutic Area-Based Insights: Based on therapeutic area, the patient engagement technology market is segmented into fitness, chronic diseases, women's health, and others. The chronic diseases segment held the largest market share in 2021. However, the fitness segment is anticipated to register the highest CAGR during the forecast period. Delivery Mode-Based Insights: Based on delivery mode, the patient engagement technology market is bifurcated into cloud-based and on-premises. The cloud-based segment held the largest market share in 2021 and is anticipated to register the highest CAGR during the forecast period. Application-Based Insights: Based on application, the patient engagement technology market is segmented into health management, financial health management, home health management, and others. The health management segment held the largest market share in 2021, and it is anticipated to register the highest CAGR during the forecast period. End User-Based Insights: Based on end user, the patient engagement technology market is segmented into patient, payers, providers, and others. In 2021, the providers segment held the largest share of the market. However, the payer's segment is expected to register the highest CAGR in the patient engagement technology market from 2022 to 2028. Buy Premium Copy of Patient Engagement Technology Market Size, Share, Revenue, Strategic Insights and Forecasts 2022-2028 Research Report at: https://www.theinsightpartners.com/buy/TIPRE00029385/ Impact of COVID-19 Pandemic on Patient Engagement Technology Market: The COVID-19 pandemic has significantly affected the global healthcare system and has disrupted the global economies. To combat the spread of SAR-CoV-2, governments have imposed stringent policies to prevent and reduce the mortality rate. To reduce the risk of virus transmission to either patients or health care workers within their practice, healthcare providers postponed elective and preventive visits, such as annual physicals, and converted in-person visits to telemedicine visits. This has increased the demand for virtual consultation and telemedicine; however, home quarantine has further created the need for remote patient monitoring, which has increased the use of patient engagement technology. Moreover, the increasing prevalence of chronic disorders, such as diabetes, obesity, and cardiovascular disorders, with a surge in COVID-19 cases has led to complications among patients. Furthermore, the rise in consumer awareness regarding health, increase in healthcare IT infrastructure globally, and high adoption rate of patient engagement technology in developing economies are also expected to support the market growth. Moreover, an increase in clinical trials regarding COVID-19 vaccines has boosted the demand for patient engagement technology, which helped fasten the process and led to the launch of vaccines. Thus, the COVID-19 pandemic has positively impacted the global patient engagement technology market growth. Browse Adjoining Reports: Patient Engagement Solutions Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Component (Services, Hardware, Softwares); Therapeutic Area (Fitness, Chronic Diseases, Women's Health, Others); Delivery Mode (Cloud-Based Solutions, On-Premise Solutions); Application (Health Management, Financial Health Management, Home Healthcare Management, Others); End User (Patients, Payers, Providers, Others) and Geography Population Health Management Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Hardware, Services, Software); Solution (Data Integration and Management, Analytics, Patient Engagement, Care Coordination); Delivery Mode (On-Premise, Cloud-Based); End-User (Healthcare Providers, Healthcare Payers, others) Integrated Vehicle Health Management Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Diagnostics, Prognostics); Component (Software, Hardware); Vehicle Type (Passenger Car, Commercial Vehicle) and Geography Healthcare Predictive Analytics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Application (Clinical Analytics, Financial Analytics, Operations Management Analytics, Population Health Management Analytics); Delivery Model (Stand-alone, Integrated); End user (Payers, Providers, Others) and Geography Ambulatory Electronic Health Record Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Deployment mode (Cloud-based, and On-premise); Practice size (Large Practices, Small-to-Medium-sized Practices, and Solo Practices); Application (Practice Management, Patient Management, e-Prescribing, Referral Management, Population Health Management, Decision Support, and Health Analytics); End User (Hospital-Owned Ambulatory Centers, Independent Centers, and Others), and Geography Chronic Disease Management Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Disease Type (Diabetes, Cancer, Cardiovascular Diseases (CVD), Asthma, Arthritis, Chronic Obstructive Pulmonary Disorders (COPD), Stroke, Others); Service Type (Consulting Service, Implementation Service, Educational Services, Others); Deployment Mode (On-Premise, Cloud-Based, Web-Based); End-User (Provider, Payer, Others) mhealth Solutions Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Connected Devices (Glucose and Blood Pressure Monitor, Peak Flow Meter, Pulse Oximeter, Neurological Monitors, Other Connected Medical Devices); Application (Weight Loss, Women Health, Diabetes Management, Mental Health, Chronic Disease Management Apps, Diagnostic Apps, Others); Services (Remote Monitoring, Consultation, Diagnosis Services, Treatment Services, Fitness and Wellness Services, Prevention Services.) and Geography Preventive Healthcare Technologies and Services Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Technologies (Early Detection and Screening Technologies, Chronic Disease Management Technologies, Vaccines, Advanced Technologies To Reduce Errors) and Geography About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us: If you have any queries about this report or if you would like further information, please contact us: Contact Person: Sameer Joshi E-mail: [email protected] Phone: +1-646-491-9876 Press Release: https://www.theinsightpartners.com/pr/patient-engagement-technology-market SOURCE The Insight Partners	https://www.prnewswire.com/news-releases/patient-engagement-technology-market-worth-59-billion-globally-by-2028-at-18-5-cagr---exclusive-report-by-the-insight-partners-301557674.html	2022-05-31T12:47:49	en	0.906382
"Gold standard" security certification affirms BAS company's commitment to safeguarding customer data and privacy SAN FRANCISCO, May 31, 2022 /PRNewswire/ -- Picus Security, the pioneer of Breach and Attack Simulation (BAS) technology, today announced that it has achieved Service Organization Controls 2 (SOC 2) Type 2 Compliance. SOC 2 is a security audit and attestation for Software-as-a-Service (SaaS) companies developed by the American Institute of Certified Public Accountants (AICPA). It is recognized as a gold standard for information security globally. Data protection, privacy and operational resilience are important considerations for organizations evaluating SaaS providers. As a result, an increasing number, particularly within the United States, now use SOC 2 reports to help assess and minimize supply chain risks. Picus Security achieved SOC 2 Type 2 compliance following an independent audit by Prescient Assurance. It verifies that the company and its cloud-native Security Control Validation Platform meet AICPA's rigorous Trust Service Criteria and that all relevant controls and processes in place are operationally effective. "In order to minimize risks, it's crucial that organizations choose technology providers that meet the highest standards of data protection and operational security," said Volkan Evrin, Information Security Director at Picus Security. "SOC 2 Type 2 compliance demonstrates Picus' ongoing commitment to protecting our customers. By choosing The Picus Platform, organizations not only benefit from the most complete BAS technology for security control validation. They also obtain assurance that their data and privacy are in safe hands." About Picus Security Picus Security is the pioneer of Breach and Attack Simulation (BAS). The Picus Complete Security Control Validation Platform is trusted by leading organizations worldwide to continuously validate the effectiveness of security controls against cyber-attacks and supply actionable mitigation insights to optimize them. Picus has offices in North America, Europe and APAC and is supported by a global network of channel and alliance partners. The company is dedicated to helping security professionals become more threat-centric and via its Purple Academy offers free online training to share the latest offensive and defensive cybersecurity strategies. For more information, visit www.picussecurity.com To learn more about the information security requirements of SOC 2, visit: www.aicpa.org SOURCE Picus Security	https://www.prnewswire.com/news-releases/picus-security-achieves-soc-2-type-2-compliance-301557708.html	2022-05-31T12:47:55	en	0.912615
- Over 200 Forbes 2000 companies rely on SpendEdge' s actionable insights. - SpendEdge Is the Preferred Procurement Market Intelligence Partner for 120+ Fortune 500 Firms. - Li and Fung, HH Global, and Ennis are a few of the key suppliers in the promotional products market NEW YORK, May 31, 2022 /PRNewswire/ -- The Procurement Promotional Products will grow at a CAGR of 2.98% by 2026. Prices will increase by 1%- 3% during the forecast period and suppliers will have a moderate bargaining power in this market. This report offers key advisory and intelligence to help buyers identify and shortlist the most suitable suppliers for their Procurement Promotional Products requirements. Get a Sample Sourcing and Procurement Report on Promotional Products Market's Trends and Drivers Procurement Promotional Products Procurement report explains key category management objectives that should form the base for sourcing strategy, including: - Top-line growth - Scalability of inputs - Green initiatives - Category innovations - Supply base rationalization - Demand forecasting and governance - Minimalization of ad hoc purchases - Adherence to regulatory nuances - Cost savings - Customer retention - Reduction of TCO - Supply assurance Sign Up for a Sample Procurement Promotional Products Procurement Market Report: www.spendedge.com/report/promotional-products-sourcing-and-procurement-intelligence-report Price Strategies and Benchmark To optimize the value of the purchase, it is crucial to keep a track of current and future price trends. Price forecasts are beneficial in purchase planning, especially when supplemented by the constant monitoring of price influencing factors. During the forecast period, the market expects an incremental spend of USD 6.87 billion due to various market drivers prevalent across multiple regions. Also, the report speaks about various cost-saving factors through analysis of the below factors: - Identify favorable opportunities in promotional products TCO (total cost of ownership) - Expected changes in price forecast and factors driving the current and future price changes - Identify pricing models that offer the most rewarding opportunities. Key Selling Reports: 1. Mobile Device Management - Forecast and Analysis: The mobile device management procurement category is projected to grow at a CAGR of 12.22%. International Business Machines Corp., BlackBerry Ltd., and Microsoft Corp. are among the prominent suppliers in mobile device management market. Click the above link to download the free sample of this report. 2. Corporate Training Sourcing and Procurement Report: Corporate Training Procurement, prices will increase by 8.93% - 9.40% during the forecast period and suppliers will have a Moderate bargaining power in this market.. Click the above link to download the free sample of this report. 3. Temporary Corporate Housing - Sourcing and Procurement Intelligence Report: This report offers detailed insights and analysis of the major cost drivers, volume drivers, and innovations of the temporary corporate housing procurement and sourcing market, which the global suppliers have been leveraging to gain a competitive edge across regions. Click the above link to download the free sample of this report. Table of Content - Executive Summary - Market Insights - Category Pricing Insights - Cost-saving Opportunities - Best Practices - Category Ecosystem - Category Management Strategy - Category Management Enablers - Suppliers Selection - Suppliers under Coverage - US Market Insights - Category scope About SpendEdge: SpendEdge shares your passion for driving sourcing and procurement excellence. We are the preferred procurement market intelligence partner for 120+ Fortune 500 firms and other leading companies across numerous industries. Our strength lies in delivering robust, real-time procurement market intelligence reports and solutions. Contact SpendEdge Anirban Choudhury Marketing Manager Ph No: +1 (872) 206-9340 https://www.spendedge.com/contact-us SOURCE SpendEdge	https://www.prnewswire.com/news-releases/promotional-products-sourcing-and-procurement-report--forecast-and-analysis-2022-2026-spendedge-301557335.html	2022-05-31T12:47:56	en	0.876971
WASHINGTON, May 31, 2022 /PRNewswire/ -- With more than 28,000 cases of multiple sclerosis reported to the Department of Veterans Affairs annually, Paralyzed Veterans of America – the nation's premier nonprofit of choice for disabled veterans, their families, and caregivers – is expanding its membership as medical technology advances early detection of MS, inviting all veterans with MS to join. According to Charles Brown, national president of Paralyzed Veterans of America, "PVA has long helped veterans with MS involving the spinal cord who needed quality health care and disability benefits due to their diagnosis. Our National Service Officers are experts in securing their benefits, navigating the VA system, and helping these veterans throughout their continuum of care. It's important we keep pace with the improvements in MRI technology, which provides more precise imaging resulting in the early detection of MS. We want to help even more veterans living with the disease and become their go-to resource." The membership expansion means all Veterans with MS are now eligible to become a PVA member and obtain the same vital benefits as their counterparts with spinal cord injuries and diseases, like ALS. Among the benefits now available are: access to educational materials specific to MS; support from on-staff licensed architects who can review plans and provide subject matter expertise for making their homes more accessible; admission to PVA's private, members-only Facebook Groups that keep members abreast of important news that impact them; engagement with over 33 chapters across the country that support advocacy efforts specific to the MS community; and opportunities to take part in important surveys and webinars, as well as participate in sports and recreation events both virtually and in-person around the country. "Every case of MS reported is a person… a mother, a father, a son, a daughter, a proud Veteran, who selflessly served our nation, and they deserve our care and support now," continued Brown. "By expanding PVA's membership, we are not only helping more veterans but also honoring our roots, recognizing veterans like Gilford Moss – PVA's first president, who also had MS. We want all veterans with MS, from those actively serving to those who already served, to know that PVA is here and they are not alone." In August 2021, PVA created its first-ever MS Committee – a permanent committee of the Board of Directors – made up of eight PVA members from across the country who represent the everyday interests of veterans with MS. The committee acts as a voice on legislative issues concerning veterans with MS; provides first-hand input from its members with MS; puts out a weekly podcast on issues specific to those with MS; and serves as an expert resource for all veterans living with the disease. In addition to its committee and advocacy efforts, PVA also partners with expert groups in the field of MS, including the National MS Society and the VA's Multiple Sclerosis Centers of Excellence. To learn more about MS and how PVA helps military personnel thrive after diagnosis, visit: PVA.org/MS. To become a PVA member today visit PVA.org/Membership. Paralyzed Veterans of America is a 501(c)(3) non-profit and the only congressionally chartered veterans service organization dedicated solely for the benefit and representation of veterans with spinal cord injury or disease like MS and ALS. For 75 years, the organization has ensured that veterans receive the benefits earned through service to our nation; monitored their care in VA spinal cord injury units; and funded research and education in the search for a cure and improved care for individuals with paralysis. As a life-long partner and advocate for veterans and all people with disabilities, Paralyzed Veterans of America also develops training and career services, works to ensure accessibility in public buildings and spaces, and provides health and rehabilitation opportunities through sports and recreation. With more than 70 offices and 33 chapters, Paralyzed Veterans of America serves veterans, their families, and their caregivers in all 50 states, the District of Columbia, and Puerto Rico. Learn more at PVA.org. Contact: Oname Thompson [email protected] (703) 864-5980 cell SOURCE Paralyzed Veterans of America	https://www.prnewswire.com/news-releases/pva-expands-membership-invites-all-veterans-with-ms-to-join-301557506.html	2022-05-31T12:48:02	en	0.963235
RESTON, Va., May 31, 2022 /PRNewswire/ -- QTC Medical Services, Inc. (QTC), a Leidos (NYSE: LDOS) company, was recently awarded two prime contracts to provide medical disability examination services to both veterans and separating or retiring service members. The indefinite delivery/indefinite quantity, firm-fixed-price contracts were awarded by the Veterans Benefits Administration, Medical Disability Examination Office. The contracts each have six-month base periods of performance with six one-year options and a combined estimated value of $1.7 billion, if all options are exercised. "We are pleased to continue our work with Veterans Benefits Administration to support service members as they transition to civilian life and veteran status," said Liz Porter, Leidos Health Group President. "Our innovative delivery models enable us to better serve veterans and service members. Using our capabilities in telehealth, our mobile medical units and our nationwide provider network, we're bringing our services closer to veterans and service members, especially in rural areas." "For over 20 years, we have provided mission-oriented support for Department of Veterans Affairs and Department of Defense pre-discharge programs," said Larry Schaefer, QTC chief executive officer. "Pre-discharge programs are important for assessing readiness and force strength, expediting receipt of disability benefits. Last year, QTC completed over 1.1 million appointments for 446,000 examinees. This expanded exam capacity supports timely adjudication of claims for veterans and military service members." Through these contracts, QTC will provide medical disability examination services to meet Department of Veterans Affairs (VA) and Department of Defense (DOD) requirements for separating and retiring service members. These services will support 124 military installations participating in the Benefits Delivery at Discharge (BDD) and Integrated Disability Evaluation System (IDES) pre-discharge programs. QTC will also provide medical disability examination services to support claimants living in locations outside the continental Unites States. This international component includes both compensation and pension exams as well as joint VA and DOD pre-discharge programs. These contracts extend QTC's decades of experience supporting the joint VA and DOD pre-discharge programs. QTC's innovative delivery models include telehealth, mobile medical units, clinics on or near military installations and a nationwide provider network. About QTC Management QTC Management, Inc. (QTC), acquired by Leidos in 2016, partners with each customer to identify existing and forecasted program needs and delivers a full complement of disability-focused medical examination and diagnostic testing services. Since 2000, QTC has provided more than 9 million physical examinations and diagnostic tests. For more information, visit www.qtcm.com. About Leidos Leidos is a Fortune 500® technology, engineering, and science solutions and services leader working to solve the world's toughest challenges in the defense, intelligence, civil, and health markets. The company's 43,000 employees support vital missions for government and commercial customers. Headquartered in Reston, Virginia, Leidos reported annual revenues of approximately $13.7 billion for the fiscal year ended December 31, 2021. For more information, visit www.Leidos.com. Certain statements in this announcement constitute "forward-looking statements" within the meaning of the rules and regulations of the U.S. Securities and Exchange Commission (SEC). These statements are based on management's current beliefs and expectations and are subject to significant risks and uncertainties. These statements are not guarantees of future results or occurrences. A number of factors could cause our actual results, performance, achievements, or industry results to be different from the results, performance, or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, the "Risk Factors" set forth in Leidos' Annual Report on Form 10-K for the fiscal year ended December 31, 2021, and other such filings that Leidos makes with the SEC from time to time. Readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Leidos does not undertake to update forward-looking statements to reflect the impact of circumstances or events that arise after the date the forward-looking statements were made. Contact: Melissa Dueñas (571) 526-6850 [email protected] Thomas Doheny (571) 474-4735 [email protected] Brandon VerVelde (571) 526-6257 [email protected] SOURCE Leidos	https://www.prnewswire.com/news-releases/qtc-awarded-1-7-billion-veteran-and-service-member-medical-disability-exam-contracts-301556649.html	2022-05-31T12:48:08	en	0.937089
RETURN OF MARTINI REINVENTION: elit™ Vodka's Global Cocktail Competition is Back with a Sustainable Twist NEW YORK, May 31, 2022 /PRNewswire/ -- elit™ Vodka has announced the launch of the latest evolution of the brand's global cocktail competition elit Martini Masters. Previously known as the Art of Martini, the competition is back after a four-year hiatus – promising even tougher competition and offering a once in a lifetime "money can't buy" prize. As a 10-time platinum award winning vodka and advocate of social responsibility, elit Vodka is pairing with the best bartenders in the industry from 13 countries (United Kingdom, France, Austria, Spain, Italy, Greece, Israel, South Africa, Australia, Turkey, Dominican Republic, United Arab Emirates and Mexico) to bring the perfect sustainable martini to life and unearth the future of the classic cocktail. Todays' consumers are ever more conscious of the environmental impact of the brands they choose, and elit Vodka is proud to lead the sustainability agenda amongst luxury spirits brands by inspiring bartenders to rethink the martini in an eco-conscious way. elit Vodka believes the future of the martini is sustainable, and through the elit Martini Masters is looking to welcome the global bartender community's' take on how to make sustainability not only the future of the cocktail, but bring it into the present through their creations. Following the country heats, where the entries will be judged on three criteria: Sustainability, Performance and Perfection, the winner from each market will get the chance to mix their drinks at the global finals in Greece at the Athens Bar Show this November. To be successful, elit Vodka recommends each competition serve to showcase the Five T's of a perfect sustainable martini: Trend, Technique, Taste, Temperature and Tall Tale. More information about both the judging criteria and the guiding Five T's is available via the elit Martini Masters private Facebook groups in each market and here. The sustainability challenge for this year's edition falls in line with elit Vodka's dedication to championing sustainability, diversity, and inclusion – further demonstrated by the brand's partnership with Formula E team ROKiT Venturi Racing. The winner will become the Global elit Martini Master and will visit three Formula E events during the 2023 racing season, receiving the opportunity to present their winning drink at elit's events during race weekends. Formula E aspires to accelerate change towards an electric future, one race and one city at a time. Using the spectacle of sport, they are sending a powerful and meaningful message to help alter perceptions, with elit Vodka fully aligned with spreading the word off the track. Damian McKinney, CEO of Stoli Group commented: "The martini is an iconic cocktail and reinventing it is no easy task. To make it even more challenging, we're pushing the boundaries of cocktail-making, asking bartenders to demonstrate their knowledge, skill and performance and develop this classic drink with a sustainable twist." The best bartenders will compete in local heats before heading to the global final, taking place in Athens from 7th – 8th November 2022. To learn more about elit Martini Masters, follow us on Facebook and Instagram @elitvodka and #elitMartiniMasters across social channels. For more information about elit Vodka visit https://elitvodka.com/. About Stoli® Group Stoli® Group was established in 2013 and is responsible for the production, management, and distribution of a global spirits and wines portfolio. Mainly known for the Stoli® Vodka brand, Stoli Group has expanded to appeal to luxury on-premise and more sophisticated global consumers. Signature brands are: Stoli® Vodka, elit™ Vodka, Bayou® Rum, Kentucky Owl™, Villa One™, Gator Bite™ Rum Liquers, Cenote™ Tequila, Tulchan Gin™, Se Busca™ Mezcal and Stoli Group's wine division, Tenute del Mondo®. With a presence across a network of more than 176 markets, Stoli Group works with a passionate team of 200 distributors around the world. Headquartered in Luxembourg, Stoli has production facilities in Spain, Italy, Argentina, and the United States, some of which are steeped in history dating back to the early part of the last century. For more information, visit stoli-group.com. About elit™ Vodka Part of the Stoli Group's brands, elit™ Vodka is one of the highest-rated white spirits in the world, receiving 10 platinum awards and has been named as the best vodka of the year on 10 occasions by the Beverage Tasting Institute, Chicago, USA. Photo - https://mma.prnewswire.com/media/1829284/elit_Martini_22_competition.jpg Photo - https://mma.prnewswire.com/media/1829285/elit_Martini_22_competition.jpg SOURCE elit™ vodka	https://www.prnewswire.com/news-releases/return-of-martini-reinvention-elit-vodkas-global-cocktail-competition-is-back-with-a-sustainable-twist-301557737.html	2022-05-31T12:48:14	en	0.916875
Revolutionary Heart Therapy Offers Hope to Patients and Investors Alike PALM BEACH, Fla., May 31, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Diabetes is a chronic health condition that occurs when your body's blood glucose, also called blood sugar, is too high. Blood sugar must be carefully regulated to ensure the body functions properly. Too much blood sugar can then cause serious damage to organs, blood vessels and nerves. Over time, that can cause health problems, such as vision loss, kidney disease, and heart disease. That's why heart failure is closely linked to diabetes. Here we consider this issue with reference to Eli Lilly & Co (NYSE: LLY), Novo Nordisk (NYSE: NVO), Sanofi (NASDAQ: SNY), Viatris Inc (NASDAQ: VTRS), and Cardiol Therapeutics (NASDAQ: CRDL). Individuals suffering from type 2 diabetes, when a person can't properly use insulin made in their bodies, are two to four times more likely to develop heart failure than non-diabetics. Therefore, heart failure is a substantial risk to anyone who has diabetes. Over 90% of diabetics suffer from type 2 in the United States. Diabetes is primarily treated with insulin. Major players in the pharma space are involved in manufacturing insulin offerings to treat people with diabetes. These include Eli Lilly & Co., Novo Nordisk, Sanofi, and Viatris. Diabetes can lead to heart failure, with both often occurring together, reducing the quality of life and exacerbating the cost burden on individuals and the health service. Meanwhile, heart failure presents itself in different ways, and some, such as acute myocarditis and diastolic heart failure are yet to achieve a recognized standard of care. As heart failure and diabetes are visibly linked, it makes sense that treating one could reduce the risk of succumbing to the other. HEALING HEARTS Annually, more than 550k new cases of heart failure are diagnosed in the United States. That's why Cardiol Therapeutics (NASDAQ: CRDL) is developing treatments to reduce the discomfort faced by so many living with this devastating condition. Cardiol currently has one multi-national clinical trial ongoing, an acute myocarditis clinical trial expected to commence imminently, and a recently announced multicenter open-label pilot study in recurrent pericarditis. The company's trials are supported by strong pre-clinical evidence showing the molecule being investigated could prove revolutionary in the cardiovascular space. Therefore, it's providing hope to both patients and investors alike. Cardiol Therapeutics is a clinical-stage life sciences company focused on researching and developing cannabidiol (CBD) as an anti-fibrotic and anti-inflammatory therapy to treat cardiovascular disease (CVD). Cardiol's lead product candidate, CardiolRx™, is a pharmaceutically produced oral formulation being clinically developed for use in cardiovascular medicine. Advising Cardiol are some of the world's leading experts in cardiovascular medicine. The company boasts an esteemed variety of individuals on its Board of Directors and doctors on its steering committees, providing invaluable knowledge and expertise to guide Cardiol through its clinical trials. REASONS TO SUCCEED Diastolic heart failure represents around half of all heart failure. Furthermore, heart failure is possibly the most significant medical issue the western world faces. And this is rapidly escalating due to the rise of diabetes, obesity, and high blood pressure. That's why Cardiol Therapeutics has made treating diastolic heart failure its overarching goal, with its ongoing pre-clinical development of a solution its priority. Many want to see Cardiol's trials succeed because, to date, there's never been a satisfactory treatment for diastolic heart failure. If the Company's drug proves to be that elusive treatment, it will surely be a cause for celebration. With heart failure being a colossal health problem in the western world, if Cardiol's achieves its long-term goal of developing life-changing drugs for this growing area of concern, the addressable market is huge. INJECTION VS ORAL FORMULATION Cardiol's administration of CardiolRx™ for acute myocarditis patients is in an oral formulation. For treating diastolic heart failure patients, the CardiolRx™ formulation is expected to be administered via subcutaneous injection, similar to the way people with diabetes use insulin. The oral formulation of CardiolRx™ allows the treatment to be administered quickly and aggressively at very high doses. This is particularly important when dealing with acute myocarditis patients who require urgent care. However, diastolic heart failure tends to be much more chronic than urgent and, in many cases, is something patients must learn to live with. That's why a subcutaneous formulation is a more suitable form of treatment that could lead to less frequent dosing. Cardiol believes its subcutaneous formulation will allow it to be injected and taken up via the bloodstream. There are 64.3 million people with heart failure globally, and it remains a leading cause of death and hospitalization. Associated annual healthcare costs in the U.S. alone exceed $30bn. If Cardiol Therapeutics achieves its long-term goal of developing a treatment for diastolic heart failure, their business has significant upside potential. TACKLING RECURRENT PERICARDITIS Recently, the U.S. FDA recently approved Cardiol's Investigational New Drug Application (IND) to commence a Phase II open-label pilot study designed to evaluate the tolerance and safety of CardiolRx™ in patients with recurrent pericarditis. Recurrent pericarditis refers to inflammation of the pericardium – the membrane, or sac, that surrounds the heart. The study will also assess the improvement in objective measures of disease and, during an extension period, evaluate the feasibility of weaning concomitant background therapy, including corticosteroids, while taking CardiolRx™. Recurrent pericarditis is an orphan disease in the United States, thereby making CardiolRx™ eligible for orphan drug status under the FDA's Orphan Drug Designation program. CardiolRx™ is now eligible for orphan drug status in two indications. The Cardiol Therapeutics team aspires to become a much bigger organization by developing life-changing drugs for this growing area of concern. Heart failure cases are a mounting burden to the national healthcare system, and rising diabetes cases compounds this problem. Eli Lilly & Co (NYSE: LLY) is celebrating the U.S. FDA approval of Mounjaro (tirzepatide), its type 2 diabetes and weight loss medication. More than 30 million people in the U.S. have type 2 diabetes. Mounjaro is a first-in-class, dual-action drug that is injected once a week, with the dosage adjustable to the patient's needs. Novo Nordisk (NYSE: NVO) reported strong growth last year. The Danish pharma company is a leader in the diabetes space and is also tackling obesity and Alzheimer's disease. Novo Nordisk recently initiated a share repurchase program. The company has also announced a strategic collaboration with Flagship Pioneering to create a portfolio of transformational medicines. Sanofi (NASDAQ: SNY) recently conducted the InRange randomized controlled trial (RCT), which met its primary and secondary endpoints for people with type 1 diabetes. The company presented its findings at the 15th International Conference on Advanced Technologies and Treatments of Diabetes. Viatris Inc (NASDAQ: VTRS) is a global healthcare company. It provides access to medicines and sustainable operations along with support services such as diagnostic clinics, educational seminars, and digital tools. The company is committed to meeting its sustainability goals. This includes impacting 100 million patients via healthcare professional education and outreach regarding prevention, diagnosis and treatment options for cardiovascular disease, diabetes, cancer and other chronic conditions. Viatris and Biocon Biologics just launched Abevmy® (Bevacizumab), their third oncology biosimilar, in Canada. DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM has been compensated twenty six hundred dollars for news coverage of the current press releases issued by Cardiol Therapeutics by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements. Contact Information: Media Contact email: [email protected] +1(561)325-8757 SOURCE FinancialNewsMedia.com	https://www.prnewswire.com/news-releases/revolutionary-heart-therapy-offers-hope-to-patients-and-investors-alike-301557590.html	2022-05-31T12:48:16	en	0.936116
Partnership to Increase Access to Comprehensive Care for Americans Living in Rural Areas SAN FRANCISCO, May 31, 2022 /PRNewswire/ -- Today, Homeward, a company committed to improving access to high-quality, comprehensive care in rural communities, announced a strategic partnership with Rite Aid (NYSE: RAD) to provide access to comprehensive care for those living in rural areas across the U.S. Pharmacists are among the most trusted members of a local community – especially for the more than 50 percent of Americans living with a chronic condition[1]. Today, Rite Aid has over 6,300 pharmacists across 2,300 locations, including 700 pharmacy locations in rural areas, many of which are healthcare deserts with limited access to doctors and hospitals. Beginning this summer, Homeward and Rite Aid will partner to connect underserved seniors with providers and other clinical services. Rite Aid pharmacists will be able to introduce Medicare-eligible customers to Homeward's clinical services, including annual wellness visits, screenings, and risk assessments. In addition, Rite Aid will host Homeward's mobile care units at select rural Michigan locations to provide care and services to underserved communities with the goal of expanding to additional markets nationwide. "As we rearchitect health and care for rural Americans, we must consider the specific needs of millions living in these communities and so-called healthcare deserts. In these areas, we can't assume that 'if you build it, they will come.' Instead, we're creating convenient opportunities for care within the daily lives and routines of rural Americans," said Dr. Jennifer Schneider, CEO, Homeward. "Rite Aid is a highly recognized and trusted pharmacy services company with rural locations that serve many thousands of people every day. Through our partnership, we'll be able to connect individuals to our services as we improve access to critical, frontline services in these communities." "Rite Aid is deeply committed to improving the lives of our customers with expanded pharmacy and healthcare services in underserved rural communities," said Rite Aid President and CEO Heyward Donigan. "We are proud to support the innovative work that Homeward is doing to introduce a new, hybrid care model that will play a critical role in our customers' health journeys." To date, much of the innovation in healthcare has been applied only to urban populations, leaving rural populations saddled with widespread hospital closures2 and physician shortages3, both of which exacerbate health disparities, significantly poorer clinical outcomes and higher total costs. To address these significant gaps, Homeward announced plans to provide high-quality, accessible care for the 60 million Americans living in rural communities using a unique, hybrid model that is designed to meet their distinctive needs. Similarly, Rite Aid is focused on improving healthcare in underserved rural communities. "Our pharmacists have trusted relationships with millions of seniors built on years of frequent interactions and counseling in regards to medication and whole health needs. By partnering with Homeward, we will use our scale and suite of services to help close gaps in care and improve medication adherence," Donigan said. "Being part of the hybrid model that Homeward is building is an exciting opportunity to truly improve the health and wellness of our rural communities." Homeward deploys an integrated care model that combines mobile, community-based care with centralized clinical oversight and ongoing care management. Homeward providers see members both in community-based, mobile clinics and in members' homes, as preferred. Homeward care teams conduct physical exams, perform basic diagnostic tests, and when needed, refer members to regional health systems and specialists if more complicated diagnostics are required. Homeward's technology-enabled care model also includes virtual visits and in-home, cellular-based remote monitoring that keeps patients connected to their multidisciplinary care team. Homeward will provide in-network services, including primary care and specialty care beginning with cardiology, in Q3 2022 for individuals covered by Medicare and Medicare Advantage plans. The company will set aside the fee-for-service model – which defaults to in-clinic care settings and limits the ability to leverage new, innovative technology and services – in favor of a value-based, total capitation model. Homeward is rearchitecting rural health and care for the 60 million Americans living in rural communities. Homeward employs an in-network multidisciplinary care team, available both virtually and on the ground via mobile care units, with in-home remote monitoring to better connect patients to high-quality, accessible, and comprehensive care. Today, the company partners with Medicare and Medicare Advantage plans, taking on the full risk of their members to improve outcomes and reduce costs. For more information, please visit www.homewardhealth.com. Rite Aid Corporation is on the front lines of delivering healthcare services and retail products to Americans 365 days a year. Our pharmacists are uniquely positioned to engage with customers and improve their health outcomes. We provide an array of whole being health products and services for the entire family through over 2,400 retail pharmacy locations across 17 states. Through Elixir, we provide pharmacy benefits and services to millions of members nationwide. For more information, visit www.riteaid.com. Press Contact: Jen Long [email protected] 617-784-3245 Press Contact: Terri Hickey [email protected] 717-975-5718 1 In a recent Gallup poll, more than 79% of patient respondents found pharmacists to be a reliable source of general health information beyond general medication questions. 1Since 2005, at least 163 rural hospitals have closed, more than 60% of them since 2012. Rural health clinics are faltering too; 388 clinics closed between 2012 and 2018, which left 4,245 in operation. 2There are fewer physicians in rural areas: 39.8 physicians per 100,000 people, compared to 53.3 physicians per 100,000 in urban areas. Nearly 80% of rural counties are short on primary care doctors and 9% have none. And this problem is only going to worsen. More than 25% of primary care physicians in rural areas are 60 or older, compared with 18% in urban areas. SOURCE Homeward	https://www.prnewswire.com/news-releases/rite-aid-and-homeward-partner-to-support-seniors-in-underserved-communities-301557433.html	2022-05-31T12:48:22	en	0.9513
WIXOM, Mich., May 31, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that it has entered into securities purchase agreements with Armistice Capital Master Fund Ltd., a leading healthcare investor, to purchase $15 million of common stock (or common stock equivalents in lieu thereof) and warrants. The combined purchase price for one share of common stock (or common stock equivalent) and a warrant to purchase one share of common stock is $1.515. The warrants have an exercise price of $1.39 per share and have a term of 5.5 years. The Company is offering $12 million of securities in a registered transaction under the Company's shelf registration statement on Form S-3. The remaining $3 million of securities are being sold in a private placement transaction that is exempt from registration under Section 4(a)(2) of the Securities Act of 1933. The receipt of the $15 million in proceeds is expected to trigger a subsequent $7.5 million investment from DaVita, Inc. on terms previously disclosed. The Company intends to use the net proceeds to restructure its dialysis business and, pending FDA clearance, to advance the development of ferric pyrophosphate citrate (FPC) for patients with iron deficiency anemia who are receiving home infusion therapy. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Rockwell Medical is a commercial-stage biopharmaceutical company developing and commercializing its next-generation parenteral iron technology platform, Ferric Pyrophosphate Citrate (FPC), which has the potential to lead transformative treatments for iron deficiency in multiple disease states, reduce healthcare costs and improve patients' lives. The Company has two FDA-approved therapies indicated for patients undergoing hemodialysis, which are the first two products developed from the FPC platform. Rockwell Medical is also advancing its FPC platform by developing FPC for the treatment of iron deficiency anemia in patients outside of dialysis, who are receiving intravenous medications in the home infusion setting. In addition, Rockwell Medical is one of two major suppliers of life-saving hemodialysis concentrate products to kidney dialysis clinics in the United States. For more information, visit www.RockwellMed.com. Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as, "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "could," "can," "would," "develop," "plan," "potential," "predict," "forecast," "project," "intend," "look forward to," "remain confident" or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include, but are not limited to those risks more fully discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2021, as such description may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law. SOURCE Rockwell Medical Technologies, Inc.	https://www.prnewswire.com/news-releases/rockwell-medical-announces-15-million-at-market-offering-301557657.html	2022-05-31T12:48:28	en	0.957378
HARRISON, N.Y., May 31, 2022 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address difficult-to-treat cancers, announced today the completion of a $41 million Series B financing. The financing was led by new investor NexPoint and included participation from existing investors Bristol Myers Squibb, Eshelman Ventures and Kingdon Capital. As part of the financing, a convertible note provided by NexPoint in December 2021 was converted into Series B shares. "We are proud of Sapience's significant growth toward becoming a leading oncology company. From attracting a quality investor syndicate in our financing announced today to establishing clinical proof-of-concept with a confirmed partial response in Phase 1 with our lead program, ST101, we continue to execute on our corporate goals and deliver on our mission to improve the lives of patients with cancer," said Dr. Barry Kappel, Sapience's Chief Executive Officer and President. Marisa Frackman, Sapience's Chief Financial Officer, added, "We are pleased to have such high-quality investors join us in our pursuit to address difficult-to-treat cancers. The proceeds from this financing will advance our programs through meaningful clinical read-outs and will enable us to expand our pipeline that targets protein-protein interactions, which we believe hold considerable promise in oncology." Commenting on the investment, Michael Jeong, MD, a Director of Public and Private Investments at NexPoint, said: "This financing is an important step forward to advance Sapience's next-generation peptide therapeutics that have demonstrated the potential to effectively drug protein-protein interactions, targets that have been largely elusive for the pharmaceutical industry. We are impressed with the strength of the Sapience team, their technologies and their commitment to innovating the oncology field. We are proud to lead this financing and look forward to supporting Sapience through its next phase of growth." Sapience intends to use the proceeds from the financing to accelerate the advancement of its pipeline of peptide therapeutics designed to disrupt protein-protein interactions and drug well-validated cancer pathways. The proceeds will support the advancement of its lead program, ST101, which is currently in Phase 2 for patients with advanced solid tumors, and progress its second program, ST316, from IND-enabling studies to the commencement of a Phase 1 study. In addition, the financing will support the advancement of Sapience's platform to discover new therapies against high-value targets for difficult-to-treat oncology indications. About ST101 ST101, a first-in-class antagonist of C/EBPβ, is currently being evaluated in the Phase 2 portion of an ongoing Phase 1-2 clinical study in patients with advanced unresectable and metastatic solid tumors (NCT04478279). ST101-101 is an open-label, two-part, Phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 in patients with advanced solid tumors. The study consists of two phases: a Phase 1 dose escalation/regimen exploration phase and a Phase 2 expansion phase. In the ongoing dose escalation study, ST101 has demonstrated clinical proof-of-concept with a durable RECIST 1.1-confirmed partial response (PR) in a patient with cutaneous melanoma and evidence of long-lasting stable disease in several additional patients. In the ongoing Phase 2 dose expansion part of the study, Sapience is actively enrolling patients with GBM, metastatic cutaneous melanoma, locally advanced or metastatic hormone-receptor positive breast cancer and castration-resistant prostate cancer. ST101 has been granted Fast Track designation for recurrent GBM and advanced cutaneous melanoma in patients who have disease progression on or after anti-PD-1/anti-PD-L1 therapy, as well as orphan designations from the FDA for advanced melanoma, glioma and AML, and from the European Commission for the treatment of glioma. About ST316 ST316, a first-in-class β-catenin antagonist, is currently being evaluated in IND-enabling studies. β-catenin is a critical member of the canonical Wnt signaling pathway, a well-known development stage pathway that has been considered an "undruggable" cancer target, as small molecules have proven ineffective or toxic. Wnt/β-catenin signaling drives cancer initiation and contributes to tumor growth, angiogenesis and metastasis. ST316 exerts its activity through disruption of the BCL9/β-Catenin interaction to suppress transcription of Wnt target genes regulating proliferation, migration, invasion, and the metastatic potential of tumor cells. About Sapience Therapeutics Sapience Therapeutics, Inc. is a privately held, clinical-stage biotechnology company focused on discovering and developing peptide therapeutics for major unmet medical needs, particularly high mortality cancers. Sapience's approach holds potential to target intracellular interactions that are traditionally considered "undruggable targets". Its lead program, ST101, is a peptide antagonist of C/EBPβ that has demonstrated clinical proof-of-concept in Phase 1 with a durable confirmed partial response (PR). ST101 is currently being evaluated in the Phase 2 portion of an ongoing Phase 1-2 clinical study with potential applications in various solid tumors and hematologic malignancies. For more information on Sapience Therapeutics, please visit www.sapiencetherapeutics.com and engage with us on LinkedIn. Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements. Any statements herein other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements may include, among other things, statements regarding future events that involve significant risks and uncertainties (including with respect to Sapience's preclinical and clinical development programs). These forward-looking statements are based on management's current expectations, and actual results and future events may differ materially as a result of certain factors, including, without limitation, our ability to obtain additional funds, and meet applicable regulatory standards and receive required regulatory approvals. Forward-looking statements speak only as of the date of this press release. Sapience does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise, except as required by law. Contacts Sapience Therapeutics, Inc. Barry Kappel, Ph.D., M.B.A. President and Chief Executive Officer [email protected] Media and Investor Contact: Amy Conrad Juniper Point (858) 366-3243 [email protected] SOURCE Sapience Therapeutics, Inc.	https://www.prnewswire.com/news-releases/sapience-therapeutics-announces-41-million-series-b-financing-to-advance-pipeline-of-peptide-therapeutics-targeting-protein-protein-interactions-301557720.html	2022-05-31T12:48:34	en	0.92979
Johnny Depp-Amber Heard trial: Jury to continue deliberations in defamation case FALLS CHURCH, Va. - A Virginia jury will continue deliberations on Tuesday in Johnny Depp’s $50 million libel trial against his ex-wife Amber Heard, a closely-watched case that has drawn millions of viewers online and much public debate surrounding the claims. Testimony throughout the six-week trial provided an ugly glimpse into the couple's seemingly toxic relationship and captivated the public, with some fans even camping out and spending tens of thousands of dollars for a chance to witness the court proceedings in person. Both sides gave their closing arguments on Friday and the civil case went into the hands of the seven-person jury. Depp sued Heard for libel in Fairfax County Circuit Court over a December 2018 op-ed she wrote in The Washington Post describing herself as "a public figure representing domestic abuse." The article never even mentions Depp by name, but his lawyers say he was defamed nonetheless. Most of the article discusses public policy as it relates to domestic violence, and Heard's lawyers say she has a First Amendment right to weigh in. (L) Actor Amber Heard testifies in the courtroom at the Fairfax County Circuit Courthouse in Fairfax, Virginia, on May 16, 2022. (R) Actor Johnny Depp returns to the courtroom after a lunch break at the Fairfax County Circuit Court during his defamat In the first passage, Heard wrote that "two years ago, I became a public figure representing domestic abuse, and I felt the full force of our culture’s wrath." Depp’s lawyers called it a clear reference to Depp, given that Heard publicly accused Depp of domestic violence in 2016 — two years before she wrote the article. In a second passage, she stated, "I had the rare vantage point of seeing, in real-time, how institutions protect men accused of abuse." Depp's lawyers are also seeking damages over a headline that appeared above the online version of the article, even though Heard didn't write it. Heard also filed a $100 million counterclaim against the former "Pirates of the Caribbean" star after his lawyer called her allegations a hoax. During the trial, Heard testified about more than a dozen episodes of physical and sexual assault that she said Depp inflicted on her. Depp says he never struck Heard and that she concocted the abuse allegations. He has said he was the one physically attacked by Heard multiple times. What does the Johnny Depp-Amber Heard trial jury have to decide? The jury is now tasked with deciding whether those passages in the Washington Post are defamatory. And the verdict form gives them step-by-step instructions on how to determine that. They also must come to a unanimous decision for a verdict. Because both Heard and Depp are Hollywood actors, they're considered public figures under the law — meaning there's a higher bar to clear to prove defamation. Depp has to prove that Heard acted with actual malice, meaning she knew she was lying when she made her claims or she acted with reckless disregard for the truth. And though the counterclaim has received less attention at the trial, Heard's lawyer Elaine Bredehoft said it provides an avenue for the jury to compensate Heard for the abuse Depp inflicted on her even after they split by orchestrating a smear campaign. If the jury finds that either party defamed the other, they have to calculate how much that defamation damaged the hurt party financially. The jury also has to consider the value of reputation loss. When is the verdict for the Depp-Heard trial? The seven-person civil jury began its deliberations at 3 p.m. Friday and finished for the day about two hours later. They will resume Tuesday, looking at all the testimony, pictures and videos submitted into evidence. The judge said the jury will deliberate into the evening each day that they do their work, but not over weekends or holidays. Johnny Depp and Amber Heard’s relationship timeline The two met in 2009 while filming "The Rum Diary." Despite their 22-year age difference, Heard testified there was an instant connection when Depp met with her as he considered her for a role in the film. "I was a no-name actor. I was 22. He was twice my age. He’s this world-famous actor and here we are getting along about obscure books, old blues" music, testified Heard, who’s now 36. While they had chemistry during the filming of the movie, she said they didn’t begin dating until doing a press tour for the film’s release in 2011. At the outset, they kept their relationship a secret. Heard testified that the first act of physical abuse against her by Depp happened in 2013. The two married in February 2015 reportedly at their Los Angeles home, but the nuptials didn’t last long. In May 2016, Heard filed for divorce and obtained a temporary restraining order against Depp. Their divorce was finalized in early 2017, with Heard saying she was going to donate her $7 million settlement to charity. Heard’s op-ed was published in The Washington Post in 2018. In 2019, Depp filed a $50-million defamation lawsuit against her. Heard countersued Depp for $100 million. The defamation trial began on April 12, 2022. Johnny Depp-Amber Heard abuse claims In order to rule on Depp’s libel claim, the jury must decide whether the facts in the case prove Depp, in fact, abused Heard. Depp said he never physically abused her, while Heard said she was assaulted on more than a dozen occasions. Depp also alleged he was the victim of abuse inflicted by her. Heard testified the first act of physical violence against her happened in 2013. She said it happened when the two were talking about one of Depp’s tattoos, and she said she made the mistake of laughing at it. She said Depp responded by slapping her. Thinking the slap must be a joke, she laughed more. Depp responded by slapping her twice more, with the third slap knocking Heard off balance. Depp, while he was on the stand, flatly denied it occurred. The tattoo in question was one that used to say "Winona Forever," which Depp got when he was dating actor Winona Ryder. He had it altered to "Wino Forever" when they broke up. Depp and Heard both agreed the worst violence occurred in March 2015 in Australia while Depp was shooting the fifth "Pirates of the Caribbean" movie, but that’s where their agreement of the account ends. Heard said Depp sexually assaulted her with a bottle of Maker’s Mark bourbon as part of an alcohol-fueled rage that included accusing her of infidelity with a co-star. Depp said he was the victim of violence because Heard was irate over a pending post-nuptial agreement and his struggles with sobriety. Depp testified Heard threw a liquor bottle at him twice, and that one smashed against his hand while it rested on a counter and severed the tip of his middle finger. Photos of the aftermath showed Depp wrote vulgar messages to his wife in blood on the walls of the house. Jurors also saw contemporaneous text messages Depp sent to others in which he said he cut off his own finger. Depp said he made up that story to protect Heard and avoid police involvement. A hand surgeon later testified that Depp could not have lost the tip of his middle finger the way he told jurors it happened. Why is Depp-Heard trial happening in Virginia? The trial is taking place in Fairfax County Circuit Court in Fairfax, Virginia. Heard’s lawyers had sought to have the case tried in California, where the actors reside. But a judge ruled that Depp was within his rights to bring the case in Virginia because The Washington Post’s computer servers for its online edition are located in the county. Depp’s lawyers have said they brought the case in Virginia in part because the laws there are more favorable to their case. Advertisement This story was reported from Cincinnati. The Associated Press, Megan Ziegler and FOX 5 DC contributed.	https://www.fox29.com/news/johnny-depp-amber-heard-trial-jury-deliberations-verdict-update	2022-05-31T12:48:36	en	0.980906
Seemplicity Raises $32 Million with First-of-its-Kind Productivity Platform for Modern Security Teams to Scale Risk Reduction Efforts Seemplicity's productivity platform empowers modern security teams to automate, optimize, and scale risk reduction efforts across the organization, cutting time spent on manual operations by up to 80% and increasing remediation throughput by 6X TEL AVIV, Israel, May 31, 2022 /PRNewswire/ -- Seemplicity, the first risk reduction and productivity platform for modern security teams, launched today with $32 million in funding. The funding includes a $26 million Series A round led by Glilot Capital Partners through its early growth fund, Glilot+, with participation from new investors NTTVC and Atlantic Bridge and existing investors S Capital and Rain Capital. The company previously raised a $6 million seed round led by S Capital. Seemplicity is already serving over 20 customers globally, including Fortune 500 and publicly traded companies. In an effort to drive down risk, organizations heavily invest in hiring security talent and deploy multiple security solutions. Yet time to remediation remains stubbornly long and thousands of hours are wasted on manually pushing remediation tasks across the organization. With remediation often depending on people, procedures, and infrastructure beyond the security team's direct control, a huge amount of time is wasted on untangling, delegating, and following up on the status of every security finding scattered across the organization. In today's rapidly evolving risk landscape and technology stack, these practices simply cannot scale. Seemplicity's Productivity Platform has a simple goal - to connect security findings with those who can fix them, thus removing security teams as the bottleneck. Seemplicity aggregates, normalizes, and orchestrates findings from multiple siloed security tools to generate a single consistent security backlog. This enables security teams to easily build out and automate risk reduction workflows in the platform, streamlining handovers between teams and synchronizing all stakeholders, including developers, DevOps, and cloud engineers. By consolidating the data from cloud misconfiguration, vulnerability management, AppSec, penetration testing, API security, SaaS security, and other security tools into a unified platform, Seemplicity cuts out time wasted on manual operations by as much as 80% and increases remediation throughput by 6X. "No one can think of developing software without Jira, so why do security teams still work with spreadsheets?" said Yoran Sirkis, co-founder & CEO of Seemplicity. "While the security industry excels at identifying weaknesses and vulnerabilities, it falls incredibly short when it comes to remediation and assurance. Security teams need a workflow tool to help them keep the queue moving, remediate more issues in less time, and scale their operations." Seemplicity was founded by Yoran Sirkis, Ravid Circus, and Rotem Cohen Gadol, three cybersecurity veterans with hands-on experience in building security programs and developing data-driven software, who created the platform they wished they had as security leaders. Renowned cyber security investors including René Bonvanie, Tom Banahan, Mark Smith, Elad Yoran, and Kevin Mahaffey also participated in the financing rounds. "The ever-changing threat landscape of cybersecurity opens up organizations to more risks, necessitating the adoption of more security solutions. Ironically, the more cybersecurity tools a company uses, the less efficient its security team becomes at controlling and reducing risk," said Lior Litwak, Managing Partner of Glilot+, Glilot Capital's early growth fund. "By streamlining the operational element of cybersecurity and building a dynamic, real-time bridge between security and remediation teams, Seemplicity enables organizations to both significantly improve their cyber risk posture and address their ever-increasing workloads." "From the get-go we knew we were dealing with strong founders who are leading subject matter experts. The vision they set out quickly translated into a platform that provides significant value to its customers, which over the past year has continued to grow," said Aya Peterburg, Managing Partner of S Capital. "CISOs are having to rethink their security automation and processes as they navigate challenges with access to talent and lead increasingly distributed teams," said Vab Goel, Founding Partner at NTTVC. "Seemplicity offers a unique, simple, and powerful automation platform that aligns the entire security organization around the highest impact actions." About Seemplicity Seemplicity is revolutionizing the way security teams drive and scale risk reduction efforts across organizations by orchestrating, automating, and consolidating all remediation activities into one workspace. As the first productivity workflow platform created for modern security teams, Seemplicity transforms the remediation process into a streamlined and collaborative effort that can easily be utilized by developers, DevOps, and IT across the organization, helping them achieve complete operational resilience and establish a truly scalable security program. Seemplicity was founded in 2020 by cybersecurity veterans Yoran Sirkis, Ravid Circus, and Rotem Cohen Gadol, and its customers include Fortune 500 and publicly traded companies. For more information visit www.seemplicity.io Seemplicity Media Contact: David Hoffman [email protected] +972-52-842-1955 SOURCE Seemplicity	https://www.prnewswire.com/news-releases/seemplicity-raises-32-million-with-first-of-its-kind-productivity-platform-for-modern-security-teams-to-scale-risk-reduction-efforts-301557582.html	2022-05-31T12:48:41	en	0.941286
Lynyrd Skynyrd legend Ronnie Van Zant's childhood home put up for sale The house in Jacksonville, Florida where Lynyrd Skynyrd rock legend Ronnie Van Zant and his brothers Donnie and Johnny grew up is now up for sale. The home is on the market for $629,000 and comes with eight lots, a fourplex home and a manufactured home. The property also includes a historical marker that was placed in the front yard in 2018. The sign reads, "The Van Zants’ legacy, memorialized in this house, commemorates their prodigious contribution to the world of rock music." "That house was our life, that neighborhood was our neighborhood," Johnny Van Zant said in 2018. "We all learned how to play drums in that house, we all learned how to swing on the swing-set out there — that’s where we learned to sing. We didn’t have 700 channels like today. We didn’t have nothing but four channels. We weren’t super rich." According to property records, Blue Horizon Property Solutions purchased the home in 2015 for $67,500. Ronnie Van Zant and friends from the west Jacksonville neighborhood formed Lynyrd Skynyrd in the 1960s, and the band became Southern Rock superstars in the 1970s. He and several others died in a plane crash in 1977. His brother Johnny Van Zant has been the lead singer for Lynyrd Skynyrd since 1987. FILE - Rickey Medlocke, Johny Van Zant and Gary Rossington of Lynyrd Skynyrd perform on stage at Resorts World Arena on June 30, 2019, in Birmingham, England. (Photo by Steve Thorne/Redferns) And brother Donnie Van Zant founded another 1970s rock band, .38 Special, but hearing problems forced him to retire in 2013. INFLATION CAUSING INCREASED ‘CONCERN’ FOR HOMEBUILDERS: NAHB CEO Johnny and Donnie both still live in northeast Florida. Advertisement	https://www.fox29.com/news/lynyrd-skynyrd-legend-ronnie-van-zants-childhood-home-put-up-for-sale	2022-05-31T12:48:44	en	0.962401
NEW YORK, May 31, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: American Campus Communities, Inc. (NYSE: ACC)'s sale to Blackstone related entities for $65.47 per share in cash. If you are an American Campus shareholder, click here to learn more about your rights and options. Manning & Napier, Inc. (NYSE: MN)'s sale to Callodine Group, LLC for $12.85 per share. If you are a Manning & Napier shareholder, click here to learn more about your rights and options. Flexible Solutions International, Inc. (NYSE: FSI)'s merger with Lygos, Inc. If you are a Flexible Solutions shareholder, click here to learn more about your rights and options. SailPoint Technologies Holdings, Inc. (NYSE: SAIL)'s sale to Thoma Bravo for $65.25 per share in cash. If you are a SailPoint shareholder, click here to learn more about your rights and options. Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected]. Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Halper Sadeh LLP Daniel Sadeh, Esq. Zachary Halper, Esq. (212) 763-0060 [email protected] [email protected] https://www.halpersadeh.com SOURCE Halper Sadeh LLP	https://www.prnewswire.com/news-releases/shareholder-notice-halper-sadeh-llp-investigates-acc-mn-fsi-sail-872550109.html	2022-05-31T12:48:47	en	0.875594
'No place for a horse': Animal control rescues horse found abandoned on streets of Philadelphia PHILADELPHIA - A horse that was abandoned in the streets of Philadelphia is now in need of a new home. The horse was found wandering down Darien Street in Hunting Park after allegedly being left by a man who brought him. Concerned residents notified authorities and staff from Philadelphia's Animal Care & Control Team responded. The horse, which has since been named Darien, is now in ACCT custody for treatment and care. The agency says the horse is underweight and in need of some extra care. It is not illegal to own a horse in Philadelphia, but the ACCT says there are better places to keep horses for adequate care and safety. Advertisement	https://www.fox29.com/news/no-place-for-a-horse-animal-control-rescues-horse-found-abandoned-in-streets-of-philadelphia	2022-05-31T12:48:50	en	0.973065
LAKEWOOD, Colo. (AP) _ Mesa Laboratories Inc. (MLAB) on Tuesday reported a fiscal fourth-quarter loss of $1.8 million, after reporting a profit in the same period a year earlier. The Lakewood, Colorado-based company said it had a loss of 34 cents per share. Earnings, adjusted for amortization costs and stock option expense, came to $2.22 per share. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of $1.88 per share. The quality control instruments and disposable products maker posted revenue of $58.9 million in the period, which also beat Street forecasts. Three analysts surveyed by Zacks expected $55.5 million. For the year, the company reported profit of $1.9 million, or 35 cents per share. Revenue was reported as $184.3 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MLAB at https://www.zacks.com/ap/MLAB	https://www.chron.com/business/article/Mesa-Labs-Fiscal-Q4-Earnings-Snapshot-17209081.php	2022-05-31T12:48:50	en	0.952005
Orphan drug designation applies to patients with primary mitochondrial myopathy due to nuclear DNA mutations (nPMM) in the NuPower Phase 3 clinical trial NuPOWER Phase 3 trial is currently enrolling patients with multiple clinical trial sites initiated in the United States and Europe BOSTON, May 31, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the European Medicines Agency (EMA) has granted orphan drug designation (ODD) for elamipretide for the treatment of myopathic mitochondrial DNA depletion syndrome (M-MDS), a designation which applies to patients with nPMM eligible for enrollment in the NuPOWER Phase 3 clinical trial, which is currently enrolling patients at multiple clinical trial sites in the United States and Europe. "We are pleased that EMA has recognized the high unmet need for innovative treatments for this rare genetic condition which significantly limits the quality of life of affected individuals," said Chief Executive Officer Reenie McCarthy. "Orphan drug designation for M-MDS marks an important step toward advancing our regulatory initiatives in Europe. As we continue to enroll patients in this pivotal trial, this designation strengthens our ability to support partnership opportunities in the European markets" ODD is granted to investigational therapies intended for the safe and effective treatment of rare diseases with an unmet medical need that affect fewer than 5 in 10,000 people in the European Union. This designation provides companies with certain benefits and incentives including clinical protocol assistance, differentiated evaluation procedures for Health Technology Assessments in certain countries, access to a centralized marketing authorization procedure valid in all EU Member States, and if approved, marketing exclusivity in the EU for 10 years. About M-MDS and nPMM M-MDS is caused by mutations in nuclear DNA genes encoding for enzymes responsible for maintenance and replication of mitochondrial DNA. Mitochondrial DNA replication, which is critical to support muscular energy demands, can be impaired as a result of these mutations, leading to signs and symptoms of M-MDS. M-MDS is characterized by muscle weakness, exercise intolerance, peripheral neuropathy and, in some cases, progressive external ophthalmoplegia. These patients are also considered to have primary mitochondrial myopathy, or PMM, for which the Company has previously received orphan drug designation from the US FDA. There are currently no FDA- or EMA-approved therapies for patients with M-MDS. About Stealth We are a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases and are involved in many common age-related diseases, typically involving organ systems with high energy demands such as the heart, the eye, and the brain. We believe our lead product candidate, elamipretide, has the potential to treat both rare metabolic cardiomyopathies, such as Barth, Duchenne muscular dystrophy and Friedreich's ataxia, rare mitochondrial diseases entailing nuclear DNA mutations, as well as ophthalmic diseases entailing mitochondrial dysfunction, such as dry age-related macular degeneration. We are evaluating our second-generation clinical-stage candidate, SBT-272, and our new series of small molecules, SBT-550, for rare neurological disease indications following promising preclinical data. We have optimized our discovery platform to identify novel mitochondria-targeted compounds which may be nominated as therapeutic product candidates or utilized as mitochondria-targeted vectors to deliver other compounds to mitochondria. Forward-looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Stealth BioTherapeutics' plans, strategies and expectations for the clinical advancement of its drug development programs, including its ongoing clinical trial of elamipretide in nPMM and its expectations regarding regulatory interactions and partnership opportunities. Statements that are not historical facts, including statements about Stealth BioTherapeutics' beliefs, plans and expectations, are forward-looking statements. The words "anticipate," "expect," "hope," "plan," "potential," "possible," "will," "believe," "estimate," "intend," "may," "predict," "project," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Stealth BioTherapeutics may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements as a result of known and unknown risks, uncertainties and other important factors, including: Stealth BioTherapeutics' ability to obtain additional funding and to continue as a going concern; the impact of the COVID-19 pandemic; the ability to successfully demonstrate the efficacy and safety of Stealth BioTherapeutics' product candidates and future product candidates; the preclinical and clinical results for Stealth BioTherapeutics' product candidates, which may not support further development and marketing approval; the potential advantages of Stealth BioTherapeutics' product candidates; the content and timing of decisions made by the FDA, the EMA or other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies, which may affect the initiation, timing and progress of preclinical studies and clinical trials of Stealth BioTherapeutics product candidates; Stealth BioTherapeutics' ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Stealth BioTherapeutics' ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; and general economic and market conditions. These and other risks are described in greater detail under the caption "Risk Factors" included in Stealth BioTherapeutics' most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission ("SEC"), as well as in any future filings with the SEC. Forward-looking statements represent management's current expectations and are inherently uncertain. Except as required by law, Stealth BioTherapeutics does not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances. Investor Relations Kendall Investor Relations Adam Bero [email protected] SOURCE Stealth BioTherapeutics Inc.	https://www.prnewswire.com/news-releases/stealth-biotherapeutics-receives-orphan-drug-designation-from-the-european-medicines-agency-for-elamipretide-for-the-treatment-of-myopathic-mitochondrial-dna-depletion-syndrome-301557422.html	2022-05-31T12:48:53	en	0.938775
Police: Woman struck by stray bullet in deadly triple shooting in West Philadelphia PHILADELPHIA - A "targeted" shooting in West Philadelphia left one dead and two others injured Monday night. Police say a 32-year-old man died after he was found with multiple gunshot wounds to his head and body at 41st and Parish streets around 11 p.m. Another shooting victim was found a couple blocks away at 38th and Brown streets. He ran after reportedly being shot twice in the leg, and is said to be in stable condition. Police believe these two victims were targeted. However, a third victim is also in critical condition after being hit by a stray bullet. The innocent woman was struck in the face and neck while driving nearby on Lancaster Avenue, according to police. She was in the passenger seat. Her car ran several red lights and stop signs before being stopped by police, who then escorted her to the hospital. MORE HEADLINES: - Police: Nearly 70 shots fired in North Philadelphia double shooting - DA: Man charged with killing 2 women, unborn child in Chester County - 'No place for a horse': Animal control rescues horse found abandoned on streets of Philadelphia Police say 44 spent shell casings were found on scene. Advertisement The shooting is under investigation, with no word on suspects or motive.	https://www.fox29.com/news/police-woman-struck-by-stray-bullet-in-deadly-triple-shooting-in-west-philadelphia	2022-05-31T12:48:56	en	0.981735
HAMILTON HM 11, Bermuda (AP) _ Nordic American Tankers Ltd. (NAT) on Tuesday reported a loss of $27 million in its first quarter. The Hamilton Hm 11, Bermuda-based company said it had a loss of 14 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 11 cents per share. The tanker company posted revenue of $15.5 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NAT at https://www.zacks.com/ap/NAT	https://www.chron.com/business/article/Nordic-American-Tankers-Q1-Earnings-Snapshot-17209043.php	2022-05-31T12:48:56	en	0.948902
SteroTherapeutics Granted Orphan Drug Designation to ST-003, a Novel Drug Candidate for the Treatment of Primary Sclerosing Cholangitis - Designation provides fast track reviews and a 30% fungible tax credit for all future clinical development expenses - Company on track to submit IND in 2023 DOYLESTOWN, Pa., May 31, 2022 /PRNewswire/ -- SteroTherapeutics LLC, a clinical-stage company targeting metabolic and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for ST-003, a novel galanin receptor inhibitor, for the treatment of primary sclerosing cholangitis (PSC). PSC is a rare, heterogeneous, idiopathic, inflammatory disorder of the bile ducts resulting in strictures and scarring of the ducts that can gradually cause serious liver damage. ST-003 is designed to halt the impact of excessive galanin concentrations that increase cholangiocyte proliferation and fibrogenesis, as demonstrated in humans and in specific mouse models. "This important designation is a milestone in the development of ST-003 and highlights the need for potential new treatment options for patients with PSC," said Manohar Katakam, Ph.D., Chief Executive Officer of SteroTherapeutics. "Orphan designation for ST-003 is a critical step toward clinical development as we now have fast track reviews and a 30% fungible tax credit for all future clinical development expenses. ST-003 has the potential to be an important treatment by addressing a host of disease factors found in the PSC disease state. We are especially pleased that this is the second program in our pipeline to receive this designation, as it validates and adds value to our programs." SteroTherapeutics expects to submit an Investigational New Drug (IND) application to the FDA for ST-003 in 2023 and marks the second program, following ST-002 for the treatment of Cushing's syndrome, to receive Orphan Drug Designation by the FDA. FDA Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the United States. Orphan drug status provides benefits to drug developers, including assistance in the drug development process, tax credits for clinical costs, exemptions from certain FDA fees and seven years of post-approval marketing exclusivity. About Primary Sclerosing Cholangitis: Primary sclerosing cholangitis (PSC) is a chronic liver disease in which the bile ducts inside and outside the liver become inflamed and scarred, and eventually narrowed or blocked. When this happens, bile builds up in the liver and causes further liver damage. About SteroTherapeutics: SteroTherapeutics, a clinical stage company is focused on developing novel orphan disease therapeutics with significant unmet needs as well as potentially larger indications affecting large patient populations. SteroTherapeutics' lead programs, ST-002 to treat Cushing's syndrome, ST-003 to treat primary sclerosing cholangitis and ST-004 to treat multiple myeloma, have been proven in previous animal and human studies to possess a strong safety profile and established mechanisms of action. Both ST-002 and ST-003 have received Orphan Drug Designation from the U.S. FDA. The company's strategic intent is to focus on platform technologies and corresponding disease pathways in disease states with significant unmet or underserved medical needs. In each individual disease target SteroTherapeutics embraces the opportunity to provide safe, effective treatments and restore an optimal quality of life. Learn more at sterotx.com Investor/Media Contact: Lisa Sher [email protected] Tel: 970-987-2654 SOURCE Sterotherapeutics LLC	https://www.prnewswire.com/news-releases/sterotherapeutics-granted-orphan-drug-designation-to-st-003-a-novel-drug-candidate-for-the-treatment-of-primary-sclerosing-cholangitis-301557462.html	2022-05-31T12:48:59	en	0.926645
Rising US traffic deaths put focus on one Philadelphia road PHILADELPHIA - Just one more step and the stroller would have been on the curb. The thought haunts Latanya Byrd years after a driver racing down Roosevelt Boulevard in Philadelphia struck and killed her 27-year-old niece, Samara Banks, and three of Banks’ young sons as they crossed the 12-lane road. Today, many of the conditions that led to the fatal 2013 crash still exist. Since the crash, Byrd became an advocate for safer streets, fighting to get automated speed cameras placed along the boulevard where 10% to 13% of the city's traffic fatalities happened each year prior to the pandemic, city officials said. And now, amid a national surge in traffic fatalities that federal officials have called a crisis and studies showing Black communities have been hit even harder during the pandemic, plans to redesign the city's "corridor of death" could be gaining traction. Roosevelt Boulevard is an almost 14-mile maze of chaotic traffic patterns that passes through some of the city's most diverse neighborhoods and census tracts with the highest poverty rates. Driving can be dangerous with cars traversing between inner and outer lanes, but biking or walking on the boulevard can be even worse with some pedestrian crossings longer than a football field and taking four light cycles to cross. "You would not design a street or a road like that today," said Christopher Puchalsky, policy director for Philadelphia’s Office of Transportation, Infrastructure and Sustainability. "It feels like an expressway, but it’s in the middle and between neighborhoods." Many of the city's ideas for fixing Roosevelt have been championed under new federal strategies. In the wake of increasing fatalities, Transportation Secretary Pete Buttigieg has pushed a "safe system" approach, encouraging cities and states to take into account more than just driver behavior when designing roads. RELATED HEADLINES - Police: 1 killed, 2 hurt in violent two-car crash on Roosevelt Boulevard in Olney - Police: Woman fatally struck on Roosevelt Boulevard - 15-car pileup closes southbound lanes of Roosevelt Boulevard - 3 hurt in violent motorcycle crash on Roosevelt Boulevard, police say The Biden administration also created funding for safety improvements, including the bipartisan infrastructure law and a $5 billion federal aid package to cities over the next five years. Federal officials have pledged to prioritize equity when making funding decisions in the wake of a disproportionate 23% jump in Black traffic fatalities in 2020. "We’ll certainly remind the federal government when we are applying for grants of the equity priorities that the leadership has set out," Puchalsky said. Kelley Yemen, director of Philadelphia’s Complete Streets program, said the city is hoping for federal money to begin a long-term redesign of Roosevelt outlined in a study released in 2019. The two options would either make the center lanes a restricted expressway, or cut speeds and convert car lanes to bicycle and transit lanes. Both carry billion-dollar price tags. The study includes a series of smaller projects to improve safety at high-fatality stretches on the road by 2025, some already started, but residents are skeptical. Eva Gbaa has been impatient to see changes. Her 17-year-old nephew, John "JJ" Gbaa Jr., was killed in a November 2018 hit-and-run as he tried to cross Roosevelt while walking home after hanging out with friends. He was alone at the time and a lot of the circumstances of the crash were unknown. A passerby found JJ and called the police, but he died at a hospital. No arrest has been made, and the family still agonizes over how someone could leave the big-hearted boy to die. "JJ would ask me for money ... but I didn’t know until his friends told me after he passed that he would buy them food if they didn’t have any," said John Gbaa Sr., JJ's father. "He loved people. He’d give out his last dollar to his friends." JJ and his father had moved to Philadelphia in 2017 to be closer to family and JJ was making huge strides in school. He loved being near his cousins and he would hang on his aunt as she cooked traditional African rice dishes. "He would say, ‘Auntie, when I graduate, I will go to college and then I will take care of you.’ But he never had the chance," Eva Gbaa said, tamping down tears. "I hope, I hope they do something to make sure no family goes through this, so it doesn’t happen again." The family has started a school in JJ's honor in their home country of Liberia, the John G. Gbaa Jr. Academy for kindergarten through eighth grade, in hopes of giving his dream of education to others. They pay the teachers and send food, clothing and books to the students with the help of small donations. Around Philadelphia, aggressive driving during the pandemic drove fatalities to 156 in 2020, a sharp increase from 90 deaths in 2019. Preliminary data from the Philadelphia Police Department showed a decrease in 2021 to 133 fatalities, still above pre-pandemic levels. The data doesn’t include the race or ethnicity of the people killed, but an Associated Press analysis showed fatalities in neighborhoods where more than 70% of residents are people of color increased from about 50% in 2019 to more than 67% in 2021. The number of accidents happening in the poorest neighborhoods also increased slightly. Sonia Szczesna, director of active transportation for the Tristate Transportation Campaign, a nonprofit transportation advocacy organization, said Black and brown communities and low-income communities are often the most impacted by high-fatality roads. "They divide these communities, and often residents have to travel these roadways by bike or by foot without access to high-quality public transportation. So there is an inequity in this infrastructure," Szczesna said. Data for the first four months of 2022 showed more pedestrians died on Philadelphia roads so far this year than people in cars. And hit-and-runs were higher in the first four months of this year than the same timeframe in the previous two years, worrying police and other city officials. But fatalities on Roosevelt stayed steady during the pandemic rather than increasing, Yemen said, largely because, she believes, of the pilot speed cameras. Byrd, who co-founded the nonprofit advocacy group Families for Safe Streets, lobbied hard for the speed cameras, writing hundreds of personal letters to legislators telling them about her niece and her kids. The cameras went live at eight intersections in June 2020, but only after state legislation, a city ordinance and negotiations with the Philadelphia Parking Authority, which manages the program. More than 224,000 warning tickets for driving more than 11 mph over the speed limit were issued in the first 30 days of a 60-day warning period, but by February 2021, that number had dropped to fewer than 17,000 tickets, according to data from the parking authority. Overall, speeding is down by more than 91% on the road, city and parking authority officials said. Despite the impact, the cameras will sunset in 2023 unless extended by the Legislature. The Federal Highway Administration gave states the green light this year to tap into federal funding to install speed cameras, saying they can reduce the number of injury crashes by 50%. Byrd’s niece Samara Banks was 21 and pregnant with her first child in 2007 when she found a four-bedroom house a few blocks south of Roosevelt Boulevard. Her family had reservations because she'd have to cross the boulevard any time she wanted to visit. But Banks' mother had just died and she needed the larger home so she could take in her four younger siblings and raise her own family. Byrd said Banks was the kind of mom and auntie who always had something planned. "At all of the family get-togethers, she would always get all the kids in a circle and have them playing games and doing dances, or she'd make up these little skits for them to do. She always had a plan and the kids always came first," Byrd said. After spending a hot July day visiting and swimming and having water balloon fights with the kids, Banks decided to walk home rather than calling a cab to take her the mile across Roosevelt, as she usually did. She was pushing her 7-month-old, Saa’mir Williams, and 23-month-old, Saa’sean Williams, in a double stroller. Her 4-year-old, Saa’deem Griffin, was holding onto the stroller and walking beside her. Witnesses told police that two cars had been racing, weaving between other cars and speeding down the boulevard. One of the drivers lost control and slammed into the family, throwing Banks more than 200 feet and crumpling the stroller. She and the three children died. Banks’ younger sister and 5-year-old son, Saa’yon Griffin, were walking ahead and survived the crash. Officials have since installed a traffic signal and pedestrian crossing at the intersection, renamed Banks Way in honor of the young mother. The two men accused of racing were eventually convicted or pleaded guilty to charges in the deaths. One of the men was a teenager when his own mother had died crossing Roosevelt Boulevard. "It was hard. I would tell Saa'yon he needed to be strong, and I remember there was this once he just stomped his foot and said no," Byrd said. "He told me he was tired of being strong and he just wanted his mom and his brothers back. We all do." ___ Advertisement Associated Press researcher Jennifer Farrar and Race & Ethnicity Team video journalist Noreen Nasir in New York and data journalist Angeliki Kastanis in Los Angeles contributed to this report.	https://www.fox29.com/news/rising-us-traffic-deaths-put-focus-philadelphia-road	2022-05-31T12:49:02	en	0.978404
This is a carousel. Use Next and Previous buttons to navigate Celebrity birthdays for the week of June 5-11: June 5: Actor-singer Bill Hayes (“Days of Our Lives,” “Your Show of Shows”) is 97. News correspondent Bill Moyers is 88. Country singer Don Reid of the Statler Brothers is 77. Guitarist Fred Stone of Sly and the Family Stone is 75. Singer-performance artist Laurie Anderson is 75. Country singer Gail Davies is 74. Financial expert Suze Orman (“The Suze Orman Show”) is 71. Drummer Nicko McBrain of Iron Maiden is 70. Jazz drummer Peter Erskine (Steps Ahead, Weather Report) is 68. Saxophonist Kenny G is 66. Singer Richard Butler of Psychedelic Furs is 66. Actor Beth Hall (“Mom,” ″Mad Men”) is 64. Actor Jeff Garlin (“The Goldbergs,” ″Curb Your Enthusiasm”) is 60. Actor Ron Livingston (“Sex and the City,” ″The Practice”) is 55. Singer Brian McKnight is 53. Musician Claus Norreen (Aqua) is 52. Actor-singer Mark Wahlberg is 51. Actor Chad Allen (“Dr. Quinn, Medicine Woman”) is 48. Bassist P-Nut of 311 is 48. Actor Navi Rawat (“Numb3rs”) is 45. Actor Liza Weil (“How To Get Away With Murder,” ″Gilmore Girls”) is 45. Bassist Pete Wentz of Fall Out Boy is 43. Guitarist Seb Lefebvre of Simple Plan is 41. Actor Chelsey Crisp (“Fresh Off The Boat”) is 39. Actor Amanda Crew (“Silicon Valley”) is 36. Musician Harrison Mills of Odesza is 33. Musician DJ Mustard is 32. Actor Sophie Lowe (“Once Upon a Time in Wonderland”) is 32. Actor Hank Greenspan (“The Neighborhood”) is 12. June 6: Singer-songwriter Gary “U.S.” Bonds is 83. Country singer Joe Stampley is 79. Jazz pianist Monty Alexander is 78. Actor Robert Englund (Freddie Krueger) is 75. Singer Dwight Twilley is 71. Playwright-actor Harvey Fierstein is 70. Actor-comedian Sandra Bernhard is 67. Actor Amanda Pays is 63. Record producer and musician Jimmy Jam (The Time) is 63. Comedian Colin Quinn is 63. Guitarist Steve Vai is 62. Singer-bassist Tom Araya of Slayer is 61. Actor Jason Isaacs (“Harry Potter” films) is 59. Bassist Sean Ysealt (White Zombie) is 56. Actor Max Casella (“Analyze This,” ″Doogie Howser, M.D.”) is 55. Actor Paul Giamatti is 55. Singer Damion Hall of Guy is 54. Guitarist James “Munky” Shaffer of Korn is 53. Country singer Lisa Brokop is 49. Singer Uncle Kracker is 48. Actor Sonya Walger (“Lost”) is 48. Actor Staci Keanan (“Step By Step,” ″My Two Dads”) is 47. Jazz singer Somi is 46. Actor Aubrey Anderson-Emmons (“Modern Family”) is 15. June 7: Actor Virginia McKenna (“Born Free”) is 91. Singer Tom Jones is 82. Talk show host Jenny Jones is 76. Actor Liam Neeson is 70. Actor Colleen Camp (“Die Hard: With A Vengeance”) is 69. Actor William Forsythe is 67. Record producer L.A. Reid is 66. Latin pop singer Juan Luis Guerra is 65. Singer-guitarist Gordon Gano of Violent Femmes is 59. Drummer Eric Kretz of Stone Temple Pilots is 56. Guitarist Dave Navarro is 55. Actor Helen Baxendale (“Friends”) is 52. Actor Karl Urban (2009′s “Star Trek”) is 50. TV personality Bear Grylls (“Man Vs. Wild”) is 48. Guitarist-keyboardist Eric Johnson of The Shins is 46. Actor Adrienne Frantz (“The Bold and the Beautiful,” “The Young and the Restless”) is 44. Comedian Bill Hader (“The Mindy Project,” ″Saturday Night Live”) is 44. Actor Anna Torv (“Fringe”) is 43. Actor Larisa Oleynik (“3rd Rock From The Sun,” ″Boy Meets World) is 41. Actor Michael Cera (“Juno,” ″Arrested Development”) is 34. Actor Shelley Buckner (“Summerland”) is 33. Rapper Iggy Azalea is 32. Model-actor Emily Ratajkowski (“Gone Girl”) is 31. Rapper Fetty Wap is 31. June 8: Actor James Darren is 86. Singer Nancy Sinatra is 82. Singer Chuck Negron (Three Dog Night) is 80. Singer Boz Scaggs is 78. Actor Sonia Braga is 72. Actor Kathy Baker (“Picket Fences”) is 72. Singer Bonnie Tyler is 71. Actor Griffin Dunne is 67. “Dilbert” cartoonist Scott Adams is 65. Actor-director Keenan Ivory Wayans is 64. Singer Mick Hucknall of Simply Red is 62. Keyboardist Nick Rhodes of Duran Duran is 60. Singer Doris Pearson of Five Star is 56. Actor Julianna Margulies (“The Good Wife,” ″ER”) is 55. Actor Dan Futterman (“Judging Amy”) is 55. Actor David Sutcliffe (“Private Practice,” “Gilmore Girls”) is 53. Actor Kent Faulcon (“Tyler Perry’s For Better or Worse”) is 52. Singer Nicci Gilbert of Brownstone is 52. Actor Kelli Williams (“The Practice”) is 52. Actor Mark Feuerstein (“West Wing,” ″Good Morning, Miami”) is 51. Guitarist Mike Scheuchzer of MercyMe is 47. Actor Eion Bailey (“Once Upon a Time”) is 46. Rapper Ye (formerly Kanye West) is 45. Singer-songwriter Sturgill Simpson is 44. Guitarist Derek Trucks (Allman Brother Band, Tedeschi Trucks Band) is 43. Singer Alex Band of The Calling is 41. Fiddler Sara Watkins of Nickel Creek is 41. Actor Torrey DeVitto (“Pretty Little Liars”) is 38 June 9: Sports commentator Dick Vitale is 83. Guitarist Mick Box of Uriah Heep is 75. Film composer James Newton Howard is 71. Actor Michael J. Fox is 61. Actor Johnny Depp is 59. Actor Gloria Reuben (“The Agency,” ″ER”) is 58. Singer-actor Tamela Mann (“Meet The Browns,” ″Medea” films) is 56. Bassist Dean Felber of Hootie and the Blowfish is 55. Bassist Dean Dinning (Toad the Wet Sprocket) is 55. Musician Ed Simons of the Chemical Brothers is 52. Actor Keesha Sharp (“Lethal Weapon”) is 49. Singer Jamie Dailey of Dailey and Vincent is 47. Actor Michaela Conlin (“Bones”) is 44. Actor Natalie Portman is 41. Actor Mae Whitman (“Parenthood,” ″Arrested Development”) is 34. Actor Lucien Laviscount (“Scream Queens”) is 30. June 10: Actor Alexandra Stewart (“Under the Cherry Moon”) is 83. Singer Shirley Alston Reeves of The Shirelles is 81. Actor Jurgen Prochnow (“The English Patient,” “Das Boot”) is 81. Actor Frankie Faison (“The Village,” “The Wire”) is 73. Actor Andrew Stevens (“Dallas”) is 67. Bassist Kim Deal of The Pixies and The Breeders is 61. Singer Maxi Priest is 61. Actor Gina Gershon is 60. Actor Jeanne Tripplehorn is 59. Drummer Jimmy Chamberlin of Smashing Pumpkins is 58. Actor Kate Flannery (“The Office”) is 58. Model-actor Elizabeth Hurley is 57. Guitarist Joey Santiago of The Pixies is 57. Actor Doug McKeon (“On Golden Pond”) is 56. Guitarist Emma Anderson (Lush) is 55. Country guitarist Brian Hofeldt of The Derailers is 55. Rapper The D.O.C. is 54. Singer Mike Doughty (Soul Coughing) is 52. Singer JoJo of K-Ci and JoJo is 51. Singer Faith Evans is 49. Actor Hugh Dancy is 47. Singer Lemisha Grinstead of 702 is 44. Actor DJ Qualls (“Memphis Beat,” ″Hustle and Flow”) is 44. Actor Shane West (“ER,” ″Now and Again”) is 44. Country singer Lee Brice is 43. Singer Hoku is 41. Actor Leelee Sobieski is 40. Bassist Bridget Kearney of Lake Street Dive is 37. Actor Titus Makin (TV’s “The Rookie”) is 33. Actor Tristin Mays (2018′s “MacGyver,” ″The Vampire Diaries”) is 32. Actor Eden McCoy (“General Hospital”) is 19. June 11: Singer Joey Dee of Joey Dee and the Starliters is 82. Actor Roscoe Orman (“Sesame Street”) is 78. Actor Adrienne Barbeau (“Maude”) is 77. Drummer Frank Beard of ZZ Top is 73. Singer Graham Russell of Air Supply is 72. Singer Donnie Van Zant of .38 Special and of Van Zant is 70. Actor Peter Bergman (“The Young and the Restless”) is 69. Actor Hugh Laurie (“House”) is 63. Talk show host Dr. Mehmet Oz (“The Dr. Oz Show”) is 62. Singer Gioia Bruno of Exposé is 59. Bassist Dan Lavery of Tonic is 56. Country singer Bruce Robison is 56. Actor Peter Dinklage (“Game of Thrones”) is 53. Bassist Smilin’ Jay McDowell (BR5-49) is 53. Actor Lenny Jacobson (“Nurse Jackie”) is 48. Bassist Tai Anderson of Third Day is 46. Actor Joshua Jackson (“Fringe,” ″Dawson’s Creek”) is 44. Actor Shia LaBeouf is 36.	https://www.chron.com/entertainment/article/Celebrity-birthdays-for-the-week-of-June-5-11-17209058.php	2022-05-31T12:49:03	en	0.869023
TORONTO, May 31, 2022 /PRNewswire/ - Sun Life Financial Inc. (TSX: SLF) (NYSE: SLF) is hosting an IFRS 17 investor education session and Q&A today, Tuesday, May 31, 2022 at 8:30 a.m. ET. Materials related to the presentation are now available online at www.sunlife.com/UpcomingEvents. To listen to the live webcast visit www.sunlife.com/UpcomingEvents 10 minutes prior to the start of the presentation. An archive will be available on the website following the event. To listen via telephone, please call 10 minutes prior to the scheduled start time as follows: Participant Dial In (Toll Free): 1-(877) 658-9101, conference ID 2486270 Participant Dial In (International): (602) 563-8756, conference ID 2486270 A replay of the conference call will be available from Tuesday, May 31, 2022 at 12 p.m. ET until 12 p.m. ET on Tuesday, June 14, 2022 by calling 404-537-3406 or 1-855-859-2056 (toll free within North America) using Conference ID: 2486270. About Sun Life Sun Life is a leading international financial services organization providing asset management, wealth, insurance and health solutions to individual and institutional Clients. Sun Life has operations in a number of markets worldwide, including Canada, the United States, the United Kingdom, Ireland, Hong Kong, the Philippines, Japan, Indonesia, India, China, Australia, Singapore, Vietnam, Malaysia and Bermuda. As of March 31, 2022, Sun Life had total assets under management of $1.35 trillion. For more information please visit www.sunlife.com. Sun Life Financial Inc. trades on the Toronto (TSX), New York (NYSE) and Philippine (PSE) stock exchanges under the ticker symbol SLF. Note to editors: All figures in Canadian dollars SOURCE Sun Life Financial Inc.	https://www.prnewswire.com/news-releases/sun-life-hosting-ifrs-17-investor-education-call-301557714.html	2022-05-31T12:49:05	en	0.858751
Uvalde grieves at funerals for 19 children, 2 teachers after Texas shooting UVALDE, Texas - It should have been the first day of a joyous week for Robb Elementary School students — the start of summer break. Instead, the first two of 19 children slain inside a classroom were being remembered at funeral visitations. The gathering for 10-year-old Amerie Jo Garza was at Hillcrest Memorial Funeral Home on Monday in Uvalde, Texas, directly across from the grade school where the children, along with two teachers, were shot to death last week before the gunman himself was killed. Visitation for another 10-year-old, Maite Rodriguez, was at the town's other funeral home. Over the next two-and-a-half traumatic weeks, people in the southwestern Texas town will say goodbye to the children and their teachers, one heart-wrenching visitation, funeral and burial after another. As family and friends unleash their grief, investigators will push for answers about how police responded to the May 24 shooting, and lawmakers have said they'll consider what can be done to stem the gun violence permeating the nation. This week alone, funerals are planned for 11 children and teacher Irma Garcia. RELATED: Justice Department to investigate police response to Uvalde school shooting On Monday, some mourners at Amerie’s visitation wore lilac or lavender shades of purple — Amerie’s favorites — at the request of her father, Angel Garza. Many carried in flowers, including purple ones. The little girl who loved to draw had just received a cellphone for her 10th birthday. One of her friends told Angel Garza that Amerie tried to use the phone to call police during the assault on her fourth-grade classroom. People arrive to pay their respects during visitation for Amerie Jo Garza at Hillcrest Memorial Funeral Home on May 30, 2022, in Uvalde, Texas. (Photo by Michael M. Santiago/Getty Images) Among the mourners at Amerie's visitation were some of Maite's relatives. Like many people, they were attending both. Maite's family wore green tie-dye shirts with an illustration showing Maite with angel wings. Before going into the funeral home, they stopped at the ditch to see the metal gate gunman Salvador Ramos crashed a pickup truck into before crossing a field and entering the school. "How did he walk for so long?" asked Juana Magaña, Maite's aunt. Hillcrest Memorial itself and the shooting will be forever linked. After Ramos wrecked the truck, two men at the funeral home heard the crash and ran toward the accident scene. Ramos shot at them. He missed and both men made it to safety. Eliahna "Ellie" Garcia’s funeral will be June 6 — the day after she was supposed to turn 10. Her family had been preparing a big birthday bash at her grandmother’s house this coming weekend. She had been hoping to receive gifts related to the Disney movie "Encanto." "She loved that movie and talked a lot about it," said her aunt, Siria Arizmendi. Ellie was quiet even around family but loved doing videos and had been already practicing with her older sister a choreography for her quinceañera party — the celebration of a girl's 15th birthday — even though it was still five years away, Arizmendi said. Ellie's older sister is doing OK, Arizmendi said, understanding their family and others face a long road to recovery. "It is just sad for all the children," she said. Funeral directors, embalmers and others from across Texas arrived to help. Jimmy Lucas, president of the Texas Funeral Directors Association, brought a hearse and volunteered to work as a driver, pitch in for services, or do whatever he could, he told NBC News. Other arriving morticians were there to help with facial reconstruction services given the damage caused by the shooter's military-style rifle. Gov. Greg Abbott, speaking at a Memorial Day event in Longview, urged Texans to keep Uvalde in their prayers. "What happened in Uvalde was a horrific act of evil," Abbott said. "And as Texans, we must come together and lift up Uvalde and support them in every way that we possibly can. It is going to take time to heal the devastation that the families there have gone through and are going through, But be assured, we will not relent until Uvalde recovers." RELATED: Meet the group teaching America’s mayors how to respond to mass shootings The U.S. Department of Justice announced Sunday a review of the law enforcement response. Police have come under heavy criticism for taking well over an hour to kill Ramos inside the adjoining classrooms where he unleashed carnage. Officials revealed Friday that students and teachers repeatedly begged 911 operators for help as a police commander told more than a dozen officers to wait in a hallway. Officials said the commander believed the suspect was barricaded inside an adjoining classroom and that there was no longer an active attack. The revelation raised new questions about whether lives were lost because officers did not act faster to stop the gunman, who was ultimately killed by Border Patrol tactical officers. Authorities have said Ramos legally purchased two guns not long before the school attack: an AR-style rifle on May 17 and a second rifle on May 20. He had just turned 18, permitting him to buy the weapons under federal law. A day after visiting Uvalde and pledging, "We will," in response to people chanting, "Do something," President Joe Biden on Monday expressed some optimism that there may be some bipartisan support to tighten restrictions on the kind of high-powered weapons used by the gunman. "I think things have gotten so bad that everybody’s getting more rational, at least that’s my hope," Biden told reporters before honoring the nation’s fallen in Memorial Day remarks at Arlington National Cemetery. "The Second Amendment was never absolute," Biden said. "You couldn’t buy a cannon when the Second Amendment was passed. You couldn’t go out and buy a lot of weapons." A bipartisan group of senators talked over the weekend to see if they could reach even a modest compromise on gun safety legislation. Encouraging state "red flag" laws to keep guns away from those with mental health issues, and addressing school security and mental health resources were on the table, said Sen. Chris Murphy, who is leading the effort. The group will meet again this week under a 10-day deadline to strike a deal. RELATED: '2nd Amendment was never absolute,' Biden says in gun reform talk ___ Advertisement Nathan Ellgren in Uvalde and Jim Salter in O’Fallon, Missouri, contributed to this report.	https://www.fox29.com/news/uvalde-texas-school-shooting-funerals-for-children-teachers	2022-05-31T12:49:08	en	0.977757
This is a carousel. Use Next and Previous buttons to navigate WASHINGTON (AP) — When President Joe Biden and first lady Jill Biden disagree, they don't hash it out in front of other people. Instead, she says, they argue by text — “fexting” as they call it. Jill Biden also told Harper's Bazaar magazine in an interview that her divorce from her first husband taught her to be independent and that she has drilled that lesson into her daughter and granddaughters. She says she could soon be sharing White House living quarters with a teenage granddaughter. When Joe Biden was vice president, the couple decided to settle disagreements by text to avoid fighting in the presence of their Secret Service agents — and dubbed it fexting. After she recently texted him in a fit of pique, he told her, "'You realize that’s going to go down in history. There will be a record of that,’” she said. Presidential communications are preserved for the historical record. She told her interviewer, “I won’t tell you what I called him that time.” The first lady appears on the cover of the publication's June-July issue, available on newsstands June 7. Harper's Bazaar said it’s the first time in its 155-year history that a U.S. first lady has been so prominently featured. Jill Biden was 18 when she married her first husband. But by her mid-20s, she was divorced, alone and on her own for the first time in her life. The breakup dealt her an emotional blow as she had idolized her parents' union and thought she'd have a marriage as long-lasting as theirs. She finished college and became a teacher. “I knew I would never, ever put myself in that position again, where I didn’t feel like I had the finances to be on my own, that I had to get the money through a divorce settlement,” she said. “I drummed that into (my daughter), Ashley, ‘Be independent, be independent.’ And my granddaughters," she said. “You have to be able to stand on your own two feet.” Jill Biden met then-Sen. Joe Biden in 1975, and they were married two years later. She kept teaching throughout his rise in national politics, eventually becoming the first first lady to hold a paying job outside the White House. She fits her responsibilities as first lady around her twice-a-week teaching schedule at Northern Virginia Community College. Granddaughter Naomi is engaged to be married and is planning a White House wedding reception in November. Another granddaughter recently told the first lady that she landed an internship in Washington and would like to move into the executive mansion for the summer. “I'm going to be raising a teenager?” Jill Biden exclaimed.	https://www.chron.com/living/article/Jill-Biden-says-she-president-settle-arguments-17209061.php	2022-05-31T12:49:09	en	0.989384
NETANIA, Israel, May 31, 2022 /PRNewswire/ -- TAT Technologies Ltd. (NASDAQ: TATT) ("TAT" or the "Company"), a leading provider of products and services to the commercial and military aerospace and ground defense industries, reported today its unaudited results for the three-month period ended March 31, 2022. Financial highlights for the first quarter of 2022: - Revenues for Q1 2022 increased by 8.1% to $19.9 million compared to $18.4 million in Q1 2021. - Gross profit for Q1 2022 was $3 million (15.2% of revenues) compared to $3.4 million in Q1 2021 (18.5% of revenues). - Adjusted EBITDA for Q1 2022 decreased to $0.5 million compared to $1.6 million in Q1 2021. - Net loss for Q1 2022 was $1.6 million compared to a net income of $0.6 million in Q1 2021. - Q1 2021 Gross Profit, EBITDA and Net Income included government rants in the amount of $1.4 million ($1 million recorded in the COGS and an additional $0.4 million recorded in G&A) Mr. Igal Zamir, TAT's CEO and President commented on the results: "As air travel begins to recoup and more and more plains resume flights, we see a growing demand for our services and products and an increase in order intake. We are working relentlessly to meet this demand despite strong headwinds resulting from supply chain issues and shortages in raw materials, which are hampering our ability to fully ramp up our production. During Q1 of 2022 we continued making significant steps in improving our manufacturing efficiencies as we successfully completed merging our 2 facilities in Israel to a single manufacturing site. We believe the cost savings expected from this unification will begin to impact us toward the second half of 2022. In addition we continue to invest in building additional MRO and production capabilities, following the strategic contacts recently signed with Honeywell and hope to have these new capabilities available by the end of this year." "Given our growing backlog, the continued recovery of commercial airline traffic and the strategic agreements we signed with Honeywell, coupled with the actions we have taken and to improve our manufacturing efficiencies, I am optimistic about our ability to continue our topline and bottom line growth." concluded Mr. Zamir Mr Zamir added: "Mr. Ron Ben-Haim has informed our Board of Directors of his retirement from his directorship position effective, May 30, 2022. I wish to thank Ron for his service on behalf of the Company, its board of directors, its management and its employees" Non-GAAP Financial Measures To supplement the consolidated financial statements presented in accordance with GAAP, the Company also presents Adjusted EBITDA. The adjustments to the Company's GAAP results are made with the intent of providing both management and investors a more complete understanding of the Company's underlying operational results, trends and performance. Adjusted EBITDA is calculated as net income excluding the impact of: the Company's share in results of affiliated companies, share-based compensation, taxes on income, financial (expenses) income, net, and depreciation and amortization. Adjusted EBITDA, however, should not be considered as alternative to net income and operating income for the period and may not be indicative of the historic operating results of the Company; nor it is meant to be predictive of potential future results. Adjusted EBITDA is not measure of financial performance under generally accepted accounting principles and may not be comparable to other similarly titled measures for other companies. See reconciliation of Adjusted EBITDA in pages 13 below. About TAT Technologies LTD TAT Technologies Ltd. is a leading provider of services and products to the commercial and military aerospace and ground defense industries. TAT operates under four segments: (i) Original equipment manufacturing ("OEM") of heat transfer solutions and aviation accessories through its Gedera facility; (ii) MRO services for heat transfer components and OEM of heat transfer solutions through its Limco subsidiary; (iii) MRO services for aviation components through its Piedmont subsidiary; and (iv) Overhaul and coating of jet engine components through its Turbochrome subsidiary. TAT controlling shareholders is the FIMI Private Equity Fund. TAT's activities in the area of OEM of heat transfer solutions and aviation accessories primarily include the design, development and manufacture of (i) broad range of heat transfer solutions, such as pre-coolers heat exchangers and oil/fuel hydraulic heat exchangers, used in mechanical and electronic systems on board commercial, military and business aircraft; (ii) environmental control and power electronics cooling systems installed on board aircraft in and ground applications; and (iii) a variety of other mechanical aircraft accessories and systems such as pumps, valves, and turbine power units. TAT's activities in the area of MRO Services for heat transfer components and OEM of heat transfer solutions primarily include the MRO of heat transfer components and to a lesser extent, the manufacturing of certain heat transfer solutions. TAT's Limco subsidiary operates an FAA-certified repair station, which provides heat transfer MRO services for airlines, air cargo carriers, maintenance service centers and the military. TAT's activities in the area of MRO services for aviation components include the MRO of APUs, landing gears and other aircraft components. TAT's Piedmont subsidiary operates an FAA-certified repair station, which provides aircraft component MRO services for airlines, air cargo carriers, maintenance service centers and the military. TAT's activities in the area of overhaul and coating of jet engine components includes the overhaul and coating of jet engine components, including turbine vanes and blades, fan blades, variable inlet guide vanes and afterburner flaps. For more information of TAT Technologies Ltd., please visit our web-site: www.tat-technologies.com Contact: Mr. Ehud Ben-Yair Chief Financial Officer Tel: 972-8-862-8503 [email protected] Safe Harbor for Forward-Looking Statements This press release contains forward-looking statements which include, without limitation, statements regarding possible or assumed future operation results. These statements are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties that could cause our results to differ materially from management's current expectations. Actual results and performance can also be influenced by other risks that we face in running our operations including, but are not limited to, general business conditions in the airline industry, changes in demand for our services and products, the timing and amount or cancellation of orders, the price and continuity of supply of component parts used in our operations, the change of control that will occur on the sale by the receiver of the Company's shares held by our previously controlling stockholders, and other risks detailed from time to time in the Company's filings with the Securities Exchange Commission, including, its annual report on form 20-F and its periodic reports on form 6-K. These documents contain and identify other important factors that could cause actual results to differ materially from those contained in our projections or forward-looking statements. Stockholders and other readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. We undertake no obligation to update publicly or revise any forward-looking statement. SOURCE TAT Technologies Ltd.	https://www.prnewswire.com/news-releases/tat-technologies-reports-first-quarter-2022-results-301557751.html	2022-05-31T12:49:11	en	0.947488
This is a carousel. Use Next and Previous buttons to navigate KATHMANDU, Nepal (AP) — Rescuers have recovered all 22 bodies from the site where a plane crashed on a mountainside in Nepal, the airline said Tuesday. All the bodies were flown to Kathmandu and taken to the Tribhuvan University Teaching Hospital where doctors are performing autopsies, Tara Air said in a statement. The bodies will be handed over to relatives once autopsy is done, it said. While 10 bodies were flown to Kathmandu on Monday, the remaining were brought by army helicopter on Tuesday. Relatives of the crash victims waited outside the hospital building for authorities to release the bodies. The Tara Air turboprop Twin Otter aircraft lost contact with the airport tower Sunday while flying on a scheduled 20-minute flight in an area of deep river gorges and mountaintops. Four Indians and two Germans were on the plane, Tara Air said. The three crew members and other passengers were Nepali nationals, it said. Local news reports said the passengers included two Nepali families, one with four members and the other with seven. The plane crashed Sunday in Sanosware in Mustang district close to the mountain town of Jomsom, where it was heading after taking off from the resort town of Pokhara, 200 kilometers (125 miles) west of the capital Kathmandu. The plane’s destination is popular with foreign hikers who trek on its mountain trails, and with Indian and Nepalese pilgrims who visit the revered Muktinath temple. The Twin Otter, a rugged plane originally built by Canadian aircraft manufacturer De Havilland, has been in service in Nepal for about 50 years, during which it has been involved in about 21 accidents, according to aviationnepal.com. The plane, with its top-mounted wing and fixed landing gear, is prized for its durability and its ability to take off and land on short runways.	https://www.chron.com/news/article/All-bodies-recovered-from-Nepal-plane-crash-17209010.php	2022-05-31T12:49:15	en	0.972392
Repurchase program will have $500 million in availability for repurchases through December 31, 2023 SCOTTSDALE, Ariz., May 31, 2022 /PRNewswire/ -- Taylor Morrison Home Corporation (NYSE: TMHC) today announced that its Board of Directors authorized an increase in the amount available for repurchases of its common stock to $500 million from $250 million previously. Repurchases of the Company's common stock under the program may occur from time to time in open market purchases, privately negotiated transactions or other transactions through December 31, 2023. "The increase in our share repurchase authorization provides us with enhanced flexibility to create value for our shareholders and reinforces the meaningful opportunity we see in our equity," said Chairman and Chief Executive Officer Sheryl Palmer. "Enabled by our strong cash flow generation and solid balance sheet, our disciplined capital allocation philosophy prioritizes investing in our business for future growth, managing our leverage position and opportunistically returning excess capital to shareholders." Future repurchases under the stock repurchase program are subject to prevailing market conditions and other considerations, including the Company's liquidity, the terms of its debt instruments, planned land investment and development spending, acquisition and other investment opportunities and ongoing capital requirements. About Taylor Morrison Headquartered in Scottsdale, Arizona, Taylor Morrison is one of the nation's leading homebuilders and developers. We serve a wide array of consumers from coast to coast, including first-time, move-up, luxury, and 55-plus active lifestyle homebuyers under our family of brands—including Taylor Morrison, Esplanade, Darling Homes Collection by Taylor Morrison, and Christopher Todd Communities built by Taylor Morrison. From 2016-2022, Taylor Morrison has been recognized as America's Most Trusted® Builder by Lifestory Research. Our strong commitment to sustainability, our communities, and our team is highlighted in our latest Environmental, Social, and Governance (ESG) Report on our website. For more information about Taylor Morrison, please visit www.taylormorrison.com. CONTACT: Investor Relations Taylor Morrison Home Corporation (480) 734-2060 [email protected] SOURCE Taylor Morrison	https://www.prnewswire.com/news-releases/taylor-morrison-increases-stock-repurchase-authorization-301557439.html	2022-05-31T12:49:17	en	0.928718
Global efforts are detailed in TE's annual corporate responsibility report SCHAFFHAUSEN, Switzerland, May 31, 2022 /PRNewswire/ -- TE Connectivity, a world leader in connectors and sensors, has continued to make progress toward environmental, social and governance goals. Its efforts are detailed in TE's annual corporate responsibility report, Connecting Our World, published today. Working toward the 2030 One Connected World goals, TE this past year successfully reduced absolute greenhouse gas emissions by 30% and procured 37% of its electricity from zero-emissions sources, including renewable energy. The company also adopted two new sustainability targets for 2025. By then, TE aims to reduce its hazardous waste by 15%. It will also work to reduce water usage at 30 targeted sites in water-stressed areas by 15%. Additionally, TE has increased diversity, with 67% of its board of directors identifying as diverse and a growing number of women in leadership positions. Charitable efforts by TE and the TE Foundation have succeeded in reaching more than 1.5 million people in science, technology, engineering and math (STEM) education in the last two years, already more than halfway toward the 2030 goal of 3 million. The company also launched its first enterprise global human rights policy. "Despite the challenges of the last two years, we have not lost sight of leveraging our purpose and values to become a more sustainable company, in the products we make and in our value chain," said CEO Terrence Curtin. "I am proud of the efforts of our global employees in helping us to work toward our goals." To view the full FY2021 corporate responsibility report, visit TE.com/responsibility. TE Connectivity (NYSE:TEL) is a global industrial technology leader creating a safer, sustainable, productive and connected future. Our broad range of connectivity and sensor solutions, proven in the harshest environments, enable advancements in transportation, industrial applications, medical technology, energy, data communications and the home. With more than 85,000 employees, including over 8,000 engineers, working alongside customers in approximately 140 countries, TE ensures that EVERY CONNECTION COUNTS. Learn more at www.te.com and on LinkedIn, Facebook, WeChat and Twitter. SOURCE TE Connectivity Ltd.	https://www.prnewswire.com/news-releases/te-connectivity-charges-toward-2030-sustainability-goals-301556741.html	2022-05-31T12:49:23	en	0.954568
BERLIN (AP) — Authorities in Germany raided the offices of Deutsche Bank and its subsidiary DWS on Tuesday following claims that it was exaggerating the sustainable credentials of some of the products it sold. German news agency dpa quoted Frankfurt prosecutors saying the probe focused on allegations of investment fraud, but no specific suspects had been identified yet. A former manager in charge of sustainability at DWS has claimed that the asset management firm exaggerated the environmental and climate credentials of certain funds — referred to as “greenwashing.” “The measures of the Public Prosecutors are directed against unknown people in connection with greenwashing allegations against DWS,” Deutsche Bank said in a statement. “DWS said that they have continuously cooperated fully with all relevant regulators and authorities on this matter and will continue to do so.”	https://www.chron.com/news/article/Deutsche-Bank-subsidiary-raided-over-17209034.php	2022-05-31T12:49:27	en	0.980292
THE WOODLANDS, Texas, May 31, 2022 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE:TTI) announced that its senior management will be presenting at the Louisiana Energy Conference ("LEC 2022"). The conference is being held at the Ritz-Carlton in New Orleans, Louisiana on June 1-3, 2022. Tim Moeller, Senior Vice President of Chemicals and Supply Chain, and Jacek Mucha, Vice President of Finance for TETRA's Energy Services Group and Corporate Treasurer, will be participating on a panel titled "U.S. Onshore Oil Field Services - How are Companies Reacting to Increased Demand for Services" on June 3, 2022 and hosting one-on-one meetings on June 2-3, 2022. Interested parties who would like to listen to the panel discussion or participate in a one-on-one with TETRA's management, please register on the following link (https://louisianaenergyconference.com/). LEC 2022 is an in-person Energy Conference in New Orleans directed to investment professionals including buy-side and sell-side analysts and portfolio managers, private equity and wealth management executives and trust officers, as well as energy industry participants. LEC 2022 will feature a series of approximately 21 presentations, panels and discussions that will address key domestic and international oil, natural gas, renewables and clean energy developments and topics. Confirmed investment professional attendees will also be given the opportunity to participate in one-on-one sessions during the conference. TETRA Technologies, Inc. is an industrial and oil & gas products and services company operating on six continents focused on bromine-based completion fluids, calcium chloride, water management solutions, frac flowback and production well testing services. Calcium chloride is used in the oil and gas, industrial, agricultural, road, food and beverage markets. TETRA is evolving its business model by expanding into the low carbon energy markets with its chemistry expertise, key mineral acreage and global infrastructure. Recently announced initiatives include commercialization of TETRA PureFlow® an ultra-pure zinc bromide for stationary batteries and energy storage; advancing an innovative carbon capture utilization and storage technology with CarbonFree to capture CO2 and mineralize emissions to make commercial, carbon-negative chemicals; and development of TETRA's lithium and bromine mineral acreage to meet the growing demand for oil and gas products and energy storage. Visit the Company's website at www.tetratec.com. SOURCE TETRA Technologies, Inc.	https://www.prnewswire.com/news-releases/tetra-technologies-inc-to-participate-in-the-louisiana-energy-conference-301557036.html	2022-05-31T12:49:29	en	0.934889
DUBAI, United Arab Emirates (AP) — Iran disrupted internet access to the outside world as angry demonstrators rallied over the collapse of a tower in southwestern Iran that has killed at least 34 people, experts said Tuesday as outrage and grief continued to grow in the country. The disruption has plunged the southwestern province into digital isolation, making it difficult for journalists to authenticate events on the ground and for activists to share footage and organize protests. It's a tactic the Iranian government has repeatedly employed during times of unrest, rights activists say, in a country where radio and television stations already are state-controlled and journalists face the threat of arrest. The internet interference in the oil-rich Khuzestan province started in early May, weeks before the fatal collapse, said Amir Rashidi, a researcher at Miaan Group, which focuses on digital security in the Middle East. The province, home to an ethnic Arab population that long has alleged discrimination, was a flashpoint in protests over the sinking economy and skyrocketing prices of food staples. Disruptions then intensified in the area after the Metropol Building collapse last week, according to data shared by the Miaan Group. The disaster ignited widespread anger in Abadan, where residents alleging government negligence gathered nightly at the site of the collapse to shout slogans against the Islamic Republic. Videos of the protests have circulated widely online, with some showing officers clubbing and firing tear gas at demonstrators. The footage analyzed by The Associated Press corresponded to known features of Abadan, some 660 kilometers (410 miles) southwest of the capital, Tehran. The number of casualties and arrests remains unclear. In response to the protests, Iranian authorities at times completely shut down the internet and other times allowed only tightly controlled use of a domestic Intranet, reported the Miaan Group. During the day, authorities also appear to have restricted bandwidths to make it very difficult for people to share large files, such as video, without leaving Abadan altogether, said Mahsa Alimardani, a senior researcher at Article 19, an international organization that fights censorship. Last Friday, as massive crowds took to the streets to chant against top officials, a digital barricade of sorts went up between Iran and the world, data showed. Only certain government-approved national websites could stream content but not websites based abroad. “There has been a pattern that we’ve seen when it gets dark where Google isn’t working but the website of the Supreme Leader is working well,” Rashidi said. The Iranian mission at the United Nations did not immediately respond to request for comment. Meanwhile, rescue workers pulled another body from the rubble on Tuesday, bringing the death toll to 34 amid fears more people could be trapped in the ruins. Five of the victims were school-age children, the official IRNA news agency reported. Another 37 people were injured in the collapse, with two still hospitalized. Officials have blamed the building’s structural failure on shoddy construction practices, lax regulation and entrenched corruption, raising questions about the safety of similar towers in the earthquake-prone country. Authorities reported they evacuated residents from buildings near the disaster site, fearing structural damages. The rising political and economic pressures come as talks to restore Tehran's tattered nuclear deal with world powers have hit a deadlock. Hostilities have simmered as Iran accelerates its nuclear program far beyond the limits of the nuclear deal and last week seized two Greek tankers on a key oil route through the Persian Gulf. In a sign of those rising tensions, Iran's Foreign Ministry sharply criticized the International Atomic Energy Agency on Tuesday over its quarterly report released the day before on Iran's nuclear program. Foreign Ministry spokesman Saeed Khatibzadeh rebuked the report's findings that Iran's highly enriched uranium stockpile had increased by 18 times since the 2015 nuclear deal as “not fair and balanced.” The U.N. nuclear watchdog also said that Iran has still failed to explain traces of uranium particles that IAEA inspectors found at former undeclared sites in the country — long a sore point between Iran and the agency despite a recent push for a resolution by June. Khatibzadeh said the agency's statements “did not reflect the reality of talks between Iran and the agency." “The agency should be watchful and not to destroy the path we walked down, with difficulty," he told reporters in Tehran.	https://www.chron.com/news/article/Experts-Iran-disrupts-internet-tower-collapse-17209048.php	2022-05-31T12:49:33	en	0.961937
DUBLIN, May 31, 2022 /PRNewswire/ -- The "Austria Loyalty Programs Market Intelligence and Future Growth Dynamics Databook - 50+ KPIs on Loyalty Programs Trends by End-Use Sectors, Operational KPIs, Retail Product Dynamics, and Consumer Demographics - Q1 2022 Update" report has been added to ResearchAndMarkets.com's offering. Loyalty Programs market in Austria has recorded strong growth over the last four quarters, supported by brands and retailers focusing on the customer retention. According to the Q1 2022 Global Loyalty Programs Survey, Loyalty Programs Market in Austria is expected to grow by 11.6% on annual basis to reach US$ 575.3 million in 2022. In value terms, the Loyalty Programs Market in Austria has recorded a CAGR of 12.1% during 2017-2021. The Loyalty Programs Market in Austria will continue to grow over the forecast period and is expected to record a CAGR of 11.1% during 2022-2026. Loyalty Programs Market in the country will increase from US$ 515.6 million in 2021 to reach US$ 876.7 million by 2026. Reasons to buy - In-depth Understanding of Loyalty Programs Market Dynamics: Understand market opportunities and key trends along with forecast (2017-2026). - Insights into Opportunity by end-use sectors - Get market dynamics by end-use sectors to assess emerging opportunity across various end-use sectors. - Develop Market Specific Strategies: Identify growth segments and target specific opportunities to formulate loyalty strategy; assess market specific key trends, drivers, and risks in the industry. Key Topics Covered: 1 About this Report 2 Austria Loyalty Spend Market Size and Future Growth Dynamics by Key Performance Indicators, 2017-2026 3 Austria Loyalty Spend Market Size and Future Growth Dynamics by Functional Domains, 2017-2026 3.1 Austria Loyalty Spend Share by Functional Domains, 2017-2026 3.2 Austria Loyalty Spend Value by Loyalty Schemes, 2017-2026 3.3 Austria Loyalty Spend Value by Loyalty Platforms, 2017-2026 4 Austria Loyalty Spend Market Size and Future Growth Dynamics by Loyalty Program Type, 2017-2026 4.1 Austria Loyalty Spend Share by Loyalty Program Type, 2021 Vs 2026 4.2 Austria Loyalty Spend Value by Point-based Loyalty Program, 2017-2026 4.3 Austria Loyalty Spend Value by Tiered Loyalty Program, 2017-2026 4.4 Austria Loyalty Spend Value by Subscription Loyalty Program, 2017-2026 4.5 Austria Loyalty Spend Value by Perks Loyalty Program, 2017-2026 4.6 Austria Loyalty Spend Value by Coalition Loyalty Program, 2017-2026 4.7 Austria Loyalty Spend Value by Hybrid Loyalty Program, 2017-2026 5 Austria Loyalty Spend Market Size and Future Growth Dynamics by Channel, 2017-2026 5.1 Austria Loyalty Spend Share by Channel, 2017-2026 5.2 Austria Loyalty Spend Value by In-Store, 2017-2026 5.3 Austria Loyalty Spend Value by Online, 2017-2026 5.4 Austria Loyalty Spend Value by Mobile, 2017-2026 6 Austria Loyalty Spend Market Size and Future Growth Dynamics by Key Sectors, 2017-2026 6.1 Austria Loyalty Spend Share by Key Sectors, 2021 Vs 2026 6.2 Austria Loyalty Spend Value in Retail, 2017-2026 6.3 Austria Loyalty Spend Value in Financial Services, 2017-2026 6.4 Austria Loyalty Spend Value in Healthcare & Wellness, 2017-2026 6.5 Austria Loyalty Spend Value in Restaurants & Food Delivery, 2017-2026 6.6 Austria Loyalty Spend Value in Travel & Hospitality (Cabs, Hotels, Airlines), 2017-2026 6.7 Austria Loyalty Spend Value in Telecoms, 2017-2026 6.8 Austria Loyalty Spend Value in Media & Entertainment, 2017-2026 6.9 Austria Loyalty Spend Value in Others, 2017-2026 7 Austria Loyalty Spend Market Size and Future Growth Dynamics by Retail, 2017-2026 7.1 Austria Loyalty Spend Share by Retail Segments, 2021 Vs 2026 7.2 Austria Loyalty Spend Value by Diversified Retailers, 2017-2026 7.3 Austria Loyalty Spend Value by Department Stores, 2017-2026 7.4 Austria Loyalty Spend Value by Specialty Stores, 2017-2026 7.5 Austria Loyalty Spend Value by Clothing, Footwear & Accessories, 2017-2026 7.6 Austria Loyalty Spend Value by Toy & Hobby Shops, 2017-2026 7.7 Austria Loyalty Spend Value by Supermarket and Convenience Store, 2017-2026 7.8 Austria Loyalty Spend Value by Home Merchandise, 2017-2026 7.9 Austria Loyalty Spend Value by Other, 2017-2026 8 Austria Loyalty Spend Market Size and Future Growth Dynamics by Accessibility, 2017-2026 8.1 Austria Loyalty Spend Share by Accessibility, 2021 Vs 2026 8.2 Austria Loyalty Spend Value by Card Based Access, 2017-2026 8.3 Austria Loyalty Spend Value by Digital Access, 2017-2026 9 Austria Loyalty Spend Market Size and Future Growth Dynamics by Consumer Type, 2017-2026 9.1 Austria Loyalty Spend Share by Consumer Type, 2021 Vs 2026 9.2 Austria Loyalty Spend Value by B2C Consumers, 2017-2026 9.3 Austria Loyalty Spend Value by B2B Consumers, 2017-2026 10 Austria Loyalty Spend Market Size and Future Growth Dynamics by Loyalty Platforms, 2017-2026 10.1 Austria Loyalty Spend Share by Loyalty Platform, 2021 Vs 2026 10.2 Austria Loyalty Spend Value by Software, 2017-2026 10.3 Austria Loyalty Spend Value by Services, 2017-2026 11 Austria Loyalty Spend Market Size and Future Growth Dynamics by Software Platforms, 2017-2026 11.1 Austria Loyalty Spend Share by Software Platforms, 2021 Vs 2026 11.2 Austria Loyalty Spend Value by Custom Built Platform, 2017-2026 11.3 Austria Loyalty Spend Value by Off the Shelf Platform, 2017-2026 12 Austria Loyalty Spend Market Size and Forecast by Consumer Demographics & Behavior, 2021 12.1 Austria Loyalty Spend Share by Age Group, 2021 12.2 Austria Loyalty Spend Share by Income Level, 2021 12.3 Austria Loyalty Spend Share by Gender, 2021 13 Further Reading For more information about this report visit https://www.researchandmarkets.com/r/26sody Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets	https://www.prnewswire.com/news-releases/the-austria-loyalty-programs-industry-is-expected-to-reach-876-7-million-by-2026--301557704.html	2022-05-31T12:49:35	en	0.757529
You need to enable JavaScript to run this app.	https://sportspyder.com/nba/boston-celtics/articles/39657964	2022-05-31T12:49:36	en	0.738227
BERLIN (AP) — Police raided homes and offices in northern and western Germany on Tuesday as part of an investigation into a case involving five men accused of fraudulently applying for 26 million ($28 million) worth of pandemic-linked aid. The German government drew up a series of aid packages to help businesses withstand the impact of lockdowns and other restrictions at the height of the coronavirus pandemic. The suspects in this investigation — men aged 26 to 62 — are suspected of making at least 363 aid applications under false pretenses “for their own purposes and for companies that commissioned them,” according to a police statement. It's believed to have resulted in a loss of several million euros, it added. The investigation was launched in April 2020 after a development bank in the northern state of Lower Saxony reported suspicious activity. Twenty-five properties were raided on Tuesday, including the five suspects' homes, but police said there were no arrests. They froze assets totaling 3.5 million euros, seizing cash and expensive watches. In a separate case, a 20-year-old man was on Monday convicted of fraud in the southwestern city of Freiburg for taking 5.7 million euros from a doctors' association last year for a test center he never opened, German news agenc dpa reported. A bank later returned the money. The court will decide after a year's probation whether to impose a sentence under juvenile law. He was ordered to pay 1,500 euros to charity and cover the costs of the proceedings, dpa reported. ___ Follow all of AP’s pandemic coverage at https://apnews.com/hub/coronavirus-pandemic	https://www.chron.com/news/article/German-police-mount-raids-in-COVID-19-aid-fraud-17209025.php	2022-05-31T12:49:40	en	0.968141
Covid-19 testing at point of care peaked in Q1 2022. Is testing waning? What is COVID-19's lasting effect on point-of-care testing? BOSTON, May 31, 2022 /PRNewswire/ -- COVID-19 cases peaked in Europe and North America over January 2022 yet revenue from point-of-care testing did not all peak across the board. Some market leaders continued to see rapid growth in Q1 sales from this wintertime peak, and companies that launched their first diagnostic platform via COVID-19 testing continued to grow their platform install bases. Yet others began to feel the decline throughout Q1, indicating a waning pandemic. As COVID-19 cases fall from their wintertime peak, companies are moving to prepare for the following clinical need for flu/COVID-19 multiplexed testing before the onset of the next flu season. In the report "Biosensors for Point-of-Care Diagnostics 2022-2032: Technology, Opportunities, Players and Forecasts", IDTechEx investigates how the point-of-care market has been shaped by COVID-19. IDTechEx explores the emerging technologies that are enabling point-of-care, and what applications will drive the market beyond COVID-19. Peak quarter for POC COVID-19 tests COVID-19 has been a colossal injection of sales revenue for the point-of-care industry over the last two years, with a massive expansion of the lateral flow assay market and integrated cartridges market. In the winter of 2021/2022, COVID-19 grew to its all-time global high number of cases, peaking at over 23 million per week in January 2022. This was driven by rising cases mostly in Europe and North America. Due to this climb in cases, many players reported continued rapid growth of testing revenues for Q1 of 2022. In its first quarter, market leaders announced sales between 150 and 182% over the same quarter in the previous year, exceeding their projections. The most significant sale of the quarter was a $1 billion contract awarded to Abbott Laboratories by the US Army for rapid antigen COVID-19 tests. Continued success for newly launched technologies During this pandemic, several startups have been able to launch their first platform and products by pivoting their technologies toward COVID-19 testing. These companies have been able to use the opportunity to establish footholds on the market, buoyed by government grants to develop capacity as well as faster regulatory pathways via the Emergency Use Authorization (EUA). Further, new sources of sales have emerged from large corporations transitioning from remote working back towards conventional office work, using testing to safeguard employees. Airports, events, and venues too have been new sources of revenue for test manufacturers. As such, in 2020 and 2021, these startups have been able to grow their total earnings and business operations rapidly. In the first quarter of 2022, these companies have continued to see the same success. For their technologies, COVID-19 is demonstrating the effectiveness and value of new point-of-care technologies, such as miniaturized PCRs and other point-of-care nucleic acid amplification techniques. The rapid growth of install bases will help these companies establish repeated sales beyond COVID-19 and is a launchpad from which test menus can expand to other infectious diseases. COVID-19 testing: A cooling market? Yet, the pandemic has been declining globally throughout 2022 since the January peak. The total testing in the US in May is a tenth of the peak in January. In the UK, it is a sixth. Consequently, companies are expecting this source of revenue to drop rapidly. Abbott Laboratories, for instance, projects total revenue from COVID-19 related sales this year to be 58% of the total revenue the year before. For Becton, Dickinson, and Company (BD), this shrinking of testing has already begun; in their first quarter, BD reported a decline in revenue from COVID-19-only testing. A large enabling factor for the success of COVID-19 diagnostics revenue has been the emergency use authorization (EUA) regulation adopted by the FDA (the USA food and drugs administration). This has allowed device manufacturers access to the market with EUA approval rather than the full and far more stringent full 510k authorization. However, as the US moves out of a public health emergency, the FDA will remove the EUA. When this period arrives, companies will need to further invest in submitting premarket applications for conventional regulatory authorization. The FDA has published drafts of the transitionary plan for this period, although this is yet to be finalized. "COVID-19 plus" market approaching As the pandemic wanes and the next flu season approaches, there is an emerging need for "COVID-19 plus" tests. COVID-19 and other respiratory viruses, particularly influenza, share clinical symptoms. The exception is the loss of taste for SARS-CoV-2 infections, but this symptom is only present in 17% of positive cases with the omicron variant. Therefore, there is a clinical need for a multiplex test to precisely diagnose the infectious disease which cannot be identified on symptoms alone. Both Roche and BD have already launched their SARS-CoV-2 & Flu A/B lateral flow antigen assays, and indeed BD reported that their base diagnostics business in the first quarter was driven by demand for this flu/COVID-19 test. Like many other players that launched new platforms, Cue Health are now advancing to development of a flu/COVID-19 test on theirs. The company announced that they began clinical trials in Q1. COVID-19 continues to be a critical driver in 2022 and beyond but is not the only driver affecting the shift towards point-of-care for the diagnostics industry. Point-of-care solves pain points for other infectious diseases as well as chronic diseases like diabetes and cardiovascular diseases; these pain points will worsen with population growth and aging. Consequently, IDTechEx expects the point-of-care industry to grow over the next ten years, with a forecast of $29.5 billion by 2032. The IDTechEx report "Biosensors for Point-of-Care Diagnostics 2022-2032: Technology, Opportunities, Players and Forecasts" explores in detail other key drivers and applications for point-of-care technology and examines the emerging technologies that are enabling the shift to point-of-care. About IDTechEx IDTechEx guides your strategic business decisions through its Research, Subscription and Consultancy products, helping you profit from emerging technologies. For more information, contact [email protected] or visit www.IDTechEx.com. Media Contact: Natalie Moreton Digital Marketing Manager [email protected] +44(0)1223 812300 Social Media Links: Twitter: https://www.twitter.com/IDTechEx LinkedIn: https://www.linkedin.com/company/idtechex/ Facebook: https://www.facebook.com/IDTechExResearch SOURCE IDTechEx	https://www.prnewswire.com/news-releases/the-waning-covid-19-pandemics-lasting-effect-on-point-of-care-discussed-by-idtechex-301557718.html	2022-05-31T12:49:41	en	0.9508
You need to enable JavaScript to run this app.	https://sportspyder.com/nba/boston-celtics/articles/39657989	2022-05-31T12:49:42	en	0.738227
This is a carousel. Use Next and Previous buttons to navigate BUDAPEST, Hungary (AP) — Hungary's divisive leader has once again got his own way with the European Union — this time in tough negotiations on Russian oil at a summit in Brussels. And nationalist Prime Minister Viktor Orban wasn't shy about trumpeting his success in leveraging the bloc to win significant concessions, allowing his country to continue purchasing Russian crude even as war rages on in neighboring Ukraine. The European Commission’s "proposal to ban the use of Russian oil in Hungary was defeated,” Orban said in a video statement on Facebook. “Families can sleep well tonight as the most outrageous idea has been averted.” EU leaders concluded four weeks of negotiations on Monday to impose a partial embargo on Russian oil imports. The package of sanctions, the sixth imposed by the EU since the start of the war in February, had been delayed by vigorous opposition from Orban — widely seen as the Kremlin’s closest EU ally — who threatened to derail the block’s efforts to punish Moscow for its war if they affected energy imports to Hungary. While the agreement bans all Russian oil from being brought into the EU by sea, it allowed a temporary exemption for imports delivered by the Russian Druzhba pipeline to certain landlocked countries in Central Europe — something Orban touted as a victory for Hungarian interests over what he portrayed as potentially disastrous recommendations by the EU. EU officials say the agreement will succeed in cutting off 90% of Russian oil imports by year's end. But it was the latest instance of Orban breaking ranks with his European partners, dividing the bloc’s united response to crises and ensuring that Russian President Vladimir Putin still has an economic foothold in the EU. Hungary — which gets around 65% of its oil and 85% of its gas from Russia — was alone among Ukraine's EU neighbors to refuse to supply it with military aid. It also banned the shipment of lethal weapons into Ukraine across its borders, a policy that drew the ire of many EU leaders and of Ukrainian President Volodymyr Zelenskyy. Orban has also blocked other EU decisions which require unanimity among member states, including attempts last year to issue a joint statement on China's crackdown on a pro-democracy movement in Hong Kong and a joint call for a cease-fire in the Israeli-Palestinian conflict — also in 2021 . In 2020, Hungary joined its ally Poland in vetoing the EU's seven-year budget and a massive coronavirus recovery plan, stymying efforts to jumpstart European economies during the COVID-19 pandemic and plunging the 27-nation bloc into a political crisis. Yet despite Hungary's refusal to adopt the oil embargo as proposed, EU leaders hailed Monday's agreement as a success. European Council President Charles Michel tweeted that it covers more than two-thirds of EU oil imports from Russia, “cutting a huge source of financing for its war machine.” Along with Hungary, both the Czech Republic and Slovakia sought exemptions from the EU embargo, arguing their dependence on Russian oil made an immediate cutoff unrealistic. Slovakia gets around 97% of its oil from Russia through the Druzhba pipeline, and has argued that the country’s key refiner, Slovnaft, needs to be reoutfitted to be able to process any oil type other than Russian crude, a process that could take several years. But Orban's opponents see the pipeline concession as another instance of the autocratic leader dividing the EU to serve his own purposes. In a tweet on Tuesday, Hungarian member of the European Parliament Katalin Cseh said that Orban had “navigated Hungary into a desperate dependency on Russian energy.” “He then declares ‘victory’ over the EU, whose solidarity and protection is our only chance,” Cseh wrote. At home, Orban has depicted the debate over the oil embargo as a fight to defend Hungarians' pocketbooks, especially as it concerns household utility costs which have been subsidized by the government since 2013 as a flagship policy of Orban's government. “The most important news is that we defended the utility cost reduction,” Orban said following the end of the EU summit on Tuesday. ___ Karel Janicek contributed to this report from Prague. ___ Follow the AP’s coverage of the war at https://apnews.com/hub/russia-ukraine	https://www.chron.com/news/article/Hungary-s-Orban-wins-exemption-in-EU-Russian-oil-17209039.php	2022-05-31T12:49:46	en	0.9719
You need to enable JavaScript to run this app.	https://sportspyder.com/nba/boston-celtics/articles/39658124	2022-05-31T12:49:48	en	0.738227
BERLIN (AP) — A court in Germany on Tuesday convicted five men for membership in a local cell of the Islamic State group that received orders from a leading IS figure in Afghanistan. The Duesseldorf regional court sentenced the Tajik nationals, aged 25 to 34, to lengthy prison terms. The longest sentence of nine years and six months was handed to Sunatullokh K., whose surname wasn’t released due to German privacy rules. He was also convicted of planning to kill a man who had made critical comments about Islam. The attack was foiled by authorities. The other men, identified as Muhammadali G., Azizjon B., Farhodshoh K. and Komron B., received prison sentences of between 44 months and 8.5 years for membership to a terrorist organization, with some also convicted of involvement in plans to carry out a contract killing in Albania that was later abandoned. Another man, Ravsan B., was convicted by the same court last year of membership in IS for co-founding the German cell and supporting two planned attacks. He was sentenced to seven years in prison. Prosecutors said the men honed their military skills in paintball games, and that participants in those included “other people from the Islamist scene” who were in contact with the gunman who killed four people in an attack in Vienna in November 2020. They also allegedly acquired components for an “unconventional” bomb. Federal prosecutors had sought prison terms of between four and 12 years for the men. Their lawyers had asked the court to acquit them.	https://www.chron.com/news/article/Islamic-extremists-convicted-of-membership-in-17209083.php	2022-05-31T12:49:52	en	0.987397
You need to enable JavaScript to run this app.	https://sportspyder.com/nba/boston-celtics/articles/39658130	2022-05-31T12:49:54	en	0.738227
BENTON HARBOR, Mich. (AP) — A 19-year-old man has been killed and six other people were wounded during a shooting at a club and liquor store in southwestern Michigan's Benton Harbor. Benton Harbor public safety officers responding to reports of multiple gunshots saw a large number of people in the area about 2:30 a.m. Monday, the police department said in a release. Marlon Bowman was shot multiple times in his chest and died, police said. The wounded were treated at an area hospital. Officers found multiple shell casings of various calibers, but none of the people at the scene of the shooting have come forward to give statements to police, the department said. A $2,000 reward was being offered for information that leads to the identification and arrest of anyone involved in the shooting, police said.	https://www.chron.com/news/article/Man-slain-6-people-wounded-during-shooting-in-17209068.php	2022-05-31T12:49:58	en	0.989246
Kenyan nutritionist is recognised for her work as founder and director of Food for Education - Wawira Njiru, founder of Kenya's Food for Education, is named as the recipient of the Icon Award 2022 by The World's 50 Best Restaurants - Her non-profit organisation provides nutritious meals to children in schools across the country and has delivered over 7 million meals to date - Njiru was awarded the title of UN Person of the Year 2021 in Kenya and was also the very first recipient of the Global Citizen Prize: Cisco Youth Leadership Award in 2018 LONDON, May 31, 2022 /PRNewswire/ -- In the latest pre-announced award from The World's 50 Best Restaurants 2022, it is announced today that the recipient of the Icon Award 2022 is Kenyan nutritionist Wawira Njiru, founder and director of non-profit Food for Education. The Icon Award celebrates an individual who has made an outstanding contribution to the food world worthy of international recognition and who has used their platform to raise awareness and drive positive change. With an estimated 80% of children in Kenya not receiving a school meal, Njiru believes no child should have to learn on an empty stomach. After majoring in food science at university in Australia, she founded Food for Education in 2016, at first making 25 meals a day. The organisation now feeds 40,000 children daily, providing nutritious meals to those in schools across Kenya, helping to boost attendance at primary level and combat hunger. It has delivered over seven million meals to date, leading to improved nutrition, academic performance and higher high school transition rates. By sourcing fresh food directly from farmers, Food for Education has also been able to help stimulate the local economy. Meals are prepared in a central kitchen to internationally recognised food safety standards, while the subsidised meals are delivered to students using cutting-edge technology to design a sustainable means of delivering high quality, wholesome food. During the pandemic, the organisation also provided food packages and cash transfers that delivered over 2,000,000 meals to children and their families at home due to COVID-19. Food for Education utilises Tap2Eat, a digital mobile platform whereby parents can pay for the subsidised lunches with mobile money. The amount is then credited to a virtual wallet linked to an NFC smart wristband, which students can wear and use accordingly, meaning no cash transfers and no lost money. Njiru hopes to expand the programme across more of Kenya and potentially beyond and provide meals to 1 million children over the next five years. William Drew, Director of Content for The World's 50 Best Restaurants, says: "The Icon Award recognises true trailblazers in the food sphere and we're honoured that this year we can present it to Wawira Njiru for her exceptional work. The achievements of Food for Education in just six short years have been astonishing and we know that Wawira and her organisation will go on to do incredible things in the future, across Kenya and beyond." Njiru comments on the award: "I am honoured and excited to be this year's recipient of the Icon Award for The World's 50 Best Restaurants. Hungry children cannot learn or grow and across the world, school meals are critical to children's growth and education. This has been especially exacerbated by the Covid-19 pandemic with school meals essential to recovery and rebuilding. I would like to acknowledge the entire Food for Education team that I work with and with whom I share this award, as they work tirelessly every day to provide these lunch meals. Every day we are working to ensure that more and more school-going children have access to nutritious meals and I am grateful for this award that recognises the critical work we are doing to end classroom hunger." Additional special pre-announced awards will be revealed between now and July, as part of the lead-up to The World's 50 Best Restaurants 2022 awards, sponsored by S.Pellegrino & Acqua Panna. An extensive event programme will culminate in this year's awards ceremony, to be held at Old Billingsgate market in the City of London on Monday 18th July. For media centre registration access, please visit: https://mediacentre.theworlds50best.com/ Follow 50 Best - Follow on Instagram: @TheWorlds50Best #Worlds50Best - Follow on Twitter: @TheWorlds50Best - Like on Facebook: https://www.facebook.com/50BestRestaurants - Subscribe to the YouTube channel: 50 Best Restaurants TV - Visit the website: https://www.theworlds50best.com/ About The World's 50 Best Restaurants Since 2002, The World's 50 Best Restaurants has reflected the diversity of the world's culinary landscape. The annual list of the world's most prestigious restaurants provides a snapshot of some of the best destinations for unique culinary experiences, in addition to being a barometer for and a pioneer of global gastronomic trends. The 50 Best family also includes Latin America's 50 Best Restaurants, Asia's 50 Best Restaurants, Middle East & North Africa's 50 Best Restaurants, The World's 50 Best Bars, Asia's 50 Best Bars, North America's 50 Best Bars and the #50BestTalks and 50 Best Explores series, all of which are owned and run by William Reed. 50 Best aims to bring together communities across the hospitality sector to foster collaboration, inclusivity, diversity and discovery and help drive positive change. About the main sponsor: S.Pellegrino & Acqua Panna S.Pellegrino and Acqua Panna are the main partners of The World's 50 Best Restaurants and 50 Best for Recovery. S.Pellegrino and Acqua Panna are the leading natural mineral waters in the fine dining world. Together they interpret Italian style worldwide as a synthesis of excellence, pleasure and well-being. Other Partners: - Estrella Damm – Official Beer Partner; sponsor of the Estrella Damm Chefs' Choice Award - American Express Resy – Official Credit Card & Booking Platform Partner (Resy); sponsor of the American Express One To Watch Award - Gin Mare – Official Gin Partner; sponsor of the Gin Mare Art of Hospitality Award - Flor de Caña – Official Rum Partner; sponsor of the Flor de Caña Sustainable Restaurant Award - Sosa – Official Ingredients Partner; sponsor of The World's Best Pastry Chef Award - Villa Massa – Official Limoncello and Amaretto Partner; sponsor of the Villa Massa Highest Climber Award - Beronia – Official Wine Partner - Nude Glass – Official Glassware Partner; sponsor of The World's Best Female Chef Award - Illycaffè – Official Coffee Partner - Nyetimber – Official Sparkling Wine Partner - Cinco Jotas – Official Ibérico Ham Partner - The London Essence Co. – Official Mixers Partner - Choco – Official Ordering Partner - Aspire Lifestyles – Official Concierge Partner; sponsor of the Highest New Entry Award Photo - https://mma.prnewswire.com/media/1826975/Wawira_Njiru.jpg Logo - https://mma.prnewswire.com/media/1802051/World_50_Best_2022_Logo.jpg SOURCE 50 Best	https://www.prnewswire.com/news-releases/the-worlds-50-best-restaurants-2022-announces-wawira-njiru-as-winner-of-the-icon-award-301557373.html	2022-05-31T12:49:59	en	0.922992
You need to enable JavaScript to run this app.	https://sportspyder.com/nba/boston-celtics/articles/39658150	2022-05-31T12:50:00	en	0.738227
Buying your first car is already an intimidating experience; in the midst of historic supply shortages, it’s easy to feel overwhelmed. In March of this year, the average price of a used car was $27,246, according to Cox Automotive — an automotive marketplace and data company — or 28% higher than it was a year ago. With those price increases, monthly payments have also swelled. Average payments for used cars reached $488 in the last quarter of 2021, according to Experian. On top of that, the average loan term for used vehicles was just over 67 months, or more than five years. For many, cars are a necessity. If you have little or no credit, no co-signer or just a limited budget, it can be easy to accept a loan that pushes your budget or binds you to a car for six, even seven years. Not being ready before stepping onto a car lot can open the door to making a purchase you’ll later regret. Set your limits before you ever stop at a dealership; with the right preparation, you can keep your purchase from becoming a burden. SECURE A LOAN Your first step is calculating what loan payments you can afford and the total loan amount that’s within your budget. Aim to keep your monthly loan payment below 10% of your take-home pay, and if you’re buying a used car, keep your loan term under 36 months. If you’re looking for a new vehicle, keep the term under 60 months. Limiting your loan term will save you money on interest and will lower the risk of your loan becoming upside-down — owing more than the car is worth. Numbers in hand, start looking for a lender that will give you a loan. Getting preapproved for a loan before visiting dealer lots can give you a better negotiating position, keep you from going over budget and reduce what you pay in interest. With little or no credit history — especially since you have not had a car loan before — your best shot at being approved for a loan at the lowest interest rate possible is to apply with a co-signer. But if that’s not a possibility for you, there are still financing alternatives available: — One of the first places to look are banks and credit unions, particularly institutions that you have an established relationship with. — Search your area for lenders with first-time buyer programs, which put conditions on the amount you can borrow and the vehicles you can buy but dispense with some of the credit requirements. — You can also look for loans from online lenders that offer bad-credit auto loans, since they will often have low or no minimum credit scores. These loans can carry interest rates of over 25%, so a year after taking one on, you can try to refinance for lower rates. PICK THE RIGHT CAR Finding a cheap car used to be easy — or at least easier than it is now. If you have a $10,000 budget, your options are limited, but that doesn’t mean there aren’t options. With a limited budget, most choices will be older, used cars, and that increases the annual cost to maintain your car. A 2021 Consumer Reports study found that 2016 model year vehicles cost $205 to maintain over the previous 12 months, while 2011 model year vehicles cost $430. In addition to maintenance costs, there’s also fuel, insurance, registration and taxes that all add to the cost of owning a vehicle. As you search for a car, look into the cost of ownership, since it will differ from car to car. The total cost of owning your vehicle, including your loan payment, shouldn’t exceed 20% of your take-home pay. Although some costs can’t be significantly reduced, you can minimize others — such as future maintenance, repairs and fuel — with the right car. “The most important thing to look for is a car with good maintenance history,” Joey Capparella, a senior editor at Car and Driver, said in an email. “If the previous owner has taken good care of the car and can provide service receipts, that trumps other attributes such as the number of miles or the brand. One-owner cars are desirable for this same reason.” Service and ownership history can sometimes be found through a service such as Carfax. Use this information, along with total mileage and the car’s age, to narrow down your search. When looking at vehicles for less than $10,000, the car with fewer miles will often be the better choice, if all else is equal. Once you’ve settled on a car, take it for an extensive test drive, Capparella added, and pay attention to “the seating position, the visibility out of the windows, and the sound of the engine.” If something about the car isn’t right for you, a different vehicle is likely a better choice, and don’t be afraid to be picky. You may not be buying the car of your dreams, but you could be living with your choice — and making payments on it — for years to come. _______________________________ This column was provided to The Associated Press by the personal finance website NerdWallet. Colin Beresford is a writer at NerdWallet. Email: cberesford@nerdwallet.com. Twitter: @Colin_beresford. RELATED LINK:	https://www.chron.com/news/article/Millennial-Money-Don-t-let-your-first-car-be-a-17208999.php	2022-05-31T12:50:04	en	0.963993
Following the acquisition of Cybint Solutions and Kontra Security, ThriveDX Acquires Swiss-Based Security Training and Simulation Company, Set to Position Company as Leader in Cyber Security Corporate Training MIAMI, May 31, 2022 /PRNewswire/ -- ThriveDX, today announced the acquisition of LUCY Security which closed in February, further expanding the company's cyber training offerings following recent acquisitions of Cybint Solutions and Kontra Security. LUCY Security is the most comprehensive IT Security Awareness Training solution on the market, with over 20 million trained users worldwide. LUCY will join the ThriveDX SaaS division. In its early stages, LUCY Security was originally developed as an on-premise awareness solution to meet the highest cybersecurity requirements of the Swiss banking sector. The software was then commercialized and distributed worldwide. LUCY Security allows organizations to measure and improve the security awareness of their employees and test their IT defenses with +800 attack templates and over 300 customizable training modules in more than 130 languages. The company is supporting millions of users and hundreds of corporate customers around the world, including Fortune 500 companies. "LUCY's technology, team and customers, are an amazing addition to the ThriveDX end-to-end cybersecurity training for enterprise. Together, I'm looking forward to creating synergies with our cybersecurity education offerings globally," said Roy Zur, CEO, ThriveDX SaaS. "We are excited to offer one of the best phishing simulators and hands-on cybersecurity awareness training solutions available on the market." This is the third acquisition in a series for ThriveDX to scale its learning systems to become the industry leader for skills training and digital transformation. LUCY's IT security awareness and phishing, are based on transforming the ethical hacking experience of its founders into comprehensive training software that provides a 360° view of an organization's IT security vulnerabilities from a human perspective. The ability to build this human firewall through behavior-modifying training, is integral to ThriveDX and LUCY's methodologies. "We're thrilled to partner with the team at ThriveDX SaaS to educate and better serve organizations who need to take a 360 degree approach to cybersecurity and skills training," said Oliver Muenchow, Founder of LUCY Security. "By connecting our security awareness offering with other training solutions, we can provide the necessary resources, products, and services to achieve our common goal." For more information or to book a demo, please visit https://thrivedx.com/for-enterprise ThriveDX, the global leader in cybersecurity and digital skills training, collaborates with academic institutions and corporations worldwide to deliver training and advanced professional development programs. Leveraging 15 years experience in the industry, ThriveDX has built a range of learning solutions in cyber, digital skills and information security designed to tackle the skills gap and talent shortage in these industries. ThriveDX offers award-winning bootcamps, awareness training, phishing exercises and application security training to assist its partners in closing the skills gap and talent shortage. ThriveDX was founded in 2006 and after extending their business operations in the United States in 2018 as HackerUSA, and then rebranded to ThriveDX following the acquisition of Cybint Solutions (now ThriveSaaS). Founded in 2015, LUCY has transformed the ethical hacking experience of its founders into comprehensive training software that provides a 360° degree approach to cybersecurity training. LUCY continues to receive numerous industry awards, including the Frost & Sullivan 2021 Global Competitive Strategy Leadership Award and the Cybersecurity Excellence Awards 2021 for Best Anti-Phishing and Best Security Education Platform. LUCY is a Swiss company headquartered in Zug and with offices in Austin, TX, Toronto, Canada, and support staff in France, Spain, and South Africa. Further information can be found at www.lucysecurity.com. SOURCE ThriveDX	https://www.prnewswire.com/news-releases/thrivedx-acquires-award-winning-cyber-security-training-company-lucy-security-to-expand-computer-based-it-security-training-offerings-for-corporates-301557571.html	2022-05-31T12:50:05	en	0.950149
You need to enable JavaScript to run this app.	https://sportspyder.com/nba/boston-celtics/articles/39658335	2022-05-31T12:50:06	en	0.738227
284-unit complex in the Chisholm Trail Ranch development will offer high-end amenities and access to many employment and leisure opportunities FORT WORTH, Texas, May 31, 2022 /PRNewswire/ -- Titan Development ("Titan") and Aberg Property Company, Inc. ("APC"), broke ground today on The Trailhead at Chisholm Trail Ranch, a $63 million, 284-unit luxury multifamily development in Fort Worth, Texas. The project, which is expected to be completed in the first quarter of 2025, follows Titan's strong successes in Texas' industrial, and multifamily and self-storage projects across the Southwest. The complex is part of Chisholm Trail Ranch, a 625-acre master-planned community located just west of the Chisholm Trail Parkway – an important area toll road that opened in 2014 – with direct connections to I-20 and I-30 and only a 15-minute drive from downtown Fort Worth. The Trailhead is located on 13.5 acres on the northeast corner of McPherson and Brewer Boulevard, where residents will have easy access to major and growing employers in Dallas-Fort Worth in oil and gas, manufacturing, hospitality and aerospace industries. The area hosts large employers including American Airlines, Bank of America, Exxon Mobil and Texas Health Resources, as well as 38 colleges and universities. The master plan for Chisholm Trail Ranch includes a variety of high-end retail and restaurant options, a park, community center, and an extensive hiking/biking trail system linking local parks and schools. Artwork, landscaping and other design features at The Trailhead will pay tribute to the legendary Chisholm Trail, which was established in the late 1800s by Lenape guide and rancher Black Beaver and Cherokee merchant Jesse Chisholm to drive cattle from Texas to railyards in Kansas. There is a large park on the property which offers residents wide spaces to relax in this low-density complex, with 284 units spread throughout seven apartment buildings. Residents will be offered studio, one-bedroom, two-bedroom and three-bedroom configurations that will include upscale fixtures, finishes and appliances. Other amenities on the property are garages and covered parking, bicycle storage, a pool, a dog park and unique outdoor activities such as a pickleball court. Kurt Browning, Partner at Titan Development, said, "The Trailhead in the historic Chisholm Trail Ranch area is our first multifamily project in Fort Worth and we especially enjoy creating a distinctly Western theme. Partnering with Peter and Christopher at APC has been a great experience. They have been involved in the development of Chisholm Trail Ranch masterplan for more than 10 years and are highly knowledgeable about the vision and execution of the project." "The Chisholm Trail Parkway is exploding with growth and The Trailhead is positioned to deliver much needed multifamily to this vibrant neighborhood," said Josh Rogers, Senior Vice President at Titan Development. "We believe this property, with its nearby shopping options and outdoor activities, will make this final phase of Chisholm Trail Ranch a highly attractive neighborhood with many live-work-play benefits." Peter Aberg, President at Aberg Property Company, said, "This is our first joint venture with Titan, and we are excited to be working with another firm with deep experience building upscale, Class A multifamily properties with architectural, artistic and decorative themes, in this case classic Texas Western." "The Chisholm Trail Ranch development is ideally situated in the suburbs of a city that has recently seen one of the highest population growth rates in the nation, and the data we gathered as we were planning our industrial properties in the area indicated that multifamily housing is essential to sustaining the economic growth of the area," added Christopher Ray, Executive Vice President, Development at Aberg Property Company. "We look forward to bringing best-in-class living arrangements to this growing new master-planned community along with our partners at Titan." "As the fastest growing large city in the country, we're excited to see the Trailhead at Chisholm Trail Ranch taking shape to support our booming population and thriving economy," said Robert Sturns, Director of Economic Development at the City of Fort Worth. "With its proximity to the new Tarleton State campus and other nearby amenities, this multifamily development is a welcome addition to the new growth happening in southwest Fort Worth." The Trailhead at Chisholm Trail Ranch project was funded by Titan Development Real Estate Funds II and III ("TDREF II" and "TDREF III"), which target investments in multifamily and industrial projects. This is Titan's first investment from its latest fund, TDREF III, which recently closed. Olympus Property, a full-service multifamily investment group, is an equity investor in the project. HEDK Architects serves as architect, Links Construction LLC is general contractor, and Lincoln Apartment Management will be the operator. "Links Construction is excited to partner with Titan and APC on The Trailhead," said Lee Robinson, Director of Business Development at Links Construction. "We were fortunate to partner early and work alongside the development and design teams for a year-long workup, which allowed us to manage through material price escalation and much of the volatility the industry saw in 2021. Our operations and field teams are really set up for success and we look forward to helping shape the future of south Fort Worth." About Titan Development Titan Development is a leading Southwest full-service development and real estate investment firm with proven returns, via diversified asset classes across varied geographic markets. Titan has completed more than $2.5 billion in project cost since the firm was formed in 1999. Titan Development has a wealth of real estate development experience in many asset classes including private equity fund investment and management, and has offices in Austin, TX, and Albuquerque, NM. Titan Development recently announced the close of its third fund, Titan Development Real Estate Fund III (TDREF III) at $122 million on May 12, 2022, continuing its successful strategy of focusing on multifamily and industrial investing in secondary and tertiary markets. Titan's previous fund, TDREF II, which raised $95 million, commenced in November of 2020, has identified all fund projects and is investing in 13 projects in TX, NM, CO and CA. Titan's inaugural fund, TDREF I, raised $112 million and invested in a variety of real estate asset classes. To learn more, please visit www.titan-development.com. About Aberg Property Company Aberg Property Company (APC), a Dallas, Texas based real estate investment firm, formed in 2016 to develop select Class-A multi-family projects in major markets throughout Texas and New Mexico. Together, APC's main Principals, Peter Aberg and Christopher Ray, have developed over 1,000 units in these markets over the past four years. These projects share similar characteristics including premier locations, Class-A design, and unique amenity packages geared toward resident experience in these changing times. At Aberg Property Company, we identify unique opportunities due to our leadership's extensive amount of real estate experience in land acquisition, including the zoning and marketing of well over 200 acres of multi-family land parcels over the past 25 years. Our Team's background and ability to navigate difficult zoning challenges, and local municipalities in markets with high barriers to entry, has provided consistently strong returns to our partners. Leveraging this skill set has been a critical component of APC's success as we have formed an expansive network of long-standing relationships and refined our disciplined approach to investment. The Company remains diligent and acutely focused as we take on no more than two new developments at one time. Looking forward, Aberg Property Company is pleased to start its latest new community, The Trailhead at Chisholm Trail in Fort Worth, Texas. About Links Construction Links Construction was founded in 2007 and is based in Denton, TX. Primarily serving the north Texas market, Links focuses on market rate multifamily new construction and has over 3,500 apartment units completed or under construction. Media Contacts: Lisa Baker Lambert [email protected] 603.868.1967 Amy Calderon Titan Development [email protected] 505.917.5303 SOURCE Titan Development	https://www.prnewswire.com/news-releases/titan-development-and-aberg-property-company-joint-venture-breaks-ground-on-the-trailhead-at-chisholm-trail-ranch-a-luxury-multifamily-project-in-dallas-fort-worth-301557104.html	2022-05-31T12:50:11	en	0.957323
You need to enable JavaScript to run this app.	https://sportspyder.com/nba/boston-celtics/articles/39658353	2022-05-31T12:50:12	en	0.738227
MANILA, Philippines (AP) — Philippine police killed four suspected Chinese kidnappers in a gunbattle and rescued a Chinese man they had allegedly abducted in a central city, officials said Tuesday. Backed by a SWAT team and intelligence agents, police raided a hideout in Lapu Lapu city on Monday night after tracking down the suspects, who had received a partial ransom payment through the Chinese smartphone app WeChat, police said. “Our men were met with gunfire from the suspects, prompting them to retaliate,” said police Brig. Gen. Rudolph Dimas, who heads the national police’s anti-kidnapping force. The Chinese victim, identified by police as Lyu Xingou from China’s southeastern province of Fujian, was seized from his house by Chinese-speaking gunmen last Wednesday as he prepared to leave for work in Lapu Lapu city, police said. The kidnappers called the victim’s son in China and demanded a ransom, which the family partially paid through WeChat in an arrangement that allowed the police to track down the suspects, police said, without elaborating. Police recovered four pistols, a laptop computer, cellphones and handcuffs from the slain suspects, who may have been involved in past kidnappings of Chinese working for lucrative online casinos in the Philippines that cater to Chinese clients in China, Dimas said.	https://www.chron.com/news/article/Philippine-police-say-they-killed-4-Chinese-17209082.php	2022-05-31T12:50:17	en	0.971825
- Sponsorship honors employee Meaghan Addante, who passed away from Cystic Fibrosis (CF) last year at the age of 28. - Under Meaghan's leadership, TK Elevator raised more than CA$500,000 over five years for Cystic Fibrosis Canada, a nonprofit organization dedicated to a finding a cure for CF. - CF is the most common fatal genetic disease affecting more than 4,300 Canadian children and young adults. TORONTO, May 31, 2022 /PRNewswire/ -- TK Elevator Canada was proud to support the Walk to Make Cystic Fibrosis History as a national sponsor, which took place on May 29 across Canada. The Walk to Make Cystic Fibrosis History is Cystic Fibrosis Canada's largest and most successful national event and fundraiser. Participants across more than 70 locations in Canada as well as virtual participants walked and raised money for CF Canada, supporting its mission to find a cure for CF. Six years ago, Meaghan Addante joined TK Elevator Canada tasked with raising CF awareness within the organization and communities. Through her inspirational advocacy, TK Elevator employees participated in a variety of fundraisers including bake sales, raffles, curling bonspiels, bowling events, golf tournaments and art contests. Since adopting CF Canada as its charity of choice in 2016, TK Elevator Canada has consistently exceeded the company's annual goal of raising CA$100,000 for Cystic Fibrosis Canada. To date, TK Elevator Canada has raised more than CA$500,000 as it continues Meaghan's mission after she passed away from the disease last year. "We are proud to support Cystic Fibrosis Canada and its mission to end CF once and for all. This is very personal to us. Meaghan was an inspiration to everyone who met her and her courageous battle with CF and to raise awareness around this disease is a fight we are proud to continue fighting on her behalf," said Kevin Lavallee, CEO BU North America and Group COO Field. A native of Oshawa, Ontario, Addante was diagnosed with CF when she was seven months old. Although Meaghan ultimately succumbed to the disease in 2021, she never let CF stop her from living her life to the fullest nor in her pursuit to inspire and educate others. "This world was a much better place because of Meaghan, and her efforts around CF inspired so many people throughout Canada and around the world. She was relentless in her fight, and that is a tradition we will continue in her honor as we continue working closely with CF Canada," added Gary Medeiros, President and CEO, TK Elevator Canada. Cystic Fibrosis Canada is one of the world's top three charitable organizations committed to finding a cure for Cystic Fibrosis and is an internationally recognized leader in advancing CF research and clinical care. Cystic Fibrosis Canada invests more funding in life-saving CF research and care than any other non-governmental agency in Canada. Since 1960, Cystic Fibrosis Canada has invested more than $261 million in leading research, care and advocacy, resulting in one of the world's highest estimated median age of survival for Canadians living with CF. In 2019, TK Elevator Canada was selected as the recipient of CF Canada's prestigious National Champion Award. The Award recognizes service groups, corporations, companies and businesses that have a presence in at least three regions and have provided exceptional leadership and/or financial support for CF Canada at the national level. This recognition would not have possible without the support of the entire Canada team and the tireless efforts of Meaghan. As Meaghan previously shared: "Maybe I myself won't be saved, and maybe I won't find the cure, but maybe one day people will look back and say, 'that girl made a difference'." PRESS CONTACT Dennis Van Milligen Manager, Public Relations TK Elevator North America P +1 312 525 3190 [email protected] www.tkelevator.com/ca-en/ ABOUT US TK Elevator With customers in over 100 countries served by more than 50,000 employees, TK Elevator achieved sales of around €8 billion in the fiscal year 2020/2021. Over 1,000 locations around the world provide an extensive network that guarantees closeness to customers. Over the past decades, TK Elevator has established itself as one of the world's leading elevator companies and became independent since its separation from thyssenkrupp AG in August 2020. The company's most important business line is the service business represented by over 24,000 service technicians. The product portfolio covers commodity elevators for residential and commercial buildings to cutting-edge, highly customized solutions for state-of-the-art skyscrapers. In addition, it also consists of escalators and moving walks, passenger boarding bridges, stair and platform lifts. Integrated cloud-based service solutions, such as the MAX platform, are gaining in importance. With these digital offerings, there are no limits to urban mobility anymore. TKE – move beyond. SOURCE TK Elevator	https://www.prnewswire.com/news-releases/tk-elevator-canada-sponsors-walk-to-make-cystic-fibrosis-history-301556814.html	2022-05-31T12:50:17	en	0.961575
You need to enable JavaScript to run this app.	https://sportspyder.com/nba/boston-celtics/articles/39658374	2022-05-31T12:50:18	en	0.738227
You need to enable JavaScript to run this app.	https://sportspyder.com/mlb/detroit-tigers/articles/39657380	2022-05-31T12:50:24	en	0.738227
This is a carousel. Use Next and Previous buttons to navigate 9 BELGRADE, Serbia (AP) — Aleksandar Vucic was sworn in for his second term as Serbia’s president Tuesday, pledging to keep the Balkan country on its European Union membership path and hinting that a new government might consider joining Western sanctions against Russia over the war in Ukraine. Despite voting in favor of three U.N. resolutions condemning Russia's invasion of Ukraine, Serbia remains the only European state that has not joined sanctions against its ally Moscow. In his inaugural speech in parliament, Vucic said Serbia’s priority will be its EU membership path and that the new government -- which should be formed in July -- will have to work harder on gaining entry into the 27-member bloc and consider sanctions against Moscow, although he didn't specifically refer to Russia. “Forming a new government is of utmost importance because of the situation we are in, difficult situation,” he said. “We will have to deal with new sanctions and stuff, which could damage us so we will ask our European partners to help us,” he said. Vucic, who convincingly won the presidential election mostly on his pro-Russian agenda, said that he wants to take Serbia into the EU during his new term. But he has spent recent years cementing ties with Russian President Vladimir Putin, a long-time ally. Opposition groups and foreign observers said the April vote was far from being free and fair and that Vucic's autocratic rule sidelines the government and parliament. Vucic announced on Sunday that he has secured an “extremely favorable” three-year natural gas deal with Russia during a telephone conversation with Putin -- something widely seen as his determination not to join EU sanctions despite pressure from the West. But the Serb president on Tuesday appeared to soften his pro-Russia stance, saying “we must be firm on the European path." He said Serbia will not seek NATO membership and would maintain its military neutrality. “We are not politically neutral because we want membership in the European Union,” said Vucic.	https://www.chron.com/news/article/Serb-president-pledges-EU-course-hints-Russia-17209019.php	2022-05-31T12:50:29	en	0.985591
You need to enable JavaScript to run this app.	https://sportspyder.com/mlb/detroit-tigers/articles/39657530	2022-05-31T12:50:30	en	0.738227
TALLAHASSEE, Fla., May 31, 2022 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced planned participation in upcoming conferences and events in June. - 19th Annual Craig-Hallum Institutional Investor Conference, June 1, 2022: President Steve White will participate in virtual investor meetings. - 2nd Annual Jefferies Cannabis Summit, June 2, 2022: President Steve White will participate in a panel and investor meetings in New York. - Trulieve Analyst Event, June 7, 2022: The event will include a bus tour in Florida and webcast management presentation. - Trulieve Annual Shareholder Meeting, June 8, 2022: The shareholder meeting will be held at 10:00 am ET and can be accessed at this link: www.virtualshareholdermeeting.com/TCNNF2022. - Grizzle Cannabis Con, June 8, 2022: Founder and CEO Kim Rivers will participate with a live stream on YouTube at 1:15 pm ET. Information about our events, links to events where available, and slide presentations can be found at: https://investors.trulieve.com/events-presentations About Trulieve Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S. operating in 11 states, with leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com. Facebook: @Trulieve Instagram: @Trulieve_ Twitter: @Trulieve Investor Contact Christine Hersey, Executive Director of Investor Relations +1 (424) 202-0210 [email protected] Media Contact Rob Kremer, Executive Director of Corporate Communications +1 (404) 218-3077 [email protected] SOURCE Trulieve Cannabis Corp.	https://www.prnewswire.com/news-releases/trulieve-announces-june-2022-event-participation-301557546.html	2022-05-31T12:50:35	en	0.89229
You need to enable JavaScript to run this app.	https://sportspyder.com/mlb/detroit-tigers/articles/39657892	2022-05-31T12:50:36	en	0.738227
CHICAGO , May 31, 2022 /PRNewswire/ -- According to the report "Ultralight and Light Aircraft Market by Aircraft Type (Ultralight & Light Aircraft), End Use (Civil & Commercial and Military), Flight Operation (CTOL & VTOL), Technology, Propulsion, Material, System and Region - Global Forecast to 2030", published by MarketsandMarkets™, the Ultralight and Light Aircraft Market is projected to grow from USD 7.5 billion in 2022 to USD 11.9 billion by 2030, at a CAGR of 5.9% from 2022 to 2030. The demand for commercial & ultralight and light aircraft used in personal, passenger, commercial cargo, training, survey & research, agriculture, and medical applications across various end-use industries, is one of the major driving factor for the demand of ultralight and light aircraft market. Ask for PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=181448279 By end use, the civil & commercial segment is expected to lead the market during the forecast period Civil & commercial use of ultralight and light aircraft include aircraft used for in personal flying, air sports, business travel, survey & research, medical, training, and passenger and cargo transport applications. This segment includes all ultralight and light aircraft except military and regional commercial aircraft. Light business aircraft are used for commercial passenger transport. These aircraft are lightweight and cost-effective versions of business jets. They require less runway and have a lower operating cost when compared with large business jets. By aircraft type, the light aircraft segment has the highest share in the forecasted period Light aircraft include fixed wing and rotary wing aircraft such as planes, helicopters, and UAVs. These aircraft have a defined weight category of 600 kg to 5,700 kg. Upcoming technologies such as electric/hybrid aircraft to be used for Urban Air Mobility (UAM) and cargo transport have also been included in the scope of light aircraft segment. CTOL segment has the highest share in the forecasted period Based on flight operation, the ultralight and light aircraft market is segmented into Conventional Take-off and Landing (CTOL) and Vertical Take-off and Landing (VTOL). CTOL aircraft include fixed wing ultralight and light aircraft. These aircraft require a runway or an airstrip for operation and usually have turboprop or piston engines. In the case of seaplanes, the runway is water, but the approach is similar to other passenger aircraft. CTOL aircraft are the most commonly used aircraft, and they follow the approach adopted by any conventional aircraft. Student pilots use ultralight and light aircraft to learn the basics of flying, including take-off and landing. Browse in-depth TOC on "Ultralight and Light Aircraft Market" 375 – Tables 41 – Figures 279 – Pages Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=181448279 North America has the highest share in the forecasted period. The North American region is estimated to account for a 45% share of the ultralight and light aircraft market in 2022. The aviation & aerospace sector in the North American region is growing steadily. This has consequently created a significant demand for ultralight and light aircraft. The growth of the ultralight and light aircraft market in this region is driven by factors such as rapid growth in aircraft manufacturing, technological advancements, and travel and tourism. The market for ultralight and light aircraft is expected to witness considerable growth in the US and Canada following the increased demand for various models of ultralight and light aircraft. Key players in the ultralight and light aircraft market include Textron (US), Pilatus (Switzerland), Piper Aircraft (US), Costruzioni Aeronautiche TECNAM (Italy), and Cirrus (US). The players are largely focused on new product development and launches and having a strong global presence will help them gain a competitive advantage in the ultralight and light aircraft industry. Related Reports: Business Jets Market by Aircraft Type (Light, Mid-Sized, Large, Airliner), Systems (OEM Systems, Aftermarket Systems), End User (Private, Operator), Point of Sale (OEM, Aftermarket), Services, Range and Region - Global Forecast to 2030 Helicopters Market by Point of Sale (OEM, Aftermarket), OEM Type (Light, Medium, Heavy), OEM Application (Military, Civil & Commercial), OEM Number of Engine, OEM Component & System, Aftermarket by Component & System, and Region - Global Forecast to 2025 About MarketsandMarkets™ MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: [email protected] Research Insight: https://www.marketsandmarkets.com/ResearchInsight/ultralight-aircraft-market.asp Visit Our Web Site: https://www.marketsandmarkets.com Content Source: https://www.marketsandmarkets.com/PressReleases/ultralight-aircraft.asp SOURCE MarketsandMarkets	https://www.prnewswire.com/news-releases/ultralight-and-light-aircraft-market-worth-11-9-billion-by-2030--exclusive-report-by-marketsandmarkets-301557689.html	2022-05-31T12:50:41	en	0.924238
You need to enable JavaScript to run this app.	https://sportspyder.com/mlb/detroit-tigers/articles/39658047	2022-05-31T12:50:43	en	0.738227
WFO EUREKA Warnings, Watches and Advisories for Tuesday, May 31, 2022 _____ FROST ADVISORY URGENT - WEATHER MESSAGE National Weather Service Eureka CA 417 AM PDT Tue May 31 2022 ...FROST ADVISORY REMAINS IN EFFECT UNTIL 8 AM PDT THIS MORNING... * WHAT...Temperatures as low as 35 will result in frost formation. * WHERE...Southern Trinity and Northern Trinity Counties. * WHEN...Until 8 AM PDT this morning. * IMPACTS...Frost could kill sensitive outdoor vegetation if left uncovered. PRECAUTIONARY/PREPAREDNESS ACTIONS... Take steps now to protect tender plants from the cold. Frost Advisories and Freeze Warnings are issued during the local growing season as defined by climatology and local agriculture experts. Once the growing season has ended these statements will no longer be issued until the spring. _____ Copyright 2022 AccuWeather	https://www.chron.com/weather/article/CA-WFO-EUREKA-Warnings-Watches-and-Advisories-17209018.php	2022-05-31T12:50:47	en	0.901869
Valued to be 5.3 Million Tons by 2026, Copper Pipes and Tubes Slated for Robust Growth Worldwide SAN FRANCISCO , May 31, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Copper Pipes and Tubes - Global Market Trajectory & Analytics". The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace. FACTS AT A GLANCE What's New for 2022? - Global competitiveness and key competitor percentage market shares - Market presence across multiple geographies - Strong/Active/Niche/Trivial - Online interactive peer-to-peer collaborative bespoke updates - Access to our digital archives and MarketGlass Research Platform - Complimentary updates for one year Edition: 21; Released: May 2022 Executive Pool: 1185 Companies: 137 - Players covered include Cerro Flow Products LLC; Cambridge-Lee Industries LLC; Fabrika bakarnih cevi Majdanpek; Foshan Huahong Copper Tube Co., Ltd.; Furukawa Electric Co., Ltd.; Golden Dragon Precise Copper Tube Group, Inc.; Grupo IUSA, S.A. de C.V.; H& H Tube; Hailiang Group Co., Ltd.; KME Germany GmbH; Kobelco & Materials Copper Tube, Ltd.; Luvata Oy; MM Kembla; Mueller Industries, Inc.; Ningbo Jintian Copper (Group) Co., Ltd.; Poongsan Corporation; Qingdao Hongtai Copper Co., Ltd.; Shanghai Metal Corporation; Wieland-Werke AG and Others. Coverage: All major geographies and key segments Segments: End-Use (HVAC, Industrial Heat Exchange, Plumbing, Other End-Uses) Geographies: World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa. Complimentary Project Preview - This is an ongoing global program. Preview our research program before you make a purchase decision. We are offering a complimentary access to qualified executives driving strategy, business development, sales & marketing, and product management roles at featured companies. Previews provide deep insider access to business trends; competitive brands; domain expert profiles; and market data templates and much more. You may also build your own bespoke report using our MarketGlass™ Platform which offers thousands of data bytes without an obligation to purchase our report. Preview Registry ABSTRACT- Amid the COVID-19 crisis, the global market for Copper Pipes and Tubes estimated at 4.4 Million Tons in the year 2022, is projected to reach a revised size of 5.3 Million Tons by 2026, growing at a CAGR of 4.1% over the analysis period. HVAC, one of the segments analyzed in the report, is projected to grow at a 4.6% CAGR, while growth in the Industrial Heat Exchange segment is readjusted to a revised 3.5% CAGR. Growth in the market is expected to be led by the HVAC&R Systems end-use application. Copper is the material of choice for air conditioning and refrigeration tubes (ACR tubes). Copper tube is among the most important components used in air conditioning and refrigerant systems, where the tube is used for enabling the refrigerant to flow between various systems components and also for preventing the refrigerant from escaping to the atmosphere. Copper is the best conductor of heat after precious metals, and is hence a preferred material for heat transfer applications such as air conditioning and refrigeration in residential, commercial as well as industrial sectors. In the HVAC segment, the use of copper pipes and tubes continues to be driven by the heat transfer and antimicrobial features of the material, which makes them suited for use in HVAC applications. The shift towards intelligent and energy efficient HVAC systems is likely to spur growth in demand for copper pipes and tubes, due to the high corrosion resistance, machinability and superior thermal conductivity offered by copper. Stringent new requirements, such as reduction and/or elimination of toxic emissions and demands for enhanced operating efficiency, have enabled copper tubes to remain competitive in the segment. Energy efficiency is one of the key advantages of using copper tubes in ACR products. Air conditioning and refrigeration applications are among the major contributors to greenhouse gases, as these applications are energy intensive. With most industrialized nations embarking on energy efficiency as part of Montreal and Kyoto protocols, the onus is on the air conditioning and refrigeration industry to improve efficiency of products and systems. Consequently by using reduced diameter copper tubes in coils, the energy efficiency of ACR products can be improved. With energy efficiency becoming a focus area for HVAC manufacturers, there is growing demand for higher efficiency offering components in refrigerants that are leading to new system designs. Energy efficiency is also being achieved through the use of smaller diameter copper tubes, which also cut down the material cost while reducing the size of the system. Another key advantage of using copper tubes in coils is that copper tubes and copper fins are more reliable and durable, offer improve corrosion resistance and enhance life of the component. Also driving growth is the use of Copper Pipes and Tubes in the water end-use industry. While water infrastructure requires increased investments, utilities are however facing higher volatility in cash flows and loss of revenues. Utilities are expected to register a cost and revenue impact on account to the impact of coronavirus across the country, with reductions in capital investments and delays anticipated, which will impact pipeline investments. However, in the long run demand for water pipes will grow, supported by the growing demand for clean water among the expanding population globally. The increase in industrial, commercial, and other institutions is also spurring demand for such pipes. In addition to establishment of new pipeline systems, water industry is also witnessing need to replace existing pipe networks. During the last few years, breakages in water mains have increased. This is indicative of the uncertain nature of the water infrastructure that is present underground. Some of the aspects that are taken into consideration during their installation include diameter and material, and climate and soil. Pipes that are 12 inches and smaller in diameter account for about 85% of the overall water pipe inventories. The 10-year average cost of breaks in small diameter pipes includes direct and indirect costs to the tune of over $18000. More chronic impacts relate to interruption to commercial business and notices regarding boiled water. And for bigger diameter water transmission pipes, such indirect costs are significantly high and have an impact on cities. Most utilities aim to replace 1% of their pipe network every year, which indicates a 100 year replacement cycle. The main goal of such replacements is to prevent disruptions to services, such as due to sinkholes, breaks, and leaks. Such disruptions have economic effects, with loss of revenues on account of water outages and also repair costs. While more difficult to measure, the bigger impacts are witnessed in political and social areas, through disruption of the business of industrial, governmental, commercial and individual stakeholders. The most problematic pipes are first replaced to prevent failures, thus presenting opportunities for the market. For laying water distribution infrastructure, different types of piping materials are used including plastic, aluminum, steel and copper, depending on the scale of requirement and budget outlay. Among various materials, copper has certain degree of edge over other competing materials. Low maintenance, less need for repairs, and longer life span are the major benefits of copper tubes in water distribution applications. On the other hand, laying water distribution system with copper tubes tends to be expensive, which prohibits its use in low- to mid-budget structures. Use of copper tubes for water supply is more prevalent in the US, Canada, and Western Europe countries, where building construction projects always emphasize high-quality solutions irrespective of the costs involved. However, copper emits toxic gases when it is smelted. Copper found in drinking water ranges between 0.05 to 1 mg/L due to leaching of copper-pipes and fittings. More MarketGlass™ Platform Our MarketGlass™ Platform is a free full-stack knowledge center that is custom configurable to today`s busy business executive`s intelligence needs! This influencer driven interactive research platform is at the core of our primary research engagements and draws from unique perspectives of participating executives worldwide. Features include - enterprise-wide peer-to-peer collaborations; research program previews relevant to your company; 3.4 million domain expert profiles; competitive company profiles; interactive research modules; bespoke report generation; monitor market trends; competitive brands; create & publish blogs & podcasts using our primary and secondary content; track domain events worldwide; and much more. Client companies will have complete insider access to the project data stacks. Currently in use by 67,000+ domain experts worldwide. Our platform is free for qualified executives and is accessible from our website www.StrategyR.com or via our just released mobile application on iOS or Android About Global Industry Analysts, Inc. & StrategyR™ Global Industry Analysts, Inc., (www.strategyr.com) is a renowned market research publisher the world`s only influencer driven market research company. Proudly serving more than 42,000 clients from 36 countries, GIA is recognized for accurate forecasting of markets and industries for over 33 years. CONTACTS: Zak Ali Director, Corporate Communications Global Industry Analysts, Inc. Phone: 1-408-528-9966 www.StrategyR.com Email: [email protected] LINKS Join Our Expert Panel https://www.strategyr.com/Panelist.asp Connect With Us on LinkedIn https://www.linkedin.com/company/global-industry-analysts-inc./ Follow Us on Twitter https://twitter.com/marketbytes Journalists & Media [email protected] SOURCE Global Industry Analysts, Inc.	https://www.prnewswire.com/news-releases/valued-to-be-5-3-million-tons-by-2026--copper-pipes-and-tubes-slated-for-robust-growth-worldwide-301557148.html	2022-05-31T12:50:48	en	0.917277
You need to enable JavaScript to run this app.	https://sportspyder.com/mlb/detroit-tigers/articles/39658168	2022-05-31T12:50:49	en	0.738227
WiMi Hologram Cloud Joins the Information Technology Innovation Committee of China Communications Industry Association BEIJING, May 31, 2022 /PRNewswire/ -- WiMi Hologram Cloud Inc. (Nasdaq: WIMI) ("WiMi" or the "Company"), a leading global Hologram Augmented Reality ("AR") Technology provider, today announced that it had joined the Information Technology Innovation Committee of China Communications Industry Association (CCIAITIC) after a three-month rigorous evaluation of technical indicators. WiMi had become a member of the committee and obtained the member unit certification issued by the China Communications Industry Association, which again demonstrated that the Company has a solid ability to engage in holographic AR and information software services. China Communications Industry Association ("CCIA" or the "Association") is registered with the Ministry of Civil Affairs of the People's Republic of China (MCA). It is guided by the Ministry of Industry and Information Technology (MIIT) in its business. It plays the role of a bridge and an assistant between enterprises and the government, continuously promotes the technological innovation of China's communication industry, and goes out of the country. It promotes the development of the industry and makes continuous efforts to prosper the economic development of China's communication sector. The Association is in the charge of MIIT. Under the guidance of MIIT, the Association carries out industry management, information exchange, business training, international cooperation, and consulting services. It aims to promote the technical progress of the industry, improve product quality, strengthen economic and technical cooperation between enterprises and institutions, tighten the connections and improve the quality of member units and their economic benefits. The Association also promotes communication products to meet the growing demand at home and abroad to enhance the competitiveness in the international market. To promote the development of China's communications industry in the field of national information technology innovation, and to accelerate the integration and growth of new-generation information technology and its innovation, such as 5G communications and metaverse, Internet of Things, East Digital West Computing, blockchain, artificial intelligence, the establishment of CCIAITIC has been approved by MCA and MIIT. CCIAITIC is a subsidiary organization. WiMi's admittance to CCIAITIC proves its overall comprehensive strength. WiMi is currently the leading holographic platform in China and has established a complete holographic technology research and development system, holographic content production and reserve system, and holographic commercialization system. The Company has 195 technology patents related to image processing and display, model input/output, 3D modeling, and 325 software copyrights. It has produced more than 4,600 high-quality, high-fidelity holographic contents. WiMi's Holographic XR Head-Mounted Display Device "WiMi Hologram SoftLight", Holographic AR Head-Mounted Display Device "WiMi HoloAR Lens", and its Holographic Lidar "WiMi HoloPulse LiDAR", have all been licensed and approved by the Federal Communications Commission to enter the U.S. market. In the future, WiMi will seize this opportunity to further strengthen and accelerate the continuous innovation in 5G communication, holographic AR, metaverse, artificial intelligence, and information software development. About WIMI Hologram Cloud WiMi Hologram Cloud, Inc. (NASDAQ: WIMI), whose commercial operations began in 2015, is a holographic cloud comprehensive technical solution provider that focuses on professional areas including holographic AR automotive HUD software, 3D holographic pulse LiDAR, head-mounted light field holographic equipment, holographic semiconductor, holographic cloud software, holographic car navigation, metaverse holographic AR/VR equipment, metaverse holographic cloud software, and others. Its services and holographic AR technologies include holographic AR automotive application, 3D holographic pulse LiDAR technology, holographic vision semiconductor technology, holographic software development, holographic AR advertising technology, holographic AR entertainment technology, holographic ARSDK payment, interactive holographic communication, metaverse holographic AR technology, metaverse virtual cloud service and other holographic AR technologies. For more information, please visit http://ir.wimiar.com. Safe Harbor Statements This press release contains "forward-looking statements" within the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will,""expects,""anticipates,""future,""intends,""plans,""believes,""estimates" and similar statements. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Among other things, the business outlook and quotations from management in this press release and the Company's strategic and operational plans contain forward−looking statements. The Company may also make written or oral forward−looking statements in its periodic reports to the US Securities and Exchange Commission ("SEC") on Forms 20−F and 6−K, in its annual report to shareholders, in press releases, and other written materials, and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. Several factors could cause actual results to differ materially from those contained in any forward−looking statement, including but not limited to the following: the Company's goals and strategies; the Company's future business development, financial condition, and results of operations; the expected growth of the AR holographic industry; and the Company's expectations regarding demand for and market acceptance of its products and services. Further information regarding these and other risks is included in the Company's annual report on Form 20-F and the current report on Form 6-K and other documents filed with the SEC. All information provided in this press release is as of the date of this press release. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable laws. SOURCE WiMi Hologram Cloud Inc.	https://www.prnewswire.com/news-releases/wimi-hologram-cloud-joins-the-information-technology-innovation-committee-of-china-communications-industry-association-301557706.html	2022-05-31T12:50:54	en	0.921903
You need to enable JavaScript to run this app.	https://sportspyder.com/mlb/detroit-tigers/articles/39658277	2022-05-31T12:50:55	en	0.738227
With Market Size Valued at $38.9 Billion by 2026, it`s a Healthy Outlook for the Global Fencing Products Market SAN FRANCISCO, May 31, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Fencing Products - Global Market Trajectory & Analytics". The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace. FACTS AT A GLANCE What's New for 2022? - Global competitiveness and key competitor percentage market shares - Market presence across multiple geographies - Strong/Active/Niche/Trivial - Online interactive peer-to-peer collaborative bespoke updates - Access to our digital archives and MarketGlass Research Platform - Complimentary updates for one year Edition: 18; Released: April 2022 Executive Pool: 1291 Companies: 107 - Players covered include Allied Tube & Conduit; Ameristar Perimeter Security; Associated Materials, Inc.; Betafence Corporate Services NV; Certain Teed Corporation; Gregory Industries, Inc.; Jerith Manufacturing LLC; Long Fence; NV Bekaert SA; Ply Gem Holdings, Inc.; Poly Vinyl Creations Inc. and Others. Coverage: All major geographies and key segments Segments: Material Type (Metal, Wood, Plastic & Composite, Concrete); Installation (Contractor, DIY); Application (Residential, Agricultural, Industrial) Geographies: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa. Complimentary Project Preview - This is an ongoing global program. Preview our research program before you make a purchase decision. We are offering a complimentary access to qualified executives driving strategy, business development, sales & marketing, and product management roles at featured companies. Previews provide deep insider access to business trends; competitive brands; domain expert profiles; and market data templates and much more. You may also build your own bespoke report using our MarketGlass™ Platform which offers thousands of data bytes without an obligation to purchase our report. Preview Registry ABSTRACT- Amid the COVID-19 crisis, the global market for Fencing Products estimated at US$31.7 Billion in the year 2022, is projected to reach a revised size of US$38.9 Billion by 2026, growing at a CAGR of 5.4% over the analysis period. Metal, one of the segments analyzed in the report, is projected to grow at a 5.1% CAGR, while growth in the Wood segment is readjusted to a revised 5.7% CAGR. The fencing market received stimulus from strong home renovation activity that played an important role in counterbalancing the impact of relatively weak construction activity, especially in the commercial category, amid the pandemic. The residential segment provided the needed respite and offered new growth opportunities to fencing providers during the challenging phase. COVID-19-led confinement measures, stay-at-home mandates and closure of outdoor venues coerced people to spend more time at their homes, prompting them to focus on DIY home improvement projects. A large number of homeowners focused more on exterior upgrades such as fence installations as they involve minimal or no direct interactions with contractors. Fencing products also gained from classification of home improvement and hardware stores as essential business, providing customers with access to fencing products. On the other hand, high consumer demand along with supply shortages during initial phases of the pandemic led to delay in orders and missed revenue opportunities. The scenario prompted leading retailers to expand their distribution capacity for securing key materials, including fencing, to fulfill demand. While majority of homeowners are installing vertical wood boards, the market is also receiving strong support from PVC & plastic fences and chain-link fences. The PVC & plastic fences segment is witnessing immense demand on account of steep rise in lumber prices. The incredible jump in home improvement projects and fence installation is enabling various online remodeling players to serve increasing consumer demand for outdoor improvement products. The trend is also attributed to rising focus on security and privacy along with notable surge in home improvement or repair projects related to outdoor structures, including fencing. These upgrades have considerably surpassed exterior upgrades like siding and windows. The outdoor project wave is anticipated to remain unabated owing to pent-up demand attributed to long wait of homeowners for lower prices. Another prominent factor that is favoring fencing installation is inclination of homeowners towards projects requiring low or no in-person contact with installation workers. The need is prompting an increasing number of home improvement shops to focus on approaches ensuring contact-less ordering and fencing installation. While outdoor spaces represent a prominent home remodeling trend, various shops are not in a position to cater to consumer demand for full-scale outdoor living rooms. These companies are increasingly targeting fence installation to tap the opportunity. Rising popularity of outdoor living is driving stores to expand their portfolios with the addition of fencing. These moves are also credited to heavy margins for fencing installation projects to fencing contractors. In recent years, consumer awareness regarding environmental protection has increased substantially, resulting in the development of a wide range of environment-friendly products across industries. The fencing industry is also coming up with a myriad of eco-friendly options that not only allow for privacy and aesthetics of residential properties, but also reduce their corresponding environmental impact. One important factor that makes a fencing solution environment-friendly is it having a minimal impact on its surrounding environment. In addition, the materials utilized for building the fences as well as the process utilized for converting these materials into something useful can play a major role in ascertaining whether the fencing solution is environment-friendly. One environment-friendly option is to first identify whether fencing is actually required. In case fencing is being utilized primarily for marking a property's boundary, or for screening or privacy, plants can be used in place of fencing. For instance, the use of native shrubs or trees for creating partitions, windbreaks, or privacy hedgerows can be a much better solution than fencing. However, in situations where permanent fencing is actually required, the materials used for manufacturing fencing and where these materials are sourced from are essential considerations for the fencing option to be called environment-friendly. The use of natural materials, ideally materials source from within the space or the immediate surroundings, is the most sustainable fashion in which fencing can be manufactured. For instance, fencing could be created using fallen branches, or wattle fences could be formed from hazel or other coppiced or pruned branches. Other fencing options using natural materials for manufacturing include willow lattice fencing, bamboo fencing, and log fencing. In addition, composite fencing can be considered by homeowners for their properties. Manufactured using a mixture of recycled plastic and timber, composite fencing offers a versatile and elegant fencing solution for modern homes. Composite fence is not only responsibly sourced but is also long-lasting, durable, and requires minimal maintenance. In addition, the presence of plastic components makes this fencing solution resistant to moisture and significantly increases its lifespan. For homeowners looking wanting a look and feel of timber but are not comfortable with a timber fence can opt for bamboo fencing. More MarketGlass™ Platform Our MarketGlass™ Platform is a free full-stack knowledge center that is custom configurable to today`s busy business executive`s intelligence needs! This influencer driven interactive research platform is at the core of our primary research engagements and draws from unique perspectives of participating executives worldwide. Features include - enterprise-wide peer-to-peer collaborations; research program previews relevant to your company; 3.4 million domain expert profiles; competitive company profiles; interactive research modules; bespoke report generation; monitor market trends; competitive brands; create & publish blogs & podcasts using our primary and secondary content; track domain events worldwide; and much more. Client companies will have complete insider access to the project data stacks. Currently in use by 67,000+ domain experts worldwide. Our platform is free for qualified executives and is accessible from our website www.StrategyR.com or via our just released mobile application on iOS or Android About Global Industry Analysts, Inc. & StrategyR™ Global Industry Analysts, Inc., (www.strategyr.com) is a renowned market research publisher the world`s only influencer driven market research company. Proudly serving more than 42,000 clients from 36 countries, GIA is recognized for accurate forecasting of markets and industries for over 33 years. CONTACTS: Zak Ali Director, Corporate Communications Global Industry Analysts, Inc. Phone: 1-408-528-9966 www.StrategyR.com Email: [email protected] LINKS Join Our Expert Panel https://www.strategyr.com/Panelist.asp Connect With Us on LinkedIn https://www.linkedin.com/company/global-industry-analysts-inc./ Follow Us on Twitter https://twitter.com/marketbytes Journalists & Media [email protected] SOURCE Global Industry Analysts, Inc.	https://www.prnewswire.com/news-releases/with-market-size-valued-at-38-9-billion-by-2026--its-a-healthy-outlook-for-the-global-fencing-products-market-301557145.html	2022-05-31T12:51:00	en	0.925673
WFO BROWNSVILLE Warnings, Watches and Advisories for Wednesday, June 1, 2022 _____ RIP CURRENT STATEMENT Coastal Hazard Message National Weather Service Brownsville TX 728 AM CDT Tue May 31 2022 ...HIGH RIP CURRENT RISK REMAINS IN EFFECT THROUGH WEDNESDAY EVENING... * WHAT...Dangerous rip currents. * WHERE...Kenedy Island, Cameron Island and Willacy Island Counties. * WHEN...Through Wednesday evening. * IMPACTS...Rip currents can sweep even the best swimmers away from shore into deeper water. PRECAUTIONARY/PREPAREDNESS ACTIONS... Swim near a lifeguard. If caught in a rip current, relax and float. Don't swim against the current. If able, swim in a direction following the shoreline. If unable to escape, face the shore and call or wave for help. _____ Copyright 2022 AccuWeather	https://www.chron.com/weather/article/TX-WFO-BROWNSVILLE-Warnings-Watches-and-17209098.php	2022-05-31T12:51:05	en	0.850384
MUMBAI : There are so many useful movies to share with the class or the students' group when you want to win the audience's attention. And there is certainly a range of valuable pictures that can increase students' chances to impress their professors or tutors particularly. All you have to do is to decide what you wish to discuss - whether it is a historical pattern, a social movement, or a tendency in public health. Here is a short set of evaluation essay ideas to be written for all subjects. What's Eating Gilbert Grape (1993) A fantastic movie with now-famous Johnny Depp and Leonardo DiCaprio in their younger years. Who could believe that these two starting actors with an exceptionally talented approach to their roles in this movie would manage to develop acting skills later even more? This is the best choice if the viewer needs to write a paper about the real struggles that ordinary citizens face surviving in the USA. Not all people are millionaires in this country, neither are they free enough to move to another city or simply leave their family as self-reliant grown-ups. What's Eating Gilbert Grape is an original reflection on how difficult it can be to prioritize personal desires when you want to care about your loved ones in the first place. Even though the United States has a reputation as the dream country for young people, the financial dilemma is still a burden for thousands of families. This movie can also be helpful for research essays about mental health and physical health issues. Picking such a story would make any review sound intellectual and professional. It is a modern philosophical statement in cinematography. A.I. Artificial Intelligence (2001) A.I. Artificial Intelligence is a ground-breaking cinematographic attempt to speculate about scientists' ability to recreate genuine feelings in robotic products. Although the plot seems to question the technological options of the future, it directs viewers' attention to really important things like love, sincerity, loyalty, compassion, and kindness. How could a set of metal parts generate all of them? If people can purchase custom robots to express preferable emotions, why can they forget to treat and respect them as equals? Furthermore, this problem aligns with the customer's obligation to acknowledge that purchasing a sensitive, dependent, and feeble creature implies taking a severe responsibility for its safety and wellness. The film with Jude Law also makes the audience question if robots have already become so advanced that they can have stronger feelings than some people. People are supposed to be wiser and more aware of the power of their hearts. It would be a shame if humanity became degrading in contrast to the progressing robotics sphere. As a result, despite illustrating a challenging destiny of a steel boy and other robots, A.I. Artificial Intelligence can enhance people's understanding of the necessity to protect morals. It is crucial to prevent the latter from falling apart under the pressure of technological innovations, which can become a proper theme for papers. Alexander (2004) Prior to the beginning of the war in Ukraine, heroism had started to become associated with something rather vanishing through time and yet legendary, seeming to be rare among the contemporary masses in comparison to past eras. Nonetheless, Alexander, thanks to the focus on one of the greatest rulers and war commanders in history, has the potential to inspire millions to exercise determination, bravery, and creativity nowadays. The metamorphosis of a twenty-year-old warrior turning into the most powerful person in the world makes you interested in writing your destiny worthily too, especially with starring celebrities like Angeline Jolie, Jared Leto, and Colin Farrell. The movie teaches that it is impossible to buy success and respect until you deserve them. An individual can never reach the top of their achievements if they are not ready to fight for it. There are always essential steps that you have to do yourself. For example, while you can order assistance online from services like CustomWritings, an essay writing help company will never manage to experience and feel all the emotions by watching the film or reading the book instead of you. Thus, it is vital to know when to choose a service and when to complete the significant task individually. The Help (2012) Something of the perfect quality is guaranteed when you cast Viola Davis, Emma Stone, and Jessica Chastain to work together. The Help is a masterpiece that covers diverse characters and reveals different sides of human nature. This movie is worthy of consideration for the attempt to ruin stereotypes regarding normally accepted relationships. It depicts racism in its most comfortable era when living conditions became more technological breakthroughs and whites would still neglect their humane obligations to make blacks' lives easier. At the same time, despite being deep and insightful, the topic of the film is easy enough to comprehend for those who are learning English. There are multiple ways to integrate The Help with the course materials when students have to write an essay from scratch. The college youth can also relate to Emma Stone's heroine, Skeeter, as long as she is a fresh Ole Miss graduate herself and demonstrates an unbiased and open-minded social position. It is essential to use the academic field to promote progressive values, although professors are always ready to appreciate such an attitude. Thanks to the combination of the meaningful historical setting and timeless priorities, The Help can fit the requirements of any analysis assignment. The Martian (2015) A diamond of science fiction with Matt Damon as the leading hero. The plot evolves around the expert in botany who applies the maximum of his knowledge to grow potatoes... on Mars. One of the most motivational movies which prove that trying to excel in your favorite sphere will pay off eventually. You never know when some talent or skill will save your or someone's life or change it drastically, opening unbelievable opportunities. The origin of the story is a unique example by itself too - initially, it has been simply published on the writer's website, and he could hardly expect it to cause such a resonance in the future. This movie has already gathered numerous reviews thanks to its perfectionism in everything - cast, design, special effects, music, and other influential factors that let The Martian delight any audience type. It can encourage inexperienced writers to start publishing their works on the Internet in personalized blogs either. What is more, although the observed case refers to individualism more, it shows that companies have to care about their team members most of all too. A company cannot remain successful if it hopes that maintaining workers' well-being will always be unchallenging and cheap.	https://www.tellychakkar.com/movie/movie-news/5-movies-write-evaluation-essay-220531	2022-05-31T12:52:06	en	0.955744
Some Democrats voting in GOP primaries to block Trump picks Diane Murray struggled with her decision all the way up to Election Day. But when the time came, the 54-year-old Georgia Democrat cast a ballot in last week's Republican primary for Secretary of State Brad Raffensperger. While state law allowed her to participate in either party's primary, she said it felt like a violation of her core values to vote for the Republican. But it had to be done, she decided, to prevent a Donald Trump-backed "election denier" from becoming the battleground state's election chief. "I feel strongly that our democracy is at risk, and that people who are holding up the big lie, as we call it, and holding onto the former president are dangerous to democracy," said Murray, who works at the University of Georgia. "I don't know I'll do it again because of how I felt afterward. I just felt icky." Raffensperger, a conservative who refused to support the former president's direct calls to overturn the 2020 election, probably would not have won the May 24 Republican primary without people like Murray. An Associated Press analysis of early voting records from data firm L2 found that more than 37,000 people who voted in Georgia's Democratic primary two years ago cast ballots in last week's Republican primary, an unusually high number of so-called crossover voters. Even taking into account the limited sample of early votes, the data reveal that crossover voters were consequential in defeating Trump's hand-picked candidates for secretary of state and, to a lesser extent, governor. Gov. Brian Kemp did not ultimately need Democrats in his blowout victory against his Trump-backed opponent, but Raffensperger probably did. The Republican secretary of state cleared the 50% threshold required to avoid a runoff election by just over 27,000 votes, according to the latest AP tallies. Based on early voting data alone, 37,144 former Democrats voted in the Republican primary. The total number of crossovers including Election Day votes, set to be revealed in the coming weeks, may be even higher. Crossover voting, also known as strategic voting, is not exclusive to Georgia this primary season as voters across the political spectrum work to stop Trump-backed extremists from winning control of state and federal governments. The phenomenon is playing out in multiple primary contests, sometimes organically and sometimes in response to a coordinated effort by Trump's opponents. While Trump railed against the practice over the weekend, there is nothing inherently wrong with crossover voting. Dozens of states make it legal and easy for voters to participate in either party's primary. And there are several isolated incidents of both parties engaging in strategic voting over the years. Still, Trump warned conservatives about crossover voting while campaigning Saturday in Wyoming, another state where the former president's opponents are calling for Democrats to intervene — this time to help save Rep. Liz Cheney from a Trump-backed primary challenger. Cheney, like Raffensperger and Kemp, refused to embrace Trump's lies about the 2020 election. She also voted for his second impeachment after the Jan. 6 insurrection. "Don't let the Democrats do what they did in another state last week," Trump told Wyoming supporters, complaining about what happens "when you allow Democrats to vote in a Republican primary." While the practice has Trump's attention, it is often ineffective. Trump's opponents encouraged Democrats to help defeat U.S. Rep. Marjorie Taylor Greene in her Georgia primary last week. The congresswoman, who has embraced election lies and spoken at an event organized by a white nationalist, won by more than 50 percentage points. And in some cases, Democrats have been too focused on their own competitive primaries to cast a Republican ballot. That was probably the case in Pennsylvania, where some Democrats openly encouraged their base to vote for the Republican candidate for governor, Doug Mastriano, whose extreme views they felt made him more beatable in November. On the same day, Democrats were deciding their own high-stakes Senate primary. If the advance vote in Pennsylvania is any indication, few Democrats heeded the call to vote GOP. Of Republican primary voters who cast early or absentee ballots this year, only 1.7 percent voted Democratic in the 2020 primary. Those 2,600 votes, even if ultimately bolstered by more Election Day participants, were unlikely to have moved the needle in an outcome in which Mastriano beat his closest rival by nearly 320,000. On the forefront of the crossover movement, Rep. Adam Kinzinger, R-Ill., has called for an "uneasy alliance" between Democrats, independents and Republicans to take down pro-Trump candidates in GOP primaries whenever and wherever possible. Some states have open primaries like Georgia that allow people to vote in either primary, while other states have more restrictive rules. In an interview, Kinzinger said he was pleasantly surprised by the Democrats' response in some races. He said he never expected the movement to be an "earth-shattering game-changer" right away. Kinzinger's political organization, Country First, targeted thousands of former Georgia Democrats with mailers and text messages urging them to support Raffensperger for the sake of democracy. A Country First text message widely distributed to Georgia voters in the days before the election read: "Don't wait for until the general election to go after the extremes. Vote in the Republican Primary for the candidate that supports truth and democracy." Kinzinger's team was also active in North Carolina's closely watched congressional race in North Carolina's 11th District, where voters ousted the polarizing pro-Trump freshman Rep. Madison Cawthorn in the Republican primary. As was the case in Georgia, the AP found a sizable percentage of Republican early ballots were cast by voters who participated in the Democratic primary two years ago. Specifically, more than 14% of the 38,000 early or absentee votes cast in the Cawthorn race — more than 5,400 voters — came from a Democratic 2020 primary voter. Cawthorn lost his primary by fewer than 1,500 votes. Back in Georgia, Raffensperger's team pushed back on the idea that he won the GOP primary because of Democrats. The team suggested that a number of crossover voters were actually Republicans who voted Democratic in recent years to protest Trump. "It is clear that Brad Raffensperger carried a majority of the Republican vote here in the state of Georgia, and that there are people who stopped voting in Republican primaries after 2016 who are now reengaged," said Jordan Fuchs, a consultant to the Raffensperger campaign. An AP examination of voting records from before the Trump era shows at least a portion of Georgia's 37,000 party switchers in 2022 had been in the Republican camp before Trump took office. Roughly between 9,000 to 13,000 voted Republican in the 2010, 2012 and 2014 primaries, according to the L2 data. Trump allies in the state, caught off guard by the crossover trend, were furious. "It was a Democratic version of 'Operation Chaos,'" said Debbie Dooley, president of the Atlanta Tea Party, referring to the secret Nixon-era push to infiltrate liberal groups. "I did not realize just how heavily the Democrats were going to cross over." Dooley launched a petition late last week to close Georgia's Republican primaries to non-Republicans. More than a dozen states have closed, or partially closed, primaries that block members of opposing parties from participating. Meanwhile, Kinzinger said he's already crafting plans to execute a similar playbook in coming primaries in Michigan, Wyoming and Alaska. In addition to helping Sen. Lisa Murkowski, the Alaska Republican who voted to convict Trump in his second impeachment trial, Kinzinger said he's weighing whether to invest resources in trying to block former Gov. Sarah Palin's congressional bid. "Donald Trump came in and took over the Republican Party with nationalism," Kinzinger said. "The American people have every right to determine who represents them in a congressional district, and if that's in a primary, that's in a primary. If they want to take back the Republican Party from the liar, they can do that, and I'm certainly going to help them." ___ Peoples reported from New York. Associated Press writers Jeff Amy in Atlanta and Jill Colvin in New York contributed to this report.	https://www.wxii12.com/article/democrats-vote-gop-primaries-block-trump-picks/40150387	2022-05-31T12:52:45	en	0.973278
'She was going to be someone': Families, friends remember the victims of the Uvalde school massacre Ten-year-old Maite Rodriguez wanted to be a marine biologist before she could say the word. "She loved animals," cousin Destiny Esquivel told CNN on Monday. "She was determined, she was smart. She was going to be someone." But last week, a gunman stormed into her classroom at Robb Elementary School in Uvalde, Texas, and opened fire. Maite, along with 18 other students and two teachers, was killed. Family and friends gathered Monday for a visitation and rosary service for Maite, whom they remembered as a charismatic girl with a bright future. Maite was also caring and protective of her younger cousins, Esquivel said, and tried to help others during the bloody massacre. "Her classmates said she was brave. Grabbing all of the other students, telling them where to hide," Esquivel said. "She is a hero." The devastating loss of 21 lives has deeply wounded a South Texas community that is rallying in support of one another. Nineteen of those being laid to rest will be buried in custom caskets provided by a Texas company at no cost to the families. The two funeral homes in Uvalde have also vowed to cover all expenses as more services are set for Tuesday and continuing into next week. A service was also held Monday for 10-year-old Amerie Jo Garza, whose father learned last week from two of her classmates that Amerie tried to call 911 during the shooting. "I just want people to know she died trying to save her classmates," Angel Garcia said Wednesday. "She just wanted to save everyone." Video: Flowers, tears as Bidens stop at Uvalde memorial The visitation room was filled with flowers and stuffed animals as family and friends gathered in remembrance, according to CNN affiliate KTRK. The Uvalde city council announced it would be postponing its meeting Tuesday, where several new members were set to be sworn in. "Our focus on Tuesday is on our families who lost loved ones," Mayor Don McLaughlin said Monday in a statement. "We begin burying our children tomorrow, the innocent victims of last week's murders at Robb Elementary School. The special City Council meeting will not take place as scheduled." Calls for help from the classroom One of the new members of the city council who was to be sworn in Tuesday, school police chief Pedro "Pete" Arredondo, has faced criticism from those who felt law enforcement should have acted quicker to subdue or eliminate the gunman. A timeline provided by the Texas Department of Public Safety shows the gunman was in a classroom with students for more than an hour before he was shot and killed by a Border Patrol tactical response team. Officers had responded within minutes of the suspect entering the classroom, yet were repelled by the gunman's fire and then stationed in a hallway awaiting reinforcements for more than an hour. At a Friday press conference, Texas Department of Public Safety director Col. Steven McCraw confirmed that the Uvalde school district police chief was the official who made the decision not to breach the classrooms -- though McCraw did not identify Arredondo by name. Video: Witness recalls seeing gunman According to the timeline released by Texas DPS, several 911 calls were made by children inside the classroom where the gunman was located, all while police were waiting in the hallway. One student told CNN that his teacher, who had been struck by gunfire in an adjacent classroom, texted 911 for help. Video taken from the outside of the school during the incident, obtained by ABC News, includes what appears to be dispatch audio informing officers on scene that a child is calling 911 from a classroom. "Advise we do have a child on the line," the dispatcher says. "Child is advising he is in the room full of victims." The video indicates police at the scene were informed at least one child remained alive inside the classrooms. CNN has not been able to independently confirm the video/audio. It is unclear the source of the video as well as at what point in the incident the audio is heard. CNN has reached out to authorities to answer questions about this audio. Community supported by those near and far Assistance continues to pour in from neighbors as well as strangers. Carlos Hernandez, whose restaurant is a mile from Robb Elementary, had given away more than 60 family-sized platters in less than two hours to feed mourning families and neighbors on Thursday. "It's a real tough situation, I'm just trying to show the kids that they do have us as their backbone and a support system," Hernandez told CNN. "We always provide, whether there is an incident or no incident." A team of emotional support dogs and their handlers has traveled to Uvalde and will be stationed in the town square this week -- eight golden retrievers are wearing blue vests that read "please pet me." "A lot of times after something like this people don't want to talk to a human," Bonnie Fear, a crisis response coordinator with Lutheran Church Charities, told CNN. "After traumatic events, people don't want to deal with people, sometimes they just want that thing that they can touch, talk to without being judged, and it's pretty much that simple." Video: Uvalde community comes together, helps families who lost loved ones "They show unconditional love," she added, pointing to the dogs. Elsewhere, the El Progreso Memorial Library has become a place of healing. On Wednesday, just a day after the shooting, children's librarian Martha Carreon sat in front of rows of little faces, reading, singing, and giggling with the children, taking them away to a safe place far from the school where many of them became witness to horror. "We want our building to be a safe space, a refuge that is a quiet, calm and cool haven," El Progreso Memorial Library director Mendell Morgan told CNN.	https://www.wxii12.com/article/families-friends-remember-the-victims-of-the-uvalde-school-massacre/40148805	2022-05-31T12:52:55	en	0.986001

Subsets and Splits

No community queries yet

The top public SQL queries from the community will appear here once available.